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ABSTRACT 
Pulmonary  arterial  hypertension  (PAH)  is  a  debilitating  disease  of  small  pulmonary 
resistance  arteries  with  vasoconstriction  and  vascular  remodelling  contributing  to  the 
disease  pathology.  A  genetic  basis  for  the  disease  was linked to  heterozygous  loss  of 
function  mutations  in  the  bone  morphogenetic  protein  receptor  2  (BMPR2)  gene.  The 
mutation  is  found  in  the  majority  of  familial  PAH  cases  and  a  significant  number  of 
apparently sporadic cases. The low penetrance of the disease in families carrying BMPR2 
mutations and the absence of mutations in the majority of idiopathic patients indicates that 
BMPR2 deficiency alone is insufficient to induce PAH. It is generally accepted PAH has a 
multi-factorial  pathology  with  endogenous  and  environmental  factors  acting  in concert 
with genetic pre-disposition to create the disease phenotype. Enhancement of the serotonin 
(5-HT) system has been implicated in PAH with the 5-HT transporter (5-HTT) receiving 
the most attention as a modifying gene in the development of PAH and there is compelling 
animal and human data implicating a role for increased expression of the 5-HTT as a 
modulating factor.  
 The aim of this study was to investigate if genetic pre-disposition interacts with other 
additional  modifying  factors  to  create  the  symptoms  of  PAH.  Transgenic  mice 
overexpressing  the  5-HTT  (5-HTT+),  deficient  in  BMPR2  (BMPR2
+/-)  or  a  double 
transgenic  (5-HTT+/BMPR2
+/-)  were  employed  in  addition  to mice  lacking  tryptophan 
hydroxylase 1 (Tph1), the rate limiting enzyme for the synthesis of 5-HT, and therefore 
lacking  peripheral  5-HT  (Tph1
-/-).    Additional  known  or  suspected  modifying  factors 
assessed  in  these  genetic  models  were  hypoxia,  dexfenfluramine  (Dfen)  and  its  major 
metabolite nordexfenfluramine (NDfen), 5-HT, bone morphogenetic protein-2 (BMP-2), 
KCNQ channels and the role of gender. 
 Mice  were  examined  in  vivo  for  evidence  of  a  pulmonary  hypertensive  phenotype 
following exposure to hypoxia and Dfen. Female 5-HTT+ mice were the only group to iii 
 
have a rise in two indices of PAH - namely right ventricular pressure (RVP) and vascular 
remodelling  -  in  room  air.  Female  5-HTT+  mice  also  had  an  exaggerated  pulmonary 
hypertensive phenotype in hypoxia. BMPR2
+/- mice, were, unexpectedly least susceptible 
to hypoxic induced increases in RVP although female mice deficient in BMPR2 (both 
BMPR2
+/-  and  5-HTT+/BMPR2
+/-)  had  more  extensive  vascular  remodelling  under 
hypoxia compared with WT and 5-HTT+ mice. Male mice did not express the phenotypic 
changes just outlined. No synergistic effect was observed between 5-HTT+ and BMPR2
+/- 
that resulted in a more pronounced pulmonary hypertensive phenotype.   
 WT and BMPR2
+/- mice were chronically oral-dosed with Dfen. Female mice from both 
genotypes developed similar degrees of PAH. Male mice did not develop elevated RVP but 
BMPR2
+/- males did have evidence of vascular remodelling, although at a lower level than 
the females.  Female Tph1
-/- mice did not develop PAH following Dfen indicating Dfen 
associated PAH is dependent on peripheral 5-HT synthesis. The presence of intact 5-HT 
synthesis  was  also  associated  with  an  increased  vasoconstrictor  response  to  5-HT  in 
isolated  intralobar  pulmonary  arteries  (IPAs),  a  situation  not  paralleled  with  the  other 
serotonergic vasoconstrictors, Dfen and NDfen, indicating differing mechanisms of action 
underlying the respective vasoconstrictor responses.  
 The  vasoconstrictor  action  of  5-HT,  Dfen,  NDfen  and  the  KCNQ  potassium  channel 
blocker linopirdine were all assessed in IPAs. Pulmonary arteries from BMPR2
+/- mice 
showed enhanced vasoconstriction to 5-HT and NDfen. 5-HTT+ and 5-HTT+/BMPR2
+/- 
mice showed enhanced vasoconstriction to NDfen but decreased vasoconstriction to 5-HT. 
Female 5-HTT+/BMPR2
+/- mice were the only group tested to show significantly greater 
vasoconstriction to Dfen compared with WT. The vasoconstrictor response to linopirdine 
was significantly reduced in BMPR2
+/- mice but neither linopirdine nor BMP-2 affected 5-
HT induced vasoconstriction. 
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 Female gender is an established risk factor for PAH. To investigate possible events that 
may underlie this risk, male (testosterone) and female (estradiol and 2-methoxyestradiol 
(2-ME)) sex hormones were assessed for their vasoactive properties in IPAs. All three 
hormones  relaxed  pre-constricted  vessels  but  only  at  supraphysiological  (>0.1  µM) 
concentrations. Each hormone also reduced the vasoconstriction exerted by 5-HT at 10
-5 M 
in male mice but not in females. No such effect, however, was observed in either gender at 
a  physiological  (10
-9  M)  concentration.  NDfen  induced  vasoconstriction  was  also 
unaffected by 10
-9 M estradiol. Finally, male and female mouse lungs were assessed for 
protein expression of 5-HT and BMPR2 signalling compounds (p-Smad1/5/8, p-ERK1/2 
and p-p38 MAPK).  Female mouse lungs displayed higher  expression of the mitogenic 
mediator p-ERK1/2 than male mouse lungs with the other proteins unchanged.  
 In conclusion, this study confirms overexpression of the 5-HTT as a trigger for elevated 
RVP  and  vascular  remodelling  in  mice  and  a  cause  of  more  severe  hypoxic  PAH. 
BMPR2
+/- mice are phenotypically normal in room air and show divergent pulmonary 
effects  following hypoxia with loss of BMPR2 seemingly attenuating hypoxic induced 
increases in RVP but causing a simultaneous worsening of vascular remodelling, this latter 
effect consistent with the important role BMPR2 has in maintaining vascular integrity. 
Dfen induced PAH in mice was found to be dependent on peripheral 5-HT synthesis with 
BMPR2 mutation not acting as a risk factor. Loss of BMPR2 can enhance vasoconstriction 
to serotonergic agonists and when combined with overexpression of the 5-HTT, leads to a 
dramatic increase in sensitivity to Dfen induced vasoconstriction. Evidence was also found 
for altered KCNQ channel function in transgenic animals. Unexpectedly, female gender 
emerged as the most crucial risk factor for PAH in this thesis. 
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1.1 The pulmonary circulation 
The human lung is the only organ in the body to receive the entire cardiac output (CO) at 
all times. In healthy adults the pulmonary circulation is a high-flow, low-resistance system 
that is composed of vessels that carry blood from the right side of the heart through the 
lungs and then returning it to the left side of the heart.  Deoxygenated blood from the upper 
body including head, neck and upper limbs is returned to the right atrium via the superior 
vena cava. Deoxygenated blood from elsewhere in the body is returned to the right atrium 
via the inferior vena cava. When the right atrium is filled with blood, it contracts, forcing 
blood though the tricuspid valve into the right ventricle. Blood from the right ventricle is 
pumped through the pulmonary valve and into the main pulmonary artery for distribution 
to the lungs. The main pulmonary artery bifurcates with one branch entering the right lung 
and the other entering the left lung. Inside the lungs, pulmonary arteries run parallel to the 
airways  and  branches  (thought  to  number  15  orders)  run  to  the  level  of  the  terminal 
bronchioles before forming the vast network of capillaries in the alveolar walls. It is in 
these capillaries that the exchange of carbon dioxide (CO2) and oxygen (O2) take place. 
Oxygenated blood from the capillaries is returned to the heart via venules and veins before 
entering the left atrium via four pulmonary veins, two from each lung. 
 
1.1.1 Structure of the pulmonary circulation 
Fundamentally, pulmonary arteries, capillaries and veins are structurally similar to their 
systemic counterparts. Pulmonary arteries, like systemic arteries have an innermost layer 
called the tunica intima (figure 1.1). This is composed of a single layer of endothelial cells 
lying on a basement membrane. The endothelial cells are in direct contact with the blood 
flowing through the vessel lumen. Separating the tunica intima from the tunica media is a 
layer of elastic tissue called the internal elastic lamina. The tunica media is principally a 
layer of smooth muscle and is much thinner in healthy pulmonary arteries compared with  3 
 
 
 
 
 
 
 
 
 
Figure 1.1 Structure of pulmonary artery. Illustration of the various layers that comprise 
the pulmonary arterial wall. Figure adapted from original image on teachPE.com. 
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corresponding systemic arteries. The role of the smooth muscle is to provide support for 
the vessel wall and to alter vessel diameter to regulate blood flow and pressure. A second 
layer of elastic tissue, the external elastic lamina, separates the tunica media from the 
tunica adventitia, a layer composed of connective tissue, elastic and collagen fibres in 
addition  to  other  components  such  as  dispersed  fibroblasts  and  adipose  cells.  The 
connective tissue of the adventitia is dense in the region closest to the tunica media but 
becomes thinner towards the outer edges of the vessel wall where it disperses into the 
surrounding area. 
  Although  pulmonary  arteries  are  similar  to  systemic  arteries,  there  are  important 
differences between them. The main pulmonary artery is significantly thinner walled than 
the aorta and there is less smooth muscle in the wall of intra-lobar pulmonary arteries than 
in  corresponding  systemic  vessels.  Pre-capillary  arteries  in  the  lung  are  only  partially 
muscularised and some lack smooth muscle altogether (Levitzky, 2002). 
 
1.1.2 Pulmonary vascular resistance 
One consequence resulting from the above differences in anatomy between the pulmonary 
and systemic circulations is that the pulmonary circulation has a low resistance to blood 
flow.  Pulmonary  vascular  resistance  (PVR)  is  about  1/10
th  that  of  systemic  vascular 
resistance (SVR) (Levitzky, 2002).  Pulmonary artery pressure (PAP) is normally low with 
a mean pressure of ~15 mm Hg. This differs from a mean of ~100 mm Hg in systemic 
arteries (Hickey, 1996). PAP does, however, vary with age but does not usually exceed a 
mean pressure of 20 mm Hg in people aged below 60. In people aged beyond 60, PAP can 
vary  depending  on  physiological  and  disease  conditions  (Mandegar  et  al.,  2004).    In 
addition, PAP in healthy people can be affected by factors such as altitude, sea diving or 
exercise (Mandegar et al., 2004).  PAP is the product of CO and PVR (equation 1). 
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Equation 1                            PAP = CO x PVR 
Equation  1)  Relationship  of  pulmonary  artery  pressure,  cardiac  output  and 
pulmonary vascular resistance. 
PAP  =  pulmonary  artery  pressure,  CO  =  cardiac  output,  PVR  =  pulmonary  vascular 
resistance 
 
The pulmonary and systemic circulations receive approximately the same CO; therefore, 
the lower PAP in the pulmonary circulation is entirely due to lower PVR.  Even during 
periods  of  increased  CO,  PAP  remains  relatively  stable.    There  are  two  mechanisms 
responsible for lowering PVR when intravascular pressures are increased. These are: 
1)  Recruitment. Vessels that were previously unperfused now start to conduct blood. 
2)  Distension. Vessels expand. A large radius equates with lower resistance (equation 
2). 
 
Equation  2, the  Poiseuille equation,  is a  physical  law  that  describes  three  factors  that 
determine the resistance of a fluid (in this case blood) to flow in a cylindrical tube (such as 
a blood vessel). These factors are vessel length, fluid (blood) viscosity and inner vessel 
radius. The most important of these both quantitatively and physiologically is the vessel 
radius.  Vessel length does not significantly alter and blood viscosity is usually maintained 
within  a  small  range,  although  there  are  occasions  during  which  blood  viscosity  may 
change by a greater degree. These are associated with changes in hematocrit levels or body 
temperature.  Vessel radius can be changed by contraction/relaxation of the smooth muscle 
in the tunica media and as equation 2 shows, PVR is inversely proportional to the fourth 
power of the radius of the vessel (r
4), thus PVR is extremely sensitive to changes in vessel 
radius. This is illustrated in a graph of relative radius of a single vessel plotted against 
relative flow (figure 1.2).  From this graph, it is clear that even very small changes in 
vessel radius can have dramatic effects on blood flow. Both equation 2 and figure 1.2 
assume constant laminar flow, constant viscosity and a steady pressure flow. They also 6 
 
assume the length of the vessel to be held constant and the vessel to be rigid. Although 
blood flowing through a vessel does not behave in such an ideal manner i.e. does not 
behave  as  a  Newtonian  fluid,  the  Poiseuille  equation  is  sufficient  for  conveying  the 
importance that vessel radius has on determining PVR.  
  The relationship governing the radius of a single vessel to the total resistance of the lung 
is determined by the structure of the pulmonary arterial tree. In the pulmonary arterial tree 
vessels are arranged either in series or in parallel.  A vessel is in series with its daughter 
branches and each of these branches is in parallel to each other (Richardson et al., 1998).  
The total resistance of vessels connected in series is the sum of each individual vessels 
resistance (equation 3). Conversely, when vessels are connected in parallel, the reciprocal 
of the total resistance is equal to the sum of the reciprocals of each individual vessels 
resistance (equation 4). The total resistance of vessels connected in parallel will, therefore, 
always be less than the resistance of the single vessel with the lowest individual resistance 
(equation 4).  From the resistance equations: 3 and 4, it is deducible that  the greater the 
number of vessels that exist in parallel networks, the lower the overall resistance of the 
system will be, while the greater the number of vessels there are in series, the greater the 
overall  resistance.  This  explains  why,  as  the  radius  of  pulmonary  arteries  become 
exponentially smaller from order 1 to 15, total resistance does not increase. The radius 
might decrease exponentially but the numbers of branches increase exponentially creating 
a greater number of arteries connected in parallel and thus maintaining a low PVR.  
 
 
Equation 2                            PVR = 8Lŋ 
                                                      r
4 
 
Equation 2)  The Poiseuille equation for determining the relationship of pulmonary 
vascular resistance to blood flow 
PVR = pulmonary vascular resistance, L = length of vessel, ŋ = viscosity of blood, r = 
inner radius of vessel 
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Equation 3                            RT = R1 + R2 + R3 …+ Rn                       
 
Equation 3) Relationship of individual vessel resistance to total resistance for a series 
network 
 
 
 
 
 
Equation 4                            1   = 1    + 1   + 1   + … +   1         
                                               RT    R1     R2     R3             Rn 
                    
Equation  4)  Relationship  of  individual  vessel  resistance  to  total  resistance  for  a 
parallel network 
 
1.1.2.1 Regulation of pulmonary vascular resistance 
The  regulation  of  vascular  resistance  in  the  pulmonary  circulation  is  different  to  the 
systemic circulation due to the unique properties of the pulmonary  vasculature. In the 
systemic circulation arterioles are the major site of vascular resistance whereas in the lung, 
vessels of all sizes contribute to PVR. Unlike the systemic circulation, pulmonary vessels 
have a low basal tone, display little or no autoregulation and their response to autonomic 
neuronal control is not well understood (Richardson et al., 1998). It is generally accepted 
that PVR is regulated by mechanisms that fall into two categories: 1) passive control and 
2) active control. 
 
1.1.2.1.1 Passive control 
Passive control involves changes in vessel radius/diameter independent of a change in 
vascular tone. Distension and recruitment of vessels is able to occur due to the low basal 
tone of pulmonary vessels. Small pulmonary vessels also have a larger radius than their 
systemic counterparts and these properties allow the lung to accommodate greater CO; for 
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Figure 1.2 Relationship of relative radius to relative flow in a single vessel.  
Graph illustrating the mathematical relationship between radius of vessel to flow within 
that vessel. PVR is inversely proportional to the fourth power of the radius of the vessel 
(r
4), F = blood flow, r = vessel radius. Reproduced from Klabunde, 2004. 
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example, during times of exercise, while maintaining a low PVR. 
 Gravity has a significant effect on the distribution of blood within the lung. In an upright 
person of average height the lowest point of the lungs is approximately 30 cm lower than 
the highest point. The consequence of gravity on the lung is a pressure difference between 
the top part and the bottom part of the lungs. The top part will have a PAP 15 mmHg lower 
than the mean PAP and in the lower part of the lung, PAP will be 8 mmHg higher than 
mean PAP (Guyton, 1981).  These pressure differences have important effects on blood 
flow within the lung.  In an upright person, there is low blood flow in the top section of the 
lung. Conversely, in the lower lung, blood flow may be 5-10 times greater than at the top 
(Guyton, 1981). As a consequence of hydrostatic pressure, the lung can be divided into 
three zones to represent the different dynamics of pulmonary blood flow: 
 
Zone 1: The apical regions of the lung which are predominately above the level of the 
heart. At this level, pulmonary vascular pressure tends to be lower than alveolar pressure 
(mean of ~ 0 mmHg) at both arterial and venular ends of the pulmonary capillaries.  This 
results in collapse of a large number of capillaries shutting off blood flow. Zone 1 therefore 
is an area of no blood flow.  
 
Zone 2: Vessels in this region lie just above heart level. Arterial pressure is positive (higher 
than alveolar pressure) and higher than venous pressure which remains negative (lower 
than alveolar pressure). Therefore the venous ends of capillaries remain collapsed. In Zone 
2 blood flows intermittently, with capillaries open during systole and collapsed during 
diastole. 
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Zone 3: In the lowest region of the lung, pulmonary venous pressure is generally higher 
than alveolar pressure and consequently capillaries are open at all times and blood flows 
continuously from the arteries to the veins.  
 
1.1.2.1.2 Active control 
Active  control  involves  a  wide  range  of  biological  factors  capable  of  altering  smooth 
muscle contraction/relaxation and consequently vascular tone. The mechanisms by which 
vascular tone is actively regulated are:  
1)  Neuronal control 
2)  Humoral and endothelial derived factors 
3)  Oxygen tension 
 
1.1.2.1.2.1 Neuronal control 
The  autonomic  nervous  system  is  composed  of  sympathetic  (adrenergic)  and 
parasympathetic (cholinergic) nerves and both are found in the pulmonary vasculature; 
however, their relative contribution to the regulation of vascular tone has proved difficult 
to ascertain (Downing and Lee, 1980). Using fluorescent imaging, adrenergic nerves are 
easily indentified in the adventitia of human pulmonary arteries and veins. In large elastic 
pulmonary  arteries,  nerve  fibres  penetrate  the  outer  third  of  the  media  but  in  smaller 
muscular arteries, there is no such innervation of the smooth muscle layer. No adrenergic 
fibres are found in human pulmonary arteries smaller than 30 µM (Downing and Lee, 
1980).  Fluorescent histochemistry in other mammals has shown that adrenergic nerves 
also penetrate medial smooth muscle in cats, rabbits, guinea pigs and hares although the 
levels of innervation vary between species and some species such as the hedgehog, rat and 
mouse  display  no  sympathetic  fluorescent  staining  at  all  in  pulmonary  arteries  (Cech, 
1969; Knight et al., 1981) .  11 
 
 Pulmonary  arterial  smooth  muscle  cells  (PASMCs)  express  1  and  2-ardrenoceptors 
(with  1  mediating  vasoconstriction)  in  addition  to  2-adrenoceptors  that  mediate 
vasorelaxation (Porcelli and Bergofsky, 1973; Hyman et al., 1981; Hyman et al., 1986).  
 Release of noradrenaline from sympathetic nerve terminals or an increase in circulating 
catecholamine  levels  leads  to  vasoconstriction  through  activation  of  post-synaptic  1-
ardrenoceptors. In the healthy lung, a  2-adrenergic effect helps maintain a vasodilator, 
anti-proliferative  balance  (Salvi,  1999)  but  during  periods  of  stress  such  as  alveolar 
hypoxia and hypercapnic acidosis, a pro-vasoconstrictor effect results, mediated in part, by 
1-adrenoceptors (Porcelli et al., 1977).   1-Adrenoceptors in pulmonary arteries show an 
increased affinity to noradrenaline compared with other vessels (Bevan et al., 1986) and 
this may be important in the regional regulation of vascular tone within the lung. 
 Morphological  analysis  of  cholinergic  innervation  of  the  pulmonary  vasculature  has 
largely relied on acetylcholinesterase staining as the most practical and reliable means of 
identifying cholinergic nerves. As with adrenergic nerves, cholinergic nerves have been 
found in association with pulmonary arteries in many species (Downing and Lee, 1980), 
where they are found in the adventitia and medial smooth muscle (Cech, 1973; Al-Wiel-
Bermani et al., 1982; Wojtarowitz et al., 2003) with the greatest density of innervation 
occurring  in  larger  vessels  (Downing  and  Lee,  1980;  Haberberger  et  al.,  1997).  Inter-
species  differences  are  pronounced,  with  rats  and  mice  showing  little  intra-pulmonary 
cholinergic innervation (Cech, 1973), unlike larger mammals such as rabbits and pigs that 
have a greater density of cholinergic nerves (Al-Wiel-Bermani et al., 1982; Wojtarowitz et 
al., 2003). The extent of cholinergic innervation in the human lung is not well understood. 
Amenta et al., 1983 found cholinergic innervation in human pulmonary arteries where it 
was found to be denser than in veins. Partanen et al., 1982, however, found no cholinergic 
nerves  associated  with  blood  vessels  in  the  human  lung.  Regardless  of  cholinergic 
innervation,  pulmonary  arteries  in  the  human  and  other  mammals  are  responsive  to 12 
 
acetylcholine  (Ach).  Under  conditions  of  low  basal  tone,  Ach  exerts a  vasoconstrictor 
effect on pulmonary arteries. However,  when vascular tone is increased, Ach exerts a 
vasodilator effect (Nandiwada et al., 1983; Hyman and Kadowitz, 1988). Ach induced 
relaxation is endothelium dependent and involves activation of M1 and M3 muscarinic 
receptors whereas Ach induced vasoconstriction involves activation of M1 receptors on 
smooth muscle (Norel et al., 1996).  
 There are other neuronal influences within the pulmonary  vasculature that are neither 
adrenergic nor cholinergic. These are known as nonadrenergic, non cholinergic (NANC) 
nerves and can have vasoconstrictor and vasodilator effects (Inoue and Kannaan, 1988; Liu 
et al., 1992). Adenosine triphosphate (ATP) is involved in both the vasoconstrictor and 
vasodilator effect while nitric oxide (NO) is involved in the vasodilator response (Inoue 
and Kannan, 1988; Liu et al., 1992; Gumusel et al., 2001). NO dilates both systemic and 
pulmonary vessels and is synthesised in the vessel wall from L-arginine by NO synthase 
(NOS)  of  which  there  are  three  isoforms  (endothelial  (eNOS),  inducible  (iNOS)  and 
neuronal (nNOS)) and all three are expressed in the lung (Le Cras and McMurtry, 2001).  
eNOS is the major isoform responsible for NO synthesis in pulmonary arteries with the 
other two isoforms making minor contributions (Strange et al., 2002). The extent to which 
NO produced in the airways can influence vascular tone is not clear. The vasodilator effect 
of NO is mediated by cyclic guanosine monophosphate (cGMP) and protein kinase G 
(PKG). 
 
1.1.2.1.2.2 Humoral and endothelial derived factors 
In addition to adrenergic, cholinergic and NANC factors the pulmonary vasculature  is 
exposed to many other vasoactive compounds and a tight regulation between those that are 
vasoconstrictors and those that are vasodilators is essential for maintaining low vascular 
tone.  Important vasoconstrictors of the pulmonary circulation include angiotensin II, a key 13 
 
effector  of  the  renin-angiotensin  system  and  a  potent  pulmonary  vasoconstrictor. 
Angiotensin-converting enzyme (ACE) generates angiotensin II from angiotensin I and the 
capillaries in the lung have a high expression of ACE (Studdy et al., 1983).  
 Thromboxane A2 (TXA2) is derived from arachidonic acid metabolism in platelets and is a 
constrictor of pulmonary vessels (Buzzard et al., 1993).  
 In contrast to its role as a vasodilator in the systemic circulation, histamine acts as  a 
vasoconstrictor in pulmonary vessels, acting via H1 receptors (Tucker et al., 1975).                                  
 Endothelin – 1 (ET-1) is a member of a family of vasoconstrictor peptides termed the 
endothelins that are synthesised from large precursor molecules: the big endothelins, by 
endothelin-converting  enzymes  (ECEs)  present  in  endothelial  cells  (Yanagisawa  et  al., 
1988).  Vascular  smooth  muscle  cells  can  also  synthesise  ET-1  under  inflammatory 
conditions  (Woods  et  al.,  1999).  ET-1  acts  via  ETA  and  ETB  receptors  to  induce 
vasoconstriction.  Which  of  these  receptors  mediates  the  response  is  dependent  on  the 
species being assessed, the size of the blood vessel and the local concentration of ET-1 
(Fukuroda et al., 1994; Maclean et al., 1994; McCulloch et al., 1996).  
 Serotonin (5-HT) which is stored primarily in platelets is a pulmonary vasoconstrictor 
(Gruetter  et  al.,  1981;  McGoon  and  Vanhoutte,  1984).  The  major  site  of  serotonin 
synthesis  is  in  the  enterochromaffin  cells  of  the  intestine,  however  serotonin  is  also 
released locally in the lung from neuroendocrine and neuroepithelial cells in the airways 
(MacLean et al., 2000) and from pulmonary arterial endothelial cells (PAECs) (Eddahibi et 
al., 2006). 5-HT induced vasoconstriction occurs through the 5-HT1B receptor in human 
pulmonary  resistance  vessels  (Morecroft  et  al.,  1999)  with  both  5-HT1B  and  5-HT2A 
receptors contributing to vasoconstriction in rats (MacLean et al., 1996).    
 There  are  other  circulating  factors  including  prostaglandins  of  the  F  series  and 
leukotrienes that also act as pulmonary vasoconstrictors (Back et al., 2002; Snetkov et al., 
2006). 14 
 
  In addition to NO, whose vasodilator action was discussed in relation to NANC agents, 
important vasodilators include prostacyclin (PGI2) which is a vasodilator in all vascular 
tissues including the lung (Vane and Botting, 1995). Like TXA2, PGI2 is derived from 
arachadonic acid and is, in fact, the major product of this metabolic pathway in all vascular 
tissues tested (Vane and Botting, 1995).  PGI2 is a short acting but potent vasodilator 
synthesised  in  endothelial  cells  that  induces  vasodilation  through  increasing  cyclic 
adenosine monophosphate (cAMP) and protein kinase A (PKA).               
 Vasoactive intestinal peptide (VIP) belongs to the glucagon-growth hormone-releasing 
factor  secretion  superfamily  and  acts  as  a  pulmonary  vasodilator  by  activating  VIP 
receptors (VPAC-1 and VPAC-2) that are present on the surface of smooth muscle cells in 
pulmonary  blood  vessels  (Busto  et  al.,  2000).  Stimulation  of  these  receptors  leads  to 
activation of both cAMP and cGMP.  
  A  related  compound  with  similar  sequence  homology  to  VIP  is  pituitary  adenylate 
cyclase-activating peptide (PACAP) and it possesses similar activity to VIP (Bruch et al., 
1998; Cardell et al., 1997). PACAP also binds to VPAC-1 and VPAC-2 in addition to the 
PAC1  receptor  which  is  widely  expressed  in  the  lung  (Busto  et  al.,  2000).  PAPAC 
unsurprisingly signals mainly via cAMP but some of its actions appear mediated by other 
mechanisms (Said, 2006).  
 Natriuretic  peptides  (NPs)  are  a  family  of  peptides comprised  of atrial  or  A-type  NP 
(ANP), brain or B- type NP (BNP) and C-type NP (CNP) that interact with three receptor 
subtypes, NPR-A, NPR-B and NPR-C and mRNA for all three receptors has been found in 
the lung (Li et al., 1995).  ANP and BNP are responsible for the vasodilation seen in the 
lung (Lindberg and Andersson, 1988; Zhao et al., 1999), an effect occurring through an 
increase in cGMP following ligand activation of the guanylate cyclase-linked NPR-A and 
NPR-B receptors. Knockout mice studies have shown that NPR-A is solely responsible for 
the vasorelaxant effect of ANP and BNP in this species (Zhao et al., 1999).      15 
 
 Adrenomedullin  is  a  52-amino  acid  peptide  originally  isolated  from  human 
pheochromcytoma. It is produced by vascular smooth muscle and endothelial cells (Sugo 
et al., 1994) in addition to many other cell types (Marutsuka et al., 2003). It is expressed at 
high levels in the lung (Kitamura et al., 1993) and is a vasodilator in both the pulmonary 
and systemic circulation (Marutsuka et al., 2003), an action mediated by cAMP. 
 
1.1.2.1.2.3 Oxygen tension 
Changes  in  the  partial  pressure  of  O2  (PO2)  has  the  opposite  effect  on  the  pulmonary 
circulation to that on the systemic circulation. In the systemic circulation, a decrease in 
PO2  (hypoxia) induces vasodilation which increases blood flow to hypoxic regions. In 
contrast, when alveoli are poorly ventilated resulting in a low PO2, pulmonary arteries 
constrict, preventing blood flow to hypoxic regions and diverting blood to better ventilated 
regions (George et al., 2005). O2 diffuses through the alveoli wall and into surrounding 
smooth muscle cells and a reduction in PO2 in the air spaces of the alveoli results in 
vasoconstriction of arteries in the hypoxic region (hypoxic pulmonary vasoconstriction; 
HPV). HPV occurs primarily in small pre-capillary arterioles in the hypoxic region when 
PO2  falls  below  60  mmHG  (Yuan,  2004).  The  size  of  the  hypoxic  region  can  vary 
enormously from a lobule to the entire lung. If only a small region is hypoxic, then blood 
flow can be diverted to more compliant, better perfused areas with only small rises in PAP. 
If, however, the vast majority of the lung is hypoxic, the result is widespread HPV and a 
rise in PAP, causing the heart to pump faster to overcome the associated rise in PVR 
(Yuan, 2004).   
 In the clinical setting, widespread alveolar hypoxia can occur as acute HPV (AHPV) in 
rapidly  progressing  acute  lung  conditions  including  asthma,  pneumonia  and  acute 
respiratory  distress  syndrome  (Dumas  et  al.,  1999).  The  resulting  AHPV  can  have 
detrimental  effects  including  reduced  CO,  increased  vascular  permeability  and  right 16 
 
ventricular failure  (Leach  and  Treacher,  1995).  AHPV  is  rapidly  reversible  if  alveolar 
oxygenation is restored to normal physiological values.  
 Widespread, sustained chronic HPV (CHPV) occurs in people living at high altitudes, as a 
result  of  diseases  associated  with  decreased  ventilation  such  as  chronic  obstructive 
pulmonary disease (COPD) and sleep apnea or in association with diseases that cause 
progressive lung destruction such as emphysema and fibrosing alveolitis (Dumas et al., 
1999).  CHPV  does  not  just  cause  an  increase  in  vascular  tone  but  also  vascular 
remodelling (see section 1.2.3.2.1) and together, they lead to a sustained increase in PAP 
(pulmonary hypertension) that is not reversible on return to normal alveolar PO2. 
  The processes underlying HPV are not well understood and in many experiments HPV 
presents a biphasic response (depending on experimental preparation and species tested). 
There is an initial transient vasoconstriction (phase 1) followed by vasorelaxation before a 
sustained period of vasoconstriction (phase 2). If this sustained vasoconstriction exists for 
a prolonged period of time then the symptoms associated with CHPV manifest.  HPV must 
involve an O2 sensor in addition to signal transduction to the contractile machinery of the 
smooth muscle.  Evidence suggests that the O2 sensor mediating phase 1 HPV is present on 
the smooth muscle cells themselves as both isolated pulmonary arteries (Madden et al., 
1985) and subsequently isolated PASMCs (Madden et al., 1992) were found to contract 
when  exposed  to  hypoxic  conditions.    This  would  rule  out  neuronal  or  circulating 
vasoactive  mediators  as  the  O2  sensor  and  narrow  the  search  to  factors  intrinsic  to 
PASMCs. Many factors have been put forward as candidates for the O2 sensor including 
O2-sensitive  calcium  (Ca
2+)  channels,  O2-sensitive  potassium  (K
+)  channels  and  the 
mitochondria, through changes in mitochondrial reactive oxygen species (ROS) production 
(Dumas et al., 1999). Whichever mechanism is involved in detecting changes in PO2, it 
ultimately  leads  to  an  increase in  intracellular  calcium  concentration  [Ca
2+]i,  a critical 
component  of  HPV  and  PASMC  contraction  in  general.  There  is  extensive  evidence 17 
 
supporting  the  theory  that  hypoxia  inhibits  voltage-gated  K
+  (Kv)  channels  causing 
membrane depolarisation and opening of L-type Ca
2+ channels causing Ca
2+ influx across 
the membrane and into the PASMC. The method by which hypoxia inhibits Kv channels is 
controversial.  Some  researchers  believe Kv  channel  inhibition  to  be  a consequence  of 
reduced  hydrogen  peroxide  (H2O2).  Low  H2O2  levels  result  from  a  reduction  in 
mitochondrial electron transport and superoxide ion production, a direct consequence of 
decreased O2 (Aaronson et al., 2006). Evidence exists, however, to support an alternative 
theory  also  involving  a  change  in  redox  state,  this  time  involving  an  increase  in 
mitochondrial  ROS  production  and  release  of  Ca
2+  from  intracellular  stores  and  store 
operated  Ca
2+  entry  (SOCE)  (Aaronson  et  al.,  2006;  Waypa  and  Schumacker,  2005). 
Despite the differences in these two theories, phase 1 vasoconstriction may be dependent 
on both voltage-gated Ca
2+ channels and SOCE (Weigand et al., 2005).  
 Unlike the transient phase 1, the sustained muscle contraction of phase 2 requires more 
than a high [Ca
2+]i, which stays constant in phase 2 as tension rises (Robertson et al., 
2003).    Phase  2  is  dependent  on  the  presence  of  endothelium  and  removal  of  the 
endothelium  abolishes  the  sustained  phase  but  not  the  initial  transient  phase  of  HPV.  
[Ca
2+]i is unaffected by endothelial removal (Robertson et al., 2003). Phase 2 may then 
involve two processes: one that maintains [Ca
2+]i, at the increased level induced during 
phase 1 and a second, endothelium dependent process, that increases Ca
2+ sensitisation in 
PASMCs. An increase in Ca
2+ sensitisation would mean that agonists binding to G-protein 
coupled receptors would induce greater smooth muscle contraction at a constant [Ca
2+]i. 
This  process  is  thought  to  involve  Rho-A  mediated  activation  of  Rho  kinase  (ROCK) 
(Loirand  et  al.,  2006)  and  inhibition  of  ROCK  with  the  ROCK  antagonist  Y-27632 
prevents  the  sustained  HPV  in  CHPV  (Robertson  et  al.,  2000).    The  question  then 
becomes: what is the endothelial derived vasoconstrictor that causes ROCK dependent 
Ca
2+ sensitisation and sustained HPV? The primary candidate is ET-1 which can increase 18 
 
the sensitivity of the contractile apparatus to hypoxic induced increases in [Ca
2+]i. (Waypa 
and Schumacker, 2005). Hypoxia also increases ET-1 expression and secretion in cultured 
endothelial  cells  and  BQ-123,  an  ETA  receptor  antagonist  inhibits  CHPV  in  isolated 
vessels and whole lung (Waypa and Schumacker, 2005). Additionally, the promoter of the 
ET-1 gene contains a hypoxia-inducible factor (HIF) response element (HRE; Hu et al., 
1998).  HIF-1  along with HIF-2  and HIF-3  regulate the expression of most hypoxic-
dependent  and  many  hypoxic-independent  genes  involved  in  physiological  and 
pathophysiological lung states (Tuder et al., 2007) (See section 1.2.3.2.1). In contrast to a 
supportive role for ET-1 in CHPV, Roberston et al., 2003 found that CHPV in the rat was 
unaffected  by  combined  ETA  and  ETB  receptor  blockade  and  CHPV  in  salt-solution 
perfused lungs is not significantly affected by ET-1 receptor antagonists (Aaronson et al., 
2002) so there maybe additional hypoxic induced vasoconstrictor substances released from 
the endothelium that are yet to be determined and experimental evidence exists to support 
this idea (Gaine et al., 1998; Robertson et al., 2001).  
 Research into the underlying mechanisms of HPV over the past 30 years has  yielded 
diverse and often contradictory theories regarding the mediators and modifiers of HPV. 
Many of these differences are likely due to differences in preparation  e.g. location and size 
of  pulmonary  artery,  species,  blood  or  salt  perfused  lung,  duration  of  hypoxia  and 
importantly, the  level of pre-tone in the vessel being studied. The level of existing tone in 
a muscle preparation and the stimulus used to induce that tone can have dramatic effects on 
the  subsequent  response  to  hypoxia  (Aaronson  et  al.,  2006).  Figure  1.3  illustrates  the 
possible mechanisms currently thought to occur in both phase 1 and phase 2 of HPV.  In 
addition to the mediators of HPV outlined in figure 1.3 there are a host of other vasoactive 
factors already mentioned previously capable of modulating either positively or negatively 
the degree of HPV. These include NO, prostaglandins, angiotensin II and  of particular 
relevance to this investigation, 5-HT (Dumas et al., 1999; Aaronson et al., 2002). Hypoxia 19 
 
can increase circulating 5-HT levels (Callebert et al., 2006) and increase expression of 
tryptophan hydroxylase 1 (TPH1) (Pan et al., 2006), the rate-limiting enzyme in 5-HT 
synthesis in the periphery. An increase in 5-HT could result in increased activation of the 
vasoconstrictor  receptors,  5-HT1B  and  5-HT2A,  which  can  interact  with  many  of  the 
pathways thought to mediate HPV (figure 1.3).  (See section 1.2.3.1 for more information 
on the role of 5-HT in hypoxia). HPV only occurs in the pulmonary circulation and is the 
most important regulatory mechanism for controlling vascular tone.  Sustained HPV over a 
prolonged period  of time (CHPV) is a  major contributing factor to pulmonary  arterial 
hypertension (PAH) associated with several hypoxic lung diseases and PAH induced by 
 hypoxia  is  a  model  often  used  to  study  PAH  in  rodents  and  will  be  used  in  this 
investigation (see sections 1.2.3.2.1 and 2.1.5). 
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Figure 1.3 Possible signalling mechanisms involved in phase 1 and phase 2 of hypoxic 
induced vasoconstriction in pulmonary arteries. 
Solid arrows represent pathways suggested to contribute to the physiological regulation of 
pulmonary artery tone during hypoxia. Dashed arrows represent the possible modulating 
influence of 5-HT signalling on these pathways.  
ROS,  reactive  oxygen  species;  HIF-1,  hypoxia-inducible  factor-1;  ET-1,  endothelin-1; 
ETA, endothelin receptor A; RhoK, Rho kinase; MLCK, myosin light chain kinase; MLCP, 
myosin  light  chain  phosphatase;  SR,  sarcoplasmic  reticulum;  SOCC,  store-operated 
calcium  channel;  RyR,  ryanodine  receptor;  AC,  adenylate  cyclase;  TPH1,  tryptophan 
hydroxylase 1 
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1.2 Pulmonary arterial hypertension 
PAH is characterised by an elevation in PAP and PVR. The raised PVR increases the work 
load of the right ventricle which is required to overcome the pressure increases. Over time 
this causes right ventricular failure. Clinically, PAH is defined by a mean PAP > 25 mmHg 
at rest or > 30 mmHg during exercise (Rich et al., 1987). There are often few symptoms in 
the early stages but as the disease progresses, patients present with symptoms including 
dyspnea, fatigue, edema and syncope (Rich et al., 1987). The non specific nature of these 
symptoms  often  means  diagnosis  is  delayed  and  the  progressive  nature  of  the  disease 
means, that if left untreated, death usually occurs within 3 years of diagnosis (D’Alonzo et 
al., 1991).  Sporadic PAH is rare with an incidence of 1-2 cases per million per year 
(Abenhaim et al., 1996; Gaine and Rubin 1998). The mean age at diagnosis is 36 and the 
disease occurs more frequently (~2:1) in women than in men (Loyd et al., 1984; Rich et al., 
1987). 
 Over five decades ago, the term primary pulmonary hypertension (PPH) was introduced to 
describe  the  condition  of  increased  PAP  and  associated  vascular  changes  occurring 
exclusively  in  the  pulmonary  circulation  without  an  identifiable  cause.  Additionally, 
secondary  pulmonary  hypertension  (SPH)  was  the  term  used  to  describe  pulmonary 
hypertension associated with an underlying disease condition. Over the past few decades, 
advancements  in  our  understanding  of  both  the  clinical  and  pathological  aspects  of 
pulmonary hypertension has led to the need for a more useful and accurate classification 
system. A revised classification for pulmonary hypertension was introduced following a 
World Health Organisation symposium on the condition in Evian, France in 1998.  The 
term  SPH  was  abandoned  and  the  new  classification  comprised  five  groups  to  reflect 
similarities in clinical and etiological features. The first group was PAH which included 
PPH. The other four groups included conditions that predominately affected the venous 
circulation  or  conditions  that  affected  the  pulmonary  circulation  through  changes  in 22 
 
respiratory structure or function (Mandegar et al., 2004). These groups were pulmonary 
venous hypertension, pulmonary hypertension associated with disorders of the respiratory 
system  and/or  hypoxaemia,  pulmonary  hypertension  due  to  chronic  thrombotic  and/or 
embolic disease and pulmonary hypertension due to disorders affecting the pulmonary 
vasculature  directly.  Further  advancements  in  understanding  the  pathophysiology  of 
pulmonary hypertension including the uncovering of a genetic basis for PAH meant that a 
second revision to the classification system was necessary and this took place at the third 
World  Conference  on  Pulmonary  Hypertension  in  Venice,  Italy  in  2003.  The  most 
important revision was the replacement of the term PPH with idiopathic PAH (IPAH) or 
familial PAH (FPAH) when an identifiable genetic cause is found. All other forms of PAH 
that  are  related  to  risk  factors  and  disease  conditions  were  termed  associated  PAH 
(APAH). The revised Venice classification is presented in table 2.1.  Despite the different 
clinical classifications of PAH, it is often difficult, if not impossible, to distinguish PAH of 
a particular etiology with that from another based on histopathological evidence alone.  
 
1.2.1 Pathophysiology of PAH 
Pulmonary arterial vasoconstriction, remodelling of the pulmonary vasculature and in situ 
thrombosis all contribute to an increase in PVR. As discussed previously, this increase in 
PVR  increases  the  work  load  on  the  right  ventricle  and  progressively  leads  to  right 
ventricular  hypertrophy  (RVH)  and  heart  failure.  Of  these  three  contributing  factors, 
vascular remodelling is the most important pathological change in PAH and the extent of 
remodelling at diagnosis will determine the prognosis for the patient.  
 
 
 
 23 
 
 
Revised Clinical Classification of Pulmonary Hypertension (Venice 2003) 
 
1. Pulmonary arterial hypertension (PAH) 
1.1. Idiopathic (IPAH) 
1.2. Familial (FPAH) 
1.3. Associated with (APAH): 
       1.3.1. Collagen vascular disease 
       1.3.2. Congenital systemic-to-pulmonary shunts 
       1.3.3. Portal hypertension 
       1.3.4. HIV infection 
       1.3.5. Drugs and toxins 
       1.3.6. Other (thyroid disorders, glycogen storage disease, Gaucher disease,    
       hereditary hemorrhagic telangiectasia,         
       hemoglobinopathies, myeloproliferative disorders, splenectomy) 
1.4. Associated with significant venous or capillary involvement 
       1.4.1. Pulmonary veno-occlusive disease  
       1.4.2. Pulmonary capillary hemangiomatosis  
1.5. Persistent pulmonary hypertension of the newborn 
 
2. Pulmonary hypertension with left heart disease 
2.1. Left-sided atrial or ventricular heart disease 
2.2. Left-sided valvular heart disease 
 
3. Pulmonary hypertension associated with lung diseases and/or hypoxemia 
3.1. Chronic obstructive pulmonary disease 
3.2. Interstitial lung disease 
3.3. Sleep-disordered breathing 
3.4. Alveolar hypoventilation disorders 
3.5. Chronic exposure to high altitude 
3.6. Developmental abnormalities 
 
4. Pulmonary hypertension due to chronic thrombotic and/or embolic 
disease 
4.1. Thromboembolic obstruction of proximal pulmonary arteries 
4.2. Thromboembolic obstruction of distal pulmonary arteries 
4.3. Non-thrombotic pulmonary embolism (tumor, parasites, foreign 
material) 
 
5. Miscellaneous 
Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of 
pulmonary vessels (adenopathy, tumor, fibrosing mediastinitis)  
 
 
 
Table 1.1 Revised Clinical Classification of Pulmonary Hypertension (Venice, 2003). 
The classification system contains groups classified according to clinical and etiological 
parameters.  
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1.2.1.1 Pulmonary vascular remodelling  
In the non-hypertensive lung, the thickness of the pulmonary arterial wall is maintained 
relatively constant by the balance between proliferation and apoptosis of the cells present 
in the vessel wall i.e. PASMCs, PAECs and pulmonary arterial fibroblasts (PAFs). Any 
disruption in this balance towards a pro-proliferative phenotype will lead to vascular wall 
thickening,  lumen  occlusion  and loss  of  vascular  compliance  (Mandegar  et al.,  2004).  
Together, these cellular changes create the vascular remodelling that occurs in PAH and 
has  the  ultimate  effect  of  progressively  increasing  PVR  (Mandegar  et  al.,  2004). 
Morphological  analysis  of  pulmonary  hypertensive  lungs  reveals  distal  extension  of 
smooth muscle into previously non muscularised vessels, obliteration of small pulmonary 
arteries  associated  with adventitial  and medial  hypertrophy,  concentric  laminar intimal 
lesions and fibrosis. Also present may be complex plexiform lesions which occur more 
frequently in severe PAH and are associated with a poor prognosis for the patient (Strange 
et al., 2002). The cellular processes governing the vascular remodelling in PAH are still to 
be  fully  elucidated  with  complex  vascular  changes  occurring.  These  changes  include 
vascularisation  of  the  adventitia  and  outer  media,  cell  proliferation  and  differentiation 
within  all  levels  of  the  vessel  wall,  altered  apoptosis  and  recruitment  of  circulating 
inflammatory cells. The cellular changes associated with vascular remodelling are now 
summarised.  
 
1.2.1.1.1 Intimal thickening and plexiform lesions 
Intimal thickening may be eccentric or concentric, resulting in narrowing and obliteration 
of the lumen and occurs most frequently in arteries <200 µm, with no intimal thickening 
seen in arteries >400 µM (Yi et al., 2000). Intimal thickening is the greatest contributor to 
the reduction of luminal area seen in PAH with the thickness of the intima increasing, on 
average,  30  fold  (Chazova  et  al.,  1995).  Intimal  lesions  display  varying  levels  of 25 
 
complexity with localised thrombi thought to contribute to the formation of some, while 
more  advanced  lesions can  become  fibrotic in  nature  (Tuder et al.,  2007).  In  general, 
concentric lesions are more pathological than eccentric lesions and characterise severe 
PAH. Concentric lesions can completely obliterate the vessel lumen whereas eccentric 
lesions cause only partial luminal obstruction (Yi et al., 2000) (figure 1.4 A-C).  
 Plexiform lesions are complex intimal lesions that occur at arterial branching points in 
arteries >200 µM (Chazova et al., 1995) (figure 1.4 D) and are glomeruloid structures 
containing a network of small vessels lined with PAECs (Tuder et al., 1994). Additionally, 
myofibroblasts  are  present  in  the  core  of  plexiform  lesions  and  there  is  some  debate 
regarding the relevant importance of both cell types in the origin of these lesions. Smith et 
al., 1990 and Yi et al., 2000 suggest that myofibroblast proliferation is the key initiator in 
the formation of the plexiform lesions while others believe dysfunctional PAEC growth 
following vascular injury or stimulation by growth factors is the essential mediator (Tuder 
et al., 1994; Cool et al., 1999). There is growing evidence to support the latter viewpoint 
and that plexiform lesions may be a form of angiogenesis related to phenotypic changes in 
PAECs (Cool et al., 1999). PAECs within plexiform lesions of IPAH patients display 
monoclonal expansion whereas expansion is polyclonal in patients with PAH secondary to 
other diseases (Lee et al., 1998). The polyclonal PAEC expansion in APAH is likely due to 
PAEC growth induced by high shear stress or an inflammatory response (Lee et al., 1998). 
The growth factors, platelet-derived growth factor (PDGF) and fibroblast growth factor 
(FGF) can be increased in vascular endothelium following high shear stress (Malek et al., 
1993) and these growth factors may contribute to PAEC growth. FGF and PDGF gene 
expression increases with increasing shear stress and can be as much as 4.8 fold higher 
during periods of high shear stress (Malek et al., 1993). The monoclonal PAEC expansion 
seen in plexiform lesions in IPAH cases results from a somatic mutation in one PAEC that 
confers a growth advantage. The process therefore resembles the neoplastic growth  26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Micrographs of pulmonary arteries from pulmonary hypertensive 
patients. A: Concentric intimal thickening in a pulmonary artery (~180 μM diameter; 
magnification x 100). B: Obliteration of lumen in a pulmonary artery (~ 80 μM diameter; 
magnification x 260). C: Eccentric intimal thickening (at arrow) in a pulmonary artery 
(~220 μM diameter; magnification x 130). D: Plexiform lesion (at arrow) associated with a 
muscular pulmonary artery (magnification x 110). Reproduced from Chazova et al., 1995.  
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processes  common  in  cancer  and  somatic  mutations  in  genes  associated  with  cellular 
proliferation and apoptosis have indeed been found in PAECs within plexiform lesions 
from PAH patients (Yeager et al., 2001).  Plexiform lesions are extremely detrimental to 
normal blood flow with a single lesion blocking blood flow for the length of the vessel 
(Cool et al., 1999). PAECs are also present in the concentric intimal lesions and these 
occur in association with plexiform lesions (Cool et al., 1997; Cool et al., 1999) often 
forming hybrid lesions in the pulmonary hypertensive lung that share both concentric and 
plexiform lesion features (Cool et al., 1997). It may be that rather than existing as distinct 
lesions, a number of the intimal lesions seen in PAH are lesions at different stages of 
evolution and that distinct endothelial cell phenotypes determine the development of the 
lesion (Cool et al., 1999). Contrary to a role for PAECs in concentric lesions, other studies 
have suggested concentric intimal lesions are composed of myofibroblasts (Atkinson et al., 
2002);  however,  the  origin  of  these  myofibroblasts  is  unknown.  Endothelial  cells  can 
transdifferentiate into smooth muscle cells when stimulated with growth factors such as 
transforming growth factor-   (TGF- ) (Frid et al., 2002); therefore, it is possible, although 
speculative, that the PASMC composed and PAEC composed lesions derive from common 
progenitor cells. Although the cellular and molecular determinants of the intimal lesions in 
PAH remains largely unknown they are likely to involve some or all of the following 
depending on lesion type and form of PAH;   
• Injury to vascular endothelium  
• Increase proliferation and reduced apoptosis of PAECs 
• Smooth muscle cell growth, migration and reduced apoptosis 
• Extracellular matrix (ECM) deposition 
• Reorganised thrombi 
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1.2.1.1.2 Medial thickening 
The smooth muscle layer that comprises the medial layer of pulmonary arteries provides 
support and strength to the vessel wall in addition to being the contractile machinery of the 
arteries.  The  media  is  composed  of  distinct  subpopulations  of  PASMCs  that  exist  in 
different layers within the media (Frid et al., 1997). The subpopulations are functionally 
and  phenotypically  unique,  each  with  different  expression  levels  of  contractile  and 
cytoskeletal proteins in addition to inter-population variations in response to hypoxia and 
growth factors (Frid et al., 1994; Dempsey et al., 1997; Frid et al., 1997).  Heterogeneous 
subpopulations of non-muscle like cells have also been identified in the media that have 
unique characteristics including a proliferative response to hypoxia, mimicking the in vivo 
effect of hypoxia on vascular remodelling. Certain populations of these cells are also able 
to secrete mitogens that may directly affect proliferation of ‘classical’ PASMCs (Frid et 
al., 1994; Frid et al., 1997).    
  In PAH, thickening of the media occurs in pulmonary arteries >50 µM with the increase 
in the medial layer reaching 5 fold that of control values (Chazova et al., 1995). Both 
hypertrophy  and  hyperplasia  of  PASMCs  contribute  to  medial  thickening.  PASMC 
hypertrophy is the dominant factor with hyperplasia playing a lesser role (Tuder et al., 
2007). In addition to an increase in muscularisation of small pulmonary arteries a layer of 
smooth  muscle  also  appears  in  the  small,  previously  non-muscularised    pre-capillary 
vessels <50 µM (Chazova et al., 1995). As there are no existing PASMCs in these arteries, 
hypertrophy and hyperplasia are unlikely to be essential factors in the distal extension of 
smooth  muscle  into  previously  non-muscularised  vessels.  One  possibility  which  has 
already been mentioned in relation to plexiform lesion formation is the transdifferentiation 
of  PAECs  into  PASMCs.  Frid  et  al.,  2002  found  that  cultured  bovine  PAECs  could 
transdifferentiate into PASMCs when cell-cell contact was disrupted or when cells were 
exposed to TGF- . The process was not dependent on PAEC proliferation. Moreover, 29 
 
exposure of porcine PAECs to hypoxia for 7 days resulted in the emergence of smooth 
muscle like cells (Zhu et al., 2006). Only a small number (0.01-0.03%) of PAECs undergo 
transdifferentiation  into  PASMCs  and  it  has  been  postulated  that  cells  undergoing 
transdifferentiation are bone-marrow derived progenitor cells that have been incorporated 
into the endothelial monolayer (Frid et al., 2002; Zhu et al., 2006). Other candidates for 
emergence of smooth muscle in the precapillaries include hypertrophy of pericytes and 
migration/recruitment of interstitial fibroblasts (Zhu et al., 2006; Tuder et al., 2007) and 
there is extensive evidence that fibroblasts have a unique and critical role in vascular 
remodelling (See next section). 
 Apoptosis  is  a  highly  regulated  process  for  maintaining  normal  vascular  structure  by 
removing unwanted cells such as those that have migrated into the vascular lumen or cells 
that have accumulated within the vessel wall. Cell survival depends on a delicate balance 
between expression of gene families that are pro-apoptotic or anti-apoptotic. The most 
important anti-apoptotic family is the  Bcl-2 family with important pro-apoptotic genes 
including Bax and Bad (Gurbanov and Shiliang, 2006). Apoptosis is impaired in PASMCs 
from PAH patients (Zhang et al., 2003) and Bcl-2 is overexpressed in the lungs of both 
FPAH and IPAH patients (Geraci et al., 2001). Survivin is a potent inhibitor of apoptosis 
and is found in pulmonary arteries from pulmonary hypertensive patients but not from 
control subjects (McMurty et al., 2005). Adenovirus mediated overexpression of survivin 
in rats results in mild PAH and inhibition of endogenous survivin reduces PAH induced by 
monocrotaline  (MCT)  in  rats.  Tenascin-C,  a  component  of  the  ECM  is  an  important 
survival factor for PASMCs and is induced by matrix metalloproteinases (MMPs)  and 
elastase.  Tenascin-C  is  increased  in  vessels  undergoing  remodelling  in  pulmonary 
hypertensive patients (Jones et al., 1997). Blockade of tenascin-C or its production by the 
use of elastase inhibitors results in PASMC apoptosis and regression of medial thickening 
in cultured rat pulmonary arteries (Cowan et al., 1999; Cowan et al., 2000a). Moreover, 30 
 
elastase inhibitors can reverse remodelling and improve survival in rats with MCT induced 
PAH (Cowan et al., 2000b). The importance of impaired apoptosis in pulmonary vascular 
remodelling has  further  become evident since the discovery that  FPAH was related to 
mutations in the gene for the apoptotic mediator: bone morphogenetic protein receptor 2 
(BMPR2) (See section 1.2.2). 
 
1.2.1.1.3 Adventitial thickening 
The adventitia is a connective tissue layer containing elastic and collagen fibres and is 
populated by  PAFs. The adventitial thickening associated with vascular remodelling is 
associated with PAF hyperplasia and collagen deposition (Chazova et al., 1995; Sartore et 
al.,  2001).  The  adventitia  can  reach  6  times  the  thickness  of  normal  in  PAH  patients 
(Chazova et al., 1995). PAFs have important roles in response to injury (Sartore et al., 
2001) and following such an injury, they undergo significant changes. Such changes are 
possible due to PAFs being less differentiated than PASMCs or PAECs and they can 
undergo proliferation, migration and transdifferentiation into myofibroblasts in addition to 
synthesising cytokines and ECM proteins (Mandegar et al., 2004). Myofibroblasts which 
express PASMC contractile proteins are able to migrate into the media where they may 
contribute to remodelling.  
Hypoxia  is  a  potent  stimulus  for  PAFs  and  can  modulate  most  of  the  PAF  functions 
outlined above.  PAF proliferation is the most pronounced feature of early hypoxic induced 
PAH in animal models (Belknap et al., 1997). The number of PAFs in the vessel wall of 
the hypoxic rat has shown to be increased 3 fold within 24 hours of hypoxic treatment and 
this was followed by transdifferentiation into ‘transitional cells’ displaying both smooth 
muscle  and  fibroblast  characteristics  before  complete  transdifferentiation  into  mature 
PASMCs by the 7
th day of hypoxia (Sobin et al., 1983). Further work on hypoxic rats has 
shown  that  PAFs  from  these  animals  show  an  enhanced  proliferative  phenotype  that 31 
 
continues  even  if  the  cells  are  returned  to  normoxic  conditions  (Welsh  et  al.,  2001). 
Hypoxia also triggers the release of paracrine mitogenic agents from PAFs that induce 
proliferation of PASMCs (Rose et al., 2002). The specific mitogenic compounds released 
by the PAFs are not known but may include ROS, PDGF and FGF (Rose et al., 2002; 
Stenmark  et  al.,  2006).  Like  the  PASMCs  in  the  media,  PAFs  appear  to  exist  as 
heterogeneous subpopulations (at least in the neonatal calf) with varying sensitivities to 
hypoxia (Das et al., 2002).  
 The  vasa  vasorum  micro-circulation  borders  the  adventitia  of  pulmonary  arteries  and 
brings oxygenated blood and nutrients to the outside of the vessel wall. Hypoxia increases 
the size of the vasa vasorum with the greatest increase occurring in more distal regions of 
the arterial tree. This vascularisation results in incomplete and fragile vessels which may 
allow  plasma  proteins,  blood  cells  and  circulating  progenitor  cells  into  the  adventitia 
(Davie et al., 2004). Progenitor cells derived from the bone marrow could infiltrate the 
vascular wall and contribute to the adventitial thickening observed in hypoxic PAH. Indeed 
bone marrow derived cells expressing  myofibroblast or smooth muscle like phenotype 
have been found in the adventitia of hypertensive pulmonary arteries where they contribute 
to vascular remodelling (Hayashida et al., 2005).This process is thus similar to the theory 
discussed in the previous section proposing a role for bone marrow derived progenitor cells 
in smooth muscle formation. 
 
1.2.1.1.4 Contribution of inflammatory cells to vascular remodelling 
T- and B- lymphocytes, in addition to macrophages have been found in plexiform lesions, 
supporting a role for these inflammatory cells in PAH (Tuder et al., 1994; Cool et al., 
1999).  Pro-inflammatory cytokines including interleukin-1 (IL-1) and interleukin-6 (IL-6)  
are increased in the serum of pulmonary hypertensive patients (Humbert et al., 1995) and 
IL-6 is increased in both the hypoxic and MCT animal models of PAH (Bhargava et al., 32 
 
 1999;  Wang  et  al.,  2003).  Additional  evidence  for  an  inflammatory  component  to 
pulmonary  vascular  remodelling  comes  from  the  increased  expression  of  the 
chemoattractant RANTES that is predominately expressed in vascular lesions composed of 
proliferating PAECs (Dorfmuller et al., 2002).  
 The  recently  discovered  chemokine:  fractalkine  (FKN)  has  the  unique  properties  of 
existing either as a soluble form where it acts as a chemokine or as a membrane bound 
form on PAECs (that have been activated by inflammatory cytokines) where it acts as an 
adhesion  molecule  (Bazan  et  al.,  1997).    The  membrane  bound  form  mediates  the 
recruitment and capture of leukocytes expressing the FKN receptor CX3CR1 (Foussat et 
al.,  2000).  The  FKN-CX3CR1  interaction  between  endothelium  and  leukocytes  is 
sufficient to cause cellular adhesion with no apparent involvement of integrins or other 
adhesion molecules even under conditions of high blood flow (Fong et al., 1998).  FKN 
appears  to  be  unique  amongst  chemokines  in  being  able  to  mediate  firm  leukocyte 
adhesion and has, therefore, come under attention in the investigation of several vascular 
disorders.  Two  polymorphisms  (V249I  and  T280M)  have  been  found  in    CX3CR1 
resulting  in  reduced  FKN  binding  to  CX3CR1  and  decreased  risk  for  atherosclerosis 
(McDermott et al., 2001) and coronary artery disease (Moatti et al., 2001) indicating a 
possible pathological role for CX3CR1 in these diseases. More recently, it was discovered 
that circulating T-lymphocytes from PAH patients show elevated expression of CX3CR1 
(Balabanian et al., 2002) and contrary to the protective role of the V249I and T280M 
polymorphisms in the diseases just mentioned, they are associated with an increased risk of 
systemic  sclerosis  associated  PAH  (Marasini  et  al.,  2005).  The  reasons  why  the  two 
polymorphisms  are  protective  in  atherosclerosis  and  coronary  artery  disease  but  are 
associated with an increased risk of systemic sclerosis PAH is not known but the situation 
is more complex than first thought. The presence of V249I and T280M does not protect 
against ischaemic stoke (Hattori et al., 2005) or peripheral artery disease (Gugl et al., 2003) 33 
 
and the V249I variant has been shown to display enhanced adhesive properties (Daoudi et 
al., 2004).  Tissue specific differences in the role/response to CX3CR1 in addition to the 
large individual differences noted in the expression of CX3CR1 within groups with the 
same genotype may account for some of the differences observed (Marasini et al., 2005).  
 The  excess  infiltration  of  leukocytes  and  the  release  of  inflammatory  mediators  may 
contribute to vascular remodelling. Inhibition of IL-6 attenuates MCT induced PAH in rats 
(Bhargava  et  al.,  1999)  and  mice  deficient  in  the  macrophage  derived  leukotriene:  5-
lipooxygenase (5-LO), develop less severe hypoxic PAH than control mice (Voelkel et al., 
1996). RANTES may indirectly modulate vascular tone/remodelling through release of 
ET-1 (Molet et al., 2000) and the CX3CR1 receptor has been found on PASMCs in MCT 
induced PAH where its activation induced PASMC proliferation (Perros et al., 2007).  The 
enhanced immune response, both at the cellular and molecular level coupled with the close 
relationship often found between PAH and inflammatory/auto-immune conditions provides 
compelling evidence for at least a modulating role for inflammation in PAH.  
 
1.2.1.2 Pulmonary vasoconstriction 
Vasoconstriction of pulmonary arteries can contribute significantly to an increase in PAP 
and PVR. The importance of vasoconstriction in the pathology of PAH is evident by the 
response of some patients to vasodilators such as prostacyclin, NO and endothelin receptor 
antagonists (See section 1.2.3.2.5).  The majority of patients, however, do not respond to 
current vasodilator treatment. This may be a consequence of vascular remodelling that is so 
advanced  by  diagnosis  and  the  commencement  of  treatment  that  vascular  reactivity  is 
impaired  or  it  may  be  that  in  these  patients,  vasoconstriction  does  not  contribute 
significantly to PVR. At this stage in our understanding of the disease, it is unknown if 
vasoconstriction is involved in the initiation of PAH or if it merely acts as a contributing 
factor. As mentioned previously, sustained vasoconstriction in HPV results in vascular 34 
 
remodelling but even in the absence of hypoxia, increased PAP such as that induced by 
vasoconstriction can induce vascular smooth muscle cell proliferation (Hishikawa et al., 
1994).  
 
1.2.1.3 In situ thrombosis  
In situ thrombosis in PAH is thought to occur following abnormal changes to the vascular 
endothelium  and/or  changes  in  platelets  and  clotting  factors  (Humbert  et  al.,  2004). 
Thrombotic lesions are found in lung samples from up to 50% of PAH patients and are 
often  associated  with  plexiform  lesions  (Welsh  et  al.,  1996).  There  are  noticeable 
differences in procoagulant and fibrinolytic agents in PAH patients with a decrease in 
natural anti-coagulation factors in association with a decrease in fibrinolysis (Welsh et al., 
1996). The coagulation promoting agent von Willebrand factor is upregulated in PAH and 
high  circulating  plasma levels  are correlated  with  lower  life  expectancy  (Lopes  et  al., 
1998). Von Willebrand factor promotes platelet aggregation and the increased levels of 
thromboxane  metabolites  seen  in  PAH  patients  are  evidence  of  platelet  aggregation 
(Christman et al., 1992).   Thrombotic lesions are not thought to be an initiating factor in 
PAH but to occur secondary to endothelial injury and to gain in severity with disease 
duration (Wagenvoort et al., 1993). The accumulation of platelets at a vascular lesion can 
enhance vascular remodelling by the release of vasoconstrictor and mitogenic mediators 
including TXA2, 5-HT,  vascular endothelial growth factor (VEGF), PDGF and TGF-  
(Humbert et al., 2004). 
 
1.2.2 The genetic basis of PAH 
A familial basis for  PAH was first proposed in 1954 but it was not until 1984 that a 
detailed  account  was  produced  that  indicated  many  cases  previously  thought  to  be 
idiopathic did in fact have a familial basis (Loyd et al., 1984). Observations emerged that 35 
 
illustrated why the familial basis of PAH had not been well characterised previously. The 
disease showed an autosomal dominant pattern of inheritance with incomplete penetrance 
which varied significantly between families. An interesting observation in this study was 
that the disease showed a female to male predominance of 2:1 (Loyd et al., 1984). The 
inheritance patterns just outlined in addition to incomplete family records makes a precise 
calculation of the number of familial cases difficult; however, a national prospective study 
in 1984 involving analysis of 187 families with PAH identified ~6% of cases as familial 
i.e. having two or more family members with PAH (Rich et al., 1984). The accumulation 
of family registries allowed linkage analysis studies that localised a marker for the disease 
to chromosome 2q31-32 (Nichols et al., 1997; Morse et al., 1997) and candidate genes 
were tested and identified by DNA sequencing. This resulted in the discovery of mutations 
in the BMPR2 gene. To date, over 140 mutations have been discovered in up to 70% of 
familial cases (Machado et al., 2001; Morisaki et al., 2004; Aldred et al., 2006) and 11 - 
40% of apparently idiopathic cases (Thomson et al., 2001; Morisaki et al., 2004; Koehler et 
al., 2004). The relatively large number of IPAH patients with BMPR2 mutations is partly 
related to the incorrect classification of patients as having IPAH when in fact a genetic 
basis does exist (Newman et al., 2001). Other mutations are likely to be de novo mutations 
(Aldred et al., 2006; Morrell et al., 2006). The large number of BMPR2 mutations in both 
FPAH and other non familial forms coupled with the complete absence of these mutations 
in the control population (Deng et al., 2000; Lane et al., 2000; Machado et al., 2001) makes 
the presence of a BMPR2 mutation the largest known risk factor for the development of 
PAH. The mutations uncovered occur along the entire length of the gene, affecting the 
extracellular domain, transmembrane domain, kinase domain and the long cytoplasmic 
domain  (Machado  et  al.,  2006).  About  30%  of  coding  region  mutations  are  missense 
mutations (Machado et al., 2006) occurring in highly conserved amino acid sequences, 
resulting in a failure of protein trafficking to the cell membrane or impaired signalling in 36 
 
those proteins that do integrate into the cell membrane (Machado et al., 2001; Nishihara et 
al.,  2002;  Rudarakanchana  et  al.,  2002;  Machado  et  al.,  2006).  70%  of coding  region 
mutations are frame shift or nonsense mutations that would result in premature truncation 
of the protein and loss through nonsense-mediated mRNA decay (Machado et al., 2006; 
Morrell, 2006). No gain of function mutation in BMPR2 has been discovered (Newman et 
al., 2008). The heterozygous loss of function mutations in carriers with a BMPR2 mutation 
supports  haploinsufficiency  as  the  predominant  genetic  process  in  inherited  PAH.  Not 
every case of FPAH has an identifiable BMPR2 mutation. This may be due to mutations in 
exonic coding regions yet to be studied or in intronic or regulatory regions.  Recently, an 
analysis of familial and idiopathic patients who were negative for coding region mutations 
identified gene rearrangements in 28% of FPAH and in 5.7% of IPAH patients (Aldred et 
al.,  2006).  These  were  predicted  to  have  deleterious  effects  on  protein  structure  and 
function and it is likely that with further investigation, the number of familial PAH cases 
linked to BMPR2 mutations will rise still further.  
 
1.2.2.1 BMPR2 
Bone morphogenetic proteins (BMPs) are the largest group of growth factors belonging to 
the TGF-  superfamily. In addition to BMPs, this family also includes the TGF-  isoforms 
(TGF-   1-3),  activins,  Mullerian  inhibiting  substance  (MIS)  and  other  growth  and 
differentiation  factors  (Kingsley,  1994).  BMPs  were  first  discovered as  molecules  that 
induce  bone  and  cartilage  formation  but  are  also  now  known  to  be  involved  in 
proliferation, differentiation and apoptosis of many cell types and have a  vital role in 
embryogenesis (Morrell et al., 2006). This latter role explains why BMPR2 mutations are 
only  found  in  the  heterozygous  state,  as  BMPR2  has  a  critical  role  in  early  vascular 
development. This is confirmed by the death of BMPR2
-/- mice before gastrulation (Beppu 
et al., 2000). 37 
 
 Members of the TGF-  superfamily bind to two forms of cell surface receptors, termed 
type I and type II receptors, that both contain serine/threonine kinase domains. Both type I 
and type II receptors are required for signal transduction and they exist as either oligomeric 
complexes or in monomeric form on the cell surface. As oligomers, they may be type I 
homomers, type II homomers or type I-type II heteromers (Miyazono et al., 2001). BMPs 
bind to three different type I receptors (BMPR1A/ALK-3, BMPR1B/ALK-6 and ActR-
IA/ALK-2)  and three different type II receptors (BMPR2,  ActR-IIa and ActR-IIb) and 
different tissues display different expression levels of the receptor types.  Like other type II 
receptors,  BMPR2  is  a  constitutively  active  serine/threonine  kinase.  It  exists  as  two 
isoforms: a long form and a short form. The long form is unique within the TGF-  family 
in having a long cytoplasmic tail region rich in serine and threonine residues (Kawabata et 
al., 1998).  
 There are over 30 members of the BMP family with binding affinities to type I and type II 
receptors varying significantly amongst member proteins. The most well known BMPs; 
BMP-2,  BMP-4,  BMP-7,  growth  differentiation  factor-5  (GDF-5)  and  growth 
differentiation factor-6 (GDF-6) bind with high affinity to BMPR1A and BMPR1B but 
with low affinity to BMPR2 (Morrell et al., 2006). Their respective affinities for type I 
receptors also differ, with BMP-7 and GDF-5 having higher affinities for BMPR1B than 
BMPR1A (Nishitoh et al., 1996). Other BMPs including BMP-5 and BMP-6 show higher 
affinity for BMPR2 over type I receptors (Yu et al., 2005; Morrell et al., 2006) and BMP-2 
and BMP-7 can also bind the activin receptors ActRIIa and ActRIIb albeit with lower 
affinity than activins (Kawabata et al., 1998). Although ActRIIa and ActRIIb can bind 
BMPs and transduce signals in co-operation with type I receptors, it is BMPR2 that is the 
predominant  type  II  receptor  mediating  BMP  signalling  under  normal  physiological 
conditions (Yu et al., 2005).  Over recent years it is emerging that such receptor selectivity 
and differences in spatial expression patterns of each receptor allows a high degree of 38 
 
plasticity in BMP signalling which likely underlies the tissue specific functions of BMPs in 
addition to their role in pathological conditions.  
 The TGF-  superfamily signal through a remarkably simple phosphorylation cascade that 
is highly conserved across mammals and involves the major TGF-  superfamily specific 
signalling molecules: the Smads. BMPs acting via type I and type II receptors are able to 
signal via this well documented Smad dependent pathway but also via Smad independent 
pathways that have been linked to mitogen-activated protein kinase (MAPK) activation 
(Nohe et al., 2002). Which of these pathways is activated is related to the nature of ligand 
binding  to  receptor  complex.  As  mentioned,  type  I  and  type  II  receptors  can  exist  as 
oligomers on the cell surface in addition to existing in free form. If a ligand binds to a 
preformed  heterodimeric  complex  of  one  type  I  receptor  and  one  type  II  receptor 
(predominately  BMPR2) then signalling occurs via the ‘traditional’ Smad pathway.  If, 
however, a ligand binds to a monomeric type I receptor, then this is thought to cause 
homodimerisation with another type I receptor and subsequent recruitment of a type II 
receptor.  Therefore  the  receptor  signalling  complex  is  distinct  from  the  preformed 
heterodimeric complex of type I and type II receptors and this ligand-heteromeric complex 
results in Smad independent signalling via MAP kinases (figure 1.5) (Nohe et al., 2002). 
 
1.2.2.1.1 Smad dependent signalling 
Following ligand binding to receptor complex, BMPR2 phosphorylates a glycine-serine 
rich domain on the proximal intracellular region of the type I receptor causing activation of 
the type I receptor kinase domain. The type I receptor phosphorylates and activates a group 
of  Smad  proteins  termed  ‘receptor  activated’  or  R-Smads.  This  group  is  composed  of 
Smad1, Smad5 and Smad8 that are often grouped together as Smad1/5/8 as the functional 
differences between them are not well characterised.  Smad1/5/8 must form a complex 
with the common partner Smad (co-Smad), Smad4 to allow translocation to the nucleus 39 
 
where they regulate gene transcription in association with transcriptional activators and co-
repressors (Humbert et al., 2004).  
 
1.2.2.1.2 Smad independent signalling 
Signalling  via phosphorylated Smad1/5/8 (p-Smad1/5/8) cannot explain all the cellular 
effects of BMPs and it is now recognised that other Smad independent pathways exist. 
Following  ligand  binding  to  a  type  I  receptor  followed  by  homodimerisation  and 
recruitment of a type II receptor, a p38 MAPK dependent pathway is activated (Nohe et al., 
2002). Activation of p38 is thought to be dependent on the prior activation of the MAPK, 
TAK1, whose activity is enhanced by interaction with the TAK binding protein, TAB1. 
TAB1 may provide the link to the BMPR1A/1B receptors through the adaptor protein 
XIAP (Nohe et al., 2004). In addition to p38, another major MAPK, extracellular regulated 
kinase (ERK) can be activated by BMPs (Lai and Cheng, 2002; Yang et al., 2005) although 
the molecular mechanism responsible for p-ERK1/2 activation is currently unknown. The 
long  cytoplasmic  tail  region  of  BMPR2  is  capable  of  binding  a  multitude  of  proteins 
(Hassel  et  al.,  2004)  of  which  several  have  been  investigated  in  relation  to  BMPR2 
signalling (Foletta et al., 2003; Machado et al., 2003; Wong et al., 2005; Chan et al., 2007) 
and these provide another level of complexity to BMPR2 mediated intracellular signalling 
(figure 1.5). 
 
1.2.2.1.3 Regulation of BMP signalling 
There are several levels of regulation to BMP signalling including the BMP antagonists 
noggin, chordin and members of the DAN family, the presence of accessory receptors such 
as  the  endoglin  receptor  or  inhibitory  proteins  such  as  BAMBI  (BMP  and  activin 
membrane  bound  inhibitor)  and  Smurf-1  (Smad  ubiquitination  regulatory  factor-1) 
(Massague  and  Chen,  2000).  Moreover,  phosphatases  have  recently  been  discovered 40 
 
capable of dephosphorylating and inactivating Smad-1 (Chen et al., 2006). In addition to 
Rmads and co-smads that are a third group termed inhibitory Smads comprised of Smad6 
and  Smad7.  Smad6  inhibits  BMP  signalling  through  competition  with  co-Smad4  for 
Smad1 binding yielding inactive Smad1-Smad6 complexes. Smad6 and Smad7 are thought 
to function as a negative feedback system to control signal strength (Massague and Chen, 
2000). 
 
1.2.2.2 Role of BMPR2 in the pathogenesis of PAH 
 
Mutations and dysfunctional TGF-  receptors have been associated with many diseases 
involving  deregulated  cellular  proliferation  including  over  a  dozen  cancers,  pulmonary 
fibrosis and atherosclerosis (Miyazono et al., 2001), so it was perhaps not surprising that 
BMPR2 as a member of the TGF-  superfamily should be implicated in PAH.  Unlike 
mutations in TGF-   receptors that are implicated in many disease conditions, BMPR2 
mutations have only been associated with PAH.  As already stated, BMPR2
-/- mice die 
during  early  embryogenesis  and  Smad5  mutant  embryos  have  malformed  vasculature 
associated with defective angiogenesis (Yang et al., 1999) illustrating the importance of the 
BMPR2/Smad  pathway  in  vascular  development.  BMPR2  is  expressed  on  PAEC  with 
lower levels of expression in PASMCs and macrophages (Atkinson et al., 2002). BMPR2 
expression is decreased in FPAH/IPAH with the greatest reductions found in patients  
harbouring BMPR2 mutations or in those patients that display evidence of linkage to 2q33. 
Patients with PAH secondary to other illnesses also express BMPR2 at lower levels than 
control patients (Atkinson et al., 2002) indicating a pathological role for dysfunctional 
BMPR2 in pulmonary hypertensive patients not carrying a BMPR2 mutation. The low 
level expression of BMPR2 in PAH patients who are wild-type (WT) BMPR2 carriers 
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Figure 1.5 Possible signalling mechanisms of BMPR2. 
A BMP (in this case BMP-2) may bind to a preformed receptor complex of type I (BR1) 
and type II (BR2) receptors inducing a Smad dependent pathway. Alternatively, a ligand 
may bind to a type I receptor causing homodimerisation and subsequent recruitment of a 
type II receptor. This activates the p38 dependent pathway. Both pathways may utilise 
additional adaptor proteins (X, Y and Z). p-ERK1/2 can also be activated by BMP ligands, 
however,  it  is  not  known  which  receptor  complex  mediates  this  activation.  The 
cytoplasmic tail of BMPR2 interacts with cytoplasmic signalling molecules offering the 
potential for additional signalling pathways.  
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coupled with levels of BMPR2 lower than that predicted by haploinsufficiency in mutant 
carriers  indicate  there  are  other,  as  yet  undetermined  factors,  that  suppress  BMPR2 
expression in PAH. BMPR1A receptors are also downregulated in patients with PAH of 
various etiologies (Du et al., 2003). It is not just receptor expression that is reduced but 
also  the  activated  (phosphorylated)  forms  of  downstream  Smads.  In  FPAH  and  IPAH 
patients (with and without BMPR2 mutations) p-Smad1 was found to be reduced in the 
media and intima of small pulmonary arteries (Yang et al., 2005). In contrast to these 
results, Richter et al., 2004 found no difference in p-Smad1/5/8 between PAH and control 
patients but did note a lack of expression in PAECs at the core of plexiform lesions which 
supports  the  concept  that  PAECs  involved  in  vascular  lesions  have  phenotypic 
heterogeneity.  
 Investigations of both the hypoxic and MCT animal models of PAH have yielded diverse 
results with regard to BMP signalling molecules. Hypoxia has been shown to increase p-
smad1/5/8 and inhibitor of differentiation (Id1), a downstream target of BMP signalling in 
mice (Frank et al., 2005; Long et al., 2006) but to decrease these parameters in hypoxic rats 
(Takahashi, 2007).  Moreover, BMPR2 is reduced in the lungs of rats following 1-3 weeks 
of hypoxia (Takahashi et al., 2005). Hypoxia induced PAH can also be attenuated through 
gene delivery of BMPR2 into the vascular endothelium resulting in an overexpression of 
BMPR2 (Reynolds et al., 2007). Such an approach however was unable to attenuate MCT 
induced PAH (McMurty et al., 2007). BMPR1B, BMPR2, p-Smad1 and Smads 4,5,6 and 8  
have all been found to be decreased in MCT PAH however ERK1/2 and p38 levels were 
found to be unchanged (McMurty et al., 2007; Morty et al., 2007).  
Work on cells isolated from PAH and control patients has helped understand the role that 
BMPs,  BMP  receptors  and  downstream  effectors  may  play  in  PAH.  One  important 
conclusion that can be drawn from the work to date is that the effect of BMP signalling is 
highly context specific. The nature of ligand, cell type, cellular location within vessel and 43 
 
species all determine the response recorded. BMP-2, BMP-4 and BMP-7 induce apoptosis 
of  PASMCs  from  non  hypertensive  patients  (Zhang  et  al.,  2003),  a  process  involving 
phosphorylation of Smad1, activation of caspases and downregulation of Bcl-2 (Zhang et 
al.,  2003;  Lagna  et  al.,  2006).  BMPs  also  inhibit  proliferation  of  PASMCs  in  healthy 
patients (Morrell et al., 2001; Takeda et al., 2004). The effects of BMPs are, however, very 
different in PASMCs from pulmonary hypertensive patients.  Zhang et al., 2003 found that 
PASMCs from FPAH/IPAH but not APAH patients were more resistant to BMP induced 
apoptosis and PASMCs expressing a mutant form of BMPR2 are resistant to BMP induced 
apoptosis  (Lagna  et  al.,  2006).  The  anti-proliferative  effect  of  BMPs  are  also  lost  in 
PASMCs from patients with PAH (Morrell et al., 2001) with BMP-2 and BMP-7 actually 
inducing proliferation of pulmonary hypertensive PASMCs, a process dependent on p38 
and ERK1/2 (Takeda et al., 2004).  It has been proposed that p38 and p-ERK1/2 signalling 
opposes  p-Smad1/5/8  signalling  and  that  an  imbalance  between  proliferative  p38/p-
ERK1/2 pathways and the apoptotic p-Smad1/5/8 pathway contributes to proliferation in 
BMPR2 mutant PASMCs (Yang et al., 2005). 
 Generally speaking, BMPs have the opposite effect on PAECs than they do on PASMCs, 
namely a decrease in apoptosis and stimulation of proliferation (Valdimarsdottir et al., 
2002; Teichert-Kuliszewska et al., 2006). One speculative theory regarding the initiation of 
PAH  in  the  presence  of  dysfunctional  BMPR2  is  that  apoptosis  of  PAECs  leads  to 
endothelial damage and exposure of underlying smooth muscle to mitogenic agents such as 
TGF-  (Morrell et al., 2006). The smooth muscle cells would undergo proliferation and 
perhaps migration, unchecked by the pro-apoptotic effect of BMPR2 mediating signalling. 
In addition, rapid apoptosis of PAECs could lead to the emergence of apoptosis resistant 
cell populations which would contribute to intimal lesions.   
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1.2.3 Modifying factors in PAH 
The discovery of BMPR2 mutations in patients with PAH was a significant breakthrough 
in  the  understanding  of  the  disease.  The  low  penetrance  of  the  disease  in  families 
harbouring BMPR2 mutations coupled with the fact that the majority of IPAH patients do 
not have BMPR2 mutations suggest that dysfunctional BMPR2 alone is insufficient to 
induce PAH. Current thinking points towards a disease created by ‘multiple hits’; that is, 
an underlying  genetic pre-disposition coupled with other endogenous or environmental 
factors that act in concert to create the disease phenotype. The search for an additional 
modifying gene for PAH has focused intensively on the 5-HT transporter (5-HTT).  
 
1.2.3.1 5-HT and PAH 
As mentioned previously, 5-HT is synthesised primarily in the enterochromaffin cells of 
the  intestine.  However,  the  lung  also  contains  several  sites  for  local  5-HT  synthesis 
including the neuroendocrine and neuroepithelial cells in the airways (MacLean et al., 
2000) and PAECs (Eddahibi et al., 2006). 5-HT is a product of the essential amino acid L-
tryptophan. In 5-HT producing cells, L-tryptophan undergoes hydroxylation of the benzene 
ring  by  TPH  to  yield  5-hydroxytryptophan  (5-HTP).  5-HTP  then  undergoes 
decarboxylation  via  L-amino  acid  decarboxylase  to  form  5-HT.  5-HT  is  a  pulmonary 
vasoconstrictor  (MacLean  et  al.,  1996;  Morecroft  et  al.,  1999)  and  PASMC  mitogen 
(Fanburg et al., 1997); however, normal physiological plasma concentrations are kept low 
(nanomolar concentrations) due to uptake and storage in platelets. The first indicator that 
elevated plasma levels of 5-HT may be a contributing factor in the pathology of PAH came 
following the association of PAH with ingestion of the anorexigen, aminorex fumurate 
(aminorex). Aminorex is a substituted amphetamine that was  used in several European 
countries during the 1960s. It soon became clear that people ingesting aminorex were 20 
times more likely to develop PAH than the general population (Kay et al., 1971) and 5 45 
 
years after its discontinuation, levels of PAH had returned to the levels seen prior to the 
introduction of aminorex (Kramer and Lane, 1998). While the exact mechanism of action 
of aminorex was not known, it was discovered that aminorex released 5-HT from platelets 
to a greater degree than other sympathomimetics and phenethylamines. It was also found to 
be a monoamine oxidase (MAO) inhibitor (Fristrom et al., 1977). Further support for the 
role of 5-HT in PAH came from the fawn-hooded rat, a strain with a genetic deficiency in 
platelet storage and that has high circulating plasma levels of 5-HT. The fawn-hooded rat 
develops  spontaneous  PAH  (Kentera  et  al.,  1988;  Ashmore  et  al.,  1991)  and  an 
exaggerated pulmonary hypertensive response to hypoxia compared with other rat strains 
(Nagaoko et al., 2001). A causative role for 5-HT in the fawn hooded rats’ heightened 
response to hypoxia was supported when it was shown that infusion of 5-HT for 2 weeks 
aggravates hypoxic PAH in rats (Eddahibi et al., 1997). In 1990 PAH was discovered in a 
patient with a rare familial platelet storage disease that results in elevated plasma 5-HT 
levels (Herve et al., 1990).  Elevated plasma 5-HT levels were subsequently found in a 
group of FPAH/IPAH patients that persisted even after heart-lung transplant indicating the 
increased plasma [5-HT] was not a secondary phenomenon (Herve et al., 1995). This data 
coupled with another outbreak of PAH related to an anorexigen with serotonergic effects, 
this time dexfenfluramine (Dfen) (see section 1.2.3.2.3), formed the basis of the ‘serotonin 
hypothesis’ of PAH in which 5-HT plays a causative or modulating role in the disease 
pathology.  The mechanisms by which 5-HT contributes to the vascular changes in PAH 
are still being elucidated but both 5-HT receptors and 5-HTT are thought to contribute.  
 
1.2.3.1.1 5-HT receptors in PAH 
5-HT induced vasoconstriction occurs through the 5-HT1B receptor in human pulmonary 
resistance  vessels  (Morecroft  et  al.,  1999)  with  both  5-HT1B  and  5-HT2A  receptors 
contributing  to  vasoconstriction  in  rats  (MacLean  et  al.,  1996).  The  5-HT1B  mediated 46 
 
contraction is greater in the pulmonary vessels of chronic hypoxic rats, an effect attenuated 
by the 5-HT1B/1D antagonist GR127935 (Keegan et al., 2001). This same antagonist also 
reduced the pulmonary vascular remodelling that occurs in hypoxic rats. The 5HT1B/1D 
knockout mouse paralleled the antagonist studies with reduced vascular remodelling and 
attenuated  vasoconstriction  compared  to  WT  hypoxic  mice  (Keegan  et  al.,  2001).  In 
addition to its role as a mediator of  vasoconstriction in rats, the 5-HT2A receptor also 
contributes to hypoxic induced fibroblast proliferation (Welsh et al., 2004). The 5-HT2B 
receptor has also been implicated in the pathogenesis of PAH with 5-HT2B knockout mice 
showing reduced parameters of vascular remodelling following hypoxia compared with 
WT hypoxic animals and the major metabolite of Dfen, nordexfenfluramine (NDfen) is a 
high affinity 5-HT2B agonist (Launay et al., 2002). The effect of the 5-HT2B receptor on the 
pulmonary circulation appears to be species dependent as the 5-HT2B receptor is associated 
with a vasodilator effect in pigs (Glusa and Pertz, 2000). Support for a role for this receptor 
in PAH comes from the finding that a loss of function 5-HT2B receptor mutation was found 
in a patient with Dfen associated PAH. The mutation was not found in 80 control patients 
(Blanpain et al., 2003). The contribution of 5-HT receptors to the pathogenesis of PAH is 
likely  to  involve  the  vasoconstriction  element  of  the  disease  more  than  vascular 
remodelling; however, recent evidence indicates that stimulation of 5-HT receptors may be 
necessary  for  vascular  remodelling  when  coupled  with  5-HTT  activation  (see  section 
1.2.3.1.3) and there is convincing evidence that the 5-HTT is critical to 5-HT induced 
vascular remodelling.  
 
1.2.3.1.2 The 5-HTT and PAH 
The ‘serotonin hypothesis’ initially came into being through studies implicating a rise in 
circulating 5-HT as a factor in PAH; however, the data regarding plasma 5-HT levels in 
PAH is not clear. In contrast to earlier studies, Lederer et al., 2007 found that plasma 5-HT 47 
 
levels were normal in PAH patients. People with carcinoid tumours of the 5-HT producing 
enterochromaffin cells have high plasma [5-HT] but are not at an increased risk of PAH 
and neither are users of selective serotonin reuptake inhibitors (SSRIs) which increase 
plasma 5-HT levels. If, however, 5-HT induced pulmonary hypertension is dependent on 
cellular internalisation of 5-HT via the 5-HTT then the expression and activity of the 5-
HTT may be a better indicator of the involvement of the serotonergic system in PAH than 
plasma 5-HT levels and may also explain why SSRIs are not associated with an elevated 
risk of the disease. 
 The 5-HTT belongs to a large family of membrane proteins including dopaminergic,  -
aminobutyric  acid,  noradrenaline  and  other  transporters.  The  principal  action  of  these 
transporters is to mediate cellular uptake of neurotransmitters. The 5-HTT is expressed on 
several cell types including neurons, platelets, PAECs, PASMC and PAFs. Experiments in 
bovine and rat PASMCs have demonstrated that the mitogenic action of 5-HT on these 
cells is dependent on uptake via the 5-HTT (Lee et al., 1991; Eddahibi et al., 1999) and the 
proliferative effect of 5-HT + serum on PAFs is blocked by the 5-HTT inhibitor, fluoxetine 
(Welsh  et  al.,  2004).  Levels  of  the  5-HTT  are  increased  in the  pulmonary  arteries  of 
hypoxic rats and hypoxic PASMCs have increased expression of 5-HTT coupled with an 
increased proliferative effect to 5-HT (Eddahibi et al., 1999). 5-HTT inhibitors attenuate 
vascular  remodelling  in  hypoxic  induced  pulmonary  hypertensive  mice  (Marcos  et  al., 
2003) and mice lacking the 5-HTT (5-HTT
-/- mice) also develop less severe hypoxic PAH 
than WT mice (Eddahibi et al., 2000). Conversely, mice overexpressing the 5-HTT (5-
HTT+ mice) have higher pulmonary pressures and a greater degree of remodelling and 
right ventricular hypertrophy following hypoxia than WT mice. Interestingly, normoxic 5-
HTT+ mice have a higher (up to 3 fold) right ventricular pressure (RVP) than WT mice 
(MacLean et al., 2004).  
 Human data has helped support the animal studies, with 5-HTT mRNA levels two-fold 48 
 
greater in FPAH/IPAH patients than in control subjects (Eddahibi et al., 2001). 5-HTT 
expression was shown to be greater in vessels undergoing remodelling, particularly in the 
medial  smooth  muscle  and  in  regions  of  concentric  intimal  lesions  associated  with 
proliferating  PASMCs.  PASMCs  isolated  from  the  pulmonary  hypertensive  patients 
showed a doubling of proliferation to 5-HT + serum, an effect that was abolished by 
fluoxetine and another 5-HTT inhibitor, citalopram.  The proliferative response was unique 
to 5-HT with several other growth factors including PDGF and TGF-  having similar 
effects on PASMCs from PAH patients and control subjects (Eddahibi et al., 2001). 
 The reasons for the increased levels of the 5-HTT in pulmonary hypertensive patients are 
unclear. A polymorphism exists in the promoter region of the human 5-HTT gene that 
alters its transcriptional activity. The polymorphism involves two alleles, a 44 base pair 
insertion and deletion, termed the L and S allele respectively. The L allele is associated 
with a 2 to 3 fold higher level of 5-HTT transcription than the S allele. Eddahibi et al., 
2001 found that the  L/L allele was present in 27% of the control population but was 
present in 69% of patients with either FPAH, IPAH or PAH associated with Dfen. The L/L 
genotype is also present in the majority of lung transplant patients with PAH secondary to 
other diseases (Marcos et al., 2004).  This data suggests that the L/L genotype confers a 
genetic susceptibility to PAH. Two recent studies, however, found no difference in allele 
distribution  between  FPAH/IPAH  patients  and  control  subjects  (Willers  et  al.,  2006; 
Machado et al., 2006) but Willers et al., 2006 did find that the L/L genotype correlated 
with  an  earlier  age  of  diagnosis  in  FPAH  patients,  possibly  indicating  an  interaction 
between  overexpression  of  5-HTT  with  a  BMPR2  mutation.  The  L/L  genotype  is 
correlated  with  higher  PAP  in  patients  suffering  from  PAH  associated  with  COPD 
(Eddahibi  et  al.,  2003)  and  PAH  associated  with  heart  failure  (Olson  et  al.,  2007) 
supporting a role for the 5-HTT in modulating disease severity.  
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1.2.3.1.3 5-HT signalling in the pulmonary vasculature 
5-HT can activate several signalling systems depending on whether 5-HT acts via one of 
the  many  5-HT  receptors  or  through  the  5-HTT.  The  relative  contribution  of  5-HT 
receptors  and  5-HTT  to  pulmonary  vasoconstriction  and  remodelling  is  uncertain  and 
likely differs between species. 
 The  5-HT  receptors  mentioned  above  in  relation  to  PAH  are  all  G-protein  coupled 
receptors. The 5-HT1B and 5-HT2A receptors are thought to be the most important 5-HT 
receptors with regards to PAH and these receptors are expressed on pulmonary smooth 
muscle with lower expression on endothelium (Marcos et al., 2004). 5-HT1B and 5-HT2A 
receptors  signal  via  distinct  pathways.  5-HT1B  receptors  are  coupled  to  Gi  and  inhibit 
adenylate cyclase and cAMP production resulting in vasoconstriction (Weir et al., 2004). 
5-HT2A receptors couple to Gq and activate phospholipase C (PLC) leading to an increase 
in inositol triphosphate (IP3) levels which induces release of Ca
2+ from intracellular stores 
causing vasoconstriction (Weir et al., 2004). Alternatively, 5-HT can act intracellularly 
following uptake via the 5-HTT. The 5-HTT parallels 5-HT1B and 5-HT2A expression in 
pulmonary arteries with the 5-HTT being expressed predominately in smooth muscle with 
weaker expression in the endothelium (Eddahibi et al., 2001; Marcos et al., 2004). 5-HT, 
once taken up into cells via the 5-HTT can be degraded via MAO, packaged into vesicles 
or it can initiate signalling pathways leading to proliferation and possibly vasoconstriction. 
Experiments in bovine PASMCs have shown that once inside a PASMC, 5-HT activates 
ROS which phosphorylates and activates ERK1/2 which enters the nucleus and induces 
proliferation (Lee et al., 1999) via the transcription factor, GATA-4 (Suzuki et al., 2003).  
For  ERK1/2 to translocate to the nucleus it requires the presence of ROCK and ROCK is 
increased by 5-HT stimulation of 5-HT1B/1D receptors (Liu et al., 2004). Not only does this 
provide  an  additional  mechanism  of  5-HT  induced  vasoconstriction  through  ROCK 
mediated Ca
2+ sensitisation, it also allows cross-talk between the 5-HT1B/1D receptor and 5-50 
 
HTT in relation to PASMC proliferation (figure 1.6).  In fact, blockade of either 5-HT1B/1D 
receptors or 5-HTT prevents 5-HT mediated proliferation of bovine PASMCs (Liu et al., 
2004). The situation appears different, however, in human PASMCs. In these cells it is the 
5-HTT that is required for  nuclear translocation of ERK1/2 and 5-HT1B receptors that 
activate ERK1/2 (Lawrie et al., 2005). It may be that cellular and species differences are 
important  in  the  relative  contributions  made  by  receptors  and  5-HTT  to  PASMC 
proliferation. In human lung samples and isolated PASMCs from PAH patients, the 5-HTT 
was overexpressed, whereas the 5-HT1B, 5-HT2A and 5-HT2B receptors were expressed at 
similar  levels  to  samples  from  control  patients.  Inhibition  of  the  5-HTT,  but  not  the 
receptors prevented the augmented proliferative response to 5-HT in PASMCs from PAH 
patients (Marcos et al., 2004). Like the BMPR2 receptor, the expression level of the 5-HTT 
in PAH patients is different to that predicted by genetic factors alone. In the case of the 5-
HTT, PASMCs from PAH patients have higher levels of 5-HTT than control patients with 
the same genotype indicating that other factors must act to increase 5-HTT expression in 
PAH (Marcos et al., 2004).   
 
1.2.3.1.4 Tryptophan hydroxylase 1 
There are two isoforms of TPH. The first, TPH1, is present in the periphery and is the rate 
limiting enzyme for 5-HT synthesis outside the central nervous system (CNS). The second, 
TPH2,  is  present  only  in  the  CNS  and  is  the  rate-limiting  enzyme  for  central  5-HT 
synthesis. There exists, therefore, two independent 5-HT systems allowing the generation 
of viable Tph1
-/- mice that lack peripheral 5-HT but have only minor reductions in brain 5-
HT (Walther and Bader, 2003). PAECs express TPH1 and levels of TPH1 are increased in 
PAECs from IPAH patients compared to control subjects and this is associated with 
increased 5-HT release (Eddahibi et al., 2006). Hypoxia increases TPH1 expression in 
rabbit  lung  3  fold  (Pan  et  al.,  2006)  and  hypoxic  PAH  is  attenuated  in  Tph1
-/-  mice 51 
 
(Morecroft et al., 2007; Izikki et al., 2007) indicating the importance of TPH1 and 5-HT in 
the development of hypoxic PAH.  
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Figure 1.6  Cross-talk  between the 5-HTT and 5-HT1B/1D  receptor in 5-HT  induced 
proliferation  in  bovine  PASMCs.  Following  cellular  uptake  by  the  5-HTT,  5-HT 
activates reactive oxygen species (ROS) which phosphorylates and activates the MAPK, 
ERK1/2. Rho Kinase (ROCK) which is increased by 5-HT1B/1D  receptor activation enables 
p-ERK1/2  translocation  to  the  nucleus  and  subsequent  induction  of  proliferation  via 
GATA-4.  
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1.2.3.2 Endogenous and Exogenous Modifying Factors in PAH 
1.2.3.2.1 Hypoxia 
As mentioned previously, hypoxic induced pulmonary vasoconstriction is a physiological 
regulatory mechanism for maintaining adequate oxygenation of blood. Sustained HPV and 
the  development  of  chronic  HPV  are  associated  with  several  lung  diseases  including 
COPD and sleep apnea. Hypoxic induced PAH is also an important model for studying 
PAH. This process involves exposing rodents to 50% atmospheric oxygen levels for a 
period of at least 2 weeks. The result of the hypoxic exposure is an increase in RVP, RVH 
and  vascular  remodelling  (MacLean  et  al.,  2004).  The  extent  of  the  vascular  changes 
observed is dependent on sex, species and developmental stage of the animal (Stenmark et 
al.,  2006).  Hypoxia  has  profound  effects  on  cells  within  pulmonary  arteries.  PAECs 
undergo  phenotypic  changes  involving  the  upregulation  of  inflammatory  markers, 
increased release of growth factors and ECM proteins. Cell surface receptor expression and 
plasma membrane structure also undergo pronounced alterations. The net result of the 
PAEC changes are an increase in production of growth factors and vasoconstrictors such as 
5-HT and ET-1 and decreased production of vasodilators including prostacyclin and NO. 
The  release  of  interleukins  and  leukocyte  adhesion molecules  facilitates  attraction  and 
capture of leukocytes to the vessel wall and recruitment of circulating progenitor cells 
(Stenmark  et  al.,  2006;  Nicolls  and  Voelkel,  2007).  PASMCs  also  change  towards  a 
proliferative phenotype with many of the changes observed being a direct consequence of 
the action of the endothelial derived mitogenic factors. Two important effects of hypoxia 
on PASMCs have already been mentioned, namely the effect on cellular ROS production 
and subsequent K
+ channel inhibition (See next section) and the effect on the 5-HTT. The 
role of PAFs in hypoxic PAH was briefly discussed earlier and as an early mediator of the 
hypoxic response they are involved in promoting PASMC growth and contraction through 
the release of the paracrine growth factors outlined in section 1.2.1.1.3. The mitogenic 54 
 
effect that PAFs exert on PASMCs is dependent on HIF supporting a role for PAFs as an 
oxygen sensor in hypoxic PAH (Rose et al., 2002). There are three HIF subtypes known 
(HIF-1 , HIF-2  and HIF-3 ) all acting via the HRE to induce gene transcription. HIF-1  
is expressed in the lung under normoxic conditions and is upregulated during hypoxia. 
HIF-2  is only expressed under hypoxic conditions and HIF-3  is expressed at lower 
levels than HIF-1  under normoxia but increases under hypoxia (Rose et al., 2002). The 
importance of HIF-1  in the role of PAH was evaluated in studies using heterozygous 
mice (HIF-1
+/-). These mice were found to develop less severe hypoxic PAH than WT 
mice (Yu et al., 1999). Subsequently, it was also shown that HIF-2
+/- mice were protected 
against hypoxic PAH (Brusselmans et al., 2003). The proliferative effect that hypoxia has 
on PAFs seems to be dependent exclusively on HIF-2  with both HIF-1  and HIF-2  
contributing to PAF migration (Eul et al., 2005).  
 The hypoxic model of PAH mimics many of the vascular changes of severe  PAH in 
human  patients  but  often  lacks  the  complex  intimal  lesions  seen  in  these  patients. 
Plexiform lesions, for example, are not a feature of hypoxic PAH in animal models but 
HIF-1  is overexpressed in PAECs from plexiform lesions in PAH patients. HIF-1  is 
necessary for  the production of VEGF,  which is also upregulated in plexiform lesions 
indicating an angiogenic like process within the lesion. It is not clear, however, whether 
HIF-1  expression in plexiform lesions is increased by hypoxia or by other factors such as 
growth factors or mutations (Tuder et al., 2001). 
  
1.2.3.2.2 K
+ channels 
Cell membrane potential (Vm) is regulated by the permeability of Kv channels. Inhibition 
of  Kv channel activity reduces  K
+ efflux causing depolarisation of  the cell membrane 
resulting in increased cytosolic [Ca
2+] caused by Ca
2+ entry through voltage-dependent 
calcium channels (VDCC) and Ca
2+  release from the sarcoplasmic reticulum (SR). As 55 
 
discussed previously, K
+ channel inhibition by hypoxia is involved in HPV and HPV is 
reduced in mice deficient in Kv1.5 channels (Archer et al., 2001). Both Kv1.5 and Kv2.1 
channels are present on PASMCs and both are downregulated in hypoxia causing reduced 
Kv current (Archer et al., 1998a). The importance of Kv1.5 channels in hypoxic PAH was 
revealed when gene transfer of Kv1.5 into hypoxic rats reduced pulmonary hypertensive 
parameters including RVH and arterial remodelling, offering a new potential avenue for 
therapeutic investigation (Pozeg et al., 2003).  It is not clear why some Kv channels are 
altered by hypoxia and not others but the mechanism appears to involve HIF-1 . HIF-1
+/- 
mice do not have dysfunctional Kv currents following hypoxia and inhibition of HIF-1  
restores Kv1.5 channel current in PASMCs from pulmonary hypertensive fawn-hooded 
rats (Bonnet et al., 2006). It maybe the case that certain Kv channels have HREs in their 
promoter that, when activated by HIF-1 , cause a decrease in gene transcription. 
 PASMCs from FPAH/IPAH patients have a higher cytosolic [Ca
2+] than cells from APAH 
patients  or  control  subjects.  This  is  associated  with  decreased  Kv  current  and  cell 
membrane depolarisation (Yuan et al., 1998).  The elevated [Ca2
+] concentration in the 
PASMCs would facilitate both agonist induced vasoconstriction and cellular proliferation.  
 In addition to their role in regulating intracellular [Ca
2+] and hence vasoconstriction and 
proliferation, K
+ channels also regulate apoptosis. K
+ channels control the rate of apoptotic 
volume decrease (AVD), an early feature of apoptosis. Cellular volume is controlled by ion 
concentration gradients and K
+, being the major cation in the cytosol, has a critical role in 
determining cell volume. When K
+ channels are activated, K
+ ions pass out of the cell into 
the intercellular space. This results in a corresponding efflux of chloride ions (Cl
-) out of 
the  cell  along  its  electrochemical  gradient,  a  process  that  is  further  enhanced  by  the 
membrane hyperpolarisation caused by the K
+ efflux. The accumulation of KCl outside the 
cell shifts the osmotic balance so that H20 is drawn out of the cell causing AVD, a process 
which results in activation of cytochrome-c, caspases and apoptosis (Platoshyn et al., 2002; 56 
 
Remillard and Yuan, 2004). Staurosporine (ST), a known inducer of apoptosis activates Kv 
currents in PASMCs and Bcl-2, an anti-apoptotic protein prevents apoptosis by reducing 
Kv current (Ekhterae et al., 2001). A decrease in K
+ channel function would, therefore, 
prevent the reduction in cell volume thus preventing apoptosis. In PAH this is likely to 
alter the balance between proliferation/apoptosis in PASMCs towards proliferation and 
subsequent vascular remodelling. Conversely, restoration of Kv current by  Kv1.5 gene 
transfer reduces PVR and remodelling after 14 days in rats despite continuing hypoxia 
(Pozeg et al., 2003).   Any deviation in Kv channel function and current can influence three 
major contributors to PAH, namely vasoconstriction, cellular proliferation and apoptosis so 
Kv channels are likely to be important mediators in the disease.  
 There are three groupings of Kv channels. The first group, containing Kv1-6 and Kv8-9 is 
the group that has been most studied in relation to PAH. Another group is comprised of 
Kv10-12 and the final group is composed of Kv7.1-7.5, also called KCNQ channels. In 
PASMCs the K
+ current is composed of many Kv channels with similar attributes and the 
relative contribution of the various Kv channel subunits to K
+ current differs between cell 
types  (Bonnet  and  Archer,  2007).  The  development  of  more  specific  Kv  channel 
antagonists and inactivating antibodies is helping to unravel the composition of the whole 
cell K
+ current which will enable better targeting of therapeutics. Although Kv1.5 and 
Kv2.1  are  well  established  as important  contributors  to  PASMC  K
+  current,  other  Kv 
channels also contribute and recently, KCNQ channels were found to contribute to the 
resting Vm of PASMCs. This information was derived from the use of two selective KCNQ 
channel  inhibitors  (linopirdine  and  XE991)  that  caused  powerful  vasoconstriction  of 
isolated pulmonary arteries, an effect caused by a direct action on the PASMCs (Joshi et 
al., 2006). KCNQ channels have recently been found to also contribute to the resting Vm of 
rat mesenteric arteries (Mackie et al., 2008). It is only within the last five years that KCNQ 
channels have been thought of as among the group of functional K
+ channels in vascular 57 
 
smooth muscle cells and hence their functional status or role in PAH is unknown.  
 
1.2.3.2.3 Appetite suppressants  
Appetite  suppressants,  specifically  substituted  amphetamine  appetite  suppressants  are 
important risk factors for the development of PAH. Aminorex was the first such drug to be 
associated with the disease and gave the first indication that 5-HT may be involved in the 
pathophysiology of PAH. Subsequently, it was found that fenfluramine and its more active 
dextro-isomer, Dfen were associated with an increased risk of PAH. In people who used 
fenfluramines for more than three months, the risk of PAH increased 23 fold (Abenhaim et 
al., 1996). While the risk of PAH increases with increasing exposure, even short term use 
(<1 month) can induce fatal PAH (Mark et al., 1997). Dfen is now known to have a 
complicated mechanism of action that is not fully understood. Along with other common 
appetite suppressants, Dfen is a 5-HTT substrate causing 5-HT cellular efflux while being 
taken up by the 5-HTT into the cell. Similar compounds to Dfen that are not 5-HTT 
substrates are not associated with PAH and so it seems likely that Dfens mechanism of 
action is, at least in part, due to its role as a 5-HTT substrate (Rothman et al., 1999). 5-
HTT substrates also cause far greater release of 5-HT than non substrate 5-HTT inhibitors 
such  as  fluoxetine  (Zolkowska  et  al.,  2006)  adding  further  support  to  the  serotonin 
hypothesis of PAH. In addition to its interaction with the 5-HTT, Dfen also inhibits K
+ 
channels in PASMCs (Weir et al., 1996; Perchenet et al., 2001) and the Dfen metabolite 
NDfen is an arterial vasoconstrictor acting via 5-HT2A receptors (Ni et al., 2005). Only a 
minority of Dfen users develop PAH and of those that do, some develop the disease after a 
relatively short exposure time while others may only develop the disease after years of use. 
This suggests that other underlying susceptibilities exist that predispose certain individuals 
to Dfen associated PAH. BMPR2 mutations have been found in 9% of fenfluramine users 
with PAH and these patients develop PAH after a relatively short exposure time (Humbert 58 
 
et al., 2002).  This suggests an interaction between genetic pre-disposition and Dfen to 
initiate the disease in these patients.  
 
1.2.3.2.4 Female gender as a risk factor for PAH 
PAH occurs more commonly in women than men (Loyd et al., 1984: Rich et al., 1987; 
Loyd  et  al.,  1995),  a  situation  paralleled  in  other lung  conditions  including  idiopathic 
pulmonary fibrosis, COPD in non smokers and asthma (Carey et al., 2007). Interestingly, 
the epidemiological data for asthma show that there is a higher prevalence in males during 
childhood but this reverses to a female predominance at the time of puberty and continues 
till the fifth or sex decade after which the female predominance disappears (Carey et al., 
2007). This strongly suggests an influence of female sex hormones on the progression of 
asthma. The fact that the majority of PAH cases occur in women of child-bearing age has 
also caused speculation that female sex hormones may be responsible for the increased risk 
of PAH seen in this population. Experiments that have assessed the role of female sex 
hormones  in  animal  models  of  PAH  have,  more  often  than  not,  shown  that  female 
hormones actually reduce the symptoms of PAH. For example, 17 -estradiol (estradiol) 
protects  rats  against  MCT  induced  PAH  (Farhat  et  al.,  1993)  and  estradiol  attenuates 
persistent PAH in fetal lambs (Parker et al., 2000). 2-methoxyestradiol (2-ME), a major 
metabolite of estradiol is involved in the protective effect that female hormones have in 
protecting animals against MCT induced PAH (Tofovic et al., 2005; Tofovic et al., 2006).  
Gender differences have also been noted in the response to hypoxia. During one study, 
female mice were found to be more resistant to hypoxia than males and administration of 
estradiol prolonged survival times under hypoxia (Stupfel et al., 1984). In relation to PAH, 
female  rats  were  shown  to  develop  less  severe  PAH  following  hypoxia  than  males 
(Rabinovitch et al., 1981) and ovariectomized rats develop more severe hypoxic PAH than 
rats with intact ovaries (Resta et al., 2001).  59 
 
 It  is  not  known  how  female  sex  hormones  may  influence  the  progression  of PAH  in 
animal  models  of  PAH  or  in  human  PAH  patients.  Estradiol  and  its  metabolites  can 
influence vascular tone, cellular proliferation and apoptosis through both genomic and non 
genomic mechanisms.  
 
1.2.3.2.5 Endothelial derived factors 
PAECs  secrete  a  wide  variety  of  vasoactive  mediators  that  directly  influence 
vasoconstriction  and  cellular  growth  in  pulmonary  arteries.  Some  of  these  have  been 
mentioned  previously  and  many  are  altered  in  PAH.  A  tight  balance  between 
vasoconstrictors  and  mitogenic  agents  against  vasodilators  and  pro-apoptotic  factors 
controls vascular homeostasis, low vascular tone, inflammation and tissue repair. In PAH, 
the balance is thought to favour proliferation and vasoconstriction and there have been 
many experimental observations that support this view. This is a brief summary of some of 
those observations: 
 
1.2.3.2.5.1 Nitric oxide 
As an important regulator of vascular tone (Cooper et al., 1996), NO has come under 
attention from PAH researchers but the expression and role of NOS in the pulmonary 
hypertensive lung is not clear. One study found NOS to be dramatically downregulated in 
the lungs of PAH patients compared with control subjects (Giaid and Saleh, 1995). Other 
human studies have found increased expression of eNOS in small resistance arteries in 
pulmonary hypertensive patients although with large individual variability (Mason et al., 
1998).  In this study, plexiform lesions were found to have high levels of eNOS, perhaps 
indicating  proliferating  PAECs.  It  is  uncertain  what  the  role  of  NO  might  be  in  the 
endothelium  of  plexiform  lesions  and  whether  its  effects  are  beneficial  or  detrimental 
(Mason et al., 1998). eNOS deficient mice have increased PAP and PVR compared with 60 
 
WT mice (Steudel et al., 1997). Mice lacking eNOS develop severe PAH following mild 
hypoxia (Fagan et al., 1999) and conversely, increased levels of eNOS attenuate hypoxic 
PAH in mice (Ozaki et al., 2001). Administration of the NO precursor, L-arginine reduces 
PAH following hypoxia and MCT in rats (Mitani et al., 1997) and reduces PAP and PVR 
in human patients with PAH (Mehta et al., 1995; Nagaya et al., 2001).   
 While there is some uncertainty as to any pathological role NO dysfunction may play in 
the  development  of  PAH,  its  potent  effect  as  a  pulmonary  vasodilator  has  led  to  NO 
inhalation being tested as a therapy for PAH (Pepke-Zaba et al., 1991; Goldman et al., 
1995; Hoeper et al., 2000; Krasuski et al., 2000) with results often comparable to other  
treatments currently used as inhalable vasodilators such as certain prostacyclin analogues. 
cGMP  is  the  main  signalling  molecule mediating  the  vasodilator  effect  of  NO  and  is 
degraded in the lung by phosphodiesterase type 5, (PDE5). Sildenafil, a PDE5 inhibitor is 
currently a therapeutic candidate for  the treatment of PAH. Sildenafil inhibits hypoxic 
PAH in humans and mice (Zhao et al., 2001) and can reduce PVR in humans with chronic 
PAH (Ghofrani et al., 2004). 
 
1.2.3.2.5.2 Prostacyclin 
PGI2  is  a  potent  vasodilator  that  acts  to  counteract  vasoconstriction  and  proliferation 
(Budhiraja et al., 2004). It is produced by prostacyclin synthase (PGI2-S) and this enzyme 
is decreased in pulmonary arteries from PAH patients, with the most pronounced reduction 
occurring in vessels with concentric intimal lesions (Tuder et al., 1999). Overexpression of 
PGI2-S protects mice against hypoxic PAH (Geraci et al., 1999) and administration of 
PGI2-S  via  gene  transfer  attenuates  MCT  induced  PAH  in  rats  (Nagaya  et  al.,  2000). 
Prostacyclin and its analogues have been the most successful treatments for attenuating the 
symptoms of PAH in humans to date. Epoprostenol (intravenous PGI2 analogue), beraprost 
(orally  active  PGI2  analogue),  iloprost  (inhalation  carbacyclin  PGI2  analogue)  and 61 
 
treprostenil  (PGI2  analogue  that  is  room  temperature  stable  allowing  subcutaneous 
infusion) have all been used successfully on PAH patients in all clinical categories (Saji et 
al., 1996; McLaughlin et al., 1998; Nagaya et al., 1999; Rosenzweig et al., 1999; Robbins 
et al., 2000; Olschewski et al., 2000; Hoeper et al., 2000; Simonneau et al., 2002).  
 
1.2.3.2.5.3 Endothelin-1 
ET-1, a pulmonary vasoconstrictor (Deuchar et al., 2002) and PASMC mitogen (Davie et 
al., 2002) is upregulated in both hypoxic (Li et al., 1994) and MCT (Frasch et al., 1999) 
animal models of PAH and also in the endothelium of remodelled vessels in PAH patients 
(Giaid  et  al.,  1993).  ET-1  receptor  antagonists  such  as  bosentan  and  sitaxsentan  have 
shown promise in improving symptoms and exercise capacity in PAH patients (Channick 
et al., 2001; Rubin et al., 2002; Barst et al., 2002). 
 
1.2.3.2.5.4 Thromboxane 
Produced by PAECs and platelets, TXA2 is a pulmonary vasoconstrictor, PASMC mitogen 
and activator of platelet aggregation (Tuder and Hassoun, 2004). Patients with PAH show 
elevated excretion rates of 11-dehydro-thromboxane B2, a metabolite of TXA2, in addition 
to  decreased  excretion  of  the  PGI2  metabolite,  2,3-dinor-6-keto-prostaglandin  F1 . 
(Christman et al., 1992). This is evidence for an imbalance between vasoconstrictors and 
vasodilators in PAH. Terbogrel, a combined TXA2 synthetase inhibitor and TXA2 receptor 
antagonist was tested unsuccessfully in one clinical trial as a treatment for PAH and caused 
significant side effects leading to premature termination of the study (Langleben et al., 
2002). 
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1.2.3.2.6 Non-endothelial derived factors 
1.2.3.2.6.1 Vascular endothelial growth factor 
VEGF is highly expressed in the lungs and is the most important growth factor for PAECs, 
promoting PAEC survival and tissue homeostasis (Said, 2006). VEGF is upregulated by 
hypoxia in human hepatoma cells via HIF-1  activation of a HRE (Forsythe et al., 1996). 
The  role  of  VEGF  in  hypoxic  PAH,  however,  is  uncertain.  Two  groups  found  that 
circulating levels of VEGF and lung VEGF mRNA levels are increased in hypoxic rats 
(Christou et al., 1998) and that overexpression of VEGF protects rats against hypoxic PAH 
(Partovian et al., 2000). Contradictory findings include unchanged VEGF expression in rat 
lung following hypoxia and a 90% decrease in rat lungs following MCT (Partovian et al., 
1998).  Pfeifer  and  colleagues  could also  find  no  change  in  VEGF  gene  expression  in 
hypoxic rat lungs (Pfeifer et al., 1998). Due to the critical role VEGF has in preventing 
PAEC apoptosis, it is reasonable to assume that loss of VEGF would promote PAEC 
apoptosis,  thus  having  a  detrimental  effect  on  vascular  integrity.  Indeed,  it  has  been 
demonstrated that blockade of the VEGF receptor induces mild PAH in rats and when 
combined  with  hypoxia  induces  severe  irreversible  PAH  associated  with  initial  PAEC 
apoptosis, followed by proliferation of apoptosis resistant cell populations and formation of 
obliterative intimal lesions (Taraseviciene-Stewart et al., 2001). There is also evidence that 
VEGF receptor blockade can induce transdifferentiation of endothelial derived precursor 
cells into PASMC like cells (Sakao et al., 2007) which is also thought to occur in the 
vascular remodelling associated with PAH. 
 
1.2.3.2.6.2 Platelet-derived growth factor 
PDGF is a PASMC mitogen (Yu et al., 2003) and its expression is increased in the lungs of 
PAH patients compared with control subjects (Perros et al., 2008). The PDGF receptor 
antagonist, imatinib reverses both hypoxic and MCT induced PAH in rats (Schermuly et 63 
 
al., 2005) and imatinib has been used successfully in the treatment of one isolated case of 
severe PAH (Ghofrani et al., 2005). 
 
1.2.3.2.6.3 Adrenomedullin 
Adrenomedullin  was  first  isolated  in  1993  from  human  pheochromocytoma  cells 
(Kitamura et al., 1993). It has now been found in a multitude of tissues in both animals and 
humans,  including  the  lung,  which  also  contains  a  dense  number  of  adrenomedullin 
receptors, a number that is unusually high for peptide receptors (Ichiki et al., 1994; Sakata 
et al., 1994; Owji et al., 1995). Adrenomedullin is a systemic and pulmonary vasodilator, 
acting via cAMP and is also an inhibitor of vascular smooth muscle cell proliferation 
(Kano et al., 1996). Plasma levels of adrenomedullin are increased in patients with PAH 
(Kakishita  et  al.,  1999),  the  reasons  for  which  are  unclear.  It  perhaps  acts  as  a 
compensatory mechanism against the increased PVR. The high potency of adrenomedullin 
coupled with its high expression in the lung led to its testing in animal models of PAH.  
Both  subcutaneous  and  inhaled  adrenomedullin  attenuates  MCT  induced  PAH  in  rats 
(Yoshihara et al., 1998; Nagaya et al., 2003). Adrenomedullin is also effective in reducing 
the  parameters  of  PAH  in  hypoxic  rats  (Qi  et  al.,  2006)  and  mice  deficient  in 
adrenomedullin develop more severe PAH following hypoxia than WT mice (Matsui et al., 
2004). In human IPAH patients, adrenomedullin improves pulmonary haemodynamics and 
exercise  capacity  (Nagaya  et  al.,  2004)  and  is  a  more  effective  treatment  used  in 
combination with NO than NO alone (Dani et al., 2007).  
 
1.2.3.2.6.4 Vasoactive intestinal peptide 
VIP is a pulmonary artery vasodilator (Sago and Said, 1984; Shahbazian et al., 2007) and 
PASMC growth inhibitor (Petkov et al., 2003). Pre-treatment with VIP attenuates MCT 
induced  PAH  in  rabbits  (Gunaydin  et  al.,  2002)  and  also  reduces  PVR  in  pulmonary 64 
 
hypertensive piglets (Haydar et al., 2007). There is growing evidence that VIP has a role in 
controlling  vascular stasis in the lung.  VIP knockout mice (VIP
-/-) develop pulmonary 
arterial  remodelling  and  RVH  in  normal  air  and  the  symptoms  are  reduced  in  mice 
receiving VIP (Said et al., 2007).  VIP serum levels are lower in PAH patients than control 
subjects  (Haberl  et  al.,  2007)  and  VIP,  which  is  moderately  expressed  in  pulmonary 
arteries from control subjects, is absent in pulmonary arteries from PAH patients. This was 
associated with an upregulation of VPAC-1 and VPAC-2 (Petkov et al., 2003). Petkov and 
colleagues also administered inhalation VIP to PAH  patients daily for  3 months. This 
resulted  in  significant  improvements  in  PAP,  CO  and  a  50%  reduction  in  PVR.  A 
corresponding  increase  in  exercise  tolerance  was  also  measured.  The  success  of  this 
preliminary study coupled with the lack of side effects has led to the undertaking of further 
clinical trials studying the therapeutic potential for VIP in PAH (Said, 2006). 
 
1.2.3.2.6.5 Angiopoietin-1 
Angiopoitein-1 is secreted by smooth muscle cells during development and is involved in 
angiogenesis. It binds to the endothelial-specific tyrosine kinase (TIE2) receptor which is 
present  only  on  vascular  endothelial  cells  and  helps  co-ordinate  cells  during  vascular 
development.  In  2003,  Du  and  colleagues  (Du  et  al.,  2003)  found  that  angiopoietin-1 
protein and mRNA expression were increased in the lungs of patients with PAH and that 
angiopoietin-1  levels  correlated  with  disease  severity.  Angiopoietin-1  also  decreased 
BMPR1A expression when incubated in cultured PAECs. Further work from this group 
showed  that  overexpression  of  angiopoietin-1  in  rat  lungs  induced  muscularisation  of 
pulmonary arteries and PAH (Sullivan et al., 2003). Cell culture experiments using human 
PASMCs and PAECs showed that angiopoietin-1 induced PAECs to release 5-HT that 
induced proliferation of PASMCs. The growth of the PASMCs was inhibited by fluoxetine 
(Sullivan et al., 2003). In contrast to these results, Zhao et al., 2003 put forward evidence 65 
 
for  a  protective  role  for  angiopoietin-1  in  PAH.  They  found  that  angiopoietin-1  gene 
transfer into rat PASMCs increased eNOS expression while reducing RVP, EC apoptosis 
and mortality in rats with MCT induced PAH. More recent studies support the former 
hypothesis for a deleterious action of angiopoietin-1 in PAH. Dewachter et al., 2006 also 
obtained  the  result  that  angiopoietin-1  induces  PAECs  from  both  IPAH  patients  and 
control subjects to release 5-HT with more 5-HT being released from PAECs from IPAH 
patients. PAECs from IPAH  patients also released ET-1 following angiopoietin-1. The 
greater release of growth factors from PAECs was attributable to heightened expression of 
the TIE2 receptor (Dewachter et al., 2006).  
 
1.3 Aim of thesis 
It is  generally accepted that PAH is a  multi-factorial disease with known  genetic risk 
factors such as mutations in BMPR2 coupled with possible genetic risk factors (5-HTT+ 
polymorphisms)  interacting  with  one  or  several  of  the  physiological  and  exogenous 
modifying factors outlined in the previous sections. The aim of this thesis is to investigate 
modifying factors that may interact with genetic predisposition to trigger the phenotypic 
changes  associated  with  PAH.  This  will  involve  a  combination  of  in  vivo,  in  vitro 
pharmacological  and  biochemical/histological  techniques.  Transgenic  (TG)  mice 
overexpressing the 5-HTT (5-HTT+), deficient in BMPR2 (BMPR2
+/-) or a double (cross) 
transgenic 5-HTT+/BMPR2
+/- (Cross TG) will be employed in addition to mice lacking 
peripheral  5-HT  (Tph1
-/-).      Additional  modifying  factors  assessed  in  these  transgenic 
models were: 
• Hypoxia 
• Dfen and NDfen 
• 5-HT  
• BMP-2 66 
 
• KCNQ channels 
• Gender 
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Chapter 2 
Materials and methods 68 
 
2.1 Animals 
All animals were bred in the Central Research Facility, University of Glasgow and when 
required  for  experimental  use,  were  housed  in  a  holding  room  with  a  controlled 
environment: temperature (21 C), humidity (60%) and regular cycling of filtered air. A 12 
hour light/dark cycle was maintained. Animals were kept in cages with a suitable supply of 
water and diet and checked daily. All experiments were conducted under a HO Project 
Licence number 60/3773 granted to Prof M MacLean. 
 
2.1.1 WT mice 
WT mice were C57BL/6 strain. 
 
2.1.2 The 5-HTT+ mouse 
5-HTT+ mice were donated to Prof M MacLean by Prof A Harmar, Edinburgh University. 
The  C57BL/6xCBA  WT  strain  was  employed  to  generate  the  5-HTT+  mouse.  The 
transgene was a 500-kb yeast artificial chromosome (YAC35D8) containing the h5-HTT 
gene flanked by 150 kb of 5’ and 300 kb of 3’ sequence with the short allele of the 5-
HTTLPR in the promoter region and the 10-repeat allele of the variable-number tandem 
repeat (VNTR) in intron 2 (Shen et al., 2000a). YAC35D8 was modified to include a 
hemagglutinin epitope tag at the C-terminus of the 5-HTT protein and a lacZ promoter 
gene downstream of an internal ribosomal entry site as described previously (Shen et al., 
2000b). The phenotype was verified by RT-PCR by Mrs Lynn Loughlin in Prof MacLean’s 
laboratory. 
 
2.1.3 The BMPR2
+/- mouse 
The BMPR2
+/- mice were donated to Prof M MacLean by Prof N Morrell, University of 
Cambridge. 69 
 
The C57BL/6 WT strain was employed to generate the BMPR2
+/- mouse. A replacement 
gene  targeting  vector  was  constructed  with  exons  4  and  5  (which  encode  the  entire 
transmembrane domain and the amino-terminal region of the kinase domain respectively) 
deleted and replaced by a cassette of SE IRED/LacZ/loxP/pgk neo/loxP. The targeting 
vector was transfected into embryonic stem cells by electroporation. Positive recombinant 
clones were injected into blastocysts from C57BL/6 mice. These chimeric mice were then 
bred with C57BL/6 females and offspring analysed for presence of the BMPR2 mutation 
by southern blotting. Mice positive for the BMPR2 mutation were BMPR2
+/- (Beppu et al., 
2000). The phenotype was verified by RT-PCR by Mrs Lynn Loughlin in Prof MacLean’s 
laboratory. 
 
2.1.4 The 5-HTT+ x BMPR2
+/- mouse 
5-HTT+ and BMPR2
+/- mice were bred together (usually 1 male to 2 females) to produce a 
double (cross) TG strain that are 5-HTT+/BMPR2
+/- and will be referred to in this thesis as 
Cross TG mice. This cross breeding was carried out under the supervison of Dr Yvonne 
Dempsie and Dr Ian Morecroft and the phenotype verified by Mrs Lynn Loughlin in Prof 
MacLean’s laboratory. 
 
2.1.5 The Tph1
-/- mouse 
Tph1
-/-  mice  were  donated  by  Prof  M  Bader,  Max-Delbrück-Center  for  Molecular 
Medicine Berlin-Buch, Germany. 
The C57BL/6 WT strain was employed to generate the Tph1
-/- mouse. A 1 kb (short arm) 
and 5.2 kb (long arm) fragment were used to construct a targeting vector containing a 
neomycin-resistance  cassette  and  a  thymidine  kinase  cassette.  The  construct  was 
transfected in embryonic stem cells by electroporation. Positive recombinant clones were 
injected into blastocysts from C57BL/6 mice. These chimeric mice were then bred with 70 
 
C57BL/6 females and offspring analysed for presence of the targeted Tph1 mutation by 
southern blotting. Mating of the resulting Tph1
+/- mice generated Tph1
-/- mice (Walther et 
al., 2003).  
 
2.1.6 Animal weights 
2-3 months mice: 15-40 grams 
5-6 months mice: 25- 50 grams 
 
2.2 Hypoxic model of PAH 
As  covered  extensively  during  the  preceding  chapter,  hypoxia  is  one  of  two  principal 
methods commonly used to induce PAH in animals.  For the purposes of this investigation 
hypoxia involved housing mice in an atmosphere of approximately 10% O2 for a period of 
14 days. To achieve hypoxia, mice were kept in a hypobaric chamber. The chamber is built 
from perspex with a removable door.  Caged mice were placed into the hypobaric chamber 
and a pump activated that continuously removes air at a constant rate. The chamber door is 
sealed by the pressure gradient between the chamber and outside environment which is 
created  by  a  small  controllable  inlet  valve  on  the  door  that  controls  air  flow  into  the 
chamber. By opening and closing the valve, chamber pressure can be raised and lowered 
respectively. As the atmospheric pressure of the chamber decreases, the partial pressure of 
the chamber gases decreases and so controlling chamber pressure allows the control of O2 
concentration. The chamber pressure was lowered by 50 mbar per hour over two days to 
550 mbar at which point, the O2 concentration is ~ 10%. The chamber was in an animal 
holding room which  was continuously ventilated with room air at 45 L per minute to 
prevent accumulation of CO2 and to maintain low humidity. Chamber temperature was 
monitored by two thermometers, one inside the chamber and one resting on the outside of 
the chamber. Internal chamber temperature was within 2 C of the outside temperature 71 
 
which was maintained at approximately 21 C. Chamber conditions and status of mice were 
checked daily and information logged.  The chamber was briefly recompressed every 3 
days to clean cages and replenish food and water.  
 
2.3 In vivo haemodynamic measurements 
Anaesthesia of mice was induced by 3% isoflurane in O2 and body weight measured. Mice 
were  then  placed  in  a  supine  position  with  limbs  secured  by  tape.  Anaesthesia  was 
maintained by 1 – 1.5% isoflurane in O2 supplied via a face mask. Sufficient level of 
anaesthesia was determined by absence of hind limb and tail reflex.  
 A  small  area  of  fur  and  skin  was  removed  over  the  sternum  in  preparation  for 
transdiaphragmatic cardiac puncture that would allow recording of RVP. Right ventricular 
haemodynamic function is the most critical factor in determining survival in patients with 
PAH (D’alonzo et al., 1991) and elevated RVP has been used extensively as an index of 
PAH (Eddahibi et al., 2000; Launay et al., 2002; Maclean et al., 2004).  These reasons 
coupled with the relative simplicity of measuring RVP through cardiac puncture compared 
with measuring PAP led to RVP being the haemodynamic measurement of choice in this 
thesis.  The procedure employs a polypropylene hypodermic needle (25 gauge) attached to 
a  an  E751A  pressure  transducer  (Elcomatic,  Glasgow,  UK)  which  is  mounted  onto  a 
micromanipulator (Stoelting Co., Wood Dale, IL). The needle and transducer are filled 
with  0.9%  saline  solution  containing  heparin  (25  units/ml)  (LEO  Pharma  Inc,  Princes 
Risborough, UK). The tip of the needle was aligned with the mid point of the sternum and 
then adjusted approximately 2 mm to the right. The needle was advanced under the rib 
cage, through the diaphragm and into the right ventricle (RV). Entry of the needle into the 
RV was confirmed by the waveform trace on the computer screen. 
 Systemic arterial pressure (SAP) was measured by carotid artery cannulation. A small area 
of fur was removed at the top of the thorax and blunt dissection was used to expose and 72 
 
isolate the right carotid artery. Surgical thread was used to tie off the distal end of the 
artery. A small clip was placed over the proximal end of the artery to prevent blood loss 
following arterial incision. The incision was made towards the distal end of the artery and a 
cannula (0.75 mm OD, Portex) was advanced in the proximal direction. A second piece of 
thread was used to tie around the cannula and artery and the arterial clip removed to allow 
blood flow into the vessel. Both SAP and RVP were recorded by a MP100 data acquisition 
system (BIOPAC Systems Inc, Santa Barbra, CA) and relayed to a computer. Following 
completion  of  the  haemodynamic  measurements,  the  animal  was  euthanised  by  5% 
isoflurane in O2 followed by cervical dislocation. The thorax was opened and hearts and 
lungs from each animal were removed and placed in ice cold Krebs solution (Composition 
(mM): NaCL 118, NaHCO3 25, D-glucose 11, KCl 4.7, CaCl2 2.5, KH2PO4 1.2, MgSO4 1.2 
(pH7.4)) for further analysis.   
 
2.3.1 Data analysis of in vivo data 
Results were analysed using the Acquiknowledge 3.7 software package (BIOPAC Systems 
Inc, Santa Barbra, CA). A minimum of 5 minutes telemetry data was acquired per animal 
for  both RVP and SAP.  Figure 2.1 displays a  sample screenshot of approximately 15 
seconds of telemetry data. Data acquisition involved the analysis of data in three separate 
10 second segments spread over the 5 minutes of telemetry. The highlighted area in figure 
2.1 represents one of these 10 second segments.  The top half of the screen displays RVP 
and the bottom SAP. Systolic RVP (sRVP) was calculated by recording the value of 4 
peaks during systole in each of the three 10 second segments giving 12 values in total 
which were averaged to give the final sRVP value. Mean RVP (mRVP) was taken from the 
automatic calculation, provided by the software, for each three segments and then averaged  
to give the final mRVP. Heart rate (HR) was calculated by highlighting 10 systolic peaks 
within the 10 second segment and recording the time in seconds for 10 systolic peaks 73 
 
 
 
 
 
 
 
 
Figure 2.1 Sample of RVP and SAP telemetry trace. 
RVP  is  displayed  in  red  and  SAP  in  blue.  Highlighted  segment  is  approximately  10 
seconds of data. Three of these segments taken during 5 minutes of data recording were 
used to derive sRVP, mRVP, mSAP and HR. 
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(beats) to occur. By dividing 60 (seconds) by this value and multiplying by 10 gives the 
HR in beats per minute. This was repeated for the two additional segments and averaged to 
give the final HR.  mSAP was recorded in the same manner as mRVP. 
 
2.4 Measurement of right ventricular hypertrophy 
Adipose and connective tissue were carefully removed from around the heart and lungs 
and hearts separated from the lungs. Atria and large calibre blood vessels were dissected 
from the rest of the heart. The RV free wall was then dissected away from the left ventricle 
(LV) and septum. The LV + septum along with the RV were blotted dry and weighed 
separately. The ratio of RV/(LV+S) was used as an index of RVH.  
 
2.5 Lung Histology 
One sagittal section was obtained from either the left or right lungs. Sections were paraffin 
wax fixed and stained with Elastica-Van Gieson stain (by Mrs M Nilsen in Prof MacLean’s 
laboratory)  and  microscopically  assessed  for  evidence  of  muscularisation  of  small 
pulmonary  arteries  (<80  µm  diameter).  Arteries  were  considered  muscularised  if  they 
possessed  a  distinct  double-elastic  lamina  visible  around  at  least  70%  of  the  vessel 
circumference.  At  least  150  vessels  per  section  were  counted.  The  percentage  of 
muscularised  (remodelled)  vessels  was  calculated  as  the  number  of  remodelled 
vessels/total number of vessels counted x 100. 
 
2.6 In vitro pharmacological studies 
2.6.1 Wire myography 
Myography is a technique for pharmacological investigation of small vessels and was first 
described by Bevan and Osher (1972) and developed in 1976 by Mulvany and Halpern, 
allowing analysis of contractile response in vessels with 100-400 µM internal diameter. 75 
 
Vessels  of  this  size  are  studied  by  wire  myography,  a  relatively  atraumatic  technique 
providing accurate measurements of muscle contraction.  
 
2.6.1.1 Wire myography equipment 
For this study, the Mulvany/Harpern small vessel wire myograph (model 610M) was used; 
purchased  from  Danish  Myo-technology  Ltd,  Aarhus,  Denmark.  The  unit  has  four 
individual stainless steel organ chamber baths, each capable of holding one vessel. Each 
organ bath chamber contains two vessel support heads, one is attached to a highly sensitive 
isometric force transducer and the other to a metal support arm. The metal support arm is 
connected to a micropositioner which allows adjustment of the support arm and hence the 
distance between the two support heads. When a vessel is mounted in the chamber, the 
alteration in distance between support heads alters the tension applied to the vessel.  Each 
chamber has a moveable metal swing arm that enters the top of the chamber and has a dual 
function. The first is a pipe to control gas flow into the organ bath and the second is a 
suction pipe for removing fluid from the chamber. Myograph chamber temperature control 
(± 0.1 C) is maintained by electronic internal heating units. Temperature and force from 
each chamber are digitally displayed on the base unit. The myograph is connected to a 
computer  and  all  information  is  recorded  using  Myodaq20  software  (Danish  Myo-
technology Ltd, Aarhus, Denmark) and analysed using Myodata (Danish Myo-technology 
Ltd, Aarhus, Denmark). 
 
2.6.1.2 Intralobar pulmonary artery dissection 
Lungs  were  obtained  from  freshly  culled  mice  (intraperitoneal  injection  of  200  mg/kg 
sodium pentobarbitone (Euthatal) (Merial Ltd, Harlow, UK) or from mice following  in 
vivo procedure. The larger left lung was separated from the rest of the lungs and fixed to a 
dissecting dish using pins. The lung was orientated with the parietal surface lying in an 76 
 
inferior position. The tissue was regularly washed with ice cold Krebs during dissection to 
keep tissue hydrated.  Using a dissecting microscope (Zeiss), an incision was made at the 
opening of the airway, cutting down the airway length from the large proximal airway, 
along the bronchial tree to the distal bronchiole. Remaining bronchiole tissue lying directly 
above  the  intralobar  pulmonary  artery  (IPA)  was  carefully  removed  exposing  the 
underlying IPA. Surrounding connective tissue was dissected free and up to two 2 mm 
strips of IPA were cut from the lung attached IPA and placed into ice cold Krebs solution.  
 
2.6.1.3 Vessel mounting procedure 
Each myograph chamber was filled with 5mls of Krebs solution and bubbled with a gas 
mixture containing 16% O2/ 5% CO2 (balance N2). This mixture is set to mimic the arterial 
partial pressure of each gas in vivo. Gas was fed to each myograph chamber from a pre-
filled Douglas bag via an electronic Dymax 30 pump (Charles Austen Pumps Ltd, Byfleet, 
UK). 2 mm sections of IPA dissected previously were placed into a petri dish containing 
cold Krebs solution. A 40 µm steel wire was slowly advanced through the vessel lumen 
using two pairs of fine forceps, one pair holding the steel wire and the other gently holding 
the other end of the vessel. The wire and vessel were then placed into the myograph organ 
chamber and positioned between the two mounting head jaws.  The wire was secured in 
place by advancing the adjustable mounting head towards the other till there was sufficient 
pressure between the two sets of jaws to hold the wire in place. The vessel is situated in a 
space between the mounting head jaws. The steel wire was then secured at each end of the 
left mounting head (the head attached to the micropositioner) by wrapping each end of the 
wire around top and bottom screws which were tightened to create tension (figure 2.2A). 
The two mounting heads were then separated and another section of 40 µm steel wire 
inserted through the vessel lumen (figure 2.2B). The two heads were once again brought 
together until the second wire was securely fixed (figure 2.2C) and the wire secured 77 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Mounting procedure for a vessel on a wire myograph. A 2mm section of 
IPA containing a steel wire through vessel lumen is secured between mounting jaws to 
mounting head (A). A second wire is threaded through vessel lumen (B) and attached to 
other mounting head (C-E). Mounting jaws are then separated slightly in preparation for 
normalisation.  
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in place around the two screws on the right  mounting head (the head attached to the force 
transducer)  (figure  2.2D  and  E).  The  heads  were  then  separated  slightly  (figure  2.2F) 
before the chamber was replaced back onto the myograph base unit and the heating unit 
initialised to maintain temperature at 37 C.  
 
2.6.1.4 Vessel normalisation 
Normalisation is a procedure for setting vessels to standard initial conditions to mimic, as 
closely  as  possible,  the  in  vivo  environment.  This  is  achieved  by  setting  an  optimal 
transmural pressure that matches the in vivo transmural pressure of the vessel studied. The 
Laplace equation, which links the wall tension in a cylinder with its internal radius and 
transmural pressure, can be modified to convey the relationship between variables for a 
blood vessel on a myograph (equation 2.1). 
 
Equation 2.1)                    Pi =       T 
                                                       IC/2π 
 
Equation 2.1 Laplace equation for calculation of effective pressure in a cylinder 
Pi = effective pressure (the pressure required to extend vessel to the measured internal 
diameter,) T = wall tension, IC = internal circumference 
 
Wall tension is calculated from the following equation: 
 
Equation 2.2)                    T =  F 
                                                  2L 
 
Equation 2.2 Calculation of vessel wall tension 
T = wall tension, F = force, L = vessel wall length 
Each vessel has an upper and lower wall thus the equation requires vessel length to be 
multiplied by 2. 
The  internal  circumference  is  calculated  from  the  micropositioner  readings  and  by 
incorporating the size of diameter of each steel wire within the vessel lumen (40  m): 79 
 
Equation 2.3)                 IC = (π + 2)d + 2 (Xi  - Xo) 
Equation 2.3 Calculation of vessel internal circumference 
IC = internal circumference, d = diameter of wire, (Xi - Xo) = distance between the 40  m 
steel wires 
 
To calculate Xo, the two mounting head jaws are brought together until they gently touch 
causing a negative pressure trace on the computer screen. The reading is taken at this point 
from the reading on the micropositioner. Xi is the value recorded from the micropositioner 
at any given amount of stretch applied to the vessel by adjusting the distance between 
mounting jaws.  
Equation 2.1 can be rearranged to give: 
 
Equation 2.4)                   Pi = 2πT 
                                                   IC 
 
 
Equation 2.4 Rearranged Laplace equation for calculation of effective pressure 
 
Using the value of IC calculated above, this can be used, together with the substituted 
values for wall tension to give the following equation: 
 
 
Equation 2.5)                   Pi =   2πF 
                                                   2L x IC 
 
Equation 2.5 Calculation of transmural pressure of vessel by its relationship to wall 
tension and internal circumference 
 
                   
 
This equation allows the calculation of transmural pressure for a vessel. By adjusting the 
level of stretch on a vessel by small increments, pressure can be increased or decreased 
until the optimum physiological pressure is achieved which in mouse pulmonary  vessels is 
~15 mmHg. A range of 12-16 mmHg was considered acceptable.  
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2.6.1.5 General experimental procedure 
Following mounting and normalisation, vessels were left to equilibrate for approximately 
30 minutes in Krebs solution (37ºC; 16% O2/ 5% CO2 (balance N2) gas mixture infused). A 
final bath concentration (FBC) of 50 mM potassium chloride (KCl) was added to each 
chamber to stimulate vessels and to assess their viability. Once contractile response was 
maximal and stable, the vessels were washed 6-8 times with fresh Krebs solution and left 
to return to baseline tension. The KCl procedure was then repeated and this contractile 
response was used as a reference response.  Further experiment specific details can be 
found in the methods section of individual results chapters. 
 
2.6.1.6 Data analysis of pharmacological studies 
The output from the myograph was recorded on a computer using Myodaq20 software 
(Danish Myo-technology Ltd, Aarhus, Denmark) and analysis of the data performed using 
Myodata software (Danish Myo-technology Ltd, Aarhus, Denmark). When data produced 
sigmoidal concentration-response curves, analysis of the data was performed by fitting the 
data with a Hill equation model using Graphpad Prism 4 (GraphPad Software Inc, CA, 
USA)  This  provided  values  for  pEC50  (a  measure  of  drug  potency)  and  Emax  (the 
maximum response induced by a drug). The Hill equation also provides a value derived 
from the steepness of the slope of the curve. This is called the slope function or  Hill 
coefficient. The Hill coefficient was found to be generally uniform across experiments. In 
those instances where significant differences were observed, these are stated in the results 
section.    Where  concentration-response  curves  clearly  did  not  follow  the  classical 
sigmoidal shape or where maximal contractile response was not achieved at concentrations 
tested, the contractile response at each concentration tested was measured and analysed for 
intergroup differences.  
For all the above measurements, individual concentration-response curves were 81 
 
constructed for each experimental group and mean ± SEM calculated for each group of 
vessels. 
 
2.7 Biochemical analysis 
2.7.1 Preparation of tissue  
2.7.1.1 WT and Tph1
-/- male mice (for p-ERK1/2 and p-Smad1/5/8 analysis) 
Each mouse was killed by intraperitoneal injection of 200 mg/kg Euthatal and heart and 
lungs immediately dissected out and placed in ice cold Krebs solution. Heart and lungs 
were  fixed  with  pins  to  a  dissecting  dish  and  washed  regularly  with  ice  cold  Krebs. 
Adipose and connective tissue were dissected from around the heart and lungs to expose 
the main pulmonary artery. The main pulmonary artery was cut at the entry point to the 
heart and at the entry point of both the left and right lung. The artery was then transferred 
into several drops of ice cold Krebs on a petri dish. The lungs were placed into a beaker of 
ice cold Krebs and the heart and remaining tissue discarded. Once in the petri dish, the 
main artery was cut into small pieces using dissection scissors before being transferred into 
a small plastic dish containing lysis buffer (20 mM Tris (Fisher Scientific, Loughborough, 
UK), 1 mM dithiothreitol (Melford Laboratories Ltd, Ipswich, UK) and a Complete, Mini, 
EDTA-free serine/cysteine protease inhibitor (Roche Applied Science, Burgess Hill, UK)). 
The IPA from the left lung was then dissected out as described previously, placed into a 
few drops of Krebs on a petri dish, cut into small segments and placed into the ice cold 
lysis buffer. The IPA from the right lung was processed in a similar manner. This process 
was completed for 24 WT animals and 24 Tph1
-/- animals so that there were 3 groups of 8 
animals for each genotype.  Each group contained IPAs + main pulmonary arteries in 200 
l of lysis buffer. The lysis buffer + tissue samples were transferred into 12 x 75 mm 
culture tubes (WWR International, Lutterworth, UK) and homogenised using a Miccra-D1 
homogeniser (ART Moderne Labortechnik, Mulheim, Germany) for 30 seconds. Samples 82 
 
 were then placed in ice cold sealed eppendorf tubes and stored at - 80 C. 
 
2.7.1.2 WT and Tph1
-/- male mice (for BMPR2 analysis) 
Procedure as above except lysis buffer  was composed of 125 mM Tris, 10% glycerol 
(Riedel-de Haen, Seelze, Germany), 2% Sodium dodecyl sulphate (SDS) (Fisher Scientific, 
Loughborough, UK) and Complete, Mini, EDTA-free serine/cysteine protease inhibitor. 
Experiment utilised 3 groups of 4 animals for each genotype.  Quantity of lysis buffer used 
was reduced proportionally. 
 
2.7.1.3 Male and female WT mice (for p-ERK1/2, p-p38 and p-Smad1/5/8 analysis) 
Each mouse was killed by intraperitoneal injection of 200 mg/kg of Euthatal and heart and 
lungs immediately dissected out and placed in ice cold Krebs solution. Heart and lungs 
were placed into a petri dish containing a small quantity of cold Krebs solution. The left 
lung  alone  would  yield  sufficient  tissue  for  analysis  (personal  communication,  Lynn 
Loughlin). The left lung was dissected free of the remaining heart and lung tissue and 
placed onto a separate petri dish containing a small quantity of cold Krebs. The left lung 
was cut into small pieces using scissors and transferred into 250  l of lysis buffer (20 mM 
Tris,  1  mM  dithiothreitol  and  a  Complete,  Mini,  EDTA-free  serine/cysteine  protease 
inhibitor). The lysis buffer + left lobe was transferred into a 12 x 75 mm culture tube and 
homogenised for 30 seconds. Sample was placed into an ice cold sealed eppendorf tube 
and stored at -80 C. This process was repeated to give a total of 6 male and 6 female tissue 
samples.  
 
2.7.2 Preparation of samples and running of acrylamide gel 
It was not possible to determine protein concentration of tissue samples using the Bradford 
assay. Protein concentration was found to be below the level of detection. Subsequently the 83 
 
plate  reader  was  found  to  be  malfunctioning  and  further  attempts  to  obtain  protein 
concentration were not possible.  It was deemed sufficient to use GAPDH and α – tubulin 
as loading controls to which western results could be normalised to. The volume of tissue 
sample +  lysis buffer  and sample buffer  used in the experiments outlined below have 
previously  been  shown  to  be  appropriate  for  reliable  detection  of  proteins  (personal 
communication, Lynn Loughlin). 
 Tissue samples were removed from -80 C freezer and kept on ice (0 C). To pre-cooled, 
labelled,  top-pierced  eppendorf  tubes  8  l  (for  experiments  performed  in  the  smaller 
volume 12 well polyacrylamide gels) or 10  l (for experiments performed in the larger 
volume  10  well  polyacrylamide  gels)  of  Nupage  4x  LDS  sample  buffer  (Invitrogen, 
Paisley,  UK)  was  added  followed  by  3  l  of  Nupage  (10x)  sample  reducing  agent 
(Invitrogen, Paisley, UK). Finally, protein samples were added to the eppendorf tubes so 
that protein sample and sample buffer were in a 1:1 ratio. Samples were then placed in a 
heating block (Grant Instruments, Cambridge, UK) pre-heated to 70 C for  10 minutes 
before  being  centrifuged  (Biofuge  15  centrifuge,  Heraeus  Sepatech  GmbH,  Osterode, 
Germany)  at  10,000  rpm  for  60  seconds.  Samples  were  then  placed  back  on  ice  in 
preparation for gel loading. Running buffer containing 5% NuPage MOPS SDS running 
buffer (20x) (Invitrogen, Paisley, UK) and 95% water was prepared. 200 mls of buffer was 
placed into a separate beaker and 500  l of antioxidant (Invitrogen, Paisley, UK) added. 
 The electrophoresis cell (X Cell, Novex, San Diego, CA) was prepared according to the 
manufacturer’s instructions and contained either 1 or 2 10 well or 12 well Nupage 10-12% 
Bis-Tris  polyacrylamide  gels  (Invitrogen,  Paisley,  UK)  depending  on  experimental 
requirements. Gels were removed from their protective packaging and briefly rinsed with 
cold water. The casting comb was gently removed and wells washed with running buffer + 
antioxidant before being placed into the cell. The outer chamber of the cell contained the 
running  buffer  and  the  inner  chamber  containing  the  gels  contained  running  buffer  + 84 
 
antioxidant.  Using  long  gel  loading  pipette  tips  10  l  of  SeeBlue®  Plus2  prestained 
standard (1x) (Invitrogen, Paisley, UK) followed by 19  l (12 well gels) or 23  l (10 well 
gels) of tissue sample/sample buffer/reducing agent was loaded to the gel. The lid was 
placed  over  the  cell  electrodes  and  attached  to  an  E861  electrophoresis  power  supply 
(Consort, Belgium). The gel was run at 150 volts until the dye had reached the bottom of 
the gel. This process usually required 1 – 1½ hours.  
 
2.7.3 Protein transfer  
This protocol is for experiments using 2 gels in one cell. 
In  preparation  for  protein  transfer  from  gel  to  transfer  membrane,  4  sheets  of    3mm 
Whatman filter paper (Whatman plc, Maidstone, UK) and 6 foam sponges were pre-soaked 
in transfer buffer (750 mls distilled water, 50 mls Nupage transfer buffer (20x), 200 mls 
methanol (Riedel-de Haen, Seelze, Germany) and 1ml Nupage antioxidant). Two 8cm x 8 
cm  sections  of  Immobilon-P  polyvinylidene  difluoride  (PVDF)  Transfer  Membrane 
(Sigma-Aldrich, Poole, UK) were cut and activated by immersion in methanol for 1 minute 
before being transferred into the transfer buffer. In an X Cell II transfer module (Novex, 
San Diego, CA) 2 soaked sponges were placed. Gel 1 was removed from its plastic casing 
and placed onto a sheet of Whatman paper with the PVDF membrane placed on the other 
side of the gel and placed face up into the cassette. A second sheet of Whatman paper was 
placed over the PVDF membrane, followed by 2 more sponges. Gel 2 was then removed 
from its casing and orientated on top of the sponges in the same manner as Gel 1. To 
complete the setup two final sponges were placed over the final piece of Whatman paper 
on top of the second PVDF membrane and the module lid was fitted in place and the entire 
transfer module placed into the electrophoresis cell. Both the inner and outer chambers of 
the cell were filled with transfer buffer. The lid was fitted and the gels run at 30 volts for 1 
hour.  85 
 
2.7.4 Blocking of PVDF membrane  
Tris buffered saline (TBS) solution was prepared from a TBS stock (0.2 M Tris, 1.37 M 
sodium chloride (Riedel-de Haen, Seelze, Germany) in 5 litres of distilled water). The TBS 
stock  solution  was  diluted  1:10  with  distilled  water and  the  pH  adjusted  to  7.6  using 
concentrated 37% hydrochloride acid (Riedel-de Haen, Seelze, Germany). Tween (Sigma-
Aldrich, Poole, UK) was added at 0.1% giving a Tween-TBS solution (TBST) that would 
be used as a buffer for washing the PVDF membrane.  
Following protein transfer, the gels were safely disposed of and the PVDF membranes 
were washed in TBST for 5 minutes before blocking of unoccupied protein binding sites in 
5% skimmed milk powder (Marvel, Premier Brands, Spalding, UK) in TBST for 1 hour at 
room temperature under gentle rocking. Membranes were then washed (3 x 15 minutes) in 
TBST. 
 
2.7.5 Detection 
After  blocking,  primary  antibody  was  added  at  the  appropriate  dilution  and  in  the 
appropriate dilutent (table 2.1). The incubation was carried out overnight at 4 C under 
moderate agitation. Membranes were then washed (3 x 15 minutes) in TBST before being 
incubated with the appropriate secondary antibody (table 2.1) diluted in 5% Marvel at 
room temperature for 1 hour under gentle rocking. Membranes then had a final round of 
TBST washing (3 x 15 minutes) before being immersed and shaken gently for 1 minute in 
ECL  Western  Blotting  chemoluminescent  substrate  (Pierce,  Rockford,  IL).  Membranes 
were then placed in a hypercassette (Amersham International plc, Little Chalfont, UK) and 
in a dark room were exposed to x-ray film (Kodak, Hemel Hempstead, UK) for ~1-5 s (α- 
Tubulin), ~5-60 s (GAPDH), ~10-60 s (p-ERK1/2) and ~5-30 mins (p-p38 and BMPR2) 
before being developed by a Kodak X-omat imaging machine. 
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2.7.6 Data analysis of western blots 
For WT and Tph1
-/- comparison experiments (p-ERK1/2 and p-Smad1/58) there were three 
lots of samples for each genotype, each containing IPAs and main pulmonary arteries from 
8 mice. Each of these samples was run 4 times giving a total of 12. For WT and Tph1
-/- 
comparison experiments (BMPR2) there were 3 lots of samples for each genotype, each 
containing IPAs and main pulmonary arteries from 4 mice. Each of these samples was run 
3 times giving a total of 9. Not all results were useable, however, due to poor detection of 
protein bands or too high a background signal. This is reflected in the n numbers for 
experiments being lower than 12 and 9 for respective experiments. For male and female 
comparison experiments whole lung was used for efficiency, yielding a greater volume of 
tissue for analysis. In these experiments there were 6 males and 6 females, each run on 
separate lanes in the one experiment yielding an n of 6 of each gender. Densitometric 
analysis of films following exposure was performed to determine the normalised level of 
protein expression using TotalLab version 2 (TotalLab Ltd, Newcastle, UK). 
 
2.8 Statistical analysis 
When  comparing  two  groups  of  data,  a  Student’s  unpaired  two-tailed  t-test  was  used. 
When comparing three or more groups of data, analysis of variance (ANOVA) was used. 
ANOVA was either one-way (when comparing one variable) or two-way (when comparing 
two variables). Newman-Keuls multiple comparison post test was applied to investigate 
statistical differences following one-way ANOVA and  Bonferroni multiple comparison 
post test was applied to investigate statistical differences following two-way  ANOVA.  
P<0.05 was deemed to indicate statistical significance. All statistics were calculated using 
GraphPad Prism 4. 
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1  Antibody 
 
Company 
 
 Dilution 
 
Dilutent 
 
2  Antibody 
 
Company 
 
Dilution 
Phospho-
ERK1/2 
Cell Signalling 
Technology Inc, 
Beverly, MA 
 
1:1000  TBST/BS
A* 
Anti-rabbit 
IgG 
Sigma-
Aldrich Ltd, 
Poole, UK 
1:1500 
Phospho-p38  Cell Signalling 
Technology Inc, 
Beverly, MA 
 
1:500  TBST/BS
A* 
Anti-rabbit 
IgG 
Sigma-
Aldrich Ltd, 
Poole, UK 
1:1500 
Phospho-
Smad 1/5/8 
Millipore (UK) 
Ltd, Croxley, UK 
1:1000  TBST/BS
A* 
Anti-rabbit 
IgG 
Sigma-
Aldrich Ltd, 
Poole, UK 
1:1500 
BMPR2  BD Biosciences, 
Oxford, UK 
1:500  5% 
marvel 
Anti-mouse 
IgG 
Sigma-
Aldrich Ltd, 
Poole, UK 
1:3000 
 - Tubulin  Abcam Ltd, 
Cambridge, UK 
1:5000  5% 
marvel 
Anti-mouse 
IgG 
Sigma-
Aldrich Ltd, 
Poole, UK 
1:5000 
GAPDH  Abcam Ltd, 
Cambridge, UK 
1:20000  5% 
marvel 
Anti-mouse 
IgG 
Sigma-
Aldrich Ltd, 
Poole, UK 
1:5000 
* 1.5 mls TBST + 1.5 mls (10% bovine serum albumin (BSA) made in TBST) 
 
Table 2.1 Primary and secondary antibodies used for Western blotting. 
p-Smad1/5/8  and  BMPRR2  1º  and  2º  dilutions  were  pre-determined  by  a  series  of 
optimisation  experiments  until  distinct  protein  bands  were  observed  against  a  clear 
background.  p-ERK1/2,  p-p38,  α-tubulin  and  GAPDH  optimal  dilutions  had  been 
experimentally derived previously (personal communication, Yvonne Dempsie).  
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Chapter 3 
Effect of hypoxia on transgenic mice 89 
 
3.1 Introduction 
Genetic manipulation of mice has provided a vast amount of information for the study of 
human disease and many genes implicated in PAH have been altered in mice to assess 
what, if any, role they may have in the pathogenesis of PAH. As discussed previously, 
these include NOS (Fagan et al., 1999; Ozaki et al., 2001), PGI2-S (Geraci et al., 1999), 
adrenomedullin (Matsui et al., 2004), VIP (Said et al., 2007) and K
+ channels (Archer et 
al., 2001; Pozeg et al., 2003). Of importance to this investigation has been the development 
of BMPR2
+/- mice and 5-HTT+ mice.  The BMPR2
+/- mouse developed by Beppu et al., 
2000 that is used in this investigation and another BMPR2 deficient heterozygous mouse 
line (carrying an in-frame deletion of exon 2 resulting in the loss of the extracellular ligand 
binding domain) (Delot et al., 2003) both may mimic the heterozygous loss of BMPR2 
function associated with PAH and hence provide a suitable genetic model for studying the 
disease. Results from the BMPR2
+/- mouse used in this investigation to date have been 
inconclusive with an early study indicating a mild pulmonary hypertensive phenotype in 
normal air (Beppu et al., 2004) but a later study by a different group finding no evidence of 
PAH under normoxia (Long et al., 2006).  There have also been some discrepancies in data 
between Beppu et al., 2004 and Long et al., 2006 derived from BMPR2
+/- mice following 
exposure to hypoxia. Neither of these studies, however, found a greater susceptibility to 
hypoxic PAH in BMPR2
+/- mice compared with WT.  
 Given  the  conflicting  results  obtained  so  far  with  this  BMPR2
+/-  mouse  and  the 
importance that both BMPR2 deficiency and hypoxia have in PAH, there is a need for 
greater  characterisation  of  the  BMPR2
+/-  mouse  phenotype  under  both  normoxia  and 
hypoxia and this investigation will continue the analysis of these mice for susceptibility to 
PAH. The normoxic 5-HTT+ mouse has increased PAP and under hypoxia, has elevated 
PAP, vascular remodelling and RVH compared with WT mice (MacLean et al., 2004). 
This investigation will analyse the 5-HTT+ mice again for evidence of PAH. 90 
 
The limited animal data gathered so far on the BMPR2
+/- mouse does not suggest a strong 
association with a pulmonary hypertensive phenotype in either normoxia or hypoxia. The 
human and animal data outlined previously supporting a modulating role for the 5-HTT in 
the development of PAH created the rationale of developing a mouse model that was 
BMPR2
+/- and 5-HTT+, mimicking a human with BMPR2 mutation and who had the L/L 
genotype for the 5-HTT. This model would allow assessment of whether the two genetic 
factors act synergistically to increase the risk of PAH under normoxia or under challenge 
from an environmental stimulus, in this case hypoxia.  
 One important aspect that has to be taken into account when interpreting the in vivo results 
just outlined in relation to the BMPR2
+/- and 5-HTT+ mice is the role that gender plays in 
determining the phenotypic outcome. Beppu et al., 2004 used both males and females with 
the majority being females and found no gender differences in results. Long et al., 2006 
used exclusively males. The 5-HTT+ mice used by MacLean et al., 2004 were exclusively 
females. In this study, both male and female WT, 5-HTT+, BMPR2
+/- and Cross TG mice 
will  be  assessed  allowing  the  interaction  of  gender  with  genetic  predisposition  to  be 
determined. 
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3.2 RESULTS 
All mice were age 5-6 months. 
 
3.2.1 Pulmonary and systemic haemodynamics in male mice 
sRVP  and  mRVP  were  assessed  in  male  mice  under  both  normoxic  and  hypoxic 
conditions. The results are shown in figure 3.1. WT mice had higher sRVP than Cross TG 
mice under normoxia (WT: 25.6 ± 0.9 mmHg, n=5, Cross TG: 15.8 ± 1.0 mmHg, n=6) and 
5-HTT+  mice had significantly higher sRVP (23.5 ±  2.4 mmHg, n=5) than Cross TG 
normoxic animals (5-HTT+: 23.5 ± 2.4 mmHg, n=5, Cross TG: 15.8 ± 1.0 mmHg, n=6). 
Inter-group differences were also observed for sRVP in hypoxic mice. WT mice (38.4 ± 
2.2 mmHg, n=6) had significantly higher sRVP than both BMPR2
+/- (15.1 ± 1.0 mmHg, 
n=5) and Cross TG (25.3 ± 2.2 mmHg, n=6) mice. 5-HTT+ hypoxic mice had similar 
sRVP (39.2 ± 1.5 mmHg, n=8) to WT mice which was greater than the sRVP recorded in 
BMPR2
+/- and Cross TG animals. No significant inter-group differences in mRVP were 
found for either normoxic or hypoxic animals. 
 Hypoxia caused a significant rise in sRVP in WT, 5-HTT+ and Cross TG mice (WT: 
p<0.001, 5-HTT+: p<0.001, Cross TG: p<0.01) but not in BMPR2
+/- mice (figure 3.1A). 
Similar results were obtained for mRVP with hypoxia causing a significant increase in 
mRVP in WT (p<0.001), 5-HTT+ (p<0.001) and Cross TG (p<0.05) mice (figure 3.1B). 
 No inter-group differences were observed for either mSAP or HR and these parameters 
were not significantly altered by hypoxia (figure 3.2) 
 
3.2.2 Pulmonary and systemic haemodynamics in female mice 
The results are shown in figure 3.3. In normoxic conditions, unlike male mice, 5-HTT+ 
female mice had higher sRVP than both WT and BMPR2
+/- (5-HTT+: 29.0 ± 3.4 mmHg, 
n=6,  WT:  15.9  ±  2.1  mmHg,  n=4,  BMPR2
+/-:  16.8  ±  3.2,  n=4)  mice.  No  inter-group 92 
 
differences were observed in hypoxic animals. The only significant difference in mRVP 
was  between  normoxic  5-HTT+  and  WT  with  the  5-HTT+  group  having  the  higher 
pressure (5-HTT+: 19.8 ± 3.1 mmHg, n=6, WT: 8.3 ± 1.9, n=4).  
 Hypoxia increased sRVP in WT (p<0.01), BMPR2
+/- (p<0.05) and Cross TG (p<0.05) 
mice (figure 3.3A) and mRVP was increased in WT (p<0.01), 5-HTT+ (p<0.05) and Cross 
TG (p<0.05) mice (figure 3.3B). 
 No significant differences were observed in mSAP under normoxia. Under hypoxia, 5-
HTT+ mice had elevated mSAP compared with the other three groups (5-HTT+: 99.0 ± 3.6 
mmHg, n=6, WT: 84.5 ± 2.2 mmHg, n=6, BMPR2
+/-: 75.1 ± 3.8 mmHg, n=4, Cross TG: 
83.1 ± 4.9 mmHg, n=4). Hypoxia only affected mSAP in BMPR2
+/- mice where it caused a 
decrease in pressure (p<0.05) (figure 3.4A). 
 HR was similar amongst groups under normoxia (figure 3.4B). Under hypoxia, however, 
BMPR2
+/- mice had significantly lower HR compared with the other groups (BMPR2
+/-: 
297.8 ± 4.4 bpm, n=9, WT: 438.0 ± 12.6 bpm, n=9, 5-HTT+: 445.2 ± 18.3 bpm, n=9, 
Cross TG: 409.0 ± 43.7 bpm, n=4). Similar to the mSAP results, hypoxia caused a decrease 
in HR in BMPR2
+/- mice (p<0.05) while the other groups were unchanged. 
 
3.2.3 Right ventricular hypertrophy and vascular remodelling in male mice 
RVH and vascular remodelling data are presented in figure 3.5. There were no inter-group 
differences  in  RVH  in  either  normoxic  or  hypoxic  conditions.  Hypoxia  significantly 
increased RVH in BMPR2
+/-  (p<0.01) and Cross TG (p<0.01) mice. Remodelling was 
similar between groups in both normoxia and hypoxia. When comparing normoxic and 
hypoxic  groups,  there  was  a  greater  than  5  fold  difference in  each  of  the  4  genotype 
(p<0.001 for each group except BMPR2
+/- where significance was p<0.01) groups.  
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Figure 3.1 Effect of 14 days hypoxia in WT, 5-HTT+, BMPR2
+/- and Cross TG male mice 
(n=4 to 8 mice per group) on sRVP (A) and mRVP (B). Results expressed as mean ± SEM. 
*  p<0.05,  **  p<0.01,  ***  p<0.001  using  Newman-Keuls  multiple  comparison  test.  † 
p<0.05, †† p<0.01, ††† p<0.001 versus corresponding normoxic value using an unpaired 
two-tailed t-test.  94 
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Figure 3.2 Effect of 14 days hypoxia in WT, 5-HTT+, BMPR2
+/- and Cross TG male mice 
(n=2 to 8 mice per group) on mSAP (A) and HR (B). Results expressed as mean ± SEM. 
Newman-Keuls multiple comparison test of  inter-genotype differences and an unpaired 
two-tailed  t-test  comparison  of  normoxic  and  hypoxic  groups  revealed  no  significant 
differences.  
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Figure 3.3 Effect of 14 days hypoxia in WT, 5-HTT+, BMPR2
+/- and Cross TG female 
mice (n=4 to 6 mice per group) on sRVP (A) and mRVP (B). Results expressed as mean ± 
SEM.  *  p<0.05  using  Newman-Keuls  multiple  comparison  test.  †  p<0.05,  ††  p<0.01 
versus corresponding normoxic value using an unpaired two-tailed t-test. 96 
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Figure 3.4 Effect of 14 days hypoxia in WT, 5-HTT+, BMPR2
+/- and Cross TG female 
mice (n=2 to 9 mice per group) on mSAP (A) and HR (B). Results expressed as mean ± 
SEM. * p<0.05, ** p<0.01, *** p<0.001 using Newman-Keuls multiple comparison test. † 
p<0.05 versus corresponding normoxic value using an unpaired two-tailed t-test. 
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3.2.4 Right ventricular hypertrophy and vascular remodelling in female mice 
RVH and remodelling data for female mice are presented in figure 3.6. No significant 
differences were noted for RVH between groups under normoxia. Under hypoxia, 5-HTT+ 
mice had a higher degree of RVH compared with WT and Cross TG (WT: 0.35 ± 0.01, 
n=19, 5-HTT+: 0.39 ± 0.01, n=18, Cross TG: 0.33 ± 0.02, n=7) mice. Hypoxia increased 
RVH in WT (p<0.001), 5-HTT+ (p<0.001), BMPR2
+/- (p<0.001) and Cross TG (p<0.05) 
mice. 5-HTT+ normoxic mice had more remodelled vessels than WT and BMPR2
+/- (WT: 
3.3 ± 0.6%, n=4, 5-HTT+: 8.2 ± 1.2%, n=4, BMPR2
+/-: 3.7 ± 0.7%, n=4) mice. There was 
considerable inter-group variability in remodelling in the hypoxic animals. 5-HTT+ mice 
had more remodelled vessels than WT and BMPR2
+/- mice had more remodelled vessels 
than WT and 5-HTT+ mice. Cross TG mice had a similar level of remodelling to the 
BMPR2
+/- mice and this value was significantly greater than WT and 5-HTT+ mice (WT: 
18.3 ± 1.1%, n=10, 5-HTT+: 24.7 ± 1.5%, n=10, BMPR2+/-: 36.3 ± 5.0%, n=4, Cross TG: 
35.4 ± 2.2%, n=4).  Hypoxia increased remodelling in all groups (p<0.001) compared with 
respective normoxic animals.  
 
3.2.5 Gender differences 
To determine if any gender differences existed, male vs female results were plotted for 
sRVP, mRVP, mSAP, HR, RVH and vascular remodelling (figures 3.7 to 3.12). Under 
normoxic conditions, WT female mice had lower sRVP compared with WT males (male: 
25.6 ± 0.9 mmHg, n=5, female: 15.9 ± 2.1 mmHg, n=4) (figure 3.7). A similar difference 
was noted under hypoxia (male: 38.4 ± 2.2 mmHg, n=6, female: 28.5 ± 2.2 mmHg, n=5).  
Cross TG female mice had higher sRVP under normoxia compared to Cross TG males 
(male: 15.8 ± 1.0 mmHg, n=6, female: 23.3 ± 1.5 mmHg, n=5) and although female Cross 
TG mice had higher sSVP compared with males following hypoxia, it did not reach  
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Figure 3.5 Effect of 14 days hypoxia in WT, 5-HTT+, BMPR2
+/- and Cross TG male mice 
(n=4 to 8 mice per group) on RVH (A) and remodelling (B). Results expressed as mean ± 
SEM. Newman-Keuls multiple comparison test of inter-genotype differences revealed no 
significant  differences.  ††  p<0.01,  †††  p<0.001  versus  corresponding  normoxic  value 
using an unpaired two-tailed t-test. 
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Figure 3.6 Effect of 14 days hypoxia in WT, 5-HTT+, BMPR2
+/- and Cross TG female 
mice (n=4 to 19 mice per group) on RVH (A) and remodelling (B). Results expressed as 
mean  ±  SEM.    *  p<0.05,  **  p<0.01,  ***  p<0.001  using  Newman-Keuls  multiple 
comparison test. ††† p<0.001  versus corresponding normoxic value using an unpaired 
two-tailed t-test. 
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significance (figure 3.7). There was a significant difference, however, between BMPR2
+/- 
male and female mice under hypoxia with female mice having higher pressures (male: 15.1 
± 1.0 mmHg, n=5, female: 29.5 ± 3.2 mmHg, n=5). No such difference between male and 
female BMPR2
+/- mice was observed under normoxia. Mean RVP data is presented in 
figure 3.8. Only for WT mice under normoxia, did the mean RVP  closely parallel the 
sRVP results. 
Mean RVP was significantly lower in WT female mice compared with males (male: 13.6 ± 
0.7  mmHg,  n=5,  female:  8.3  ±  1.9 mmHg,  n=4;  figure  3.8).  There  was  no  difference 
between male and female WT mice under hypoxia but there  was a substantial rise in 
mRVP in 5-HTT+ female mice compared with males under hypoxia (male: 19.1 ± 0.9 
mmHg, n=8, female: 30.1 ± 2.8 mmHg, n=5). No significant differences were observed 
between males and females for either BMPR2
+/- or Cross TG mice under normoxia or 
hypoxia (figure 3.8).  
 Mean SAP was similar between male and female in all groups studied except WT mice 
under hypoxia where females had lower mean SAP than males (male: 100.6 ± 4.8 mmHg, 
n=5, female: 84.5 ± 2.2 mmHg, n=6) (figure 3.9).   
 Figure 3.10 displays HR by gender. 5-HTT+ female mice had a higher HR than males 
under normoxia (male: 377.2 ± 10.1 bpm, n=5, female: 461.2 ± 30.9 bpm) and hypoxia 
(male: 370.8 ± 16.3 bpm, n=8. female: 445.2 ± 18.3 bpm, n=9). There was also a small, but 
significant difference in HR in BMPR2
+/- mice under hypoxia (male: 353.8 ± 18.8 bpm, 
n=5, female: 297.8 ± 4.4 bpm, n=4). 
 RVH data is presented in figure 3.11. The only gender difference noted was in 5-HTT+ 
hypoxic animals with female mice having a greater degree of RVH than males (male: 0.31 
± 0.02, n=8, female: 0.39 ± 0.01, n=18). 
 The  remodelling  results  are  outlined  in  figure  3.12.  5-HTT+  female  mice  had  more 
remodelled vessels than males under normoxia (male: 3.1 ± 1.3%, n=4, female: 8.2 ± 1.2, 101 
 
n=4) but not hypoxia. The only other gender difference observed was for WT mice under 
hypoxia where female mice had less remodelling than males (male: 24.9 ± 0.7%, n=4, 
female: 18.3 ± 1.1%, n=10). 
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Figure 3.7 Comparison of male and female sRVP in WT and 5-HTT+ mice (A) and in 
BMPR2
+/- and Cross TG mice (B) (n= 4 to 8 mice per group) under both normoxic and 
hypoxic conditions. Results expressed as mean ± SEM.  * p<0.05, ** p<0.01 versus male 
using an unpaired two-tailed t-test. 
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Figure 3.8 Comparison of male and female mRVP in WT and 5-HTT+ mice (A) and in 
BMPR2
+/- and Cross TG mice (B) (n= 4 to 8 mice per group) under both normoxic and 
hypoxic conditions. Results expressed as mean ± SEM.  * p<0.05, *** p<0.001 versus 
male using an unpaired two-tailed t-test. 
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Figure 3.9 Comparison of male and female mSAP in WT and 5-HTT+ mice (A) and in 
BMPR2
+/- and Cross TG mice (B) (n= 2 to 6 mice per group) under both normoxic and 
hypoxic conditions. Results expressed as mean ± SEM.  * p<0.05 versus male using an 
unpaired two-tailed t-test. 105 
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Figure 3.10 Comparison of male and female HR in WT and 5-HTT+ mice (A) and in 
BMPR2
+/- and Cross TG mice (B) (n= 4 to 9 mice per group) under both normoxic and 
hypoxic conditions. Results expressed as mean ± SEM.  * p<0.05, ** p<0.01 versus male 
using an unpaired two-tailed t-test. 106 
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Figure 3.11 Comparison of male and female RVH in WT and 5-HTT+ mice (A) and in 
BMPR2
+/- and Cross TG mice (B) (n= 4 to 19 mice per group) under both normoxic and 
hypoxic conditions. Results expressed as mean ± SEM.  *** p<0.001 versus male using an 
unpaired two-tailed t-test. 
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Figure 3.12 Comparison of male and female remodelling in WT and 5-HTT+ mice (A) 
and in BMPR2
+/- and Cross TG mice (B) (n= 4 mice per group) under both normoxic and 
hypoxic conditions. Results expressed as mean ± SEM.  * p<0.05, ** p<0.01 versus male 
using an unpaired two-tailed t-test. 
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3.3 Discussion 
There were two principle objectives in this series of experiments. The first was to monitor 
RVP  in  vivo  in  WT  and  TG  animals  followed  by  assessment  of  RVH  and  vascular 
remodelling post-mortem under normal room air conditions. The second was to determine 
the effect of hypoxia on these same parameters. Female 5-HTT+ mice were found to have 
elevated  mRVP  compared  to  WT  mice  under  normoxia,  a  phenotype  previously 
characterised  in  these  mice  (MacLean  et  al.,  2004).  This  investigation,  however,  also 
showed that female 5-HTT+ mice have a greater number of remodelled vessels, the first 
time this phenotypic change has been observed in 5-HTT+ mice. Female 5-HTT+ mice 
also  developed  an  exaggerated  pulmonary  hypertensive  phenotype  following  hypoxia 
indicating  an  interaction  between  overexpression  of  the  5-HTT  and  a  pulmonary 
hypertensive  risk  factor.  These  phenotypic  changes  in  5-HTT+  mice  were  unique  to 
females  with  male  mice  showing  similar  results  to  WT.  Interesting  results  were  also 
obtained from BMPR2
+/- animals. Both male and female normoxic BMPR2
+/- mice were 
similar to WT in all parameters tested, however, both male and female BMPR2
+/- mice 
were  surprisingly  less  susceptible  to  hypoxic  induced  increases  in  mRVP.    The 
remodelling  results  in  female  BMPR2
+/-  hypoxic  animals  were  markedly  different, 
however, with these animals displaying significantly more remodelling following hypoxia 
than  mice  with  normal  BMPR2  levels.  This  enhanced  hypoxic  remodelling  is  a  novel 
finding in the BMPR2
+/- mouse. Despite these modulating effects of BMPR2 deficiency 
and 5-HTT overexpression on the pulmonary phenotype of mice, no synergistic effect 
between these two genetic changes was observed in either male or female Cross TG mice 
that resulted in a more severe pulmonary hypertensive phenotype compared with either 5-
HTT+ or BMPR2
+/- mice.  
 It has been established that the proliferative effect of 5-HT on PASMCs is dependent on 
uptake via the 5-HTT (Lee et al., 1991; Eddahibi et al., 1999) and that 5-HTT levels are 109 
 
increased in pulmonary arteries in FPAH/IPAH patients. The finding that 5-HTT levels are 
highest in vessels undergoing remodelling is convincing evidence for a central role of the 
5-HTT in this critical component of the disease (Eddahibi et al., 2001).  The increased 
vascular remodelling seen in 5-HTT+ normoxic mice is thought to occur following higher 
levels of 5-HT being taken up by PASMCs and subsequent activation of  ROS and p-
ERK1/2 which contributes to the mitogenic effect of 5-HT on PASMCs (Lee et al., 1999). 
The remodelling observed in female 5-HTT+ mice was relatively modest and is unlikely to 
make a significant contribution to the elevated RVP observed. The RVP in the female 5-
HTT+ mice was not higher than the RVP reported by MacLean et al., 2004 in which no 
remodelling was found. The mechanisms that underlie the increased RVP in 5-HTT+ mice 
is unknown. It maybe that overexpression of the 5-HTT has as yet unknown effects on 
other vasoactive mediators that may contribute to increasing RVP.   
 It has been shown previously that female 5-HTT+ mice have an exaggerated response to 
hypoxia compared with WT mice.  RVP, RVH and vascular remodelling are all higher in 
5-HTT+ mice than in WT mice following hypoxia (MacLean et al., 2004) and the results 
presented here are broadly in agreement with these findings. Hypoxia induced an increase 
in RVH in all female groups with 5-HTT+ mice displaying a greater degree of RVH than 
WT or Cross TG mice. 5-HTT+ hypoxic mice also had more remodelling and a trend 
towards a higher mRVP compared with WT. None of these phenotypic changes observed 
in 5-HTT+ female mice under either normoxic or hypoxic conditions were observed in 
respective male mice. 5-HTT inhibitors attenuate vascular remodelling in hypoxic induced 
pulmonary hypertensive mice (Marcos et al., 2003) and mice lacking the 5-HTT (5-HTT
-/- 
mice) also develop less severe hypoxic PAH than WT mice (Eddahibi et al., 2000).  It 
would  be  logical  to  assume  from  these  studies  that  perhaps  hypoxia  increases  5-HTT 
expression in the pulmonary vasculature but this has not been the case in several studies to 
date. 5-HTT transcription, receptor number and protein were decreased in both WT and 5-110 
 
HTT+ mice following hypoxia (MacLean et al., 2004) and 5-HT uptake is reduced in the 
lungs of WT hypoxic mice (Launay et al., 2002).  Conflicting information has emerged 
from studies on hypoxic rats. Hypoxic rat PASMCs have increased expression of the 5-
HTT that is associated with a greater proliferative response to 5-HT (Eddahibi et al., 1999) 
yet 5-HT uptake is reduced in the lungs of hypoxic rats (Jeffery et al., 2000). Significant 
experimental differences such as strain, age, sex and duration of hypoxia are likely to be 
important factors in explaining these observed differences.  
 Hypoxia has previously been shown to increase circulating 5-HT levels in mice (Callebert 
et  al.,  2006)  and  infusion  of  5-HT  exaggerates  the  hypoxic  pulmonary  hypertensive 
phenotype of rats (Eddahibi et al., 1997).  Conversely, Tph1
-/- mice, lacking peripheral 5-
HT, display attenuated RVP and vascular remodelling following hypoxia compared with 
WT mice (Morecroft et al., 2007).  It is clear from data presented here that overexpression 
of the 5-HTT is sufficient to induce elevated RVP and vascular remodelling in female 
mice. It maybe that hypoxia increases circulating 5-HT levels which results in a greater 
uptake of 5-HT into PASMCs activating  vasoconstrictor and mitogenic pathways. The 
downregulation  of  the  5-HTT  observed  in  hypoxic  mice  may  be  a  compensatory 
mechanism for the rise in plasma [5-HT].  Overexpression of the 5-HTT may also affect 
other signalling pathways involved in inducing the pulmonary hypertensive phenotype. 
Mice  that  overexpress  the  5-HTT  in  smooth  muscle  under  the  control  of  the  SM22 
promoter develop spontaneous PAH which worsens with age (Guignabert et al., 2006). 
Moreover, these mice also develop more severe PAH following both hypoxia and MCT.  
The SM22-5-HTT+ mouse was found to have reduced expression of Kv1.5 and Kv2.1 in 
the lung which would reduce Kv current promoting vasoconstriction, proliferation and a 
reduction  in  apoptosis.  It  is  not  known  if  Kv  channel  subunits  are  downregulated  in 
PASMCs in the 5-HTT+ mouse in a similar way to the SM22-5-HTT+ mouse. If they are, 
they are likely to contribute to the pulmonary hypertensive phenotype and may partly 111 
 
explain  the  enhanced  response  to  hypoxia  despite  an  apparent  reduction  in  5-HTT 
expression. Hypoxia reduces Kv1.5 and Kv2.1 expression (Archer et al., 1998a; Platoshyn 
et al., 2001) and it maybe be the Kv current is impaired to a greater degree in hypoxic 5-
HTT+ mice compared with WT mice resulting in a greater degree of PAH. The study by 
Guignabert et al., 2006 also reveals that overexpression of the 5-HTT in smooth muscle 
alone  is  sufficient  to  induce  PAH.  This  rules  out  changes  in  circulating  5-HT  or 
bioavailability as a modulating factor in these mice.   
 Hypoxic 5-HTT+ female mice had higher mSAP than the other three groups; however, the 
pressure was still within the normal physiological range. The serotonin system is involved 
in controlling SAP at several levels. 5-HT acts neuronally to modulate the parasympathetic 
and sympathetic nervous systems thus influencing CO, HR and ventricular contractility. 5-
HT  also  acts  via  5-HT1  and  5-HT2  receptors  on  peripheral  systemic  arteries  to  alter 
vascular tone (Cote et al., 2004). Given that there was no difference between 5-HTT+ and 
WT mice under normoxia, it may be that hypoxia increases circulating 5-HT levels as 
previously described (Callebert et al., 2006) and through a central or peripheral site of 
action, acts to increase mSAP.  
  Both male and female normoxic BMPR2
+/- mice were similar to WT in all parameters 
tested. There was no evidence of increased RVP, RVH or vascular remodelling.  These 
results concur with earlier studies in the same BMPR2
+/-  mouse which found that the 
pulmonary vascular phenotype was similar to WT (Song et al., 2005; Long et al., 2006) but 
differ from results obtained by Beppu et al., 2004 whose BMPR2
+/- mice had elevated 
PAP, PVR and an increased wall thickness of muscularised pulmonary arteries. SAP, like 
in this investigation was normal. The reasons for these discrepancies are unclear but are 
unlikely  to  be  related  to  age  as  Song  et  al.,  2005  compared  RVP  between  WT  and 
BMPR2
+/- mice throughout the life cycle of the animals and the ages of mice utilised by 
Long et al., 2005 were comparable to those used by Beppu et al., 2004. Similar to this 112 
 
investigation,  Beppu  et  al.,  2004  studied  both  male  and  female  mice  and  found  both 
genders displayed the altered pulmonary vascular phenotype and thus gender difference 
can be ruled out as a mitigating factor for the difference between this study and Beppu et 
al.,  2004.  The  accumulated  data  for  this  particular  BMPR2
+/-  mouse  indicates  that 
pulmonary vascular abnormalities are, at most, subtle. Given that the BMPR2
+/- mouse is 
thought to mimic the haploinsufficiency seen in FPAH and that only a minority of human 
carriers  of  the  BMPR2  mutation  develop  PAH,  it  is  perhaps  not  surprising  that  the 
BMPR2
+/-  mouse  does  not  display  a  pulmonary  hypertensive  phenotype  under  normal 
physiological conditions. 
  The  BMPR2
+/-  mouse  is,  however,  more  susceptible  to  PAH  following  exposure  to 
secondary risk factors such as 5-HT (Long et al., 2006) and the interaction of BMPR2 and 
the serotonergic system will be further investigated in subsequent chapters.  The study in 
this  chapter  uncovered  an  important  interaction  between  dysfunctional  BMPR2  and 
hypoxic  induced  vascular  remodelling.  BMPR2
+/-  female  mice  were  more  sensitive  to 
hypoxic  induced  remodelling,  having  more  remodelled  vessels  than  mice  with  normal 
BMPR2 levels. Similar to the 5-HTT+ mice, this phenotypic change was not observed in 
male BMPR2 hypoxic mice which had a similar level of remodelling to WT mice. Taken 
together,  these  results  from  the  5-HTT+  and  BMPR2
+/-  mice  reveal  an  important 
interaction between gender and genetic changes relevant to PAH.  Unexpectedly, both 
male  and  female  BMPR2
+/-  mice  were more  resistant to  hypoxic  induced  increases  in 
mRVP and mRVP was not significantly different to normoxic BMPR2
+/- mice. Although 
female BMPR2
+/- mice showed similar increases compared to WT, the power of the data is 
lower due to a lower n number and larger standard error which unfortunately is a weakness 
of  the  experiment.  The  mSAP  and  HR  measurements,  however,  suggest  an  altered 
cardiovascular response in the BMPR2
+/- mouse, at least in the females. Hypoxia decreased 
mSAP in BMPR2
+/- female mice compared with their normoxic controls. HR was also 113 
 
decreased in female BMPR2
+/- mice following hypoxia to a level that was over 100 bpm 
slower than the other 3 genotypes.   A decrease in mSAP has previously been shown in 
BMPR2
+/- mice following hypoxia (Beppu et al., 2004).  BMPs are involved in normal 
heart development (Chen et al., 2004) and the changes observed in mSAP and HR may 
relate to a cardiac phenotypic change, currently uncharacterised in BMPR2
+/- mice, that 
interacts with hypoxia. The pulmonary results presented here contradict those presented by 
Beppu et al., 2004 who found that pulmonary haemodynamics were similar between WT 
and BMPR2
+/- mice following hypoxia but that vascular remodelling as assessed by wall 
thickness was less in hypoxic BMPR2
+/- mice than in WT.  Long et al., 2006 also found 
that RVP and RVH were similar between WT and BMPR2
+/- mice following hypoxia. It is 
unclear why the study by Beppu et al., 2004 found less vascular remodelling in BMPR2
+/- 
animals  following  hypoxia  which  is  in  contrast  to  the  greater  degree  of  vascular 
remodelling seen in female BMPR2
+/- mice in this thesis or to the levels similar to WT as 
seen in the males. The age range of the animals used by Beppu et al., 2004 was greater 
than that used in this study (2-5 months versus 5-6 months) and although the authors state 
that  the  pulmonary  haemodynamic  response  was  similar  between  male  and  female 
BMPR2
+/-  mice,  it  is  unclear  which  gender  was  employed  in  the  morphological 
examination of lung samples. Moreover, the duration of hypoxia differed between studies 
which may account for some of the discrepancies observed. Duration of hypoxia was found 
to be a factor in experiments using the BMPR2
+/- mouse developed by Delot et al., 2003 
(BMPR2
∆E2) which does have higher RVP and RVH following hypoxia but only after 5 
weeks exposure and these mice do not have increased vascular remodelling. No differences 
were observed in RVP, RVH or remodelling between BMPR2
∆E2 and WT mice after 3 
weeks hypoxia or under normoxia (Frank et al., 2008).  There was also no difference in 
PVR between WT and BMPR2
+/- mice (which may have indicted evidence of vascular 
remodelling) under hypoxia in the study by Long et al., 2006 but this study only used male 114 
 
mice and no differences were noted in vascular remodelling between male BMPR2
+/- and 
WT mice in this investigation.  
 PASMCs from BMPR2
+/- and WT mice have similar levels of p-Smad1/5/8 (Beppu et al., 
2004;  Long et al., 2006) and both display similar elevated expression of p-Smad1/5/8 
following hypoxia (Long et al., 2006). PASMCs from BMPR2
+/- mice do, however, show 
less increase in p-Smad1/5/8 following incubation with BMP-2 than WT PASMCs (Beppu 
et al., 2004; Long et al., 2006) indicating impaired BMP signalling. BMP ligands have 
previously been shown to have anti-proliferative effects on human PASMCs (Zhang et al., 
2003), a process dependent on activation of p-Smad1 (Yang et al., 2005). The elevated p-
Smad1/5/8 seen in hypoxic murine PASMCs may act to try to counteract the proliferative 
response that hypoxia has on these cells. It is thought that hypoxia acts through numerous 
pathways to induce proliferation of PASMCs including G-protein mediated activation of 
ERK1/2 by mitogenic factors such as 5-HT and ET-1 released by PAECs and by growth 
factors and ROS released by PAFs (Stenmark et al., 2006). Hypoxia can also inhibit Kv 
channels  present  on  PASMCs  inducing  vasoconstriction  and  promoting  proliferation 
(Archer et al., 1998a; Platoshyn et al., 2001). As BMPR2 is decreased in all cells in the 
BMPR2
+/- mouse, changes in BMP signalling in either the endothelium or smooth muscle 
layer of pulmonary arteries may facilitate hypoxic induced remodelling.  Using a smooth 
muscle  specific  dominant  negative  BMPR2  (SM22-tet-BMPR2
delx4+)  West  et  al.,  2004 
showed that mice expressing dominant negative BMPR2 in smooth muscle have increased 
RVP,  RVH  and  vascular  remodelling  at  2  months  old  indicating  that  severe  loss  of 
functional  BMPR2  in  smooth  muscle  is  sufficient  to  induce  PAH.  The  level  of 
muscularistion of pulmonary arteries was relatively modest in the SM22-tet-BMPR2
delx4+ 
mice  and  the  increased  RVP  and  RVH  is  likely  to  be  related  more  to  enhanced 
vasoconstriction than remodelling. A later study with these same TG mice showed that 
both males and females were equally susceptible to the pulmonary hypertensive phenotype 115 
 
(Tada et al., 2007). From the results presented in this thesis, it can be determined that only 
female BMPR2
+/- mice develop exaggerated remodelling following hypoxia and it may be 
that age is just as an important factor as gender. It may be that in mice of 2 months, 
vasoconstriction  contributes  more  to  the  pulmonary  hypertensive  phenotype  than 
remodelling  but  that  mice  that  are  5-6  months  old  are  more  sensitive  to  vascular 
remodelling. If loss of BMPR2 in smooth muscle induces PAH in unchallenged mice but 
not in unchallenged BMPR2
+/- mice, it may that other factors i.e. hypoxia in this case are 
required  that  further  suppress  BMPR2  signalling  in  PASMCs  that  lead  to  a  loss  of 
apoptosis and increased proliferation following stimulation by growth factors activated by 
hypoxia in the lung. Further studies using the SM22-tet-BMPR2
delx4+ have shown that these 
animals have reduced whole lung Kv channel expression and that the elevated RVP could 
be brought back to control values by administration of Nifedipine, an L-type  Ca
2+ channel 
blocker.  Administration  of  BMP-2  to  human  PASMCs  increased  Kv1.5  expression 
indicating  regulation  of  Kv  channels  by  BMP  signalling  (Young  et  al.,  2006).  If  Kv 
channels were decreased in PASMCs in BMPR2
+/- mice then further suppression of these 
channels  by  hypoxia  may  promote  an  increase  in  intracellular  Ca
2+  concentration 
promoting  vasoconstriction  and  proliferation  of  these  cells.  The  SM22-tet-BMPR2
delx4+ 
mouse  also  has  elevated  levels  of  IL-6  and  TGF-  β  and  BMP-2  reduces  both  these 
cytokines in human PASMCs (Hagen et al., 2007). It is unknown if the BMPR2
+/- mice 
used here have higher than normal lung expression of TGF-β or IL-6 similar to SM22-tet-
BMPR2
delx4+ mice. If they do, it could enhance the effect of hypoxia. Hypoxia increases 
both these agents (Stenmark et al., 2006) and both are implicated in the progression of 
PAH.  IL-6  is  increased  in  serum  from  PAH  patients  (Humbert  et  al.,  1995)  and 
administration of IL-6 induces a pulmonary hypertensive like phenotype in rats (Miyata et 
al., 2001). 
 Under normoxia, male Cross TG mice had similar mRVP to the other three groups. In 116 
 
female mice, Cross TG animals had almost double the level of RVP compared to WT 
although this was not significant. This is possibly due to relatively low n numbers for the 
Cross TG mice due to the extreme difficulties in breeding these animals. There was no 
significant differences in mRVP between Cross TG mice and 5-HTT+ mice indicating that 
the  presence  of  dysfunctional  BMPR2  is  not  enhancing  the  predisposition  towards 
enhanced  mRVP  in  mice  who  are  5-HTT+.  RVH  and  vascular  remodelling  were  not 
present in Cross TG males. In female mice there was a trend towards an increase in RVH 
in  Cross  TG  mice  similar  to  that  observed  for  5-HTT+  mice.  As  for  mRVP,  the 
predominant factor for this increase is overexpression of the 5-HTT and the BMPR2
+/- 
genotype  confers  no  greater  susceptibility.  When  the  remodelling  data  is  analysed,  it 
appears that Cross TG mice have less remodelled vessels than 5-HTT+ mice and unlike the 
5-HTT+ mice, Cross TG mice did not have significantly more remodelling than WT mice.  
It is unlikely, however, that the presence of the BMPR2 mutation is offering any protection 
against vascular remodelling especially considering the data for remodelling in BMPR2
+/- 
female mice following hypoxia. Moreover, half the Cross TG mice (2 of 4) assessed for 
remodelling had evidence of remodelling similar to that seen for 5-HTT+ mice. Individual 
variations between animals may be the source of the differences between the 5-HTT+ and 
Cross TG groups.   
 Cross  TG  mice  did  not  display  an  exaggerated  pulmonary  hypertensive  phenotype  to 
hypoxia  relative  to the  single transgenics.  In  fact,  the  effect  of  hypoxia  on  RVH  was 
significantly  less  in  female  cross  TG  mice  compared  with  female  5-HTT+  mice. 
Overexpression of the 5-HTT did not enhance the vascular remodelling in hypoxic Cross 
TG females compared with BMPR2
+/- single transgenic animals. The only indicator of any 
worsening of PAH was a trend towards an increase in the percentage of remodelled vessels 
in male hypoxic animals. There does not appear to be any significant cross talk between 
the 5-HTT and dysfunctional BMPR2 in the mice studied here, at least none that influence 117 
 
the parameters analysed. Long et al., 2005 found that 5-HT could downregulate p-Smad1/5 
in WT and BMPR2
+/- PASMCs and increase p-ERK1/2 in PASMCs from BMPR2
+/- mice. 
These effects are likely to contribute to the increased proliferation 5-HT had on BMPR2
+/- 
PASMCs, an effect that was blocked by ketanserin but not by a 5-HTT antagonist. Thus, 
cross-talk between 5-HT and BMPR2 in the context of PASMC proliferation may be 5-
HT2A mediated and not 5-HTT mediated. There is currently little further data regarding the 
interactions  between  5-HT  and  BMPR2  within  the  pulmonary  vasculature  and  how  a 
genetic change in one signalling system may affect the other. Urinary excretion of 5-HT is 
similar in the BMPR2
+/- mouse utilised here compared with WT (Song et al., 2005) and 
mice  that  overexpress  the  5-HTT  in  smooth  muscle  have  normal  expression  levels  of 
BMPR2, BMPR1A, BMPR1B, BMP-2 and BMP-4 (Guignabert et al., 2006). It has to be 
remembered also, that in human patients with PAH, both BMPR2 levels (in patients with 
mutations) and 5-HTT levels are lower and higher respectively than can be explained by 
genetic factors alone. More subtle changes in intracellular signalling molecules may occur 
via cross regulation between internalisation of 5-HT and BMPR2 pathways that don’t by 
themselves uncover a pulmonary hypertensive phenotype. Evidence for this already exists 
in this thesis, in this chapter and in subsequent chapters related to the discovery that female 
mice are more prone to the pulmonary effects of the underlying genetic abnormalities. 
Some  as  yet  unknown  agent  which  differs  between  male  and  female  mice  alters  the 
susceptibility of females to PAH relative to males perhaps through direct interactions with 
either the 5-HT or BMPR2 systems (see chapter 8 for more information on interactions 
between 5-HT, BMPR2 and gender). 
 As described in section 2.3.1, both sRVP and mRVP values were recorded. sRVP was, in 
general, more variable between experiments. This was partly related to inconsistent wave 
trace amplitudes recorded from animals in one experimental batch compared with animals 
in another which itself was related to experimental design and technical proficiency of the 118 
 
procedure. mRVP, which should remain uniform regardless of wave amplitude is likely to 
be a better indicator for comparing RVP of different animals and will be solely used for 
interpreting pulmonary pressure data in this thesis. 
 To summarise, overexpression of the 5-HTT results in spontaneous elevation of mRVP 
and vascular remodelling. 5-HTT overexpression was also associated with a worsening of 
hypoxic  PAH.  BMPR2
+/-  mice  are  phenotypically  normal  in  room  air  and  were  less 
susceptible to hypoxic induced rises in mRVP. Despite this, female BMPR2
+/- mice did 
show elevated vascular remodelling following hypoxia compared with WT and 5-HTT+ 
mice,  a  result  that  highlights  the  important  role  BMPR2  has  in  modulating  vascular 
integrity and how deficiency in BMPR2 can interact with an additional risk factor for PAH 
to promote vascular changes characteristic of the disease. This study also demonstrated 
through the use of the novel Cross TG mice that no synergistic effects were observed 
between BMPR2 deficiency and 5-HTT overexpression that resulted in a more pronounced 
pulmonary hypertensive phenotype.  Perhaps the most surprising and key finding from this 
work was the discovery that only female TG mice express the exaggerated pulmonary 
hypertensive  changes  indicating  an  important  interaction  between  gender  and  genetic 
predisposition to cause the symptoms of PAH.  
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Chapter 4 
Dexfenfluramine dosing study in BMPR2
+/- mice 120 
 
4.1 Introduction 
While the risk of PAH is increased in people exposed to Dfen (Abenhaim et al., 1996), it is 
not known why some people develop PAH following Dfen and others do not.  Even a 23 
fold increased risk of PAH in long-term Dfen users (Abenhaim et al., 1996) still represents 
an extremely low risk of developing the disease suggesting genetic predisposition plays an 
important part. Humbert et al., 2002 analysed fenfluramine users with PAH for BMPR2 
mutations  and  found  that  9%  of  patients  carried  BMPR2  mutations.  As  the  authors 
acknowledge, the actual number of patients that may carry the BMPR2 mutation may be 
much higher due to incomplete screening of the BMPR2 gene. A BMPR2 mutation was 
also  found  in  a  patient  that  developed  PAH  following  the  ingestion  of  the  appetite-
suppressant amfepramone (Abramowicz et al., 2003). The need for genetic predisposition 
in Dfen associated PAH is supported by animal data where administration of Dfen has 
failed to induce PAH in mice (Launay et al., 2002) and rats (Mitani et al., 2002; Rochefort 
et al., 2006). The BMPR2
+/- mouse used in this thesis has previously been shown to be 
more susceptible to PAH induced by inflammatory stress. The inflammatory response was 
induced by adenovirus mediated pulmonary overexpression of 5-LO (Song et al., 2005). Of 
particular interest to this investigation was the discovery by Long et al., 2006 that infusion 
of 5-HT for 2 weeks increased RVP in BMPR2
+/- mice but not in WT mice, an effect that 
was exaggerated in hypoxia. It would, therefore, be beneficial to determine if BMPR2
+/- 
mice are susceptible to Dfen induced PAH. In this chapter WT and BMPR2
+/- mice will be 
administered Dfen and assessed for evidence of a pulmonary hypertensive phenotype. The 
results in the last chapter clearly demonstrated the importance of gender in determining the 
pulmonary hypertensive phenotype. To determine if the response to Dfen is affected by 
gender, both male and female mice will be studied. 
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4.2 Methods  
Mice  (male  and  female)  were  2  months  old  at  commencement  of  Dfen  dosing  and  3 
months  old  at  time  of  experimental  analysis.  Mice  were  dosed  with  dexfenfluramine 
hydrochloride (Sigma-Aldrich Ltd, Poole, UK) (5 mg/kg/day) dissolved in H2O via oral 
gavage dosing for 28 days before analysis of pulmonary haemodynamics as described in 
section 2.3.  
 
4.3 Results 
4.3.1 Pulmonary and systemic haemodynamics in male mice 
sRVP  and  mRVP  for  WT  and  BMPR2
+/-  male  mice  dosed  with  Dfen  or  vehicle  are 
presented in figure 4.1 Dfen caused a decrease in sRVP (vehicle: 23.7 ± 0.5 mmHg, n=19, 
Dfen: 18.4 ± 2.0 mmHg, n=9) and mRVP (vehicle: 12.7 ± 0.3 mmHg, n=19, Dfen: 10.8 ± 
0.7 mmHg, n=9) in WT mice but had no effect on either sRVP or mRVP in BMPR2
+/- 
mice. There were no differences noted between WT and BMPR2
+/- mice.  
 mSAP was similar between the 4 groups (figure 4.2A). Dfen increased HR in BMPR2
+/- 
mice compared with Dfen treated WT mice (WT: 383.9 ± 12.9 bpm, n=9, BMPR2
+/-: 428.3 
± 18.3 bpm, n=8) (figure 4.2B). 
 
4.3.2 Pulmonary and systemic haemodynamics in female mice 
sRVP and mRVP for WT and BMPR2
+/- female mice dosed with Dfen or vehicle are 
presented in figure 4.3. Dfen increased sRVP (vehicle: 17.3 ± 1.5 mmHg, n=8, Dfen: 32.0 
± 0.5 mmHg, n=7) and mRVP (vehicle: 11.6 ± 0.9 mmHg, n=8, Dfen: 18.3 ± 1.1 mmHg, 
n=7) in WT mice. sRVP (vehicle: 17.5 ± 2.2 mmHg, n=7, Dfen: 27.9 ± 3.1 mmHg, n=6) 
and mRVP (vehicle: 12.7 ± 1.3 mmHg, n=7, Dfen: 20.2 ± 2.6 mmHg, n=6) were also 
increased in Dfen treated BMPR2
+/- mice. There were no significant differences in sRVP 
or mRVP between WT and BMPR2
+/- animals. There was insufficient data for a 122 
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Figure 4.1 Effect of Dfen ingestion in WT and BMPR2
+/- male mice (n = 7 to 19 mice per 
group) on sRVP (A) and mRVP (B). Results expressed as mean ± SEM. * p<0.05, ** 
p<0.01 versus WT vehicle using Bonferroni multiple comparison test. 
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Figure 4.2 Effect of Dfen ingestion in WT and BMPR2
+/- male mice (n = 3 to 19 mice per 
group) on mSAP (A) and HR (B). Results expressed as mean ± SEM. * p<0.05 versus WT 
Dfen using Bonferroni multiple comparison test. 124 
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Figure 4.3 Effect of Dfen ingestion in WT and BMPR2
+/- female mice (n = 6 to 8 mice per 
group) on sRVP (A) and mRVP (B). Results expressed as mean ± SEM. ** p<0.01, *** 
p<0.01 versus WT vehicle, † p<0.01 versus BMPR2
+/- vehicle using Bonferroni multiple 
comparison test. 125 
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Figure 4.4 Effect of Dfen ingestion in WT and BMPR2
+/- female mice (n = 6 to 8 mice per 
group) on HR. Results expressed as mean ± SEM. * p<0.05 versus WT vehicle, ** p<0.01 
versus WT Dfen using Bonferroni multiple comparison test. 
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comparison of mSAP in female mice but HR was lower in BMPR2
+/- mice, both for  
vehicle (WT: 445.0 ± 16.0 bpm, n=8, BMPR2
+/-: 392.1 ± 8.9 bpm, n=7) and Dfen (WT: 
436.1 ± 10.8 bpm, n=7, BMPR2
+/-: 358.5 ± 18.7 bpm, n=6) treated animals (figure 4.4). 
 
4.3.3 Right ventricular hypertrophy and vascular remodelling in male mice 
Figure 4.5 illustrates RVH and vascular remodelling data for male mice. There were no 
differences  observed  for  RVH  between  groups.  BMPR2
+/-  mice  dosed  with  Dfen  had 
approximately twice the number of remodelled vessels compared to WT mice treated with 
Dfen and BMPR2
+/- vehicle treated mice (WT Dfen: 3.0 ± 0.9%, n=4, BMPR2
+/- vehicle: 
3.1 ± 0.7%, n=4, BMPR2
+/- Dfen: 6.0 ± 0.3%, n=4) 
 
4.3.4 Right ventricular hypertrophy and vascular remodelling in female mice 
Female RVH and remodelling data is shown in figure 4.6. RVH was  not significantly 
different  between  groups.  There  was,  however,  a  substantial  increase  in  remodelling 
following Dfen in both WT (vehicle: 3.2 ±  0.3%, n=4, Dfen: 12.1 ±  1.2%, n=4,) and 
BMPR2
+/- (vehicle: 4.0 ±  0.7%, n=4,  Dfen: 12.5 ±  1.2, n=4) mice with similar levels 
between the two genotypes.  
 
4.3.5 Gender differences 
The preceding data was subjected to a gender analysis and is presented in figures 4.7 to 
4.9. The most striking gender difference noted regarding RVP was the increase in sRVP 
elicited by Dfen in the females compared with the males (figure 4.7A). This occurred in 
both WT (male: 18.4 ± 2.0 mmHg, n=9, female: 32.0 ± 0.5 mmHg, n=7) and BMPR2
+/- 
(male: 17.4 ± 1.0 mmHg, n=7, female: 27.9 ± 3.1 mmHg, n=6) mice. Similar differences 
also occurred for mean RVP (WT male: 10.8 ± 0.7 mmHg, n=9, WT female: 18.3 ± 1.1 
mmHg, n=7, BMPR2
+/- male: 11.0 ± 0.8 mmHg, n=7, BMPR2
+/- female: 20.2 ± 2.6 127 
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Figure 4.5 Effect of Dfen ingestion in WT and BMPR2
+/- male mice (n = 4 to 18 mice per 
group) on RVH (A) and remodelling (B). Results expressed as mean ± SEM. ** p<0.01 
versus WT Dfen and BMPR2
+/- vehicle using Bonferroni multiple comparison test.  
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Figure 4.6 Effect of Dfen ingestion in WT and BMPR2
+/- female mice (n = 4 to 13 mice 
per group) on RVH (A) and remodelling (B). Results expressed as mean ± SEM. *** 
p<0.001 versus WT vehicle, † p<0.001 versus BMPR2
+/- vehicle using Bonferroni multiple 
comparison test. 
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mmHg, n=6) (figure 4.7B). In vehicle treated animals, male WT animals had higher sRVP 
than females (male: 23.7 ± 0.5 mmHg, n=19, female: 17.3 ± 1.5 mmHg, n=8). There was, 
however, no such difference for mean RVP. 
There was insufficient data to do a male versus female comparison for mean SAP except 
for vehicle dosed BMPR2
+/- mice where there was no significant difference (male: 82.4 ± 
2.0 mmHg, n=5, female: 78.4 ± 7.4 mmHg, n=4). Variations in HR were noted between 
males and females treated with Dfen (figure 4.8). There was an increased HR in female 
WT mice compared with males (male: 383.9 ± 12.9 bpm, n=9, female: 436.1 ± 10.8 bpm, 
n=7) and a decreased HR in female BMPR2
+/- mice compared with males (male: 428.3 ± 
18.3 bpm, n=8, female: 358.5 ± 18.7 bpm, n=6). 
 RVH was higher in male WT mice in both vehicle treated (male: 0.28 ± 0.01, n=18, 
female: 0.22 ± 0.01, n=13) and Dfen treated (male: 0.26 ± 0.01, n=11, female: 0.21 ± 0.01, 
n=9) groups (figure 4.9A). The extent of RVH was similar in all four BMPR2
+/- groups.  
Remodelling  data  is  shown  in  figure  4.9.  Dfen  significantly  increased  the  number  of 
remodelled vessels in female WT mice compared to males (male: 3.0 ± 0.9%, n=4, female: 
12.1 ± 1.2 %, n=4). There was also a marked increase in remodelling in female BMPR2
+/- 
mice compared to males (male: 6.0 ± 0.3 %, n=4, female: 12.5 ± 1.2 %, n=4) (figure 4.9B). 
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Figure 4.7 Comparison of male and female sRVP (A) and mRVP (B) in vehicle and Dfen 
treated WT and BMPR2
+/- mice (n= 6 to 9 mice per group). Results expressed as mean ± 
SEM. ** p<0.01 versus male, *** p<0.001 versus male using an unpaired two-tailed t-test. 
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Figure  4.8  Comparison  of  male and  female  HR  in  vehicle  and  Dfen  treated WT  and 
BMPR2
+/- mice (n = 6 to 19 mice per group). Results expressed as mean ± SEM. * p<0.05, 
** p<0.01 versus male using an unpaired two-tailed t-test. 
 
 
 
 
 132 
 
0.0
0.1
0.2
0.3
                      vehicle        Dfen             vehicle       Dfen
      WT               BMPR2+/-
**
male
female
***
R
a
t
i
o
 
(
R
V
/
L
V
+
S
)
 
A 
 
 
0
5
10
15
                      vehicle        Dfen             vehicle       Dfen
      WT               BMPR2+/-
** *** male
female
%
 
o
f
 
v
e
s
s
e
l
s
 
r
e
m
o
d
e
l
l
e
d
 
B 
 
Figure 4.9 Comparison of male and female RVH (A) and remodelling (B) in vehicle and 
Dfen treated WT and BMPR2
+/- mice (n=8 to 18 mice per group). Results expressed as 
mean ± SEM. ** p<0.01 versus male, *** p<0.001 versus male using an unpaired two-
tailed t-test. 133 
 
4.4 Discussion 
This study shows Dfen to be a robust inducer of a pulmonary hypertensive phenotype in 
both  WT  and  BMPR2
+/-  female  mice.  Results  were  similar  between  both  genotypes 
indicating BMPR2 haploinsufficiency in this genetic model does not lead to a worsening of 
PAH in female mice. Neither WT nor BMPR2
+/- male mice developed PAH following 
Dfen, indicating a critical role for female gender in Dfen induced PAH. Male BMPR2
+/- 
mice did, however, show susceptibility, although at a lower level, to Dfen induced vascular 
remodelling.  
 Dfen induced PAH in female WT mice, increasing both mRVP and vascular remodelling 
but without causing RVH. Male WT mice were not susceptible to either of these effects 
and actually showed a decrease in mRVP following administration of Dfen. This decrease 
was  very  modest  and  perhaps  partly  related  to  a  vasodilator  response  in  the  male 
vasculature acting to compensate the Dfen/5-HT induced vasoconstriction. The finding 
here, that male mice are resistant to Dfen induced pulmonary hypertension may help to 
explain why some previous animal studies that may have employed male rodents have 
failed to induce Dfen associated pulmonary hypertension. The Dfen data presented here 
indicates that female mice are more prone to a pulmonary hypertensive phenotype when 
challenged with a disease risk factor. There was no evidence at all in male WT mice for 
PAH. The results in chapter 3 showed that male WT mice did develop hypoxic induced 
PAH.  Dfen appears to be a less potent inducer of PAH at the dose tested than hypoxia, 
with hypoxia causing a higher increase in mRVP and a greater degree of remodelling in 
female mice compared with Dfen. Male mice; therefore, may require a greater pulmonary 
challenge to overcome an inherent protective mechanism before a pulmonary hypertensive 
phenotype emerges.  
 No differences were noted between female WT and BMPR2
+/- mice with both mRVP and 
vascular remodelling increased by a similar margin in both genotypes. Interestingly, male  134 
 
BMPR2
+/- mice did show a small but significant increase in the number of remodelled 
vessels following Dfen, something not  observed in WT males.  As outlined in the last 
chapter  and  shown  by  Beppu  et  al.,  2004  there  may  be  subtle  vascular  changes  in 
BMPR2
+/- mice that predispose these animals to an increase in remodelling. This is shown 
quite convincingly by the hypoxic female data and now also demonstrated in the Dfen 
treated  BMPR2
+/-  males.  The  previous  study  by  Long  et  al.,  2006  that  found  a  mild 
pulmonary hypertensive phenotype in BMPR2
+/-  mice infused with 5-HT utilised male 
mice,  indicating  that  male  BMPR2
+/-  mice  are  more  susceptible  to  the  mitogenic  and 
vasoconstrictor effect of 5-HT which is thought to be the major mediator of Dfen induced 
PAH (see chapter 5 for further information on the mechanism of action of Dfen).  
  It is unclear if underlying mutations in BMPR2 increase the risk of developing PAH 
following  anorexigen  administration.  Current  evidence  regarding  human  patients  is 
inconclusive.  BMPR2  mutations  have  been  found  in  patients  taking  fenfluramines 
(Humbert  et  al.,  2002). The  duration  of  fenfluramine exposure  was  relatively  short  in 
patients with BMPR2 mutation, further indicating a facilitation of PAH through interaction 
with  BMPR2  mutation  and  anorexigen  use  (Humbert  et  al.,  2002).  The  majority  of 
mutations recorded in the fenfluramine using patients do not, however, appear to be as 
detrimental on protein function as other mutations found in FPAH (Machado et al., 2006).  
Missense mutations in the ligand binding domain of BMPR2 in FPAH patients result in 
cysteine residue substitution with negative consequences for protein structure but cysteine 
residues are not affected by the missense mutations found in APAH patients. Some of the 
missense mutations discovered in APAH patients appear to occur in regions of the protein 
with no known functional significance. Similarly, of the three kinase domain mutations 
found, only 1 is proven to have a negative effect on kinase function (Machado et al., 2006). 
A mutation in the cytoplasmic domain with more functional significance (Machado et al., 
2006) was found in a patient who had been exposed to amfepramone (a sympathomimetic 135 
 
amphetamine-like anorexigen) and Abramowicz et al., 2003 suggest the time course of 
disease development and ingestion of amfepramone are a link that indicates the drug was 
the causative agent (Abramowicz et al., 2003). The fact that this is an isolated case makes 
any conclusion regarding a link between amfepramone and PAH impossible and it is far 
from certain that amfepramone was the cause of the disease.  Moreover, in a large study 
performed in the USA, only fenfluramines were associated with the diagnosis of PAH. 
Other anorexigens, including amfepramone, were not associated with an increased risk of 
PAH (Rich et al., 2000).  Proving a link between BMPR2 mutations and anorexigen use in 
humans is a difficult task and will require more accurate information on the distribution of 
BMPR2  mutations.  Studies  to  date  that  have  analysed  APAH  patients  for  BMPR2 
mutations did not analyse the entire gene (Humbert et al., 2002) thus raising the possibility 
that the percentage of BMPR2 mutant carriers in this population may be greater. More 
detailed information on the functional consequences of the mutations that have been found 
in APAH patients and information on the varying penetrance of distinct BMPR2 mutations 
will all help to better characterise the interaction of BMPR2 mutations with other risk 
factors. It has been suggested that a pre-existing deficiency in pulmonary NO levels may 
act as a risk factor for Dfen APAH (Archer et al., 1998b). Inhibition of NO increases the 
pressor response to Dfen in rat lung (Weir et al., 1996) and Dfen users who develop PAH 
have been found to have lower levels of NO in the lung compared with control subjects 
(Archer et al., 1998b). This was found to be in contrast to patients with FPAH/IPAH who 
had increased lung expression of NO which is theorised to act as a counterbalance to the 
vasoconstriction observed in the diseased lung. The decreased levels of NO were found to 
persist for years after discontinuation of the anorectic agent perhaps indicating that the NO 
deficiency was independent of drug use and perhaps was an underlying genetic deficiency 
that on its own was of no clinical concern but interacted with Dfen to cause PAH (Archer 
et al., 1998b). This question can not be answered as NO levels were unknown prior to 136 
 
disease onset but deserves more investigation. A further interesting discovery related to 
dysfunctional NO signalling in fenfluramine APAH comes from one fenfluramine user 
with PAH who carried a loss of function mutation in the 5-HT2B receptor (Blanpain et al., 
2003).  This  receptor  induces  NO  in  several  cell  lines  through  C-terminus  dependent 
activation of eNOS and iNOS (Manivet et al., 2000) and mediates vasorelaxation in pig 
porcine arteries, a receptor that shares 95% homology with the human 5-HT2B receptor 
(Glusa and Pertz, 2000). It could be speculated that this patient would have impaired 5-
HT2B mediated NO synthesis (assuming 5-HT2B receptors were to mediate NO release in 
human pulmonary arteries) reducing the vascular protective effect of NO in PAH.  The 5-
HT2B receptor has, however also been highlighted as playing a role in promoting vascular 
remodelling in animal models of the disease and partly mediating the effects of NDfen. 
The next chapter will discuss further the role of 5-HT receptors in fenfluramine APAH. 
 To conclude, this study reveals Dfen to be a robust inducer of PAH in female WT and 
BMPR2
+/- mice. The pulmonary hypertensive effect of Dfen was completely negated in 
male  WT  mice  while  BMPR2
+/-  males  did  develop  limited  vascular  remodelling  but 
without elevated RVP. These results suggest female gender is a critical risk factor for 
development of Dfen APAH. Presence of BMPR2 mutation did not affect the degree of 
PAH  in  female  mice  but  may  pre-dispose  the  male  vasculature  to  Dfen  induced 
remodelling.  
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Chapter 5 
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5.1 Introduction 
The development of the Tph1
-/- mouse offers a valuable genetic model for assessing the 
contribution of peripheral 5-HT in the development of PAH. As mentioned previously, 
levels of TPH1 in PAECs are increased in cells from IPAH patients compared to control 
subjects and this is associated with increased 5-HT release (Eddahibi et al., 2006). It has 
also recently been shown that hypoxic PAH is diminished in Tph1
-/- mice compared with 
WT mice (Morecroft et al., 2007; Izikki et al., 2007).  
 As outlined previously, Dfen has complex effects on the serotonergic system. It is a 5-HT 
releaser  (Zolkowska  et  al.,  2006),  a  5-HTT  substrate  (Rothman  et  al.,  1999)  and  is 
converted to NDfen that induces vasoconstriction through activation of 5-HT2A receptors 
(Ni et al., 2005). It is unclear, however, whether Dfen induced PAH is caused by 5-HT 
release,  through  a  direct  vasoconstrictor/mitogenic  action  of  Dfen  or  through  NDfen 
induced activation of 5-HT receptors. It is possible that a combination of these factors 
coupled with an inhibition of K
+ channels contribute to Dfens mechanism of action. By 
utilising the Tph1
-/- mouse, it should be possible to determine whether Dfen induces PAH 
through a direct 5-HT independent effect or whether peripheral 5-HT synthesis and release 
by Dfen is the mode of action. To answer this, female Tph1
-/- mice were dosed with Dfen 
and pulmonary haemodynamics measured as in sections 2.3 and 4.2. The decision to use 
female mice was arrived at following the results obtained in the last chapter that showed 
only female mice develop Dfen associated PAH. 
 Morecroft  et  al.,  2007  performed  pharmacological  experiments  on  pulmonary  arteries 
from  normoxic  and  hypoxic  Tph1
-/-  mice.  That  study  showed  that  5-HT  induced 
vasoconstriction is increased in Tph1
-/- mice compared with WT. Unlike WT mice, where 
5-HT induced vasoconstriction was enhanced following hypoxia, there was no difference 
in response to 5-HT between normoxic and hypoxic Tph1
-/- mice. It would be useful to 
further determine pharmacological differences between WT and Tph1
-/- mice and if 139 
 
administration of Dfen affects the pharmacology of pulmonary arteries in either group.  
To  better  understand  any  interaction  that  may  exist  between  peripheral  5-HT, 
administration of Dfen and activity of 5-HT vasoconstrictor receptors, pulmonary arteries 
from WT and Tph1
-/- female mice dosed with vehicle and Dfen were used to construct 
cumulative concentration-response curves (CCRCs) to 5-HT, Dfen and NDfen.  
 The final part of this study sought to investigate any cross-talk that might exist between 5-
HT and BMPR2 signalling pathways. This involved western blot analysis of BMPR2 and 
p-Smad1/5/8 in tissue samples (IPAs + main pulmonary arteries) isolated from WT and 
Tph1
-/- male mice. Both main pulmonary artery and IPA was utilised for analysis to ensure 
adequate protein expression for detection. Male mice were used due to availability of TG 
animals owing to the large number of female animals utilised in the in vivo study. Despite 
female mice being a necessity for studying the in vivo effects of Dfen in Tph1
-/- mice, male 
mice were deemed sufficient for studying the interaction of 5-HT and BMPR2 signalling. 
This is derived from previous work studying the interaction of these two pathways in both 
whole lung and isolated PASMCs in BMPR2
+/- and WT mice, a study that utilised only 
male mice (Long et al., 2006).  Due to the important role p-ERK1/2 has in 5-HT mediated 
proliferation in PASMCs, it was also examined.  
 
5.2 Methods 
5.2.1 Animals 
Mice (female) were 2 months old at commencement of Dfen dosing and 3 months old at 
time of experimental analysis. Western blotting experiments were performed on 2 month 
old male mice. 
 
5.2.2 Myography 
IPAs were isolated from mice from each of the four treatment groups and used for wire 140 
 
myography experiments as described previously.  
Following attainment of maximal contractile response to KCl as outlined in section 2.6.1.5, 
vessels were left to equilibrate for 30 minutes before CCRCs were performed for 5-HT 
(Sigma-Aldrich Ltd, Poole, UK), Dfen or NDfen (National Institute of Health, Maryland, 
USA).  All drugs were dissolved in H2O to give a solution of 10
-2 M from which serial 
dilutions were created up to 10
-6 M giving the range necessary for a 1 nM- 300  M CCRC 
to be constructed. Each vessel segment was subjected to only one treatment.  
 
5.3 Results 
5.31 Dfen dosing study in Tph1
-/- mice 
Dfen dramatically increases both sRVP and mRVP in female WT mice (figure 5.1). In 
Tph1
-/- female mice, however, Dfen has no effect on either sRVP (vehicle: 15.5 ± 1.0 
mmHg, n=8, Dfen: 14.1 ± 1.0 mmHg, n=9) or mRVP (vehicle: 11.4 ± 0.9 mmHg, n=8, 
Dfen: 9.5 ± 1.0 mmHg, n=9). 
 Tph1
-/- vehicle dosed mice had a lower HR compared with WT vehicle treated animals 
(WT: 445 ± 16 bpm, n=8, Tph1
-/-: 388.9 ± 21.7 bpm, n=8) (figure 5.2). There was no 
difference between the Dfen treated groups or between Dfen treated animals and respective 
controls.  
 RVH was similar between the four groups (figure 5.3A). Unlike the WT female mice that 
show substantial remodelling following Dfen, Tph1
-/- mice dosed with Dfen have a similar 
level of remodelling to vehicle dosed mice (vehicle: 3.1 ± 0.4 %, n=4, Dfen: 3.6 ± 0.4 %, 
n=4) (figure 5.3B). 
 
5.3.2 Assessment of contractile response to 5-HT, Dfen and NDfen in IPAs 
Contractions in IPAs were measured relative to the contraction induced by 50 mM KCl. 
No significant differences were observed in KCl response between groups (WT veh: 2.2 ± 141 
 
0.3 mN, n=6, WT Dfen: 2.3 ± 0.2 mN, n=6, Tph1
-/- veh: 2.1 ± 0.3 mN, n=6, Tph1
-/- Dfen: 
1.9 ± 0.2 mN, n=6). CCRCs for 5-HT are presented in figure 5.4. The potency (pEC50) of 
5-HT was greater in WT mice compared with Tph1
-/- mice.  This was true for the vehicle 
dosed group (WT: 7.7 ± 0.1, n=6, Tph1
-/- : 7.2 ± 0.0, n=6) and for the Dfen dosed group 
(WT: 7.7 ± 0.1, n=6, Tph1
-/-: 7.3 ± 0.1, n=6). There was no difference between Dfen dosed 
and vehicle dosed animals. Despite the potency of 5-HT being greater in the WT mice, 
Tph1
-/-  mice  dosed  with  Dfen  did  show  a  greater  maximal  response  (Emax)  to  5-HT 
compared with the respective WT group (WT: 122.5 ± 4.8 % of the contraction induced by 
50 mM KCl, n=6, Tph1
-/-: 138.0 ± 5.3 %, n=5). There was no such difference between 
vehicle dosed animals.   
 Results for the CCRCs to Dfen are presented in figure 5.5. A maximum response to Dfen 
was  not  obtained  at  the  concentrations  tested  so  neither  pEC50  nor  Emax  could  be 
calculated.  No  significant  differences  were  found  between  groups  at  any  of  the 
concentrations used. 
 Results for the CCRCs to NDfen are presented in figure 5.6. pEC50 values were lower for 
mice dosed with Dfen than for vehicle dosed mice. This was true for both WT (vehicle: 6.1 
± 0.1, n=6, Dfen: 5.8 ± 0.1, n=6) and Tph1
-/- (vehicle: 6.4 ± 0.0, n=6, Dfen: 6.0 ± 0.0, n=6) 
mice.  Emax was significantly lower in WT mice dosed with Dfen compared with the 
vehicle dosed mice (vehicle: 103.0 ± 4.4 % of the contraction induced by 50 mM KCl, 
n=6, Dfen: 88.2 ± 5.0 %, n=6). Similar results were obtained for Tph1
-/- mice (vehicle 
109.1 ± 1.6 %, n=6, Dfen: 95.8 ± 3.2 %, n=6) however it did not reach significance. No 
significant differences were observed between WT and Tph1
-/- mice in either treatment 
group. 
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Figure 5.1 Effect of Dfen ingestion in WT and Tph1
-/- female mice (n = 7 to 9 mice per 
group) on sRVP (A) and mRVP (B). Results expressed as mean ± SEM.  *** p<0.001 
versus WT vehicle and Tph1
-/- Dfen using Bonferroni multiple comparison test. 
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Figure 5.2 Effect of Dfen ingestion in WT and Tph1
-/- female mice (n = 7 to 9 mice per 
group) on HR. Results expressed as mean ± SEM.  * p<0.05 versus WT vehicle using 
Bonferroni multiple comparison test.  
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Figure 5.3 Effect of Dfen ingestion in WT and Tph1
-/- female mice (n = 9 to 17 mice per 
group) on RVH (A) and remodelling (B). Results expressed as mean ± SEM.  *** p<0.001 
versus WT vehicle and Tph1
-/- Dfen using Bonferroni multiple comparison test. 
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Figure  5.4  Effect  of  Tph1
-/-  gene  knockout  and  Dfen  ingestion  on  5-HT  induced 
contraction in female mouse IPAs (n = 6 mice per group). Results expressed as mean ± 
SEM. pEC50:  ** p<0.01  versus WT Dfen, *** p<0.001  versus WT  vehicle. Emax:  † 
p<0.05 versus WT Dfen using Bonferroni multiple comparison test. 
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Figure  5.5  Effect  of  Tph1
-/-  gene  knockout  and  Dfen  ingestion  on  Dfen  induced 
contraction in female mouse IPAs (n = 6 mice per group). Results expressed as mean ± 
SEM.  Bonferroni  multiple  comparison  test  revealed  no  significant  differences  at  any 
concentration tested. 
 
 
 
 
 
 147 
 
 
 
 
 
 
 
-10 -9 -8 -7 -6 -5 -4 -3
0
20
40
60
80
100
120
WT vehicle
WT Dfen **, †
TPH1-/- vehicle
TPH1-/- Dfen ***
NDfen [log M]
R
e
s
p
o
n
s
e
 
(
%
 
5
0
m
M
 
K
C
l
)
 
 
 
Figure  5.6  Effect  of  Tph1
-/-  gene  knockout  and  Dfen  ingestion  on  NDfen  induced 
contraction in female mouse IPAs (n = 6 mice per group). Results expressed as mean ± 
SEM. pEC50: ** p<0.01 versus WT vehicle, *** p<0.001 versus Tph1
-/- vehicle. Emax: † 
p<0.05 versus WT vehicle using Bonferroni multiple comparison test. 
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5.3.3 Influence of peripheral 5-HT on 5-HT and BMPR2 signalling proteins 
Tph1
-/- samples had visibly more BMPR2 protein expression than WT samples (figure 
5.7). There was, however, no significant differences in the densitometric analysis between 
groups  (figure  5.7).  Data  for  p-Smad1/5/8  is  presented  in  figure  5.8.  While  some 
experiments had visibly more p-Smad1/5/8 in Tph1
-/- samples compared to WT, others 
showed no visible difference. This was reflected in the densitometry which yielded no 
significant differences between groups. Finally, p-ERK1/2 expression was assessed (figure 
5.9).  In the majority of experiments, p-ERK1/2 expression was visibly greater in WT mice 
compared with Tph1
-/- mice. No significant differences emerged from the densitometry.  
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Figure 5.7 Representative autoradiograms (one from each of the three separate groups of 
tissue samples) and densitometric analysis of BMPR2 expression in WT and Tph1
-/- male 
mouse IPAs + main pulmonary arteries (n=7). Results expressed as mean ± SEM.  An 
unpaired two-tailed t-test revealed no significant difference between groups.                                               
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Figure 5.8 Representative autoradiograms (one from each of the three separate groups of 
tissue samples) and densitometric analysis of p-Smad1/5/8 expression in WT and Tph1
-/- 
male mouse IPAs + main pulmonary arteries (n=8). Results expressed as mean ± SEM. An 
unpaired two-tailed t-test revealed no significant difference between groups.                                                                   
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Figure 5.9 Representative autoradiograms (one from each of the three separate groups of 
tissue samples) and densitometric analysis of p-ERK 1/2 expression in WT and Tph1
-/- 
male mouse IPAs + main pulmonary arteries (n=10). Results expressed as mean ± SEM. 
An unpaired two-tailed t-test revealed no significant difference between groups.                                                                  
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5.4 Discussion 
This  study  has  demonstrated  a  critical  role  for  peripheral  5-HT  synthesis  in  Dfen 
associated PAH with Tph1
-/- mice completely protected against Dfen induced increases in 
RVP  and  vascular  remodelling.  This  study  also  reveals  previously  uncharacterised 
pharmacological differences between WT and Tph1
-/- mice and between mice that received 
Dfen and those that did not. Finally, the role of peripheral 5-HT on 5-HT and BMPR2 
signalling molecules was examined. While no significant differences emerged, the results 
are  suggestive  of  an inhibiting  influence  of  5-HT  on  BMPR2  which  was  found  to  be 
expressed more than two-fold  higher in Tph1
-/- mice compared with WT.  
 Dfen, as one of the few proven pharmaceutical risk factors for PAH is an extremely useful 
research tool for understanding the pathophysiology of the disease. As demonstrated in the 
previous chapter, Dfen induces a pulmonary hypertensive phenotype in female WT and 
BMPR2
+/- mice. Understanding Dfens mechanism of action can help us gain insights into 
the underlying mechanisms of PAH. The fact that female Tph1
-/- mice were resistant to the 
effects of Dfen on the pulmonary vasculature provides important data on how Dfen may be 
acting  within  the  lung.  It  is  clear  from  this  study  that  Dfen  requires  the  presence  of 
peripheral 5-HT synthesis to exert its pulmonary hypertensive effect in mice (this data has 
been published in Dempsie et al., 2008). As a compound with multiple mechanisms of 
action, the ability of Dfen to release 5-HT from pulmonary vascular cells is determined to 
be  a  critical  component  of  its  action.  Dfen  is  a  potent  5-HTT  substrate  and  5-HTT 
substrates induce a much greater increase in extracellular 5-HT concentration compared 
with 5-HTT inhibitors (Rothman and Baumann, 2002). Moreover, the increase in plasma 
concentration of 5-HT induced by amphetamine analogues is proportional to their potency 
as  5-HTT  substrates  (Zolkowska  et  al.,  2006).  5-HTT  substrates  release  5-HT  by  two 
mechanisms.  The  first  involves  carrier  mediated  exchange  with  5-HT  at  the  plasma 
membrane  5-HTT  and  the  second
  involves  interaction  with  the  vesicular  monoamine 153 
 
transporter  type  2  (VMAT2)  present  on  intracellular  vesicles  resulting  in  5-HT  being 
transported  out  of  the  vesicle  and into the  cytoplasm  raising  intracellular  5-HT  levels 
(Partilla et al., 2006).  This not just increases the available 5-HT in the cell for carrier 
mediated exchange out of the cell but also raises the possibility of increased activation of 
5-HT dependent intracellular pathways.  MDMA (3, 4-methylenedioxymethamphetamine 
or ecstasy), which has a mechanism of action very similar to the fenfluramines has also 
been shown to act on the VMAT2 causing 5-HT release. The effect of MDMA was found 
to be dependent on an existing pool of vesicular 5-HT which MDMA released through a 
direct inhibition of VMAT2 and a disruption of the transmembrane pH gradient that drives 
5-HT uptake into the vesicle (Mlinar and Corradetti, 2003). Of these two mechanisms, a 
direct interaction with VMAT2, not dissimilar to the carrier mediated exchange that occurs 
at the 5-HTT, is thought to be the most important factor in 5-HT vesicular release (Partilla 
et al., 2006). The resulting action of Dfen following i.v. administration in the rat is a large 
(19  fold  at  1.0  mg/kg)  increase  in  plasma  5-HT  concentration  reaching  a  peak 
concentration of 20 nM. This is above the threshold required to induce mitogenesis of 
human  PASMCs  (Zolkowska  et  al.,  2006)  and  a  sustained  increase  in  plasma  5-HT 
concentration  induced  by  Dfens  role  as  a  5-HTT  and  VMAT2  substrate  may  promote 
proliferation of PASMCs.  
 5-HTT substrates differ from 5-HTT inhibitors such as fluoxetine in two crucial ways. The 
1
st being the magnitude of increase in extracellular 5-HT. The 2
nd being the uptake of 
compound into the cell and subsequent release of 5-HT from intracellular vesicles inducing 
a rise in 5-HT concentration in the cytoplasm. The combination of increased intracellular 
and extracellular 5-HT could be important in the development of vascular remodelling. 
This is a consequence of cross-talk between 5-HT1B/1D and 5-HTT signalling.  In human 
PASMCs activation of 5-HT1B receptors results in phosphorylation of ERK1/2. The signal 
for nuclear translocation of p-ERK1/2 is dependent on 5-HT uptake by the 5-HTT, MAO 154 
 
and ROS generation (Lawrie et al., 2005). As mentioned in section 1.2.3.1.3, this is in 
contrast to the methods by which p-ERK1/2 is nuclear translocated in bovine PASMCs. 
Both human and bovine PASMCs do, however, require both 5-HT1B/1D receptors and the 5-
HTT for nuclear translocation of p-ERK1/2, both of which are likely to be activated by the 
elevated  5-HT  induced  by  5-HTT  substrates  such  as  Dfen.  In  the  nucleus,  p-ERK1/2 
interacts with transcription factors such as GATA-4 (Suzuki et al., 2003) to upregulate 
gene  transcription  of  proteins  involved  in  PASMC  proliferation  such  as  S100A4/Mts1 
(Lawrie et al., 2005). S100A4/Mts1 is upregulated in PASMCs in pulmonary hypertensive 
patients  in  arterial  lesions  with  neointimal  proliferation.  Additionally,  5%  of  mice 
overexpressing S100A4/Mts1 display occlusive intimal lesions (Greenway et al., 2004). 
The role of Dfen as a 5-HTT substrate appears a critical factor in Dfen induced PAH in 
mice  but  it  may  not  be  the  only  factor  in  its  effect.  The  5-HTT  substrate  m-
chlorophenylpiperazine (mCPP) which is a greater 5-HT releaser in vitro than Dfen or its 
metabolites  is  not  associated  with  PAH.  mCPP  also  has  activity  at  multiple  5-HT2 
receptors similar to NDfen. Unlike the fenfluramines, however, mCPP does not induce 
noradrenaline release and is not an amphetamine analogue (Rothman and Baumann, 2002). 
In addition to differences in ability to release noradrenaline, there are likely to be other 
pharmacological  differences  between  non  amphetamine  and  amphetamine  5-HTT 
substrates,  perhaps  including  their  regulation  of  unique  Kv  channel  subunits  and  their 
effect on whole cell Kv current that determine their ability to induce PAH.  
 There are several unknown factors regarding the interaction of Dfen and the serotonin 
system in WT and Tph1
-/- mice. The rate of uptake of Dfen into PASMCs in Tph1
-/- mice 
compared to WT for example. This may be influenced significantly by intracellular 5-HT 
levels. The expression of the 5-HTT and 5-HT receptors may also differ between mice 
with normal and mice with no or minimal peripheral 5-HT although evidence shows that 
the function of the 5-HTT is similar in WT and Tph1
-/- mice (Ni et al., 2005).  Little is also 155 
 
known  regarding  the  effects  of  chronic  Dfen  treatment  on  the  expression  of  5-HT 
receptors.  Most  studies  assessing  the  effects  of  Dfen  on  the  serotonergic  system  have 
focussed on extracellular 5-HT levels following acute administration. Performing CCRCs 
to 5-HT, Dfen and NDfen on WT and Tph1
-/- mice treated chronically with and without 
Dfen as performed in this investigation has provided some evidence of altered serotonergic 
function. Interestingly, the potency of 5-HT was reduced in Tph1
-/- mice irrespective of 
treatment with Dfen. This is in contrast to experiments performed by Morecroft et al., 2007 
who  found  an  increased contractile  response  to  5-HT  in  IPAs  from  Tph1
-/-  mice.  The 
animals  used  in  that  investigation  were  5-6  months  old  (personal  communication,  Ian 
Morecroft) whereas the animals used here were 3 months at the time of being culled which 
may  explain  this  difference.  An  enhanced  response  to  5-HT  might  be  expected  if 
vasoconstrictor 5-HT receptors were upregulated in response to a lack of extracellular 5-
HT.  A  decreased  response  to  5-HT  in  Tph1
-/-  mice  may  be  due  to  a  component  of 
vasoconstriction in WT mice being due to 5-HT release or higher expression of either 
vasoconstrictor  receptors  or  intracellular  signalling  molecules  associated  with 
vasoconstriction, a process that would be absent in Tph1
-/- mice. A downregulation of 5-
HT receptors in Tph1
-/- mice is also not inconceivable. In relation to the 5-HTT, 5-HT 
promotes stability in transporter expression and a loss of 5-HT results in downregulation of 
the transporter in HEK239 cells (Ni and Watts, 2006). Similar processes may occur in 
relation to the 5-HT1B or 5-HT2A receptors in mice.  
 Consistent with its low affinity for 5-HT receptors (Rothman and Baumann, 2002), Dfen 
induced  vasoconstriction  only  at  high  concentrations  (>10  µM).  The  vasoconstrictor 
response to Dfen is only partly mediated by 5-HT2 receptors and a direct action on K
+ 
channels  is  also  likely  to  be  an  important  mediator  of  Dfen  induced  vasoconstriction 
(Belohlavkova et al., 2001). No differences were observed in the response to Dfen in any 
of the 4 groups indicating the dominant factor underlying Dfen induced vasoconstriction is 156 
 
similar between groups. This could be expression and activity of Kv channels or even a 
direct effect of Dfen inside the cell (Lee et al., 2001). At 10 µM Dfen is likely to be 
transported inside the cell and accumulate to a high level where it may  activate 5-HT 
signalling pathways such as ROCK promoting vasoconstriction. Dfen has been shown to 
mimic 5-HT in fibroblasts by activating mitogenic compounds such as ERK1/2 (Lee et al., 
2001) and this may also occur in relation to vasoconstrictor signalling molecules. If a 
direct  action  of  Dfen  in  the  cell  was  to  be  the  major  factor  in  Dfen  induced 
vasoconstriction it would mean that the 5-HTT is similarly expressed in WT and Tph1
-/- 
mice, is unaffected by chronic dosing with Dfen and that Dfen uptake by the 5-HTT is not 
influenced  by  intracellular  5-HT.  A  combination  of  an  intracellular  action  and    a 
contribution from either 5-HT1B or 5-HT2A receptors that owing to the low affinity of Dfen 
at these receptors only induce vasoconstriction at high concentrations may mediate the 
vasoconstriction  induced  by  Dfen  (see  next  chapter  for  more  on  Dfen  mechanism  of 
action).  
 The arterial contraction induced by NDfen, unlike the responses to 5-HT and Dfen was 
influenced by chronic administration of Dfen. The potency of NDfen was lower in both 
WT and Tph1
-/- mice dosed with Dfen and the Emax of NDfen was lower in WT mice 
dosed with Dfen compared with controls. NDfen is a potent 5-HT2B and 5-HT2C agonist 
and has moderate potency at 5-HT2A receptors (Rothman and Baumann, 2002). NDfen 
stimulation of 5-HT2C receptors most likely contributes to its anorectic properties (Curzon 
et al., 1997; Vickers et al., 1999) and activation of 5-HT2B receptors may contribute to 
vascular  remodelling  in  mice  but  without  influencing  vasoconstriction  (Launay  et  al., 
2002).  A  direct  action  at  5-HT2A  receptors  is  the  most  likely  explanation  for  NDfen 
induced  vasoconstriction  and  this  has  been  shown  to  underlie  NDfen  induced 
vasoconstriction in mouse aorta, an effect independent of endogenous 5-HT release (Ni et 
al., 2005). This is similar to results presented here where no significant differences in 157 
 
NDfen contractile response between WT and Tph1
-/- mice were found. Combining the 
pharmacological results for 5-HT, Dfen and NDfen leads to some interesting conclusions 
regarding 5-HT receptor expression between WT and Tph1
-/- mice and in Dfen and non-
Dfen treated mice.  5-HT response was reduced in Tph1
-/- mice whereas the response to 
NDfen was not and indeed, an observable trend towards an enhanced response to NDfen 
was noted in the Tph1
-/- animals. We can conclude from this that 5-HT and NDfen are 
exerting their vasoconstrictor response through different mechanisms. This may be 5-HT1B 
receptors  mediating  5-HT  and  5-HT2A  receptors  mediating  NDfen  induced 
vasoconstriction. The 5-HT1B receptor is involved in hypoxic induced vasoconstriction, 
vascular remodelling and RVH in mice (Keegan et al., 2001) and may be decreased in 
young adult Tph1
-/- mice. Assuming the 5-HT1B receptor is mediating the vasoconstriction 
to 5-HT, it is unaffected by chronic administration of Dfen. This is in contrast to the 5-
HT2A receptor, thought to underlie the NDfen vasoconstriction. Mice dosed with Dfen may 
have decreased expression of 5-HT2A receptors. This downregulation occurred in Tph1
-/- 
mice as well as WT indicating a direct action by Dfen or NDfen in downregulating the 5-
HT2A receptor perhaps as a compensatory mechanism to the potent continuous agonist 
action of NDfen over the 28 day treatment at this receptor.  
 The Tph1
-/- mouse can further be utilised to examine the role that peripheral 5-HT has on 
expression of signalling molecules relevant to PAH. In this chapter, pulmonary arteries 
from Tph1
-/- mice were examined for protein expression of BMPR2 and p-Smad1/5/8 and 
compared with WT so that the influence of 5-HT on these key regulators of  vascular 
function could be assessed. An influence of 5-HT on BMPR2 expression may also be 
relevant to Dfen induced PAH. The Tph1
-/- mouse has provided important data on the role 
of peripheral 5-HT in Dfen associated PAH and BMPR2 mutations are found in some Dfen 
users who develop PAH (Humbert et al., 2002). A discovery of altered BMPR2 expression 
between  WT  and  Tph1
-/-  mice  may  indicate  cross-talk  between  5-HT  and  BMPR2  to 158 
 
support  the  hypothesis  that  enhanced  serotonergic  function  interacts  with  BMPR2 
deficiency in PAH. The mitogenic mediator p-ERK1/2 is activated by 5-HT and Dfen (Lee 
et al., 1999; Lee et al., 2001) and by analysing expression of p-ERK1/2 in pulmonary 
arteries from Tph1
-/- mice, it can be determined if 5-HT has a basal effect on maintaining 
p-ERK1/2 level. As described previously, Long et al., 2006 uncovered evidence of cross-
talk between 5-HT and BMPR2 signalling in male PASMCs including 5-HT depressing 
BMP-2 induced phosphorylation of Smad1/5 and  an increase in 5-HT induced ERK1/2 
activation  in  BMPR2
+/-  PASMCs  compared  with  WT  PASMCs,  an  effect  thought  to 
mediate 5-HT induced proliferation of these cells. Although no significant differences were 
observed in this study between WT and Tph1
-/- animals, there is a strong suggestion of an 
influence of 5-HT on BMPR2. Expression of BMPR2 in Tph1
-/- pulmonary arteries was 
almost double the level seen in WT arteries although a large variation was seen in results 
within the Tph1
-/- group. A large standard error was also associated with both p-Smad 
1/5/8 results and those results suggest no notable differences in expression between groups. 
A trend towards decreased p-ERK1/2 expression was noted in Tph1
-/- mice and this was 
visible on some of the blots. A decrease in p-ERK1/2 in Tph1
-/- pulmonary arteries would 
not  be  surprising  given  it  is  activated  by  5-HT.  Activation  of  p-ERK1/2  may  also 
participate in 5-HT induced negative regulation of the BMPR2 pathway. p-ERK1/2 is a 
negative  regulator  of  Smad-1.  It  binds  to  a  region  of  the  Smad-1  protein  which  it 
phosphorylates causing a form of Smad-1 incapable of nuclear translocation (Massague, 
2003).  An  increase  in  p-ERK1/2  induced  by  5-HT  would  therefore  suppress  the  p-
Smad1/5/8 pathway. The BMPR2 receptor is expressed at a lower level in the lungs of 
PAH patients than genetics would predict. There was visibly more BMPR2 expression in 
pulmonary  arteries  from  Tph1
-/-  mice  compared  with  WT  mice  perhaps  indicating 
peripheral 5-HT also acts to control expression of mature BMPR2 and that elevated 5-HT 
acting via the 5-HTT or 5-HT2A receptors suppresses BMPR2 and p-Smad1/5/8 in PAH 159 
 
 patients leading to a proliferative phenotype. 
 The discovery that Dfen requires peripheral 5-HT to exert its pulmonary hypertensive 
effect supports the evidence in favour of the ‘serotonin hypothesis’ of PAH. This is further 
supported  by  other  recent  data  looking  at  peripheral  5-HT  synthesis  in  pulmonary 
hypertension both in humans and in animals. The finding that hypoxia increases Tph1 
expression in rabbit lung 3 fold (Pan et al., 2006) and hypoxic PAH is attenuated in Tph1
-/- 
mice (Morecroft et al., 2007; Izikki et al., 2007) coupled with human data indicating TPH1 
is upregulated in PASMCS in IPAH patients (Eddahibi et al., 2006) all favour a role for 
increased peripheral 5-HT in PAH.  
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Chapter 6 
Investigation of pharmacological response to dexfenfluramine and 
nordexfenfluramine  161 
 
6.1 Introduction 
Dfen has previously been shown to be a pulmonary vasoconstrictor (Belohlavkova et al., 
2001), an effect attributed to either 5-HT release, a direct action on 5-HT receptors or 
through inhibition of K
+ channels. Dfen is known to be a partial or full agonist at many 
different 5-HT receptors but shows only low affinity for the vasoconstrictor 5-HT1B and 5-
HT2A  receptors  (Fitzgerald  et  al.,  2000;  Rothman  et  al.,  2000).  As  determined  in  the 
previous  chapter,  Dfen  is  a  poor  vasoconstrictor  in  WT  and  Tph1
-/-  mice,  inducing 
vasoconstriction  only  at  concentrations  >10  µM.  To  discover  whether  Dfen  induced 
vasoconstriction may be increased by the genetic changes relevant to PAH, IPAs from WT, 
5-HTT+, BMPR2
+/- and Cross TG mice were all exposed to CCRCs to Dfen. Experiments 
were performed in IPAs from male and female mice so a gender comparison could be 
performed.  
 As already mentioned, Dfen undergoes metabolism to NDfen, a metabolite with twice the 
plasma half life of Dfen (Caccia et al., 1985). NDfen is thought to induce vasoconstriction 
through activation of 5-HT2A receptors (Ni et al., 2005) and NDfen has a significantly 
higher affinity for this receptor than Dfen (Fitzgerald et al., 2000; Rothman et al., 2000). It 
is,  therefore,  important  to  also  test  the  pulmonary  vasoconstrictor  response  to  this 
metabolite and this was performed in the same manner as for Dfen. There were, however, 
insufficient TG animals available for a gender comparison to NDfen or to use just one 
gender so both male and female mice were used in this experiment (see discussion for 
further information on gender comparison experiments).  
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6.2 Methods 
6.2.1 Animals 
All mice were age 5-6 months 
 
6.2.2 Myography 
IPAs  were  isolated  from  mice  from  each  of  the  four  genotypes  and  used  for  wire 
myography experiments as described previously.  
Following attainment of maximal contractile response to KCl as outlined in section 2.6.1.5, 
vessels were left to equilibrate for 30 minutes before CCRCs were performed for Dfen or 
NDfen. All drugs were dissolved in H2O to give a solution of 10
-2 M from which serial 
dilutions were created up to 10
-6 M giving the range necessary for a 1 nM- 300  M CCRC 
to be constructed. Each vessel segment was subjected to only one treatment.  
 
6.3 Results 
Contractions in IPAs were measured relative to the contraction induced by 50 mM KCl. 
No significant differences were observed in KCl response between genotypes or gender 
(WT male: 3.7 ± 0.3 mN, n=6, WT female: 3.0 ± 0.3 mN, n=6, 5-HTT+ male: 3.4 ± 0.5 
mN,  n=6,  5-HTT+  female:  2.7  ±  0.3  mN,  n=6,  BMPR2
+/-  male:  3.4  ±  0.6  mN,  n=6, 
BMPR2
+/- female: 3.0 ± 0.2 mN, n=6, Cross TG male: 2.8 ± 0.3 mN, n=6, 3.0 ± 0.2 mN, 
n=6). 
 
6.3.1 Dfen 
CCRCs were performed for Dfen in male mice (figure 6.1) and female mice (figure 6.2). 
Results did not allow calculation of pEC50 or Emax so each concentration tested was 
statistically  compared  between  groups.  There  were  no  significant  differences  between 
genotypes at any concentration tested for male mice (figure 6.1). In female mice, Dfen 163 
 
exerted a significantly greater contraction in Cross TG mice at 1 μM (WT: 2.0 ± 1.2% of 
the contraction induced by 50 mM KCl, n=5, 5-HTT+: 3.7 ± 2.1%, n=7, BMPR2
+/-: 1.3 ± 
0.9%, n=6, Cross TG: 33.5 ± 11.5%, n=4), 3 μM (WT: 2.8 ± 1.7%, n=5, 5-HTT+: 7.1 ± 
5.0%, n=7, BMPR2
+/-: 1.8 ± 1.2%, n=4, Cross TG: 50.5 ± 11.1%, n=4), 10 μM (WT: 5.0 ± 
1.9%, n=5, 5-HTT+: 9.0 ± 3.4%, n=7, BMPR2
+/-: 3.3 ± 1.6%, n=6, Cross TG: 48.8 ± 8.8%, 
n=4), and 30 μM (WT: 19.6 ± 9.9%, n=5, 5-HTT+: 9.7 ± 1.9%, n=7, BMPR2
+/-: 6.5 ± 
3.4%, n=6, Cross TG: 35.8 ± 7.0%, n=6) compared to the other three genotypes (figure 
6.2).  Figures 6.3 and 6.4 show a male versus female comparison for each genotype. There 
were no differences between male and female WT mice at any concentration used (figure 
6.3A).  Dfen exerted a greater contraction in IPAs in male 5-HTT+  mice compared to 
female 5-HTT+ mice at 10 μM (male: 37.8 ± 10.6% of the contraction induced by 50 mM 
KCl, n=6, female: 9.0 ± 3.4%, n=7), 30 μM (male: 38.8 ± 8.8%, n=6, female: 9.7 ± 1.9%, 
n=7) and 100 μM (male: 31.8 ± 8.9%, n=6, female: 9.0 ± 3.4%, n=7) (figure 6.3B). The 
only notable difference between genders in BMPR2
+/- mice was at 100 μM with male IPAs 
having the greatest contractile response (male: 45.0 ± 7.2%, n=4, female: 19.7 ± 6.6%, 
n=6) (figure 6.4A). In relation to the Cross TG mice, female IPAs were more sensitive to 
Dfen than male IPAs at 1 μM (male: 2.8 ± 1.7%, n=5, female: 33.5 ± 11.4%, n=4) and 3 
μM (male: 13.2 ± 8.1%, n=5, female: 50.5 ± 11.1%, n=4) (figure 6.4B). 
 
6.3.2 NDfen 
CCRCs were performed for NDfen and the data is presented in figure 6.5. NDfen was 
significantly more potent in all TG mice compared to WT (pEC50; WT:  5.7 ± 0.1, n=6, 5-
HTT+: 6.0 ± 0.1, n=6, BMPR2
+/-: 6.1 ± 0.0, n=6, Cross TG: 6.1 ± 0.0, n=6).  BMPR2
+/- 
mice displayed a higher Emax to NDfen compared with WT and Cross TG (WT: 82.2 ± 
5.8% of the contraction induced by 50 mM KCl, n=6, BMPR2
+/-: 106.2 ± 2.4%, n=6, Cross 
TG: 86.8 ± 1.6%, n=6) groups. 164 
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Figure 6.1 Cumulative concentration-response curves to Dfen in IPAs from WT, 5-HTT+, 
BMPR2
+/- and Cross TG male mice (n = 4 to 6 mice per group). Results expressed as mean 
±  SEM.  Newman-Keuls  multiple  comparison  test  revealed  no  significant  differences 
between groups at any concentration tested.  
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Figure 6.2 Cumulative concentration-response curves to Dfen in IPAs from WT, 5-HTT+, 
BMPR2
+/- and Cross TG female mice (n = 4 to 7 mice per group). Results expressed as 
mean ± SEM. * p<0.05, *** p<0.001 versus corresponding concentration in WT, 5-HTT+ 
and BMPR2
+/- mice using Newman-Keuls multiple comparison test. 
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Figure 6.3 Comparison of male and female cumulative concentration-response curves to 
Dfen in IPAs from WT (A) and 5-HTT+ (B) mice (n = 4 to 7 mice per group). Results 
expressed as mean ± SEM. * p<0.05, ** p<0.01 versus corresponding concentration in 
female mice using an unpaired two-tailed t-test. 
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Figure 6.4 Comparison of male and female cumulative concentration-response curves to 
Dfen in IPAs from BMPR2
+/- (A) and Cross TG (B) mice (n = 4 to 6 mice per group). 
Results expressed as mean ± SEM. * p<0.05 versus corresponding concentration in female 
mice, † p<0.05 versus corresponding concentration in male mice using an unpaired two-
tailed t-test.  168 
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Figure  6.5  Cumulative  concentration-response  curves  to  NDfen  in  IPAs  from  WT,  5-
HTT+,  BMPR2
+/-  and  Cross  TG  male/female  mice  (n  =  6  mice  per  group).  Results 
expressed as mean ± SEM. pEC50:  *** p<0.001 versus WT, Emax: * p<0.05 versus WT 
and Cross TG using Newman-Keuls multiple comparison test. 
 
 
 
 
 
 
 
 
 169 
 
6.4 Discussion 
Several interesting observations emerged from this series of experiments involving the role 
of gender and how the genetics of the mouse influenced which gender was more sensitive 
to Dfen. Perhaps the most interesting and important results came in the Cross TG mice 
where females were more sensitive to Dfen induced vasoconstriction than males. In the 
female Cross TG mice, Dfen induced vasoconstriction at a lower concentration than any 
other group (>30% of KCl at 1 µM). The maximum vasoconstriction recorded in the Cross 
TG females was over 50% of KCl response measured at 3µM Dfen. This was 40% higher 
than in males at the same concentration and the highest recorded contractile response to 
Dfen measured across all experiments. Results in the Cross TG mice were in contrast to 
results in the 5-HTT+ mice where Dfen induced greater vasoconstriction in male mice at 
several  concentrations  tested  compared  with  females.  There  was  a  slight  male  gender 
influence on Dfen in the BMPR2
+/- mice also with a greater response to Dfen at 100 µM. 
No differences, however, were noted in Dfen response between WT male and females 
where the response was similar to that observed in the 2-3 month old WT females in 
chapter 5. 
 The 5-HTT, unsurprisingly, is a major determinant in these experiments to the response of 
Dfen. Although no significant differences were noted between genotypes in the male group 
due to the large variability in Dfen response and low n numbers there is a clear trend 
towards enhanced vasoconstriction to Dfen in the 5-HTT+ and Cross TG mice compared 
with WT and BMPR2
+/- mice at lower concentrations. Interestingly, the 5-HTT+ females 
were  unremarkable  in  their  response  to  Dfen  compared  with  WT.  It  was  only  when 
dysfunctional  BMPR2  was  combined  with  overexpressed  5-HTT  that  the  enhanced 
sensitivity to Dfen emerged. These results suggest that in males, dysfunctional BMPR2 
may protect against the 5-HTT mediated enhanced response to Dfen whereas in females 
dysfunctional BMPR2 enhances the Dfen response. The result in the Cross TG mice is 170 
 
particularly  interesting  as  significant  vasoconstriction  occurred  to  Dfen  at  clinically 
relevant plasma concentrations. The optimum plasma concentration for  Dfen to induce 
weight  loss  is  ~  1  µM.  Cross  TG  females  were  the  only  group  to  show  significant 
vasoconstriction  at  this  concentration.  Assuming  human  pulmonary  arteries  were  to 
respond  to  Dfen  in  a  similar  way,  then  females  with  a  BMPR2  mutation  and 
overexpression  of  the  5-HTT  would  have  pulmonary  vasoconstriction  following 
administration of Dfen. Dfen induced a biphasic CCRC in mice overexpressing the 5-HTT, 
an effect most likely related to multiple sites of action. As this biphasic response was only 
observed in mice overexpressing the 5-HTT, a heightened interaction between Dfen and 
the 5-HTT would seem to cause this effect. A combination of a 5-HTT inhibitor and 5-HT 
receptor antagonists would be useful in the presence of Dfen to better understand the 
pharmacology of Dfen induced vasoconstriction. One hypothesis for the biphasic response 
is that the initial enhanced vasoconstriction observed in 5-HTT+ mice is due to either an 
intracellular effect of Dfen on vasoconstrictor pathways or an action on Kv channels that 
are perhaps already dysfunctional in 5-HTT+ mice. The secondary vasoconstriction could 
be the result of a direct effect of Dfen on vasoconstrictor 5-HT receptors that is only 
attainable at high concentrations. 
  It was during the course of the Dfen pharmacology experiments in this chapter that clear 
differences emerged in results obtained in male and female mice. These were the first of 
many experiments outlined in this thesis to look at the influence of gender as a modifying 
factor. The availability of TG animals meant that direct gender analysis experiments could 
not be performed for every experiment and priority was given to the in vivo experiments in 
preceding chapters. For this reason, a gender comparison was not performed for NDfen in 
these  sets  of  experiments  and  a  mixture  of  male  and  female  mice,  determined  by 
availability of animals, was used. A direct male versus female comparison for NDfen in 
WT mice can be found in the set of experiments looking at the influence of sex hormones 171 
 
on pulmonary vasoconstriction in chapter 8.   
 The  potency  of  NDfen  was  greater  in  all  TG  groups  with  Emax  also  increased  in 
BMPR2
+/- mice. Interestingly, the Emax of NDfen in BMPR2
+/- mice was significantly 
greater  than  Cross  TG  mice.  As  discussed  in  the  preceding  chapter,  NDfen  induced 
vasoconstriction is thought to occur via the 5-HT2A receptor (Ni et al., 2005). Ni et al., 
2005 showed that in isolated aorta, NDfen induces vasoconstriction via 5-HT2A receptors 
and that vasoconstriction was independent of any 5-HTT activity. The increase in Emax in 
BMPR2
+/-  mice  may  indicate  an  increase  in  5-HT2A  receptor  number  which  supports 
pharmacological experiments on IPAs from BMPR2
+/-  mice conducted by  Long et al., 
2006 that demonstrated an increased contractile response to the 5-HT2A agonist, α–methly-
5-HT,  compared  to  WT  mice.  Given  the  important  role  5-HT2A  receptors  have  in 
vasoconstriction and proliferation of PASMCs, any increase in activity or receptor number 
in  pulmonary  arteries  would  enhance  serotonergic  signalling.  Despite  NDfen  induced 
aortic  vasoconstriction  being  independent  of  5-HTT  activity,  this  does  not  necessarily 
apply to pulmonary arteries and a direct intracellular action of NDfen on serotonergic 
vasoconstrictor  pathways  or  Kv  channels  may  also  contribute  to  the  enhanced 
vasoconstriction observed in the TG animals.   
 The  most  important  finding  in  this  chapter  was  the  genetic  synergy  between 
overexpression of the 5-HTT and BMPR2
+/- that increased the contractile response to Dfen 
in Cross TG mice. This effect only occurred in female mice supporting female gender as a 
risk factor for Dfen induced vasoconstriction when combined with genetic pre-disposition. 
The other key finding was that all TG groups demonstrated enhanced vasoconstriction to 
NDfen, possibly indicating enhanced 5-HT2A receptor activity in IPAs from these mice.  
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Chapter 7 
Investigation of pharmacological response to 5-HT, BMP-2 and 
linopirdine 173 
 
7.1 Introduction 
5-HT  acting  via  5-HT2A  and/or  5-HT1B/1D    receptors  is  a  pulmonary  vasoconstrictor, 
however,  the  plasma  concentration  of  5-HT  that  would  be  required  to  induce 
vasoconstriction is higher than physiological 5-HT plasma concentrations (Zolkowska et 
al., 2006).  As described in section 1.2.3.1.2, it is still a matter of debate whether the 
plasma concentration of 5-HT is a good indicator of any potential pathological role for 5-
HT  in  the  disease  progression.  Moreover,  plasma  [5-HT]  may  not  reflect  local  5-HT 
concentrations in the lung with PAECs synthesising and releasing 5-HT locally at a rate 
which increases in IPAH (Eddahibi et al., 2006). It may also be the case that other factors 
act to enhance 5-HT induced vasoconstriction in PAH. Important support for this theory 
comes  from  the  finding  that  pulmonary  arteries  from  BMPR2
+/-  mice  show  a  greater 
maximum contractile response to 5-HT than corresponding vessels from WT mice (Long et 
al., 2006). Dysfunctional BMPR2 may, therefore, enhance 5-HT receptors or signalling 
molecules associated with vasoconstriction. In this chapter, the contractile response to 5-
HT and possible influencing factors upon that vasoconstriction are investigated. In the first 
part  of  this  study,  the  contractile  response  to  5-HT  was  assessed  in  WT,  5-HTT+, 
BMPR2
+/- and Cross TG mice. To further elucidate any interaction that may exist between 
BMPR2  and  5-HT  induced  vasoconstriction,  the  effect  of  BMP-2  on  the  contractile 
response to 5-HT was assessed in the four genotypes. 
 As outlined in the introduction Kv channel currents on PASMCs regulate vasoconstriction 
in addition to proliferation and apoptosis. While members of the Kv1-6, Kv8-9 group such 
as Kv1.5 and Kv2.1 have been studied most extensively in relation to PASMC K
+ current 
and PAH, the Kv7.1-7.5 (KCNQ) group have recently been found to contribute to the  
resting  Vm  in  PASMC  and  inhibition  of  these  channels  results  in  pulmonary 
vasoconstriction (Joshi et al., 2006). Changes in expression of the 5-HTT and BMPR2 can 
directly influence Kv channel subunit expression. Both Kv1.5 and Kv2.1 are decreased in 174 
 
the lungs of mice that overexpress 5-HTT in smooth muscle (Guignabert et al., 2006) and 
mice that lack BMPR2 in smooth muscle have decreased expression of Kv1.1, Kv1.5 and 
Kv4.3 (Young et al., 2006).  It is not known if KCNQ channel current is affected by 
genetic changes in the 5-HTT or BMPR2.  To help determine this, CCRCs were performed 
to the KCNQ channel blocker linopirdine in WT, 5-HTT+, BMPR2
+/- and Cross TG mice 
to look for any differences in KCNQ mediated vasoconstriction between genotypes. 
 Activation of 5-HT vasoconstrictor receptors results in G protein mediated changes in ion 
channel function (Varghese et al., 2006) but the role of Kv channels in 5-HT induced 
vasoconstriction remains unclear. To assess the role of KCNQ channels in 5-HT induced 
vasoconstriction, CCRCs to 5-HT were performed in WT, 5-HTT+, BMPR2
+/- and Cross 
TG mice in the presence and absence of linopirdine.   
 
7.2 Methods 
7.2.1 Animals 
All mice were age 5-6 months. As mentioned in chapter 6, the restricted number of TG 
animals meant that groups containing both male and female mice had to be used in the 
conduct of the following experiments.  
 
7.2.2 Myography 
IPAs  were  isolated  from  mice  from  each  of  the  four  genotypes  and  used  for  wire 
myography experiments as described previously.  
 Following  attainment  of  maximal  contractile  response  to  KCl  as  outlined  in  section 
2.6.1.5,  vessels  were  left  to  equilibrate for  30  minutes.  For  BMP-2  (R  &  D  Sytsems, 
Abingdon, UK) experiments, BMP-2 (2.34 x 10
-6 M) or H2O vehicle was added following 
equilibration and left for 3 hours before CCRCs to 5-HT were performed. To assess the 
contractile  response  to  linopirdine  (Tocris  Bioscience,  Bristol,  UK)  CCRCs  were 175 
 
performed  for  linopirdine.  To  determine  the  effect  of  linopirdine  on  5-HT  induced 
vasoconstriction,  linopirdine  (10
-7  M)  or  H2O  vehicle  was  added  to  vessels  following 
equilibration and left for 15 minutes before CCRCs to 5-HT were performed. For 5-HT 
and linopirdine CCRCs, drugs were dissolved in H2O to give a solution of 10
-2 M from 
which serial dilutions were created up to 10
-6 M giving the range necessary for a 1 nM- 300 
M CCRC to be constructed. Each vessel segment was subjected to only one treatment.  
 
7.3 Results 
Contractions in IPAs were measured relative to the contraction induced by 50 mM KCl. As 
stated in section 6.3, no significant differences were observed in KCl response between 5-6 
month WT, 5-HTT+, BMPR2
+/- and Cross TG mice or between genders. 
 
7.3.1 Effect of 2.34 x 10
-6 M BMP-2 on CCRC to 5-HT 
CCRCs to 5-HT were performed in WT and TG mice following BMP-2 (2.34 x 10
-6 M) or 
vehicle (figure 7.1). Both groups of mice overexpressing the 5-HTT+ had lower pEC50 
values for 5-HT than mice with normal 5-HTT expression. This was true for both vehicle 
treated animals (WT: 7.3 ± 0.1, n=6, 5-HTT+: 6.0 ± 0.1, n=6, BMPR2
+/-: 7.6 ± 0.1, n=6, 
Cross TG: 6.0 ± 0.1, n=6) and for BMP-2 treated animals (WT: 7.2 ± 0.1, n=6, 5-HTT+: 
6.0 ± 0.1, n=5, BMPR2
+/-: 7.2 ± 0.3, n=6, Cross TG: 6.0 ± 0.1, n=6). The presence of the 
BMPR2 mutation did not affect the potency of 5-HT in either BMPR2
+/- mice or in Cross 
TG mice. Only the potency of 5-HT was affected by overexpression of the 5-HTT with 
Emax  values  not  significantly  different  between  groups.  The  Hill  coefficient  differed 
significantly (p<0.05) between the BMP-2 treated BMPR2
+/- group and the BMP-2 treated 
Cross TG group (BMPR2
+/-: 0.5 ± 0.2, n=6, Cross TG: 1.2 ± 0.2, n=6). BMP-2 did not alter 
the pEC50 or maximal response of 5-HT in any of the four genotypes (figure 7.1). 
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7.3.2 CCRC to linopirdine 
CCRCs  to  linopirdine  are  presented  in  figure  7.2.  CCRCs  did  not  follow  a  classical 
sigmoidal  shape and  the  Hill  equation was  not  applied  to  the  data.  pEC50  and  Emax 
values,  therefore,  were  not  determined  so  each  concentration  tested  was  statistically 
compared between groups. Linopirdine induced vasoconstriction was greater in WT mice 
compared with all three TG groups. At 300 nM, linopirdine induced vasoconstriction in 
WT  mice  was  significantly  greater  than  in  BMPR2
+/-  mice  (WT:  12.7  ±  6.5%  of  the 
contraction induced by 50 mM KCl, n=6, BMPR2
+/-: 0.75 ± 0.3%, n=8).  The contractile 
response was greater in WT mice at 1  M (WT: 51.0 ± 14.9%, n=6, 5-HTT+: 1.5 ± 0.5%, 
n=6, BMPR2
+/-: 0.75 ± 0.31%, n=8, Cross TG: 1.7 ± 1.3%, n=6), 3  M (WT: 63.2 ± 
17.0%, n=6, 5-HTT+: 7.7 ± 5.5%, n=6, BMPR2
+/-: 9.4 ± 5.9%, n=8, Cross TG: 15.2 ± 
9.6%, n=6), 10  M (WT: 75.5 ± 13.3%, n=6, 5-HTT+: 21.5 ± 10.5%, n=6, BMPR2
+/-: 20.4 
± 8.9%, n=8, Cross TG: 29.2 ± 17.7%, n=6) and 30  M (WT: 77.3 ± 13.7%, n=6, 5-HTT+: 
33.8 ± 9.1%, n=6, BMPR2
+/-: 32.3 ± 5.5%, n=8, Cross TG: 43.0 ± 16.1%, n=6) compared 
with the three TG groups. Vasoconstriction to linopirdine was also greater in WT mice 
compared with BMPR2
+/-  mice at the highest concentrations of 100  M (WT:  69.8 ± 
12.3%, n=6, BMPR2
+/-: 20.4 ± 4.6%, n=8) and 300  M (WT: 33.2 ± 5.1%, n=6, BMPR2
+/-
: 6.6 ± 2.2%, n=8). 
     
7.3.3 Effect of 10
-7M linopirdine on CCRC to 5-HT 
CCRCs to 5-HT were performed in WT and TG mice following linopirdine (10
-7M) or 
vehicle (figure 7.3). The potency of 5-HT was greater in BMPR2
+/- mice compared with 
the other three groups. This was true for vehicle treated animals (pEC50; WT: 6.6 ± 0.1, 
n=6, 5-HTT+: 5.6 ± 0.1, n=6, BMPR2
+/-: 7.3 ± 0.0, n=6, Cross TG: 5.7 ± 0.0, n=6) and for 
linopirdine  treated  animals  (pEC50;  WT:  6.7  ±  0.1,  n=6,  5-HTT+:  6.1  ±  0.0,  n=6, 
BMPR2
+/-:  7.7  ±  0.3,  n=6,  Cross  TG:  5.8  ±  0.1,  n=6).  There  were  also  significant 177 
 
differences in pEC50 values between WT and 5-HTT+ and between WT and Cross TG 
mice, with 5-HT being more potent in WT mice. This was independent of  linopirdine 
treatment in Cross TG mice but only in the vehicle treated 5-HTT+ animals was 5-HT less 
potent than the corresponding WT group. No differences were observed between 5-HTT+ 
and Cross TG animals. The maximum response to 5-HT also differed between groups. 
Emax values for 5-HT were higher in BMPR2
+/- vehicle treated animals compared with 
WT and 5-HTT+ vehicle treated animals (WT: 95.3 ± 8.0% of the contraction induced by 
50 mM KCl, n=6, 5-HTT+: 97.3 ± 4.5%, n=6, BMPR2
+/-: 117.3 ± 4.6%, n=6). In the 
linopirdine treated groups, the only significant difference observed in Emax values was 
between 5-HTT+ and BMPR2
+/- mice with BMPR2
+/- mice having the higher Emax (5-
HTT+: 97.7 ± 4.9%, n=6, BMPR2
+/-: 120.2 ± 4.7%, n=6). A significant difference in the 
Hill coefficient (p<0.01) was observed between BMPR2
+/- vehicle treated mice and Cross 
TG vehicle treated mice (BMPR2
+/-: 0.6 ± 0.2, n=6, Cross TG: 1.5 ± 0.2, n=6). Linopirdine 
did not significantly affect either pEC50 or the Emax of 5-HT in any of the four groups.  
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Figure 7.1 Cumulative concentration-response curves to 5-HT following BMP-2 (2.34 x 
10
-6M) or vehicle in IPAs from WT (A), 5-HTT+ (B), BMPR2
+/- (C) and Cross TG (D) 
mice (n= 5 to 6 mice per group). Results expressed as mean ± SEM. pEC50: *** p<0.001 
versus WT vehicle and BMPR2
+/- vehicle, $ p<0.001 versus WT BMP-2 and BMPR2
+/-  
BMP-2, # p<.0001 versus WT vehicle and BMPR2
+/- vehicle, † p<0.001 versus WT BMP-
2 and BMPR2
+/- BMP2 using Bonferroni multiple comparison test. 
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Figure 7.2 Cumulative concentration-response curves to linopirdine in IPAs from WT, 5-
HTT+, BMPR2
+/- and Cross TG mice (n = 6 to 8 mice per group). Results expressed as 
mean ± SEM. * p<0.05, ** p<0.01, *** p<0.001 versus corresponding concentration in 5-
HTT+,  BMPR2
+/-  and  Cross  TG  mice.  †  p<0.05,  #  p<0.01  versus  corresponding 
concentration in BMPR2
+/- mice using Newman-Keuls multiple comparison test. 
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Figure 7.3 Cumulative concentration-response curves to 5-HT following linopirdine (10
-
7M) or vehicle in IPAs from WT (A), 5-HTT+ (B), BMPR2
+/- (C) and Cross TG (D) mice 
(n= 6 mice per group). Results expressed as mean ± SEM. pEC50: * p<0.05, ** p<0.01 
versus WT vehicle, ƒ p<0.01, *** p<0.001 versus WT lino, $, p<0.001 versus 5-HTT+ 
vehicle, # p<0.001 versus 5-HTT+ lino, † p<0.001 versus BMPR2
+/- vehicle, ‡ p<0.001 
versus  BMPR2
+/-  lino.  Emax:  §  p<0.01  versus  WT  vehicle,  ¥  p<0.05  versus  5-HTT+ 
vehicle, € p<0.01 versus 5-HTT+ lino using Bonferroni multiple comparison test. 
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7.4 Discussion 
Overexpression of the 5-HTT had a dramatic effect on 5-HT induced vasoconstriction in 
both 5-HTT+ and Cross TG mice. The decreased potency of 5-HT in mice overexpressing 
the  5-HTT  can  be  reversed  by  the  5-HTT  inhibitor  citalopram  (Dempsie et al.,  2008) 
indicating the decreased potency of 5-HT is due to overexpression of the 5-HTT. The most 
likely explanation for this effect is a greater uptake of 5-HT into the cell removing 5-HT 
available for  activation of 5-HT2A and  5-HT1B  receptors. Interestingly, the pEC50 and 
Emax  of  5-HT  was  increased  in  BMPR2
+/-  IPAs  compared  with  WT  mice.  This 
observation, however, only occurred in the set of experiments involving linopirdine (figure 
7.3) and not in the experiments involving BMP-2 (figure 7.1). The ratio of male to female 
mice  used  for  the  WT  and  BMPR2
+/-  analysis  was  similar  between  the  two  sets  of 
experiments  so  gender  difference  can  be  ruled  out  as  a  mitigating  factor  for  the 
discrepancy. An inspection of figures 7.1 and 7.3 reveals a similar response to 5-HT in the 
BMPR2
+/- mice in both the linopirdine and BMP-2 experiments and that it is, in fact, the 
response to 5-HT in WT mice that differs between experiments with a greater contractile 
response to 5-HT  in the BMP-2 control experiments. The reason for this discrepancy is not 
known. The only difference in experimental protocol was a longer period of time during 
which the vessel was in the Krebs solution on the myograph in the BMP-2 experiments 
(owing to the longer incubation of BMP-2 and consequently H2O vehicle). This is unlikely, 
however, to make a significant difference to 5-HT induced vasoconstriction, especially in 
WT but not in BMPR2
+/- animals. The result is most likely due to batch differences in the 
WT mice due to natural variations in pulmonary artery phenotype within a population. The 
enhanced vasoconstrictor effect of 5-HT in BMPR2
+/- IPAs  confirm the results obtained 
by Long et al., 2006 who found an increased maximum response to 5-HT and 5-HT2A 
agonist  α–methly-5-HT in IPAs from BMPR2
+/- mice. Long et al., 2006 did not find an 
increase in potency to 5-HT or α–methly-5-HT but did see a leftward shift in the CCRC to 182 
 
the 5-HT1 agonist 5-CT in BMPR2
+/- mice. Both the pEC50 and Emax of 5-HT were 
increased  in  IPAs  from  BMPR2
+/-  vessels  in  this  investigation  and  likely  reflects  an 
involvement of both 5-HT2A and 5-HT1B receptors and blockade of either of these receptors 
attenuates the 5-HT response in BMPR2
+/- IPAs (Long et al., 2006). A change in the Hill 
coefficient was observed between BMPR2
+/- and Cross TG mice. The Hill coefficient is a 
measure  of  the  nature  of  ligand  binding  to  receptor(s)  complexes. The  change in  Hill 
coefficient indicates different binding characteristics for 5-HT between the two genotypes, 
perhaps reflecting a change in the respective utilisation of 5-HT1B and 5-HT2A receptors or 
a  change  in  receptor  activation  following  5-HT  binding,  which  may  be  secondary  to 
overexpression of the 5-HTT.  
 Linopirdine, a selective KCNQ channel inhibitor induced vasoconstriction in WT mice 
reaching  a  maximum  contraction  at  30  µM  before  inducing  vasorelaxation  at  higher 
concentrations. Vasoconstriction to linopirdine was significantly less in all TG groups at 1 
– 30 µM with additional differences noted between WT and BMPR2
+/- groups at 300 nM, 
100 µM and 300 µM. No significant differences were noted between TG groups. The 
vasoconstriction induced by linopirdine in WT mice is independent of endothelial and 
neuronal derived factors (Joshi et al., 2006) and is via a direct action on KCNQ channels 
on PASMCs, an effect attributable to membrane depolarisation and voltage-gated Ca
2+ 
entry  (Joshi  et  al.,  2009).  The  effect  of  linopirdine  on  systemic  vessels  appears  to  be 
significantly less although results have been inconsistent in studies to date. Linopirdine and 
XE991 induced vasoconstriction was found to be minimal or completely absent in systemic 
vessels such as carotid and mesenteric arteries in studies by Joshi et al., 2006 and Joshi et 
al., 2009. This data agrees with results by Yeung et al., 2007 who found that XE991 
induced  minimal  contraction  in  femoral  and  carotid  arteries  and  no  contraction  in 
mesenteric arteries in the absence of pre-tone. Interestingly, in the presence of pre-tone 
XE991 did induce contraction of mesenteric arteries (Yeung et al., 2007). Contradictory 183 
 
results were demonstrated by Mackie et al., 2008 who found that linopirdine did induce 
vasoconstriction  in  mesenteric  arteries  on  a  pressure  myograph.  The  maximum 
vasoconstriction  induced  by  linopirdine  in  rat  mesenteric  arteries  was  ~  35%  of  KCl 
response (Mackie et al., 2008) opposed to the near 100% of KCl response induced by 
linopirdine in rat pulmonary arteries (Joshi et al., 2009).  
 The enhanced vasoconstriction to linopirdine in pulmonary arteries over systemic arteries 
may be may be attributable to the KCNQ4 subunit which is expressed at a higher level than 
other KCNQ channel subunits in pulmonary arteries (Joshi et al., 2009) and is expressed 
more than 10 fold higher in pulmonary arteries compared with mesenteric arteries (Joshi et 
al.,  2009).  The  results  by  Joshi  et  al.,  2006  and  confirmed  here  indicate  that  KCNQ 
channels are open at rest and are a major contributor to the resting membrane potential in 
murine PASMCs.  
 One possibility for the decreased response to linopirdine in TG mice is that PASMCs in 
these animals are hyperpolarised relative to WT PASMCs and therefore a greater number 
of KCNQ channels must be blocked to depolarise the cell membrane to a level sufficient to 
induce activation of VDCC.  Alternatively, KCNQ channel subunit expression or activity 
may be lower in the TG animals compared with WT reducing the effect of linopirdine. 
This may or may not be associated with electrophysiological changes. BMP-2 increases 
whole-cell K
+ current in human PASMCs and divergently regulates expression of many Kv 
subunits, altering expression of certain subunits >10 fold (Young et al., 2006; Fantozzi et 
al., 2006). Loss of BMPR2 may result in a decrease in whole-cell K
+ current and changes 
in KCNQ channel expression. The increase in whole-cell K
+ current induced by BMP-2 
would result in a shift to an apoptotic, anti-mitogenic and pro-relaxant cellular phenotype 
and thus, loss of BMPR2 would have the opposite effects. The molecular mechanism by 
which  BMPR2  interacts  with  Kv  channel  subunits  is  unknown  but  may  involve  the 
presence or absence of SMAD and c-myc binding sites in the promoter regions of Kv 184 
 
channel genes. This could account for  the divergent effects BMP-2 has on various Kv 
channel genes (Fantozzi et al., 2006). Overexpression of the 5-HTT+ was sufficient to 
reduce  linopirdine  induced  vasoconstriction  at  1  -  30  µM  compared  with  WT.  
Overexpression of the 5-HTT in smooth muscle is sufficient to reduce Kv1.5 and Kv2.1 in 
the lungs of mice (Guignabert et al., 2006) and thus it is conceivable that other Kv channel 
subunits such as KCNQ may also be downregulated by 5-HTT overexpression. Results in 
the Cross TG mice were similar to both 5-HTT+ and BMPR2
+/- groups indicating KCNQ 
channel  function/expression  is  not  additively  altered  by  5-HTT  overexpression  and 
BMPR2 downregulation. 
 The  evidence  in  this  thesis  that  linopirdine  induces  vasoconstriction  of  mouse  IPAs 
supports previous work indicating that linopirdine not only contracts isolated pulmonary 
arteries but also increases PAP in vivo (Joshi et al., 2009). Moreover, the discovery that 
KCNQ channel activators can induce relaxation of pulmonary arteries (Joshi et al., 2009) 
provides further evidence that KCNQ channels are involved in regulating pulmonary artery 
tone.  Due  to  this  important  role  for  KCNQ  channels  in  the  pulmonary  circulation, 
experiments were performed to assess how linopirdine would affect the vasoconstrictor 
response to 5-HT in WT and TG mice. Linopirdine did not alter the 5-HT response in any 
group which would indicate that 5-HT induced vasoconstriction is not dependent on the 
state  of  KCNQ  channels.  The  relative  contribution  of  voltage-dependent  and  voltage-
independent pathways that mediate 5-HT induced vasoconstriction is not known in detail 
and conflicting evidence in this area of research has emerged (Varghese et al., 2006). For 
example, 5-HT inhibits Kv current and depolarises the cell membrane in rat PASMCs and 
Ltk
-  cells  expressing  cloned  human  Kv1.5,  effects  attenuated  by  several  compounds 
including ketanserin and PKC inhibitors (Cogolluda et al., 2006). Moreover, 5-HT induced 
vasoconstriction  of  rat  pulmonary  arteries  is  also  inhibited  by  ketanserin  and  PKC 
inhibitors in addition to L-type Ca
2+ channel blockers (Cogolluda et al., 2006). 5-HT partly 185 
 
induces  vasoconstriction  of  canine  pulmonary  arteries  through  L-type  Ca
2+  channel 
activation, an effect also mediated by 5-HT2A receptors (Wilson et al., 2005). In contrast to 
these  studies,  Guibert  et al.,  2004  found  that  5-HT2A  mediated  vasoconstriction  of  rat 
pulmonary arteries was independent of voltage-gated Ca
2+ channels. Factors other than 
inhibition of Kv current could account for 5-HT induced vasoconstriction in the murine 
IPAs studied in this investigation such as Ca
2+ release from intracellular stores and Ca
2+ 
sensitisation  via  ROCK  (Rodat-Despoix  et  al.,  2008).  The  vasoconstrictor  pathways 
activated by 5-HT may also depend on the relative expression of 5-HT1B and  5-HT2A 
receptors. 5-HT induced vasoconstriction in rat pulmonary arteries can be inhibited by 5-
HT1B and 5-HT2A antagonists but 5-HT induced inhibition of Kv currents is only prevented 
by  5-HT2A  antagonists  (Cogolluda  et  al.,  2006).  It  maybe  that  Kv  channels  are  more 
important in 5-HT induced vasoconstriction in arteries with a higher concentration of 5-
HT2A receptors although this may be species specific. 
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Chapter 8 
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8.1 Introduction 
The increased risk of PAH in women of child bearing age suggests that circulating female 
sex hormones may underlie the increased risk. Experiments utilising both the MCT and 
hypoxic models, however, have generally shown that female mice are more resistant to 
developing PAH  than males and that female sex hormones attenuate the development of 
both hypoxic and MCT PAH through vasodilator and anti-mitogenic effects.  
 The  effect  of  sex  hormones  on  vascular  tone  appears  dependent  on  species,  gender, 
vascular origin of artery and whether the artery has intact endothelium. Estradiol relaxes 
isolated perfused rat tail arteries pre-contracted with noradrenaline in female rats but not in 
males and this effect is dependent on an intact endothelium (McNeill et al., 1996). This 
may indicate that estradiol modulates adrenergic effects in vivo in female rats.  Estradiol is 
also  a  vasodilator  of  human  coronary  arteries  where  it  also  acts  via  an  endothelium 
dependent process (Gilligan et al., 1994). The endothelium dependent effect of estrogens is 
thought  to  occur  either  through  the  rapid  release  of  NO  via  a  non  genomic  estrogen 
receptor (ER) mediated process (Chen et al., 1999; Stefano et al., 2000) or via a non ER 
cell surface receptor involving stereospecific interactions with an unknown receptor at the 
cell surface that induces vasodilation independent of NO and prostaglandins (Teoh et al., 
2000a; Shaw et al., 2000). Alternatively, estradiol can induce vasodilation in endothelium 
denudated vessels (Sudhir et al., 1995; Chester et al., 1995), a process governed by K
+ and 
Ca
2+ channels (Sudhir et al., 1995). The discrepancy in these results most likely involves 
differences  in  tissue  preparation,  vascular  origin  of  tissue,  sex  of  animal  and  species. 
Estradiol  can  also  act  as  a  vasoconstrictor  enhancing  the  vasoconstriction  of  several 
common vasoconstrictors (Vargas et al., 1995). Whether estrogens act as vasoconstrictors 
or vasodilators may be regional specific, for example, in the rabbit, estradiol relaxes pre-
constricted coronary and ear arteries but increases the contractile force of pre-constricted 
pulmonary and thoracic arteries. The vasoconstrictor effect of estradiol was attenuated by 188 
 
indomethacin indicating a role for prostaglandins in this process (Opgaard et al., 2002). 
Estradiol also modulates both HPV and ET-1.  For example, estradiol reduces HPV in 
sheep (Sylvester et al., 1985) and rats (Lahm et al., 2007). Estradiol also reduces lung 
levels of ET-1 and prevents hypoxia induced increases in ET-1 by preventing the action of 
HIF-1  (Earley and Resta, 2002).  Estradiol undergoes metabolism via several enzyme 
pathways to form non-estrogenic metabolites (Dubey et al., 2004). As mentioned in section 
1.2.3.2.4, one of these metabolites, 2-ME, has demonstrated to be protective in animal 
models of PAH. The vasoactive role of 2-ME in systemic and pulmonary arteries has yet to 
be determined in detail but sufficient evidence exists that it may be as important or more 
important  than estradiol  in  modulating  vasoactive  compounds.  2-ME  is  a  more  potent 
inhibitor of ET-1 (Dubey et al., 2001) and a more potent inducer of prostacyclin synthesis 
(Seeger et al., 1999) compared with estradiol in endothelial cells.  
  Testosterone has also been studied for its vasoactive properties in different vessel types 
including pulmonary and coronary arteries from several species (Littleton-Kearney and 
Hurn, 2004). While there is data supporting a vasodilator role for testosterone (Honda et 
al., 1999; English et al., 2001; Ding and Stallone, 2001), a process thought to involve 
activation  of  NO  or  a  direct  action  on  ion  channels  present  on  smooth  muscle  cells 
(Littleton-Kearney  and  Hurn,  2004),  there  is  also  opposing  data  favouring  a 
vasoconstrictor role for testosterone (Quan et al., 1999; Teoh et al., 2000a; Teoh et al., 
2000b), a process possibly related to an inhibition of prostacyclin or inhibition of  Kv 
channels (Littleton-Kearney and Hurn, 2004).  
 The concentration of sex hormones required to induce vasodilation or vasoconstriction in 
isolated tissue preparations are usually within the pharmacological range, however, HPV is 
reduced in extralobar pulmonary arteries from rats during the proestrus menstrual phase 
(Lahm et al., 2007) indicating that small changes in circulating estrogen levels can alter the 
vascular response to a vasoconstrictor stimulus. Additionally, physiological concentrations 189 
 
(1-30  nM)  of  estradiol  and  testosterone  can  influence  5-HT  and  ET-1  induced 
vasoconstriction in porcine coronary arteries (Teoh et al., 2000a).  
 The  experimental  evidence  just  outlined  offers  the  possibility  for  interaction  of  sex 
hormones  with  potential  mediators  of  PAH.  There  have  been  relatively  few  studies 
examining the role of gender in animal models of PAH and the effect that male hormones 
such as testosterone and female hormones such as estradiol and 2-ME have on pulmonary 
arteries and on PAECs and PASMCs. Many animal studies in PAH have used only male 
gender for experimental procedures or mixed gender populations that do not discriminate 
between males and females.  Indeed, several of the in vitro pharmacology experiments in 
this thesis used mixed gender groups of animals due to the limited number of TG animals 
available. It was during these in vitro experiments that clear gender differences emerged in 
the response to vasoconstrictors that subsequently resulted in specific male versus female 
comparisons being performed for the hypoxic studies in chapter 3 and the Dfen in vivo and 
in vitro pharmacology work in chapters 4 and 6. The results of these experiments coupled 
with the importance of female gender as a modifying risk factor for PAH warranted further 
experimental analysis. In this chapter, the vasoconstrictor/vasodilator properties of both 
male and female sex hormones and their effect on 5-HT vasoconstriction were analysed in 
pulmonary arteries of both male and female mice. To further determine any modulating 
effect  estradiol  might  have  on  serotonergic  induced  vasoconstriction  relevant  to  PAH, 
CCRCs were also performed to NDfen in the presence and absence of estradiol.  Male and 
female mouse lungs were also analysed for any differences in 5-HT and BMPR2 signalling 
molecules.   
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8.2 Methods 
8.2.1 Animals  
Animals were age 2-3 months 
 
8.2.2 Myography 
IPAs  were  isolated  from  male  and  female  WT  mice  and  used  for  wire  myography 
experiments as described previously. 
Following attainment of maximal contractile response to KCl as outlined in section 2.6.1.5, 
vessels were left to equilibrate for 30 minutes.  
To assess the vasoconstrictor properties of sex hormones, CCRCs to estradiol (Sigma-
Aldrich  Ltd,  Poole, UK), 2-ME  (Sigma-Aldrich  Ltd,  Poole, UK), testosterone (Sigma-
Aldrich Ltd, Poole, UK) and vehicle were performed in IPAs from male and female mice. 
To assess the vasodilator properties of sex hormones CCRCs were performed in IPAs from 
male and female mice pre-constricted with phenylephrine (a concentration in the range 10
-8 
– 10
-7 M dissolved in H2O that induced vasoconstriction equal to 70% of 50 mM KCl). All 
hormones  were  dissolved  in  ethanol  to  give  a  solution  of  10
-3  M  from  which  serial 
dilutions were created in H2O up to 10
-8 M giving the range necessary for a 10 pM – 10  
M CCRC to be constructed. 
 Following  the  final  concentration  of  hormone  (10
-5  M)  added  during  the  experiments 
assessing vasoconstriction, vessels were left for 20 minutes before a CCRC to 5-HT was 
performed to assess the effects of sex hormones on 5-HT induced vasoconstriction.  
 Separate experiments were performed to assess the effect of a physiological concentration 
(1 nM) of estradiol and testosterone on 5-HT. Hormones or ethanol vehicle were incubated 
for 20 minutes before a CCRC to 5-HT was constructed. 
 Finally, 1 nM of estradiol or ethanol vehicle was incubated for 20 minutes prior to CCRCs 
for NDfen being performed in IPAs from male and female mice. 191 
 
5-HT and NDfen were dissolved in H2O to give a solution of 10
-2 M from which serial 
dilutions were created up to 10
-6 M giving the range necessary for a 1 nM- 300  M CCRC 
to be constructed 
 As stated above, CCRCs to 5-HT following 10
-5 M of estradiol/2-ME/testosterone were 
performed  on  vessels  following  the  initial  CCRC  to  each  hormone.  For  all  other 
experiments vessels were subjected to only one treatment.  
 
8.3 Results 
Contractions in IPAs were measured relative to the contraction induced by 50 mM KCl. 
No significant differences were observed in KCl response between genders (male: 2.5 ± 
0.3 mN, n=6, female: 2.4 ± 0.2 mN, n=6). 
 
8.3.1 Assessment of contractile response to estradiol, 2-ME and testosterone in male 
and female IPAs 
CCRCs to estradiol, 2-ME and testosterone are presented in figure 8.1. No vasoconstriction 
was observed up to 10
-5 M for any hormone tested in either male or female mice.  
 
8.3.2 Assessment of vasodilator response to estradiol, 2-ME and testosterone in male 
and female IPAs 
Figure 8.2A shows CCRCs for each hormone in IPAs from male mice pre-constricted with 
phenylephrine.  All  three  hormones  displayed  significant  vasodilator  effects  at 
concentrations equal to or greater than 0.1 µM in male mice and this data is presented in 
table 8.1A.  The only significant difference noted between hormones in the relaxation 
response was at 10 µM where estradiol induced a greater degree of relaxation (p<0.05) 
compared with 2-ME (figure 8.2A). In female IPAs (figure 8.2B) testosterone induced a 
significant vasodilator effect at 3 µM and above with both female hormones exerting  a 192 
 
significant vasodilator effect from 10 µM (table 8.1B).  No significant differences were 
observed between hormones.  The only gender differences to emerge were for estradiol. 
The vasodilation induced by estradiol was greater in male mice (p<0.05) compared with 
female mice at 100 nM (male: -6.9 ± 2.9% of phenylephrine induced pre-constriction, n=6, 
female: 2.8 ± 0.7%, n=6), 300 nM (male: -6.1 ± 2.4%, n=6, female: -0.2 ± 0.8%, n=6), 1 
µM (male: -10.2 ± 2.6%, n=6, female: -0.7 ± 2.1%, n=6) and 10 µM (male: -38.6 ± 4.7%, 
n=6, female: -24.3 ± 2.8%, n=6).  
 
8.3.3 Influence of a high concentration (10
-5 M) of estradiol, 2-ME and testosterone on 
5-HT induced vasoconstriction. 
Following the CCRCs to each hormone, an additional CCRC to 5-HT was performed in the 
presence of 10
-5 M estradiol, 2-ME and testosterone (figure 8.3). In male mice (figure 
8.3A), the pEC50 of 5-HT was decreased (p<0.05) in estradiol treated vessels compared 
with vehicle (vehicle: 7.5 ± 0.1, n=7, estradiol: 7.1 ± 0.1, n=6) and there was a significant 
difference (p<0.05) in the pEC50 between the estradiol and testosterone treatment groups 
with the greater pEC50 being in animals that had been treated with testosterone (estradiol: 
7.1 ± 0.1, n=6, testosterone: 7.4 ± 0.1, n=6). Hormones affected the maximal response to 5-
HT  to  a  much  greater  degree  than  pEC50  with  each  hormone  significantly  (p<0.001) 
reducing  the  Emax  of  5-HT  compared  with  vehicle  (vehicle:  124.0  ±  4.2%  of  the 
contraction induced by 50 mM KCl, n=7, estradiol: 93.3 ± 5.9%, n=6, 2-ME: 98.3 ± 6.1%, 
n=6, testosterone: 92.0 ± 7.5%, n=6). There were no differences, however, in the maximal 
response to 5-HT between the estradiol, 2-ME or testosterone groups  
   In  female  IPAs,  testosterone  increased  (p<0.01)  the  pEC50  of  5-HT  compared  with 
estradiol and 2-ME (estradiol: 7.2 ± 0.1, n=6, 2-ME: 7.2 ± 0.1, n=7, testosterone: 7.6 ± 0.1, 
n=6)  but  did  not  differ  significantly  from  the  vehicle  group.    The  only  significant 
difference in Emax was between the testosterone and estradiol groups with testosterone 193 
 
increasing (p<0.05) the Emax of 5-HT compared to estradiol (estradiol: 93.5 ± 5.2%, n=6, 
testosterone: 120.2 ± 6.9%, n=6) (figure 8.3B). 
Data  was  analysed  to  determine  any  differences  between  5-HT  response  in  male  and 
female IPAs. No differences were found in pEC50 values but Emax values did differ 
significantly (p<0.05) in the testosterone groups (male: 92.0 ± 7.5%, n=6, female: 120.2 ± 
6.9%, n=6). 
 
 8.3.4 Influence of a low concentration (10
-9 M) of estradiol and testosterone on 5-HT 
induced vasoconstriction 
The effect of a physiological (10
-9 M) concentration of estradiol and testosterone was tested 
on the vasoconstrictor effect of 5-HT in male and female IPAs (figure 8.4). No differences 
were observed in pEC50 or Emax in 5-HT response following estradiol or testosterone in 
either male or female mice. There were also no differences between male and female 
groups for respective hormones or vehicle.  
 
 8.3.5  Influence  of  a  low  concentration  (10
-9  M)  of  estradiol  on  NDfen  induced 
vasoconstriction 
To  determine  whether  a  physiological  concentration  of  estradiol  could  influence  the 
vasoconstriction induced by NDfen, CCRCs to NDfen were performed in the presence of 
10
-9 M estradiol in male and female IPAs (figure 8.5). NDfen was significantly more potent 
in IPAs from male mice in both vehicle (pEC50; male: 6.1 ± 0.1, n=7, female: 5.5 ± 0.1, 
n=7) and estradiol (pEC50; male: 6.0 ± 0.0, n=6, female: 5.3 ± 0.1, n=6) treated groups 
with maximal response unaffected. Estradiol had no effect on vasoconstriction in either 
gender.  
 194 
 
8.3.6 Expression of 5-HT and BMPR2 signalling molecules in male and female mouse 
lung. 
Expression of p-Smad1/5/8 (figure 8.6), p-p38 MAPK (figure 8.7) and p-ERK1/2 (figure 
8.8)  were  analysed  by  western  blotting  in  male  and  female  whole  mouse  lung.  p-
Smad1/5/8 and p-p38 MAPK expression did not differ between genders but p-ERK1/2 was 
expressed more strongly in female mouse lung.  
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Figure 8.1 Cumulative concentration-response curves to estradiol, 2-ME, testosterone and 
ethanol vehicle in IPAs from male (A) and female (B) WT mice (n=6-9 mice per group). 
Results expressed as mean ± SEM. Newman-Keuls multiple comparison test revealed no 
significant differences between groups at any concentration tested.  196 
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Figure 8.2 Cumulative concentration-response curves to estradiol, 2-ME, testosterone and 
ethanol vehicle in IPAs (pre-constricted with phenylephrine) from male (A) and female (B) 
WT mice (n=6 mice per group). Results expressed as mean ± SEM (Results corrected to 
account  for  ethanol  vehicle  response).  *  p<0.05,  **  p<0.01,  ***  p<0.001  versus 
corresponding concentration for ethanol vehicle. † p<0.05 versus 2-ME using Newman-
Keuls multiple comparison test. 
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  A 
Treatment  3 µM  10 µM  30 µM 
vehicle  -0.8 ± 2.0  -4.2 ± 2.2  -2.7 ± 1.2 
estradiol  -11.8 ± 3.0  -24.3 ± 2.8 *  -41.2 ± 5.7 ** 
2-ME  -9.3 ± 3.6   -23.7 ± 8.5 *  -43.8 ± 9.3 *** 
testosterone  -15.0 ± 4.8 *  -32.5 ± 6.6 *  -58.3 ± 7.6 *** 
 
 B 
 
Table 8.1 Significant vasodilator effect of estradiol, 2-ME and testosterone in vessels pre-
constricted with phenylephrine in male (A) and female (B) IPAs (n=6 mice per group). 
Results expressed as mean (% of pre-constriction) ± SEM (Results corrected to account for 
ethanol vehicle response). * p<0.05, ** p<0.01, *** p<0.001 versus corresponding vehicle 
value. † p<0.05 versus 2-ME using Newman-Keuls multiple comparison test. 
 
Treatment     100 nM  300 nM  1 µM  3 µM 
vehicle   4.2 ± 2.1   2.8 ± 1.2  4.4 ± 1.3  4.4 ± 1.4 
estradiol  -6.9 ± 2.9 **  -6.1 ± 2.4 **  -10.2 ± 2.6 ***  -18.6 ± 2.6 *** 
2-ME  -6.5 ± 1.8 **  -7.3 ± 1.6 **  -10.1 ± 1.9 ***  -10.6 ± 3.1 *** 
testosterone  -4.4 ± 1.0 *  -3.1 ± 1.2 *  -9.2 ± 0.9 ***  -12.1 ± 1.7 *** 
Treatment     10 µM  30 µM     
vehicle   7.6 ± 1.9   11.2 ± 3.3     
estradiol  -38.6 ± 4.7 ***,†  -53.7 ± 5.8 ***     
2-ME  -24.3 ± 3.8 ***  -39.2 ± 4.9 ***     
testosterone  -31.1 ± 3.5 ***  -55.4 ± 6.9 ***     198 
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Figure  8.3  Cumulative  concentration-response  curves  to  5-HT  following  selected  sex 
hormones (10
-5 M) and ethanol vehicle in IPAs from male (A) and female (B) mice (n= 6-7 
mice  per  group).  Results  expressed  as  mean  ±  SEM.  Male  pEC50:  *  p<0.05  versus 
testosterone  and  vehicle.  Male Emax:  ***  p<0.001  versus  vehicle.  Female  pEC50:  ** 
p<0.05  versus  estradiol  and  2-ME.  Female  Emax:  *  p<0.05  versus  estradiol  using 
Newman-Keuls multiple comparison test. 199 
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Figure  8.4  Cumulative  concentration-response  curves  to  5-HT  following  selected  sex 
hormones (10
-9 M) and ethanol vehicle in IPAs from male (A) and female (B) mice (n= 4-6 
mice per group). Results expressed as mean ± SEM. Newman-Keuls multiple comparison 
test revealed no significant difference in pEC50 or Emax between groups. 200 
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Figure 8.5 Cumulative concentration-response curves to NDfen following estradiol (10
-9 
M)  and  ethanol  vehicle in  IPAs  from  male  and  female mice  (n=6-7  mice  per  group). 
Results expressed as mean ± SEM. pEC50: *** p<0.001 versus respective male treatment 
group using Bonferroni multiple comparison test.  
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Figure  8.6  Representative  autoradiograms  and  densitometric  analysis  of  p-Smad1/5/8 
expression in male and female mouse lung (n=6 mice per group). Results expressed as 
mean ± SEM. An unpaired two-tailed t-test revealed no significant difference between 
groups. 
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Figure 8.7 Representative autoradiograms and densitometric analysis of p-p38 expression 
in male and female mouse lung (n=6 mice per group).  Results expressed as mean ± SEM. 
An unpaired two-tailed t-test revealed no significant difference between groups. 
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Figure  8.8  Representative  autoradiograms  and  densitometric  analysis  of  p-ERK1/2 
expression in male and female mouse lung (n=6 mice per group).  Results expressed as 
mean ± SEM. * p<0.05 versus male using an unpaired two-tailed t-test. 
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8.4 Discussion 
The key findings from this chapter are the discovery that steroid sex hormones from both 
male and female mice have a vasodilator effect on pulmonary arteries pre-constricted with 
phenylephrine.  A  pharmacological  concentration  of  10
-5  M  (10
-5  M  was  chosen  as  a 
concentration  that  should  reliably  uncover  any  rapid  non-genomic 
vasodilator/vasoconstrictor  effect  each  hormone  may  have.  It  would  also  allow  a 
comparison with a physiological concentration giving greater insight into the vasoactive 
effects of each hormone) estradiol, 2-ME and testosterone reduced the vasoconstriction to 
5-HT in IPAs from male mice but not in female mice.  Estradiol and testosterone at a 
physiological concentration of 10
-9 M, however, were without effect on 5-HT in either 
gender. Estradiol at 10
-9 M was also without effect on NDfen which was found to be a 
more potent vasoconstrictor in male mice. Finally, p-ERK1/2 was found to be increased in 
female  mouse  lung  compared  with  males  with  p-Smad1/5/8  and  p-p38  MAPK  levels 
similar between genders. 
 The first series of myography experiments designed to assess the vasoactive effects of sex 
hormones conclusively show that both male (testosterone) and female (estradiol and 2-ME) 
sex hormones have vasorelaxant effects on murine IPAs. This is further evidence for the 
ability of steroid hormones to induce rapid non-genomic vasoactive effects on vascular 
tissue. Both estradiol and testosterone have previously been shown to dilate rat pulmonary 
vessels  pre-contracted  with  prostaglandin-F-2α  with  testosterone  inducing  the  largest 
relaxation, an effect found to be greater in male pulmonary arteries (English et al., 2001). 
This  differs  to  the  mouse  IPAs  pre-constricted  with  phenylephrine  utilised  in  this 
investigation where there was  no difference in testosterone induced relaxation between 
male and female IPAs and no significant differences emerged between testosterone and 
estradiol  in  either  gender.  There  was  an  enhanced  response  to  estradiol  in  male  mice 
compared with female mice at several concentrations tested. This would indicate a greater 205 
 
activation of vasodilator pathways in male mice. The fact that the three hormones did not 
differ significantly in effect (with the exception of a greater relaxation induced by estradiol 
at 10 µM compared with 2-ME in male IPAs) may indicate that similar pathways were 
utilised in inducing the vasorelaxation. These may involve NOS and NO activation which 
has  been  demonstrated  to  be  involved  in  estradiol  induced  vasorelaxation  in  several 
vascular beds (McNeill et al., 1996; Chen et al., 1999; Stefano et al., 2000; Scott et al., 
2007). Other studies, however, have found the vasoactive properties of sex hormones to be 
independent of NO (Chester et al., 1995; Sudhir et al., 1995; Naderali et al., 1999; Teoh et 
al., 2000a; Teoh 2000b; Shaw et al., 2000). There is sufficient evidence that estradiol 
exerts its vasoactive effects by different mechanisms depending on gender (Chester et al., 
1995; McNeill et al., 1996), species, arterial location (Opgaard et al., 2002), the inducer of 
vasoconstriction  used  in  the  experiment  (Teoh  et  al.,  2000a)  and  even  depending  on 
whether the animal is pregnant or not (Scott et al., 2007). A more consistent finding across 
the  literature  on  the  vasoactive  properties  of  sex  hormones  is  the  high  concentration 
(relative  to  physiological  concentrations)  of  hormone  necessary  to  induce  significant 
vasodilation.  Generally,  supraphysiological  (>0.1  µM,  more  commonly    >3  µM) 
concentrations have been required to induce significant relaxation (Naderali et al., 1999; 
Shaw et al., 2000; Opgaard et al., 2002; Scott et al., 2007). The results presented in this 
thesis agree with this conclusion.  0.1 µM and 3 µM in male and female mice respectively 
was the lowest concentration of hormone that induced significant vasorelaxation. Although 
each of the three hormones induced vasodilation in male mice at lower concentrations than 
in female mice, the extent of the vasodilation was small (< 10% of phenylephrine pre-
constriction at concentrations less than 1 µM). Even the concentrations required to induce 
a  small  response,  therefore,  are  higher  than  the  normal  physiological  concentration  of 
estradiol in females (<2 nM) and the plasma testosterone concentration (10-38 nM) in 
males. It is unlikely, therefore, that any rise or fall in either male or female sex hormones 206 
 
would  directly  affect  the  tone  of  pulmonary  arteries.  As  outlined  in  the  introduction, 
however, physiological concentrations of estradiol can influence HPV (Lahm et al., 2007) 
and  both  estradiol  and  testosterone  (1-30  nM)  alters  5-HT  and  ET-1  induced 
vasoconstriction in porcine pulmonary arteries (Teoh et al., 2000a). In this investigation, 
both  pharmacological  (10
-5  M)  and  physiological  (10
-9  M)  concentrations  of  male  and 
female sex hormones were tested in their respective abilities to alter the vasoconstriction 
induced by 5-HT in IPAs. Estradiol, 2-ME and testosterone decreased the Emax of 5-HT at 
10
-5  M  in  male  IPAs,  consistent  with  the  vasodilator  effect  of  these  hormones  at  this 
concentration  with  estradiol  having  the  most  pronounced  effect.  Hormones  had  more 
divergent effects at 10
-5 M when tested in female IPAs. While no hormone affected the 5-
HT response compared with vehicle, there was a trend towards enhanced vasoconstriction 
for testosterone and a trend towards decreased vasoconstriction for estradiol. This resulted 
in significant differences between testosterone and estradiol and between testosterone and 
2-ME. Similar results have previously been reported for porcine coronary arteries with 
estradiol reducing 5-HT induced vasoconstriction and testosterone enhancing it (Teoh et 
al., 2000a).  
 Interestingly, testosterone was the only hormone to alter 5-HT response between male and 
female IPAs with testosterone increasing the Emax of 5-HT in females compared with 
male  IPAs.  It  would  appear  that  the  ability  of  testosterone  to  reduce  5-HT  induced 
vasoconstriction is strongly male specific with no such effect and even a trend toward 
enhanced vasoconstriction occurring in females. This may indicate different mechanisms 
of action for testosterone in male and female IPAs and it is certainly clear that testosterone 
induces different signalling systems in different species and vascular beds. NO, Ca
2+ and 
K
+ channels, prostacyclin and androgen receptor (AR) mediated processes have all been 
suggested  as  modulators  of  testosterone  action  (Littleton-Kearney  and  Hurn,  2004). 
Testosterone and estradiol at 10
-9 M had no significant effect on the 5-HT CCRCs in either 207 
 
male or female IPAs. There was an observable trend, however, towards enhanced 5-HT 
induced vasoconstriction following 10
-9 M estradiol, an interesting observation as it is a 
trend in the opposite direction from the reduced vasoconstriction 10
-5 M estradiol had on 5-
HT.  It  is  unclear  if  this  is  evidence  of  a  true  pharmacological  effect.  Enhanced 
vasoconstriction  to  phenylephrine  has  been  observed  in  rabbit  pulmonary  arteries 
following estradiol but only at concentrations exceeding 10
-6 M (Opgaard et al., 2002). 
Additionally, a physiological concentration (7 nM) of estradiol can increase the pressor 
response to noradrenaline in rat mesenteric arteries (Vargas et al., 1995). As described in 
the introduction to this chapter, the effects of estradiol can differ between vascular beds 
and the study by Vargas et al., 1995 did not study pulmonary arteries. Currently, there is no 
evidence for  a direct  vasoconstrictor  effect of estradiol in mouse IPAs.    A similar 20 
minute exposure to 1 nM testosterone has previously been shown to reduce vasorelaxation 
induced by bradykinin and calcium ionophore A23187 (Teoh et al., 2000b) and to enhance 
vasoconstriction induced by 5-HT, ET-1 and U46619 (Teoh et al., 2000a). This latter study 
also  tested  estradiol  at  10
-9  M  and  found  this  concentration  was  sufficient  to  reduce 
vasoconstriction induced by 5-HT, ET-1 and U46619. Both studies were performed on 
mixed gender porcine coronary arteries which may be more sensitive to the vasoactive 
effects of sex hormones than murine IPAs. A final study examining whether estradiol (10
-9 
M) would act as a risk or modulating factor for NDfen induced vasoconstriction failed to 
show any influence of estradiol on NDfen. In fact, female gender acted as a protecting 
factor against the effect of NDfen with the potency of NDfen being greater in male IPAs 
possibly indicating enhanced activation of 5-HT2A mediated pathways in IPAs in young 
adult male mice.  
 Estradiol and its metabolites also affect vascular SMC proliferation with the effect being 
anti-mitogenic in most studies to date. Multiple mechanisms of actions are suggested for 
the  anti-mitogenic,  anti-migratory  effects  of  estrogens  including  inhibition  of  MAPK 208 
 
pathways,  decreased  release  of  mitogens  such  as  ET-1  and  PDGF  in  addition  to  an 
inhibition of ROS production (Dubey and Jackson, 2001). Interaction with pathways such 
as these in PASMCs possibly explains the beneficial role estradiol and 2-ME have in 
animals models of PAH as outlined in section 1.2.3.2.4.  The effect on endothelial cell 
growth by estradiols appears concentration dependent. Lower concentrations (10-100 nM) 
of  estradiol  metabolites  can  induce  proliferation  of  vascular  endothelial  cells  whereas 
higher concentrations (>100 nM) inhibit endothelial cell proliferation (Dubey and Jackson, 
2001). In rat lung ECs, estradiol induced proliferation of both male and female cultured 
cells at physiologically relevant concentrations (3-30 nM) while testosterone only induced 
proliferation of male ECs. The extent of proliferation induced by estradiol depended on the 
relevant  ratio  of  estradiol  to  both  progesterone  and  testosterone  with  testosterone 
increasing  the  proliferative  effect  of  estradiol  on  female  ECs  in  a  1:1  ratio.  Estradiol 
induced proliferation in these cells was dependent on ERs (Liu et al., 2002) highlighting 
the complexity of hormonal effects on cellular functions.  2-ME but not estradiol induces 
apoptosis of bovine PAECs. This was partly dependent on stress-activated protein kinase 
(SAPK). The EC50 value for  inducing apoptosis was 0.45  M  which is similar to the 
concentration required for inhibition of proliferation (Yue et al., 1997).  Fas,  Bcl-2,  - 
galactosidase and ROS scavenging may also contribute to its role in preventing apoptosis 
(Yue et al., 1997; Tsukamoto et al., 1998; Dubey and Jackson, 2001).  
 There is currently no direct link between sex hormones and the development of PAH. If 
hormonal agents do play a role, the effects are likely to be more subtle than those observed 
in  animal  models  using  high  plasma  concentrations.  It  may  be  that  alterations  in  the 
balance  between  estradiol  and  its  metabolites,  progesterone  and  testosterone  or  their 
receptors  are  more  important  than  any  single  rise  or  fall  in  hormone  concentration. 
Evidence for this is supported by the finding that progesterone receptors are present within 
the  intimal  lesions  in  human  PAH  but  ERs  are  absent.  Neither  of  these  receptors  are 209 
 
present in healthy lung tissue (Barberis et al., 1995). As mentioned above, the relevant 
ratio of progesterone and testosterone to estradiol modulates the proliferative effect of 
estradiol on vascular ECs. The balance of circulating hormones can affect the response to 
other circulating vasoconstrictors and growth factors. Female mesenteric arteries from rats 
display  increased  responsiveness  to  vasoconstrictors  compared  with  males  and  pre-
treatment of males with estradiol increases the responsiveness of male arteries  (Altura, 
1975).  Inherent differences in many of the candidate systems put forward as modulators in 
the pathophysiology of PAH may also exist between male and females that increase the 
risk in females when challenged with pulmonary hypertensive risk factors. It is already 
established that estrogens can modulate MAPK pathways including ERK1/2 and p38. To 
determine if these two pathways, relevant to both 5-HT and Dfen induced proliferation of 
pulmonary cells and dysfunctional BMPR2 signalling, differs in male and female mouse 
lung,  western  blot  analysis  of  these  proteins  were  performed.  The  canonical  BMPR2 
signalling  protein:  p-Smad1/5/8  was  also  analysed.  Only  p-ERK1/2  was  significantly 
different,  being  raised  in  female  mouse  lung  compared  with  males.  p-ERK1/2,  as 
previously described throughout this thesis, is implicated in 5-HT induced proliferation of 
PASMCs (Lee et al., 1999; Liu et al., 2004; Lawrie et al., 2005), BMP-2 and BMP-7 
induced proliferation of PASMCs in IPAH patients (Takeda et al., 2004) and also perhaps 
in  Dfens  mechanism  of  action  (Lee  et al.,  2001).  It  could  be  hypothesised  that  if the 
increased p-ERK1/2 observed in female mouse lung was raised in PASMCs these cells 
may be less resistant to any factor that increases p-ERK1/2 promoting proliferation and 
also acting to suppress the anti-proliferative p-Smad1/5/8 pathway through direct inhibition 
(Massague, 2003). It may also be that a combination of small differences between male 
 and female physiology are additive in creating a pulmonary vasculature at greater risk of 
PAH and some of these differences will be discussed in the final chapter.  
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9.1 General discussion 
 
Recent years have provided extensive knowledge in understanding the pathophysiology of 
PAH including genetic, cellular and molecular advances. The result of this research has 
been the discovery of BMPR2 mutations as the principal genetic basis for the disease, the 
identification of candidate molecular mechanisms that modulate the severity of the disease 
and the emergence of new vasodilator therapies for improving survival and quality of life.  
Furthermore, PAH has revealed itself to be a multifactorial disease with neither one factor 
or mutation responsible for the severe disease phenotype observed in human patients.  The 
creation of the BMPR2
+/- mouse as a genetic model to mimic the haploinsufficent state of 
FPAH in humans offers the opportunity to assess how a proven genetic risk factor may 
interact with other genetic or acquired factors speculated to be causative or modulating in 
the disease progression.  The large body of evidence outlined previously in this thesis 
implicating the serotonergic system, in particular heightened expression of the 5-HTT as a 
contributor to PAH and the existence of a 5-HTT+ mouse led to a new 5-HTT+/BMPR2
+/-  
mouse being developed to further explore genetic interaction and subsequent interaction 
with possible secondary risk factors.   
 In chapter 3, the pulmonary phenotype of cross TG mice and single TG animals was 
extensively assessed in both male and female mice and the pulmonary vascular response to 
14 days hypoxia compared with WT animals. The most significant finding from this set of 
experiments  was  the  divergent  effect  that  overexpression  of  the  5-HTT  and  BMPR2 
deficiency had on pulmonary phenotype and that these effects were only evident in female 
animals.  5-HTT+  overexpression caused a rise in mRVP and vascular remodelling in 
room  air  in  females  and  these  animals  had  a  more  severe  pulmonary  hypertensive 
phenotype under hypoxia. The increase in vascular remodelling in female 5-HTT+ mice is 
a novel finding and further strengthens a role for the 5-HTT as a modulating factor in 
PAH. Future studies will need to address the question of what molecular mechanisms are 212 
 
responsible for linking the 5-HTT to an increase in RVP and remodelling. Indeed, studies 
such as these are already under way with the recent discovery that Kv1.5 downregulation 
by the 5-HTT in PASMCs is dependent on the nuclear factor of activated T-cells (NFAT) 
c2 transcription factor (Guignabert et al., 2009). NFATc2 was found to mediate 5-HTT 
downregulation of Kv1.5 in both human PASMCs and in PASMCs from the SM22-5-
HTT+  mice  discussed  in  chapter  3.  Moreover,  gene  expression  studies  have  been 
performed on 5-HTT
-/- mice that indicate a decrease in inflammatory genes and changes in 
cell cycle genes that tend towards lower proliferation (Crona et al., 2009). The logical 
progression from this study would be a similar analysis of gene expression in the 5-HTT+ 
mouse used in this investigation that may identify genes or groups of genes that contribute 
to the pulmonary hypertensive phenotype.  Female BMPR2
+/- mice, while phenotypically 
normal in room air, did develop more severe vascular remodelling following hypoxia than 
mice without BMPR2 deficiency. As discussed in chapter 3, this investigation is the first to 
show  heightened  vascular  remodelling  in  the  BMPR2
+/-  mouse  following  hypoxia,  a 
particularly important and relevant finding to PAH in humans as it demonstrates that the 
interaction  of two  known  risk  factors  for  PAH  (namely  BMPR2  mutation  and  female 
gender) can predispose the pulmonary vasculature to more extensive changes following 
hypoxia, a factor in several diseases associated with PAH.   No synergy was observed 
between overexpression of the 5-HTT and BMPR2 deficiency in the in vivo experiments 
that resulted in an exaggerated pulmonary hypertensive phenotype. Developing a suitable 
model  for  PAH  has  proven  difficult  with  neither  the  hypoxic  or  MCT  rodent  models 
reproducing the full complexity of vascular lesions observed in human patients and genetic 
models  also  have  limitations.  Despite  mimicking  the  genetic  background  of  a 
haploinsufficent FPAH patient with L/L allele genotype for 5-HTT, the level of BMPR2 
and 5-HTT in Cross TG mice are higher and lower respectively than levels seen in PAH 
patients.    It  may  be  that  synergistic  effects  in  PASMCs  from  Cross  TG  mice  that 213 
 
predispose these cells to proliferation and vasoconstriction are too subtle to create a more 
pronounced pulmonary hypertensive phenotype following the hypoxic challenge used in 
this  investigation.  Long  et  al.,  2006  demonstrated  that  BMPR2
+/-  mice  develop  a 
pulmonary hypertensive phenotype following 2 weeks of 5-HT infusion and that PASMCs 
from these mice proliferate to a greater degree than WT PASMCs following 5-HT. Taken 
together, these results indicate that loss of BMPR2 can enhance the deleterious effect of 5-
HT in murine PASMCs.  The proliferative effect of 5-HT and inhibition of p-Smad1/5/8 
was  dependent  on  5-HT2A  receptor  activation  rather  than  5-HT  uptake  via  the  5-HTT 
which may explain the lack of synergy in the Cross TG mice used in this investigation, 
however, the 5-HTT may have contributed to the PAH observed in vivo in the study by 
Long et al., 2006.  It would be useful in future studies to infuse female BMPR2
+/- mice 
with 5-HT in the same way Long et al., 2006 did for the males. These results could be 
compared  for  gender  differences  and  could  subsequently  be  compared  with  the  Dfen 
results presented in this thesis. This would provide further information on the interaction 
between BMPR2 deficiency, gender and the serotonergic system as well as offer clues as 
to whether 5-HT alone mediates the in vivo effects of Dfen. 
 Enhancement of 5-HT2A signalling is supported by experimental results in IPAs from 5-
HTT+, BMPR2
+/- and Cross TG mice that demonstrated greater vasoconstriction to the 5-
HT2A  agonist  NDfen  compared  with  WT  IPAs.    The  greatest  vasoconstriction  was 
observed in BMPR2
+/- mice supporting the work by Long et al., 2006 of enhanced 5-HT2A 
mediated  serotonin  signalling  in  these  mice.  An  enhancement  of  5-HT2A  receptor 
signalling may be an important factor in transducing the genetic changes of 5-HTT+ and 
BMPR2
+/- into pathophysiological changes in the pulmonary vasculature, both in the TG 
animals in this thesis and also in human patients. This is due to its diverse contributory role 
in 5-HT (Maclean et al., 1996; Long et al., 2006) and NDfen (Ni et al., 2005) induced 
vasoconstriction, hypoxic induced proliferation of PAFs (Welsh et al., 2004) and 5-HT 214 
 
induced  proliferation  of  PASMCs,  an  effect associated  with  enhanced activation  of  p-
ERK1/2 (Long et al., 2006) (figure 9.1).  
 Further support for cross-talk between 5-HT and BMPR2 pathways in murine PASMCs 
came from the Dfen pharmacology experiments in chapter 6. IPAs from female Cross TG 
mice were significantly more sensitive to Dfen induced vasoconstriction than WT or single 
TG animals and displayed vasoconstriction at clinically relevant concentrations. Unlike the 
pulmonary  hypertensive  phenotype  observed  in  WT  and  BMPR2
+/-  mice  following 
treatment with Dfen, the vasoconstriction exerted by Dfen was independent of peripheral 
5-HT synthesis (at least in WT and Tph1
-/- mice). The enhanced vasoconstriction observed 
in  Cross  TG  mice  may  reflect  an  enhancement  of  intracellular  serotonergic  signalling 
capable of being activated by Dfen, enhancement of 5-HT receptors or a direct inhibitory 
action of Dfen on Kv channel function.  
This  investigation  has  found  evidence  of  abnormal  KCNQ  channel  mediated 
vasoconstriction in 5-HTT+, BMPR2
+/- and Cross TG mice. Changes in KCNQ channel 
expression  and/or  function  related  to  5-HTT  overexpression  or  loss  of  BMPR2  may 
contribute to the pathophysiology of PAH given the importance of K
+ channels in PASMC 
vasoconstriction, remodelling and apoptosis and the negative effect that factors such as 
hypoxia,  5-HT  and  Dfen  have  on  Kv  channels  in  PASMCs.    The  recent  finding  that 
flupirtine,  a  KCNQ  channel  activator,  can  reduce  hypoxic  PAH  and  the  pulmonary 
hypertensive  phenotype  of  5-HTT+  mice  (Morecroft  et  al.,  2009)  indicates  a  possible 
involvement of KCNQ dysfunction in the disease and offers a new target for potential 
therapeutic research. 
 Experiments  in  Tph1
-/-  mice  conclusively  showed  that  Dfen  requires  peripheral  5-HT 
synthesis to induce PAH, a process thought to involve massive 5-HT release related to 
Dfens  role  as  a  5-HTT  substrate.  This  is  a  key  discovery  that  not  only  answers  an 
important  question  regarding  the  mechanism  of  action  of  Dfen  but  also  supports  the 215 
 
‘serotonin hypothesis’ of PAH. This is also the first investigation to look at the effect of 
BMPR2 haploinsufficiency on Dfen APAH in vivo. BMPR2
+/- mice were not any more 
susceptible  to  the  cardiopulmonary  effects  of  Dfen  with  the  exception  of  small  but 
significant levels of remodelling in male BMPR2
+/- following Dfen compared with WT.  
Evidence  linking  BMPR2  deficiency  and  Dfen  induced  PAH  in  human  patients  is 
inconclusive. As mentioned in chapter 4 the functional significance of many of the BMPR2 
mutations found in PAH patients who had taken anorexigens is not clear.  The very fact 
that  BMPR2  mutations  have  been  found  in  APAH  patients  taking  Dfen  and  that  they 
correlate with a shorter exposure time would indicate some level of interaction between 
BMPR2 mutation and Dfen induced PAH although this may be dependent on the nature of 
the BMPR2 mutation.  
 The interaction between 5-HT and BMPR2 was further explored in chapter 5 by analysing 
expression of BMPR2, p-SMAD1/5/8 and p-ERK1/2 in IPAs from Tph1
-/- mice. Although 
no significant differences were found between Tph1
-/- and WT mice, there was a trend 
(more than two fold increase) towards heightened BMPR2 expression in Tph1
-/- mice. This 
result is suggestive, although not conclusive, of a reciprocal influence between the two 
pathways (figure 9.1). Increased BMPR2 expression in Tph1
-/- mice may contribute to the 
attenuated hypoxic induced PAH observed in these mice (Morecroft et al., 2007). 
 The in vivo experiments revealed that a 50% reduction in BMPR2 in all cells can enhance 
vascular remodelling following hypoxia in female mice. More severe loss of BMPR2 in 
PAECs  or  PASMCs  would  be  thought  to  exaggerate  the  predisposition  to  vascular 
remodelling  and experiments  over  the  last  several  years  are  beginning  to  confirm  this 
hypothesis.    As  discussed  in  chapter  3,  severe  loss  of  BMPR2  in  PASMCs  through 
dominant negative inhibition induces a pulmonary hypertensive phenotype in mice, both 
male and female (West et al., 2004; Tada et al., 2007). The SM22-tet-BMPR2
delx4+ mouse 
develops more severe PAH following hypoxia, further supporting an interaction between 216 
 
genetic  and  environmental  elements  (West  et  al.,  2004),  however,  the  SM22-tet-
BMPR2
delx4+ mouse displays relatively minor vascular remodelling. More recently, West et 
al., 2008a developed a mouse expressing a smooth muscle specific BMPR2
R899X mutation.  
This is an arginine to stop mutation present in the cytoplasmic tail of BMPR2 and is also 
found  in  FPAH.    This  is  in  contrast  to  the  BMPR2
delx4+  mutation  which  results  in  a 
premature  stop  18  amino  acids  into  the  kinase  domain  resulting  in  loss  of  the  entire 
intracellular domain including kinase activity. About one third of the mutant SM22-rtTA x 
TetO7-BMPR2
R899X      mice  had  increased  RVP  and  these  mice  had  extensive  vascular 
remodelling. The structural changes observed may partly be the result of the elevated p-
ERK1/2 and p-p38 MAPK observed in the lungs of the TG mice (West et al., 2008a). This 
evidence highlights an important point regarding the mutation specific effects of BMPR2 
disruption. Different BMPR2 mutations will have different effects on the stoichiometry of 
BMP cell surface receptor expression and the nature of intracellular signalling such as the 
degree of Smad activation and proteins controlled by the cytoplasmic tail such as LIMK-1.  
As more data is acquired on the mutation specific effect of BMPR2 mutations, this will 
allow new genetic models to be created and the pulmonary hypertensive phenotype to be 
compared between models. For example, the mouse used in this investigation mimics the 
haploinsufficent  state  that  occurs  in  the  majority  (~70%)  of  human  FPAH  patients 
(Machado et al., 2006; Morrell, 2006). That still leaves 30% of FPAH patients who carry 
missense mutations that may lead to a dominant negative effect. Missense mutations have 
recently been shown to correlate with a more severe disease phenotype in human patients 
compared with mutations resulting in haploinsufficiency (Austin et al., 2009a). Creating a 
mouse carrying a dominant negative mutation in all somatic cells will allow a comparative 
study to be performed with the haploinsufficent BMPR2
+/- mouse offering new insights 
into the interaction of specific mutation types with other risk factors. Microarray studies 
may also uncover potential genes of interest that are divergently modified between the 217 
 
 different genetic models. 
  Gender emerged unexpectedly as a crucial and in some experiments the most critical 
factor in determining the extent of vasoconstriction, vascular remodelling or RVP present 
in mice. The effect of gender was also dependent on the genetic background of the animal. 
In the hypoxic in vivo study in chapter 3 female TG mice often had a greater pulmonary 
hypertensive phenotype than the males, a situation most marked in the 5-HTT+ mouse. 
Female 5-HTT+ mice also had increased RVP and vascular remodelling in room air, a 
phenotype  not  present  in  the  males.  The  interaction  of  genetics  and  gender  was  also 
observed  during  the  Dfen  pharmacology  experiments  in  chapter  6  (Dfen  induced 
vasoconstriction was similar in male and female WT mice, greater in male 5-HTT+ mice, 
marginally greater in male BMPR2
+/- mice but greater in female Cross TG mice which 
were  the  most  sensitive  of  all  mice  to  Dfen  induced  vasoconstriction)  and  NDfen 
pharmacology experiments in chapter 8 (where male mice were more sensitive to NDfen). 
The  most  profound  result  of  all  regarding  gender  differences  was  the  absence  of  a 
pulmonary hypertensive phenotype in male WT and BMPR2
+/- animals following Dfen 
which induced robust vascular remodelling and elevated RVP in females.  BMPR2
+/- male 
mice  did  show  remodelling  following  Dfen  but  only  at  50%  of  the  level  observed  in 
females and this was not accompanied by elevated RVP.  The experiments just outlined 
indicate  an  interaction  between  female  gender  and  5-HTT  and  BMPR2  pathways.  In 
chapter 8, protein expression of p-ERK1/2 was found to be elevated in the lungs from 
female  WT  mice  compared  with  males.  As  shown  in  figure  9.1,  p-ERK1/2  can  be 
increased  in  the  context  of  dysfunctional  BMP  mediated  signalling  and  increased 
serotonergic signalling. Increased p-ERK1/2 activity in female PASMC that are BMPR2
+/- 
or  that  have  increased  expression  of  the  5-HTT  and  5-HT2A/5-HT1B/1D  receptors  may 
further  shift  the  balance  of  the  cell  towards  proliferation  and  increased  vascular 
remodelling  (figure  9.1).  Elevated  p-ERK1/2  may  be  one  of  many  factors  that  act 218 
 
collectively to increase the risk of PAH in female mice and human female PAH patients. 
One candidate gene that may also contribute to the increased risk of PAH in females is 
Cytochrome P450 1B1 (CYP1B1), an enzyme involved in the breakdown of estrogens and 
expressed  in  the  lung.  CYP1B1  has  been  found  to  be  decreased  up  to  10  fold  in 
immortalised lymphoblastic cell lines derived from female FPAH patients with BMPR2 
mutation compared with male affected BMPR2 mutation carriers or unaffected BMPR2 
mutation  carriers  (West  et  al.,  2008b).  More  recently,  a  polymorphism  in  CYP1B1 
resulting in decreased activity and previously linked to several cancers was associated with 
a 4 fold higher penetrance of PAH in BMPR2
+/- females (Austin et al., 2009b). BMPR2
+/- 
females with PAH were found to have an altered balance in estrogen metabolites compared 
with unaffected BMPR2
+/- females. The balance was shifted so that the proportion of 16α-
hydroxyestrone (16α- OHE1) was greater. 16α- OHE1 is a significantly greater mitogenic 
compound  than  other  estrogen  metabolites  and  its  increase  is  thought  to  be  a  direct 
consequence of diminished CYP1B1 (Austin et al., 2009b).  Similar to data outlined in the 
discussion  in  chapter  8  regarding  the  balance  between  testosterone,  estradiol  and 
progesterone, it may be that the balance between pro-proliferative and anti-proliferative 
estrogen metabolites is critical to the overall effect on vascular cells. The discovery that 
decreased CYP1B1 interacts with BMPR2 deficiency in human PAH patients offers the 
potential for future animal models in which to further explore the interaction of BMPR2 
mutation with female gender. This may involve creating a mouse that is BMPR2
+/- and 
deficient in CYP1B1 and then exposing this model to additional modifying factors such as 
5-HT,  hypoxia  and  Dfen.  It  is  interesting  to  note  that  in addition  to  the  discovery  of 
CYP1B1 polymorphisms in human female FPAH patients, it has recently been shown that 
PAH patients with BMPR2 mutations have an earlier age at diagnosis compared with non- 
carriers, but that this only occurs for women. Within the male subgroup, no statistical 
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Figure 9.1 Interaction of serotonergic and BMPR2 signalling pathways on pulmonary 
smooth muscle cell proliferation. 
The balance between p-ERK1/2 and p-Smad1/5/8 is thought to be crucial in determining 
the proliferative state of a PASMC. Evidence from BMPR2
+/- cells or cells from PAH 
patients suggests there is enhancement of p-ERK1/2 signalling, secondary to an increase in 
serotonergic activity or aberrant BMPR1A/1B (BR1) and BMPR2 (BR2) signalling. This 
promotes proliferation. Conversely, a decrease in p-Smad1/5/8 further shifts the balance 
towards  proliferation.  The  elevated  p-ERK1/2  expression  in  female  mouse  lung  may 
contribute to the greater risk associated with female gender, especially when combined 
with dysfunctional BMPR2 or enhanced 5-HT signalling. The dashed arrow represents a 
potential new level of cross-talk between 5-HT and BMPR2 suggested by a trend towards 
enhanced BMPR2 expression in pulmonary arteries from Tph1
-/- mice. This will require 
greater clarification in future studies.  
 220 
 
differences emerged in age at diagnosis between BMPR2 mutant carriers and non carriers 
(Austin et al., 2009a). 
  Direct interactions may also exist between BMPR2 or the 5-HTT and estrogens. Estradiol 
has been shown to suppress BMPR2/p-Smad1/5 signalling in several cell lines through 
Smad  inhibition  by  ER-α  (Yamamoto  et  al.,  2002).  The  cytoplasmic  tail  of  BMPR2 
contains estrogen sulfotransferase binding sites (Hassel et al., 2004) and this enzyme has a 
high  affinity  for  estrogens  and  is  involved  in  controlling  local  estrogen  concentration 
(Song, 2001). The state of the 5-HTT can also be influenced by estrogens with increased 
circulating  levels  of  estradiol  upregulating  5-HTT  expression  in  the  brains  of  rats 
(McQueen et al., 1997; Rivera et al., 2009).  It is still unclear why the female pulmonary 
vasculature is more susceptible to PAH and what interactions may occur between loss of 
BMPR2 or heightened serotonergic signalling and estrogenic effects in the lung. The use of 
genetic models in animals can offer clues as to which molecular pathways may warrant 
further study. Microarray studies  have indicated increased expression of cytokines and 
markers of immune response in SM22-tet-BMPR2
delx4+ mice
, an effect most prominent in 
female  mice;  with  8  week  old  SM22-tet-BMPR2
delx4+  female  mice  having  twice  the 
expression of IL-6 than males (Tada et al., 2007).  Further studies such as this will help 
characterise  pathways  that  differ  between  males  and  female  and  which  are  likely  to 
contribute to disease progression. 
 To conclude, this investigation has uncovered important interactions between genetic pre-
disposition, gender and modifying factors in PAH that implicate the serotonergic system 
(both  overexpression  of  the  5-HTT  and  peripheral  5-HT  synthesis)  as  an  important 
modulating factor in PAH. BMPR2 haploinsufficiency alone is not sufficient to induce 
PAH or to worsen Dfen associated PAH but is a risk factor for hypoxic induced vascular 
remodelling.  This investigation also uncovered increased vasoconstriction to NDfen in all 
TG mice and an increased contractile response to 5-HT in BMPR2
+/- mice. This is an 221 
 
important finding since increased pulmonary vasoconstriction is thought to be an important 
aspect in the initial stages of PAH. The enhanced vasoconstriction may partly relate to 
changes  in  K
+  channel  function  and  this  investigation  found  impaired  KCNQ  channel 
function  in  TG  mice,  an  alteration  that  may  have  detrimental  consequences  in  the 
pulmonary vasculature given the recent discovery of the role these channels play in setting 
the resting Vm of PASMCs and the ability of KCNQ activators to reduce the symptoms of 
PAH in animal models. The resistance of male mice to many of the changes characteristic 
of PAH is something that was unexpected and also an important consideration for future 
studies in animal models of PAH. Gender must be considered an essential component in 
experimental design and interpreting results, especially in studies using hypoxia or Dfen. 
The female vasculature appears more susceptible to the changes characteristic of PAH and 
an increase in p-ERK1/2 may be an important candidate in raising this risk. The use of 
novel genetic animal models containing mutations or polymorphisms derived from human 
PAH patients have provided and will continue to provide new data on the cellular and 
molecular  mechanisms  underlying  a  highly  complex  disease.  Future  genetic  models 
utilising  haploinsufficent  and  dominant  negative  BMPR2  dysfunction  combined  with 
conditional  knockout  studies  to  unravel  the  complex  cellular  specific  roles  of  such 
mutations will provide the basis for exploring the interaction of modulating factors such as 
5-HT,  K
+  channels  and  female  gender  both  at  the  genetic  and  pharmacological  level. 
Identification  of  the  modifying  factors  that  interact  with  BMPR2  deficiency  and  the 
unravelling of the molecular pathways that underlie those interactions will allow a better 
understanding of the pathophysiology of PAH and to aid the search for targeted therapies.  
 
 
 
 222 
 
References 223 
 
AARONSON PI, ROBERTSON TP, KNOCK GA, BECKER S, LEWIS TH,  SNETKOV 
V,  WARD  JPT.  (2006)  Hypoxic  pulmonary  vasoconstriction:  mechanisms  and 
controversies. J. Physiol.; 570: 52-58. 
AARONSON PI, ROBERTSON TP, WARD JPT. (2002) Endothelium-derived mediators 
and hypoxic pulmonary vasoconstriction. Respir. Physiol. Neurobiol.; 132: 107-120. 
ABENHAIM  L,  MORIDE  Y,  BRENOT  F,  RICH  S,  BENICHOU  J,  KURZ  X, 
HIGENBOTTOM  T,  OAKLEY  C,  WOUTERS  E,  AUBIER  M,  SIMONNEAU  G, 
BEGAUD  B.  (1996)  Appetite-suppressant  drugs  and  the  risk  of  primary  pulmonary 
hypertension. N. Engl. J. Med.; 335: 609-16.  
ABRAMOWICZ MJ, VAN HAECKE P, DEMEDTS M, DELCROIX M. (2003) Primary 
pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. Eur. 
Respir. J.; 22: 560-2. 
ALDRED MA, VIJAYAKRISHNAN J, JAMES V, SOUBRIER F, GOMEZ-SANCHEZ 
MA,  MARTENSSON  G,  GALIE  N,  MANES  A,  CORRIS  P,  SIMONNEAU  G, 
HUMBERT M, MORRELL NW, TREMBATH RC. (2006) BMPR2 gene rearrangements 
account for  a significant proportion of mutations in familial and idiopathic pulmonary 
arterial hypertension. Hum. Mutat.; 27: 212-3. 
ALTURA  BM.  (1975)  Sex  and  estrogens  and  responsiveness  of  terminal  arterioles  to 
neurohypophyseal hormones and catecholamines. J. Pharmacol. Exp. Ther.; 193: 403-12. 
AL-WIEL-BERMANI  ,  BLOOMQUIST  EI,  MONTVILO  JA.  (1982)  Distribution  of 
pulmonary cholinergic nerves in the rabbit. Thorax; 37: 703-710. 
AMENTA  F,  CAVALLOTTI  C,  FERRANTE  F,  TONELLI  F.  (1983)  Cholinergic 
innervation of the human pulmonary circulation. Acta Anat (Basel); 117: 58-64. 
ARCHER  SL,  DJABALLAH  K,  HUMBERT  M,  WEIR  KE,  FARTOUKH  M, 
DALL'AVA-SANTUCCI J, MERCIER JC, SIMONNEAU G, DINH-XUAN AT. (1998b) 
Nitric  oxide  deficiency  in  fenfluramine-  and  dexfenfluramine-induced  pulmonary 
hypertension. Am. J. Respir. Crit. Care Med.; 158: 1061-7. 
ARCHER  SL,  LONDON  B,  HAMPL  V,  WU  X,  NSAIR  A,  PUTTAGUNTA  L, 
HASHIMOTO  K,  WAITE  RE,  MICHELAKIS  ED.  (2001)  Impairment  of  hypoxic 
pulmonary vasoconstriction in mice lacking the voltage-gated potassium channel Kv1.5. 
FASEB J.; 15: 1801-3. 
ARCHER  SL,  SOUIL  E,  DINH-XUAN  AT,  SCHREMMER  B,  MERCIER  JC,  EL 
YAAGOUBI  A,  NGUYEN-HUU  L,  REEVE  HL,  HAMPL  V.  (1998a)  Molecular 
identification  of  the  role  of  voltage-gated  K+  channels,  Kv1.5  and  Kv2.1,  in  hypoxic 
pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary 
artery myocytes. J. Clin. Invest.; 101: 2319-30. 
ASHMORE RC, RODMAN DM, SATO K, WEBB SA, O'BRIEN RF, MCMURTRY IF, 
STELZNER TJ. (1991)  Paradoxical constriction to platelets by arteries from rats with 
pulmonary hypertension. Am. J. Physiol.; 260: H1929-34. 224 
 
ATKINSON  C,  STEWART  S,  UPTON  PD,  MACHADO  R,  THOMSON  JR, 
TREMBATH RC, MORRELL NW. (2002) Primary pulmonary hypertension is associated 
with  reduced  pulmonary  vascular  expression  of  type  II  bone  morphogenetic  protein 
receptor. Circulation; 105: 1672-1678.  
AUSTIN  ED,  COGAN  JD,  WEST  JD,  HEDGES  LK,  HAMID  R,  DAWSON  EP, 
WHEELER  LA,  PARL  FF,  LOYD  JE,  PHILLIPS  JA  3RD.  (2009b)  Alterations  in 
estrogen metabolism: Implications for higher penetrance of FPAH in females. Eur. Respir. 
J.; [epub ahead of print] 
AUSTIN ED, PHILLIPS JA, COGAN JD, HAMID R, YU C, STANTON KC, PHILLIPS 
CA, WHEELER LA, ROBBINS IM, NEWMAN JH, LOYD JE. (2009a) Truncating and 
missense  BMPR2  mutations  differentially  affect  the  severity  of  heritable  pulmonary 
arterial hypertension. Respir. Res.; 10:87 
BACK M, WALCH L, NOREL X, GASCARD JP, MAZMANIAN G, BRINK C. (2002) 
Modulation of vascular tone and reactivity by nitric oxide in porcine pulmonary arteries 
and veins. Acta. Physiol. Scand.; 174: 9-15. 
BALABANIAN K, FOUSSAT A, DORFMÜLLER P, DURAND-GASSELIN I, CAPEL 
F,  BOUCHET-DELBOS  L,  PORTIER  A,  MARFAING-KOKA  A,  KRZYSIEK  R, 
RIMANIOL AC, SIMONNEAU G, EMILIE D, HUMBERT M. (2002) CX3C Chemokine 
Fractalkine in Pulmonary Arterial Hypertension.  Am. J. Respir.  Crit.  Care.  Med.;  165: 
1419-25. 
BARBERIS  MC,  VERONESE  S,  BAUER  D,  DE  JULI  E,  HARARI  S.  (1995) 
Immunocytochemical  detection  of  progesterone  receptors.  A  study  in  a  patient  with 
primary pulmonary hypertension. Chest; 107: 869-72. 
BARST  RJ,  RICH  S,  WIDLITZ  A,  HORN  EM,  MCLAUGHLIN  V,  MCFARLIN  J. 
(2002) Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients 
with pulmonary arterial hypertension: open-label pilot study. Chest; 121: 1860-8. 
BAZAN JF, BACON KB, HARDIMAN G, WANG W, SOO K, ROSSI D, GREAVES 
DR, ZLOTNIK A, SCHALL TJ. (1997) A new class of membrane-bound chemokine with 
a CX3C motif. Nature; 385: 640-644. 
BELKNAP  JK,  ORTON  EC,  ENSLEY  B,  AND  STENMARK  KR.  (1997)  Hypoxia 
increases bromodeoxyuridine labeling indices in bovine neonatal pulmonary arteries.  Am. 
J. Respir. Cell Mol. Biol.; 16: 366–371. 
BELOHLÁVKOVÁ S, SIMÁK J, KOKESOVÁ A, HNILICKOVÁ O, HAMPL V. (2001) 
Fenfluramine-induced  pulmonary  vasoconstriction:  role  of  serotonin  receptors  and 
potassium channels. J. Appl. Physiol.; 91: 755-61. 
BEPPU H, ICHINOSE F, KAWAI N, JONES RC, YU PB, ZAPOL WM, MIYAZONO K, 
LI E, BLOCH KD. (2004) BMPR-II heterozygous mice have mild pulmonary hypertension 
and an impaired pulmonary vascular remodeling response to prolonged hypoxia.  Am. J. 
Physiol. Lung Cell. Mol. Physiol.; 287: L1241-7. 225 
 
BEPPU  H, KAWABATA M,  HAMAMOTO T,  CHYTIL  A,  MINOWA O, NODA T, 
MIYAZONO  K.  (2000)  BMP  type  II  receptor  is  required  for  gastrulation  and  early 
development of mouse embryos. Dev. Biol.; 221: 249-58. 
BEVAN JA AND OSHER JV. (1972) A direct method for recording tension changes in 
the wall of small blood vessels in vitro. Agents Actions; 2: 257-60.  
BEVAN  JA,  ORIOWA  MA,  BEVAN  RD.  (1986)  Physiological  variation  in  alpha-
adrenoceptor-mediated arterial sensitivity: relation to agonist affinity. Science; 234: 196-7. 
BHARGAVA  A,  KUMAR  A,  YUAN  N,  GEWITZ  MH,  MATHEW  R.  (1999) 
Monocrotaline induces interleukin-6 mRNA expression in rat lungs. Heart Dis.; 1: 126-32. 
BLANPAIN C, LE POUL E, PARMA J, KNOOP C, DETHEUX M, PARMENTIER M, 
VASSART G, ABRAMOWICZ MJ. (2003) Serotonin 5-HT(2B) receptor loss of function 
mutation  in  a  patient  with  fenfluramine-associated  primary  pulmonary  hypertension. 
Cardiovasc. Res.; 60: 518-28. 
BONNET S AND ARCHER SL. (2007) Potassium channel diversity in the pulmonary 
arteries and pulmonary veins: implications for regulation of the pulmonary vasculature in 
health and during pulmonary hypertension. Pharmacol. Ther.; 115: 56-69. 
BONNET S, MICHELAKIS ED, PORTER CJ, ANDRADE-NAVARRO MA, THÉBAUD 
B, BONNET S, HAROMY A, HARRY G, MOUDGIL R, MCMURTRY MS, WEIR EK, 
ARCHER  SL.  (2006)  An  abnormal  mitochondrial-hypoxia  inducible  factor-1alpha-Kv 
channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in 
fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation; 113: 
2630-41. 
BRUCH L, RUBEL S, KASTNER A, GELLERT K, GOLLASCH M, WITT C. (1998) 
Pituitary adenylate cyclase activating peptides relax human pulmonary arteries by opening 
of KATP and KCa channels. Thorax; 53: 586-587. 
BRUSSELMANS K, COMPERNOLLE V, TJWA M, WIESENER MS, MAXWELL PH, 
COLLEN  D,  CARMELIET  P.  (2003)  Heterozygous  deficiency  of  hypoxia-inducible 
factor-2alpha  protects  mice  against  pulmonary  hypertension  and  right  ventricular 
dysfunction during prolonged hypoxia. J. Clin. Invest.; 111: 1519-27. 
BUDHIRAJA  R,  TUDER  RM,  HASSOUN  PM.  (2004)  Endothelial  dysfunction  in 
pulmonary hypertension. Circulation; 109: 159-65. 
BUSTO  R,  PRIETO  JC,  BODEGA  G,  ZAPATERO  J,  CARRERO  I.  (2000) 
Immunohistochemical  localization  and  distribution  of  VIP/PACAP  receptors  in  human 
lung. Peptides; 21: 265-269. 
BUZZARD  CJ,  PFISTER  SL,  CAMPBELL  WB.  (1993)  Endothelium-dependent 
contractions in the rabbit pulmonary artery are mediated by thromboxane A2. Circ Res.; 
72: 1023-34. 
CACCIA S,  CONFORTI  I,  DUCHIER  J, GARATTINI S. (1985)  Pharmacokinetics of 
fenfluramine and norfenfluramine in volunteers given D- and DL-fenfluramine for 15 days. 
Eur. J. Clin. Plarmacol.; 29: 221-4. 226 
 
CALLEBERT  J,  ESTEVE  JM,  HERVÉ  P,  PEOC'H  K,  TOURNOIS  C,  DROUET  L, 
LAUNAY JM, MAROTEAUX L. (2006) Evidence for a control of plasma serotonin levels 
by 5-hydroxytryptamine(2B) receptors in mice. J. Pharmacol. Exp. Ther.; 317: 724-31. 
CARDELL LA, HJERT O, UDDMAN R. (1997) The induction of nitric oxide-mediated 
relaxation of human isolated pulmonary arteries by PACAP. Br. J. Pharmacol.; 120: 1096-
1100. 
CAREY MA, CARD JW, VOLTZ JW, ARBES SJ JR, GERMOLEC DR, KORACH KS, 
ZELDIN DC. (2007) It's all about sex: gender, lung development and lung disease. Trends 
Endocrinol. Metab.; 18: 308-13. 
CECH S. (1969) Adrenergic innervation of blood vessels in the lungs of some mammals. 
Acta. Anat. (Basel); 74:169-82. 
CECH S. (1973) Cholinesterase-containing nerve fibres on blood vessels in lungs of some 
laboratory animals. Z Zellforsch Mikrosk Anat.; 140: 91-100. 
CHAN MC, NGUYEN PH, DAVIS BN, OHOKA N, HAYASHI H, DU K, LAGNA G, 
HATA  A.  (2007)  A  novel  regulatory  mechanism  of  the  bone  morphogenetic  protein 
(BMP) signaling pathway involving the carboxyl-terminal tail domain of BMP type II 
receptor. Mol. Cell Biol.; 27: 5776-89. 
CHANNICK RN, SIMONNEAU G, SITBON O, ROBBINS IM, FROST A, TAPSON VF, 
BADESCH DB, ROUX S, RAINISIO M, BODIN F, RUBIN LJ. (2001) Effects of the dual 
endothelin-receptor  antagonist  bosentan  in  patients  with  pulmonary  hypertension:  a 
randomised placebo-controlled study. Lancet; 358: 1119-23. 
CHAZOVA I, LOYD JE, ZHDANOV VS, NEWMAN JH, BELENKOV Y, MEYRICK B. 
(1995)  Pulmonary  artery  adventitial  changes  and  venous  involvement  in  primary 
pulmonary hypertension. Am. J. Pathol.; 146: 389-97. 
CHEN D, ZHAO M, MUNDY GR. (2004) Bone morphogenetic proteins. Growth Factors; 
22: 233-41. 
CHEN HB, SHEN J, IP YT, XU L. (2006) Identification of phosphatases for Smad in the 
BMP/DPP pathway. Genes Dev.; 20: 648-53. 
CHEN Z, YUHANNA IS, GALCHEVA-GARGOVA Z, KARAS RH, MENDELSOHN 
ME, SHAUL PW. (1999) Estrogen receptor alpha mediates the nongenomic activation of 
endothelial nitric oxide synthase by estrogen. J. Clin. Invest.; 103: 401-6. 
CHESTER  AH,  JIANG  C,  BORLAND  JA,  YACOUB  MH,  COLLINS  P.  (1995) 
Oestrogen relaxes human epicardial coronary arteries through non-endothelium-dependent 
mechanisms. Coron. Artery Dis.; 6: 417-22. 
CHRISTMAN  BW,  MCPHERSON  CD,  NEWMAN  JH,  KING  GA,  BERNARD  GR, 
GROVES BM, LOYD JE. (1992) An imbalance between the excretion of thromboxane 
and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med.; 327: 70-5. 227 
 
CHRISTOU H, YOSHIDA A, ARTHUR V, MORITA T, KOUREMBANAS S. (1998) 
Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-
induced pulmonary hypertension. Am. J. Respir. Cell Mol. Biol.; 18: 768-76. 
COGOLLUDO A, MORENO L, LODI F, FRAZZIANO G, COBEÑO L, TAMARGO J, 
PEREZ-VIZCAINO F. (2006) Serotonin inhibits voltage-gated K+ currents in pulmonary 
artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and  KV1.5  channel 
internalization. Circ. Res.; 98: 931-8. 
COOL  CD,  KENNEDY  D,  VOELKEL  NF,  TUDER  RM.  (1997)  Pathogenesis  and 
evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and 
human immunodeficiency virus infection. Hum. Pathol.; 28: 434-442. 
COOL CD, STEWART JS, WERAHERA P, MILLER GJ, WILLIAMS RL, VOELKEL 
NF,  TUDER  RM.  (1999)  Three-dimensional  reconstruction  of  pulmonary  arteries  in 
plexiform pulmonary hypertension using cell-specific markers:  evidence for a dynamic 
and heterogeneous process of pulmonary endothelial cell growth. Am. J. Patho.; 155: 411-
19. 
COOPER  CJ,  LANDZBERG  MJ,  ANDERSON  TJ,  CHARBONNEAU  F,  CREAGER 
MA,  GANZ  P,  SELWYN  AP.  (1996)  Role  of  nitric  oxide  in  the  local  regulation  of 
pulmonary vascular resistance in humans. Circulation; 93: 266-71. 
CÔTÉ F, FLIGNY C, FROMES Y, MALLET J, VODJDANI G. (2004) Recent advances 
in understanding serotonin regulation of cardiovascular function. Trends Mol. Med.; 10: 
232-8. 
COWAN KN, JONES PL, RABINOVITCH M. (1999) Regression of hypertrophied rat 
pulmonary arteries in organ culture is associated with suppression of proteolytic activity, 
inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ.Res.; 84: 1223-33. 
COWAN  KN,  JONES  PL,  RABINOVITCH  M.  (2000a)  Elastase  and  matrix 
metalloproteinase  inhibitors  induce  regression,  and  tenascin-C  antisense  prevents 
progression, of vascular disease. J. Clin. Invest.; 105: 21-34. 
COWAN KN, HEILBUT A, HUMPL T, LAM C, ITO S, RABINOVITCH M. (2000b) 
Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. 
Nat. Med.; 6: 698-702. 
CRONA D, HARRAL J, ADNOT S, EDDAHIBI S, WEST J. (2009) Gene expression in 
lungs of mice lacking the 5-hydroxytryptamine transporter gene. BMC Pulm. Med.; 9:19. 
CURZON G, GIBSON EL, OLUYOMI AO. (1997) Appetite suppression by commonly 
used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol. 
Sci.; 18: 21-5. 
D’ALONZO  GE,  BARST  RJ,  AYRES  SM,  BERGOFSKY  EH,  BRUNDAGE  BH, 
DETRE  KM,  FISHMAN  AP,  GOLDRING  RM,  GROVES  BM,  KERNIS  JT.  (1991) 
Survival  in  patients  with  primary  pulmonary  hypertension.  Results  from  a  national 
prospective registry. Ann. Intern. Med.; 115: 343-9. 228 
 
DANI C, PAVONI V, CORSINI I, LONGINI M, GORI G, GIANNESELLO L, PERNA 
A, GRITTI G, PATERNOSTRO F, FORESTIERI A, BUONOCORE G, RUBALTELLI 
FF. (2007) Inhaled nitric oxide combined with prostacyclin and adrenomedullin in acute 
respiratory failure with pulmonary hypertension in piglets. Pediatr. Pulmonol.; 42: 1048-
56. 
DAOUDI  M,  LAVERGNE  E,  GARIN  A,  TARANTINO  N,  DEBRÉ  P,  PINCET  F, 
COMBADIÈRE C, DETERRE P. (2004) Enhanced adhesive capacities of the naturally 
occurring Ile249-Met280 variant of the chemokine receptor CX3CR1. J. Biol. Chem.; 279: 
19649-57. 
DAS M, DEMPSEY EC, REEVES JT, STENMARK KR. (2002) Selective expansion of 
fibroblast subpopulations from pulmonary artery adventitia in response to hypoxia. Am. J. 
Physiol. Lung Cell. Mol. Physiol.; 282: L976-L986. 
DAVIE N, HALEEN SJ, UPTON PD,  POLAK JM, YACOUB MH, MORRELL NW, 
WHARTON J. (2002) ET(A) and ET(B) receptors modulate the proliferation of human 
pulmonary artery smooth muscle cells. Am. J. Respir. Crit. Care Med.; 165: 398-405. 
DAVIE NJ, CROSSNO JT, FRID MG, HOFMESITER SE, REEVES JT, HYDE DM, 
CARPENTER TC, BRUNETTI JA, MCNIECE IK, STENMARK KR. (2004) Hypoxia-
induced pulmonary artery adventitial remodeling and neovascularization: contribution of 
progenitor cells. Am. J. Physiol. Lung Cell. Mol. Physiol.; 286: L668-L678. 
DÉLOT  EC,  BAHAMONDE  ME,  ZHAO  M,  LYONS  KM.  (2003)  BMP  signaling  is 
required for septation of the outflow tract of the mammalian heart. Development; 130: 209-
20. 
DEMPSEY  EC,  FRID  MG,  ALDASHEV  AA,  DAS  M,  STENMARK  KR.  (1997) 
Heterogeneity in the proliferative response of bovine pulmonary artery  smooth muscle 
cells  to  mitogens  and  hypoxia:  importance  of  protein  kinase  C.  Can.  J.  Physiol. 
Pharmacol.; 75: 936-44. 
DEMPSIE  Y,  MORECROFT  I,  WELSH  DJ,  MACRITCHIE  NA,  HEROLD  N, 
LOUGHLIN L, NILSEN M, PEACOCK AJ, HARMAR A, BADER M, MACLEAN MR. 
(2008) Converging evidence in support of the serotonin hypothesis of dexfenfluramine-
induced pulmonary hypertension with novel transgenic mice. Circulation; 117: 2928-37. 
DENG  Z,  MORSE  JH,  SLAGER  SL,  CUERVO  N,  MOORE  KJ,  VENETOS  G, 
KALACHIKOV S, CAYANIS E, FISCHER SG, BARST RJ, HODGE SE, KNOWLES 
JA. (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations 
in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet.; 67: 737-44. 
DEUCHAR  GA,  DOCHERTY  A,  MACLEAN  MR,  HICKS  MN.  (2002)  Pulmonary 
hypertension  secondary  to  left  ventricular  dysfunction:  the  role  of  nitric  oxide  and 
endothelin-1 in the control of pulmonary vascular tone. Br. J. Pharmacol.; 135: 1060-8. 
DEWACHTER L, ADNOT S, FADEL E, HUMBERT M, MAITRE B, BARLIER-MUR 
AM, SIMONNEAU G, HAMON M, NAEIJE R, EDDAHIBI S. (2006) Angiopoietin/Tie2 
pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. Am. 
J. Respir. Crit. Care Med.; 174: 1025-33. 229 
 
DING AQ AND STALLONE JN. (2001) Testosterone-induced relaxation of rat aorta is 
androgen  structure  specific  and  involves  K+  channel  activation.  J.  Appl.  Physiol.;  91: 
2742-50. 
DORFMULLER P, ZARKA V, DURAND-GASSELIN I, MONTI G, BALABANIAN K, 
GARCIA  G,  CAPRON  F,  COULOMNB-LHERMINE  A,  MARFAING-KOKA  A, 
SIMONNEAU  G,  EMILIE  D,  HUMBERT  M.  (2002)  Chemokine  RANTES  in  Severe 
Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med.; 165: 534-539. 
DOWNING SE. AND LEE JC. (1980) Nervous control of the pulmonary circulation. Ann. 
Rev. Physiol.; 42:199-210.  
DU L, SULLIVAN CC, CHU D, CHO AJ, KIDO M, WOLF PL, YUAN JX, DEUTSCH 
R, JAMIESON SW, THISTLETHWAITE PA. (2003) Signaling molecules in nonfamilial 
pulmonary hypertension.  N. Engl. J. Med.; 348: 500-9. 
DUBEY RK  AND JACKSON EK. (2001) Cardiovascular protective effects of 17beta-
estradiol metabolites. J. Appl. Physiol.; 91: 1868-83. 
DUBEY RK, JACKSON EK, KELLER PJ, IMTHURN B, ROSSELLI M (2001) Estradiol 
metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. 
Hypertension.; 37: 640-4. 
DUBEY  RK,  TOFOVIC  SP,  JACKSON  EK.  (2004)  Cardiovascular  pharmacology  of 
estradiol metabolites. J. Pharmacol. Exp. Ther.; 308: 403-9. 
DUMAS  JP,  BARDOU  M,  GOIRAND  F,  DUMAS  M.  (1999)  Hypoxic  pulmonary 
vasoconstriction. Gen. Pharmacol.; 33: 289-97. 
EARLEY S  AND RESTA TC. (2002) Estradiol attenuates hypoxia-induced pulmonary 
endothelin-1 gene expression. Am. J. Physiol. Lung Cell Mol. Physiol.; 283: L86-93. 
EDDAHIBI S, CHAOUAT A, MORRELL N, FADEL E, FUHRMAN C, BUGNET AS, 
DARTEVELLE P, HOUSSET B, HAMON M, WEITZENBLUM E, ADNOT S. (2003) 
Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic 
obstructive pulmonary disease. Circulation; 108: 1839-44. 
EDDAHIBI  S,  FABRE  V,  BONI  C,  MARTRES  MP,  RAFFESTIN  B,  HAMON  M, 
ADNOT S. (1999) Induction of serotonin transporter by hypoxia in pulmonary vascular 
smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ. Res.; 84: 
329-36. 
EDDAHIBI S, GUIGNABERT C, BARLIER-MOR AM, DEWACHTER L, FADEL E, 
DARTEVELLE  P,  HUMBERT  M,  SIMONNEAU  G,  HANOUN  N,  SAURINI  F, 
HAMON M, ADNOT S. (2006) Cross talk between endothelial and smooth muscle cells in 
pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. 
Circulation; 113: 1857-1864. 
EDDAHIBI S, HANOUN N, LANFUMEY L, LESCH KP, RAFFESTIN B, HAMON M, 
ADNOT S. (2000)  Attenuated hypoxic pulmonary hypertension in mice lacking the 5-
hydroxytryptamine transporter gene. J. Clin. Invest.; 105: 1555-62. 230 
 
EDDAHIBI S, HUMBERT M, FADEL E, RAFFESTIN B, DARMON M, CAPRON F, 
SIMONNEAU  G,  DARTEVELLE  P,  HAMON  M,  ADNOT  S.  (2001)  Serotonin 
transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia 
in primary pulmonary hypertension. J. Clin. Invest.; 108: 1141-50. 
EDDAHIBI S, RAFFESTIN B, PHAM I,  LAUNAY JM, AEGERTER P, SITBON M, 
ADNOT  S.  (1997)  Treatment  with  5-HT  potentiates  development  of  pulmonary 
hypertension in chronically hypoxic rats. Am. J. Physiol.; 272: H1173-81. 
EKHTERAE D, PLATOSHYN O, KRICK S, YU Y, MCDANIEL SS, YUAN JX. (2001) 
Bcl-2  decreases  voltage-gated  K+  channel  activity  and  enhances  survival  in  vascular 
smooth muscle cells. Am. J. Physiol. Cell Physiol.; 281: C157-65. 
ENGLISH KM, JONES RD, JONES TH, MORICE AH, CHANNER KS. (2001) Gender 
differences in the vasomotor effects of different steroid hormones in rat pulmonary and 
coronary arteries. Horm. Metab. Res.; 33: 645-52. 
EUL B, ROSE F, KRICK S, SAVAI R, GOYAL P, KLEPETKO W, GRIMMINGER F, 
WEISSMANN N, SEEGER W, HÄNZE J. (2006) Impact of HIF-1alpha and HIF-2alpha 
on proliferation and migration of human pulmonary artery fibroblasts in hypoxia.  FASEB 
J.; 20: 163-5. 
FAGAN  KA,  FOUTY  BW,  TYLER  RC,  MORRIS  KG  JR,  HEPLER  LK,  SATO  K, 
LECRAS  TD,  ABMAN  SH,  WEINBERGER  HD,  HUANG  PL,  MCMURTRY  IF, 
RODMAN DM. (1999) The pulmonary circulation of homozygous or heterozygous eNOS-
null mice is hyperresponsive to mild hypoxia. J. Clin. Invest.; 103: 291-9. 
FANBURG BL AND LEE SL. (1997) A new role for an old molecule: serotonin as a 
mitogen. Am. J. Physiol.; 272: L795-806. 
FANTOZZI I, PLATOSHYN O, WONG AH, ZHANG S, REMILLARD CV, FURTADO 
MR, PETRAUSKENE OV, YUAN JX. (2006) Bone morphogenetic protein-2 upregulates 
expression and function of voltage-gated K+ channels in human pulmonary artery smooth 
muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol.; 291: L993-1004. 
FARHAT MY, CHEN MF, BHATTI T, IQBAL A, CATHAPERMAL S, RAMWELL 
PW. (1993) Protection by oestradiol against the development of cardiovascular changes 
associated with monocrotaline pulmonary hypertension in rats.  Br. J. Pharmacol.; 110: 
719-23. 
FITZGERALD  LW,  BURN  TC,  BROWN  BS,  PATTERSON  JP,  CORJAY  MH, 
VALENTINE PA, SUN JH, LINK JR, ABBASZADE I, HOLLIS JM, LARGENT BL, 
HARTIG  PR,  HOLLIS  GF,  MEUNIER  PC,  ROBICHAUD  AJ,  ROBERTSON  DW. 
(2000)  Possible  role  of  valvular  serotonin  5-HT(2B)  receptors  in  the  cardiopathy 
associated with fenfluramine. Mol. Pharmacol.; 57: 75-81. 
FOLETTA VC, LIM MA, SOOSAIRAJAH J, KELLY AP, STANLEY EG, SHANNON 
M, HE W, DAS S, MASSAGUE J, BERNARD O. (2003) Direct signaling by the BMP 
type II receptor via the cytoskeletal regulator LIMK1. J. Cell Biol.; 162: 1089-98. 231 
 
FONG AM, ROBINSON LA, STEEBER DA, TEDDER TF, YOSHIE O, IMAI T, PATEL 
DD. (1998) Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, 
firm adhesion, and activation under physiologic flow. J. Exp. Med.; 188: 1413–1419. 
FORSYTHE JA, JIANG BH, IYER NV, AGANI F, LEUNG SW, KOOS RD, SEMENZA 
GL. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-
inducible factor 1. Mol. Cell Biol.; 16: 4604-13. 
FOUSSAT  A,  COULOMB-LHERMINE  A,  GOSLING  J,  KRZYSIEK  R,  DURAND-
GASSELIN  I,  SCHALL  T,  BALIAN  A,  RICHARD  Y,  GALANAUD  P,  EMILIE  D. 
(2000)  Fractalkine  receptor  expression  by  T-lymphocyte  subpopulations  and  in  vivo 
production of fractalkine in human. Eur. J. Immunol.; 30: 87–97. 
FRANK  DB,  ABTAHI  A,  YAMAGUCHI  DJ,  MANNING  S,  SHYR  Y,  POZZI  A, 
BALDWIN  HS,  JOHNSON  JE,  DE  CAESTECKER  MP.  (2005)  Bone  morphogenetic 
protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. 
Circ. Res.; 97: 496-504. 
FRANK DB, LOWERY J, ANDERSON L, BRINK M, REESE J, DE CAESTECKER M. 
(2008) Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice 
is associated with endothelial dysfunction in the pulmonary vasculature.  Am. J. Physiol. 
Lung Cell. Mol. Physiol.; 294: L98-109. 
FRASCH  HF,  MARSHALL  C,  MARSHALL  BE.  (1999)  Endothelin-1  is  elevated  in 
monocrotaline pulmonary hypertension. Am. J. Physiol.; 276: L304-10. 
FRID MG, ALDASHEV AA, DEMPSEY EC, STENMARK KR. (1997) Smooth muscle 
cells isolated from discrete compartments of the mature vascular media exhibit unique 
phenotypes and distinct growth capabilities. Circ. Res.; 81: 940-952. 
FRID MG, KALE VA, STENMARK KR. (2002) Mature vascular endothelium can give 
rise  to  smooth  muscle  cells  via  endothelial-mesenchymal  transdifferentiation:  in  vitro 
analysis. Circ. Res.; 90: 1189-96. 
FRID MG, MOISEEVA EP, STENMARK KR. (1994) Multiple phenotypically distinct 
smooth muscle cell populations exist in the adult and developing bovine pulmonary arterial 
media in vivo. Circ. Res.; 75: 669-81. 
FRISTRÖM  S,  AIRAKSINEN  MM,  HALMEKOSKI  J.  (1977)  Release  of  platelet  5-
hydroxytryptamine  by  some  anorexic  and  other  sympathomimetics  and  their  acetyl 
derivatives. Acta. Pharmacol. Toxicol. (Copenh.); 41: 218-24. 
FUKURODA T,  KOBAYASHI M, OZAKI S, YANO M,  MIYAUCHI T,  ONIZUKA M,  
SUGISHITA Y, GOTO K, NISHIKIBE M. (1994) Endothelin receptor subtypes in human 
versus rabbit pulmonary arteries. J. Appl. Physiol.; 76: 1976-1982. 
GAINE SP AND RUBIN LJ. (1998) Primary pulmonary hypertension. Lancet; 352: 719-
25. 
GAINE SP, HALES MA, FLAVAHAN NA. (1998) Hypoxic pulmonary endothelial cells 
release a diffusible contractile factor distinct from endothelin. Lung. Cell. Mol. Physiol.; 
18: L657-L664. 232 
 
GEORGE RB, MATTHAY MA, LIGHT LW, MATTHAY RA. (2005) Chest Medicine: 
Essentials of Pulmonary and Critical Care Medicine 5
th Edition. Lippincott Williams  & 
Wilkins. Pages 14-16. 
GERACI MW, GAO B, SHEPHERD DC, MOORE MD, WESTCOTT JY, FAGAN KA, 
ALGER  LA,  TUDER  RM,  VOELKEL  NF.  (1999)  Pulmonary  prostacyclin  synthase 
overexpression  in  transgenic  mice  protects  against  development  of  hypoxic  pulmonary 
hypertension. J. Clin. Invest.; 103: 1509-15. 
GERACI MW, MOORE M, GESELL T, YEAGER ME, ALGER L, GOLPON H, GAO B, 
LOYD JE, TUDER RM, VOELKEL NF. (2001) Gene expression patterns in the lungs of 
patients with primary pulmonary hypertension: a gene microarray analysis. Circ. Res.; 88:  
555– 562. 
GHOFRANI HA, SEEGER W, GRIMMINGER F. (2005) Imatinib for the treatment of 
pulmonary arterial hypertension. N. Engl. J. Med.; 353: 1412-3. 
GHOFRANI  HA,  VOSWINCKEL  R,  REICHENBERGER  F,  OLSCHEWSKI  H, 
HAREDZA  P,  KARADAŞ  B,  SCHERMULY  RT,  WEISSMANN  N,  SEEGER  W, 
GRIMMINGER  F.  (2004)  Differences  in  hemodynamic  and  oxygenation  responses  to 
three  different  phosphodiesterase-5  inhibitors  in  patients  with  pulmonary  arterial 
hypertension: a randomized prospective study. J. Am. Coll. Cardiol.; 44: 1488-96. 
GIAID A AND SALEH D. (1995) Reduced expression of endothelial nitric oxide synthase 
in the lungs of patients with pulmonary hypertension. N. Engl. J. Med.; 333: 214-21. 
GIAID A, YANAGISAWA M, LANGLEBEN D, MICHEL RP, LEVY R, SHENNIB H, 
KIMURA  S,  MASAKI  T,  DUGUID  WP,  STEWART  DJ.  (1993)  Expression  of 
endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med.; 328: 
1732-9. 
GILLIGAN DM, QUYYUMI AA, CANNON RO 3RD. (1994) Effects of physiological 
levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation; 
89: 2545-51. 
GLUSA E AND PERTZ HH. (2000) Further evidence that 5-HT-induced relaxation of pig 
pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br. J. Pharmacol.; 130: 
692-8. 
GOLDMAN AP, DELIUS RE, DEANFIELD JE, MACRAE DJ. (1995) Nitric oxide is 
superior to prostacyclin for pulmonary hypertension after cardiac operations. Ann. Thorac. 
Surg.; 60: 300-5. 
GREENWAY  S,  VAN  SUYLEN  RJ,  DU  MARCHIE  SARVAAS  G,  KWAN  E, 
AMBARTSUMIAN  N,  LUKANIDIN  E,  RABINOVITCH  M.  (2004)  S100A4/Mts1 
produces  murine  pulmonary  artery  changes  resembling  plexogenic  arteriopathy  and  is 
increased in human plexogenic arteriopathy. Am. J. Pathol.; 164: 253-62. 
GRUETTER  CA,  IGNARRO,  LJ,  HYMAN  AL,  KADOWITZ  PJ.  (1981)  Contractile 
effects  of  5-hydroxytryptamine  in  isolated  intrapulmonary  arteries  and  veins.  Can.  J. 
Physiol. Pharmacol.; 59: 157-62. 233 
 
GUGL  A, RENNER  W,  SEINOST  G,  BRODMANN  M,  PABST  E,  WASCHER  TC, 
PAULWEBER B, IGLSEDER B, PILGER E. (2003) Two polymorphisms in the fracalkine 
receptor CX3CR1 are not associated with peripheral arterial disease. Atherosclerosis; 166: 
339-43. 
GUIBERT C, MARTHAN R, SAVINEAU JP. (2004) 5-HT induces an arachidonic acid-
sensitive calcium influx in rat small intrapulmonary artery. Am. J. Physiol. Lung Cell Mol. 
Physiol.; 286: L1228-36. 
GUIGNABERT  C,  IZIKKI  M,  TU  LI,  LI  Z,  ZADIGUE  P,  BARLIER-MUR  AM, 
HANOUN N, RODMAN D, HAMON M, ADNOT S, EDDAHIBI S. (2006) Transgenic 
mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop 
pulmonary hypertension. Circ. Res.; 98: 1323-30. 
GUIGNABERT C, TU L, IZIKKI M, DEWACHTER L, ZADIGUE P, HUMBERT M, 
ADNOT S, FADEL E, EDDAHIBI S. (2009) Dichloroacetate treatment partially regresses 
established pulmonary hypertension in mice with SM22alpha-targeted overexpression of 
the serotonin transporter. FASEB J; 23: 4135-47. 
GUMUSEL B, ORHAN D, TOLUNAY O, UMA S. (2001) The role of nitric oxide in 
mediating nonadrenergic, noncholinergic relaxation in rat pulmonary artery. Nitric Oxide; 
5: 296-301. 
GUNAYDIN S, IMAI Y, TAKANASHI Y, SEO K, HAGINO I, CHANG D, SHINOKA 
T. (2002) The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary 
hypertensive  rabbits  following  cardiopulmonary  bypass:  a  comparative  study  with 
isoproteronol and nitroglycerine. Cardiovasc. Surg.; 10: 138-45. 
GURBANOV E AND SHILIANG X (2006) The key role of apoptosis in the pathogenesis 
and treatment of pulmonary hypertension. Eur. J. Cardiothorac. Surg.; 30: 499-507. 
 
GUYTON AC. (1981) Textbook of medical physiology 6
th Edition. Saunders. Pages 292-
293. 
HABERBERGER  R,  SCHEMANN  M,  SANN  H,  KUMMER  W.  (1997)  Innervation 
pattern  of  guinea  pig  pulmonary  vasculature  depends  on  vascular  diameter.  J  Appl 
Physiol.; 82:426-434. 
HABERL I, FREI K, RAMSEBNER R, DOBERER D, PETKOV V, ALBINNI S, LANG 
I, LUCAS T, MOSGOELLER W. (2007) Vasoactive intestinal peptide gene alterations in 
patients with idiopathic pulmonary arterial hypertension. Eur. J. Hum. Genet.; 15: 18-22. 
HAGEN M, FAGAN K, STEUDEL W, CARR M, LANE K, RODMAN DM, WEST J. 
(2007) Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. 
Am. J. Physiol. Lung Cell Mol. Physiol.; 292: L1473-9. 
HASSEL  S,  EICHNER  A,  YAKYMOVYCH  M,  HELLMAN  U,  KNAUS  P, 
SOUCHELNYTSKYI  S.  (2004)  Proteins  associated  with  type  II  bone  morphogenetic 
protein  receptor  (BMPR-II)  and  identified  by  two-dimensional  gel  electrophoresis  and 
mass spectrometry. Proteomics; 4: 1346-58. 234 
 
HATTORI  H,  ITO  D,  TANAHASHI  N,  MURATA  M,  SAITO  I,  WATANABE  K, 
SUZUKI N. (2005) T280M and V249I polymorphisms of fractalkine receptor CX3CR1 
and ischemic cerebrovascular disease. Neurosci. Lett.; 374: 132-5. 
HAYASHIDA  K,  FUJITA  J,  MIYAKE  Y,  KAWADA  H,  ANDO  K,  OGAWA  S,  
FUKUDA  K.  (2005)  Bone  marrow-derived  cells  contribute  to  pulmonary  vascular 
remodeling in hypoxia-induced pulmonary hypertension. CHEST; 127: 1793-1798. 
HAYDAR  S,  SARTI  JF,  GRISONI  ER.  (2007)  Intravenous  vasoactive  intestinal 
polypeptide lowers pulmonary-to-systemic vascular resistance ratio in a neonatal piglet 
model of pulmonary arterial hypertension. J. Pediatr. Surg.; 42: 758-64. 
HERVE P, DROUET L, DOSQUET C, LAUNAY JM, RAIN B, SIMONNEAU G, CAEN 
J, DUROUX P. (1990) Primary pulmonary hypertension in a patient with a familial platelet 
storage pool disease: role of serotonin. Am. J. Med.; 89: 117-20. 
HERVÉ  P,  LAUNAY  JM,  SCROBOHACI  ML,  BRENOT  F,  SIMONNEAU  G, 
PETITPRETZ P, POUBEAU P, CERRINA J, DUROUX P, DROUET L. (1995) Increased 
plasma serotonin in primary pulmonary hypertension. Am. J. Med.; 99: 249-54. 
HICKEY AJ. (1996) Inhalation Aerosols: Physical and Biological Basis for Therapy 1
st 
Edition. Informa Healthcare. Page 96-97. 
HISHIKAWA  K,  NAKAKI  T,  MARUMO  T,  HAYASHI  M,  SUZUKI  H,  KATO  R, 
SARUTA T. (1994) Pressure promotes DNA synthesis in rat cultured vascular smooth 
muscle cells. J. Clin. Invest.; 93: 1975-80. 
HOEPER  MM,  OLSCHEWSKI  H,  GHOFRANI  HA,  WILKENS  H,  WINKLER  J, 
BORST MM, NIEDERMEYER J, FABEL H, SEEGER W. (2000) A comparison of the 
acute  hemodynamic  effects  of inhaled  nitric  oxide  and  aerosolized  iloprost  in  primary 
pulmonary hypertension. German PPH study group. J. Am. Coll. Cardiol.; 35: 176-82. 
HONDA  H,  UNEMOTO  T,  KOGO  H.  (1999)  Different  mechanisms  for  testosterone-
induced relaxation of aorta between normotensive and spontaneously hypertensive  rats. 
Hypertension; 34: 1232-6. 
HU  J,  DISCHER  DJ,  BISHOPRIC  NH,  WEBSTER  KA.  (1998)  Hypoxia  regulates 
expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding 
site on the antisense strand. Biochem. Biophys. Res. Commun.; 245: 894-9. 
HUMBERT  M,  DENG  Z,  SIMONNEAU  G,  BARST  RJ,  SITBON  O,  WOLF  M, 
CUERVO N, MOORE KJ, HODGE SE, KNOWLES JA, MORSE JH. (2002) BMPR2 
germline mutations in pulmonary hypertension associated with fenfluramine derivatives. 
Eur. Respir. J.; 20: 518-23. 
HUMBERT M, MONTI G, BRENOT F, SITBON O, PORTIER A, GRANGEOT-KEROS 
L,  DUROUX  P,  GALANAUD  P,  SIMONNEAU  G,  EMILIE  D.  (1995)  Increased 
interleukin-1  and  interleukin-6  serum  concentrations  in  severe  primary  pulmonary 
hypertension. Am. J. Respir. Crit. Care Med.; 151: 1628-31. 
HUMBERT  M,  MORRELL  NW,  ARCHER  SL,  STENMARK  KR,  MACLEAN  MR, 
LANG  IM,  CHRISTMAN  BW,  WEIR  EK,  EICKELBERG  O,  VOELKEL  NF, 235 
 
RABINOVITCH M. (2004)  Cellular and molecular pathobiology of pulmonary arterial 
hypertension. J. Am. Coll. Cardiol.; 43: 13S-24S. 
HYMAN A. AND KADOWITZ PJ. (1988) Tone-dependent responses to acetylcholine in 
the feline pulmonary vascular bed. J. Appl. Physiol.; 64: 2002-9. 
ICHIKI Y,  KITAMURA K,  KANGAWA K,  KAWAMOTO M, MATSUO H,  ETO T. 
(1994)  Distribution  and  characterization  of  immunoreactive  adrenomedullin  in  human 
tissue and plasma. FEBS Lett.; 338: 6-10. 
INOUE  T.  AND  KANNAN  MS.  (1988)  Nonadrenergic  and  noncholinergic  excitatory 
neurotransmission in rat intrapulmonary artery. Am. J. Physiol.; 254: H1142-8. 
IZIKKI M, HANOUN N, MARCOS E, SAVALE L, BARLIER-MUR AM, SAURINI F, 
EDDAHIBI S, HAMON M, ADNOT S. (2007) Tryptophan hydroxylase 1 knockout and 
tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in 
mice. Am. J. Physiol. Lung Cell Mol. Physiol.; 293: L1045-52. 
JEFFERY  TK,  BRYAN-LLUKA  LJ,  WANSTALL  JC.  (2000)  Specific  uptake  of  5-
hydroxytryptamine is reduced in lungs from hypoxic pulmonary hypertensive rats. Eur. J. 
Pharmacol.; 396: 137-40. 
JONES  PL,  COWAN  KN,  RABINOVITCH  M.  (1997)  Tenascin-C,  proliferation  and 
subendothelial fibronectin in progressive pulmonary vascular disease. Am. J. Pathol.; 150: 
1349-60. 
JOSHI S, BALAN P, GURNEY AM. (2006) Pulmonary vasoconstrictor action of KCNQ 
potassium channel blockers. Respir. Res.; 7: 31. 
JOSHI S, SEDIVY V, HODYC D, HERGET J, GURNEY AM. (2009) KCNQ modulators 
reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary 
artery smooth muscle. J. Pharmacol. Exp. Ther.; 329: 368-76. 
KAKISHITA M, NISHIKIMI T, OKANO Y, SATOH T,  KYOTANI S,  NAGAYA N, 
FUKUSHIMA  K,  NAKANISHI  N,  TAKISHITA  S,  MIYATA  A,  KANGAWA  K, 
MATSUO H, KUNIEDA T. (1999) Increased plasma levels of adrenomedullin in patients 
with pulmonary hypertension. Clin. Sci. (Lond).; 96: 33-9. 
KANO  H,  KOHNO  M,  YASUNARI  K,  YOKOKAWA  K,  HORIO  T,  IKEDA  M, 
MINAMI M, HANEHIRA T, TAKEDA T, YOSHIKAWA J. (1996) Adrenomedullin as a 
novel antiproliferative factor of vascular smooth muscle cells. J. Hypertens.; 14: 209-13. 
KAWABATA M,  IMAMURA T, MIYAZONO K. (1998) Signal transduction by bone 
morphogenetic proteins. Cytokine Growth Factor Rev.; 9: 49-61. 
KAY JM, SMITH P, HEATH D. (1971) Aminorex and the pulmonary circulation. Thorax; 
26: 262-70. 
KEEGAN  A,  MORECROFT  I,  SMILLIE  D,  HICKS  MN,  MACLEAN  MR.  (2001) 
Contribution  of  the  5-HT(1B)  receptor  to  hypoxia-induced  pulmonary  hypertension: 
converging  evidence  using  5-HT(1B)-receptor  knockout  mice  and  the  5-HT(1B/1D)-
receptor antagonist GR127935. Circ. Res.; 89: 1231-9. 236 
 
KENTERA D, SUSIĆ D, VELJKOVIĆ V, TUCAKOVIĆ G, KOKO V. (1988) Pulmonary 
artery pressure in rats with hereditary platelet function defect. Respiration; 54: 110-4. 
KINGSLEY D.  (1994) The TGF-b superfamily: new members, new receptors and new 
genetic tests of function in different organisms. Genes Dev.; 8:  133-146. 
KITAMURA K, SAKATA J, KANGAWA K, KOJIMA M, MATSUO H, ETO T. (1993) 
Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. 
Biochem. Biophys. Res. Commun.; 194: 720-5.  
KLABUNDE RE. (2004) Cardiovascular Physiology Concepts  Lippincott Williams  and 
Wilkins. Pages 99-100. 
KNIGHT DS., ELLISON JP., HIBBS RG., HYMAN AL., KADOWITZ PJ. (1981) A light 
and electron microscopic study of the innervation of pulmonary arteries in the cat.  The 
Anatomical Record; 201:513-521.  
KOEHLER  R,  GRÜNIG  E,  PAUCIULO  MW,  HOEPER  MM,  OLSCHEWSKI  H, 
WILKENS H, HALANK M, WINKLER J, EWERT R, BREMER H, KREUSCHER S, 
JANSSEN B, NICHOLS WC. (2004) Low frequency of BMPR2 mutations in a German 
cohort  of  patients  with  sporadic  idiopathic  pulmonary  arterial  hypertension.  J.  Med. 
Genet.; 41: e127. 
KRAMER  MS  AND  LANE  DA.  (1998)  Aminorex,  dexfenfluramine,  and  primary 
pulmonary hypertension. J. Clin. Epidemiol.; 51: 361-4. 
KRASUSKI RA, WARNER JJ, WANG A, HARRISON JK, TAPSON VF, BASHORE 
TM. (2000) Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients 
with pulmonary hypertension, irrespective of etiology. J. Am. Coll. Cardiol.; 36: 2204-11. 
LAGNA G, NGUYEN PH, NI W, HATA A. (2006) BMP-dependent activation of caspase-
9  and  caspase-8  mediates  apoptosis  in  pulmonary  artery  smooth  muscle  cells.  Am.  J. 
Physiol. Lung Cell Mol. Physiol.; 291: L1059-67. 
LAHM T, PATEL KM, CRISOSTOMO PR, MARKEL TA, WANG M, HERRING C, 
MELDRUM DR. (2007) Endogenous estrogen attenuates pulmonary artery vasoreactivity 
and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle. Am. 
J. Physiol. Endocrinol.Metab.; 293: E865-71. 
LAI CF AND CHENG SL. (2002) Signal transductions induced by bone morphogenetic 
protein-2 and transforming growth factor-beta in normal human osteoblastic cells. J. Biol. 
Chem.; 277: 15514-22. 
LANE  KB,  MACHADO RD, PAUCIULO  MW, THOMSON JR, PHILLIPS JA 3RD, 
LOYD JE, NICHOLS WC, TREMBATH RC. (2000) Heterozygous germline mutations in 
BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. 
The International PPH Consortium. Nat. Genet.; 26: 81-4. 
LANGLEBEN  D,  CHRISTMAN  BW,  BARST  RJ,  DIAS  VC,  GALIÈ  N, 
HIGENBOTTAM  TW,  KNEUSSL  M,  KORDUCKI  L,  NAEIJE  R,  RIEDEL  A, 
SIMONNEAU G,  HIRSCH AM, RICH S, ROBBINS IM, OUDIZ R, MCGOON MD, 
BADESCH DB, LEVY RD, MEHTA S, SEEGER W, SOLÈR M. (2002) Effects of the 237 
 
thromboxane  synthetase  inhibitor  and  receptor  antagonist  terbogrel  in  patients  with 
primary pulmonary hypertension. Am. Heart J.; 143: E4. 
LAUNAY JM, HERVÉ P, PEOC'H K, TOURNOIS C, CALLEBERT J, NEBIGIL CG, 
ETIENNE N, DROUET L, HUMBERT M, SIMONNEAU G, MAROTEAUX L. (2002) 
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. 
Nat. Med.; 8: 1129-35. 
LAWRIE  A,  SPIEKERKOETTER  E,  MARTINEZ  EC,  AMBARTSUMIAN  N, 
SHEWARD  WJ,  MACLEAN  MR,  HARMAR  AJ,  SCHMIDT  AM,  LUKANIDIN  E, 
RABINOVITCH M. (2005) Interdependent serotonin transporter and receptor pathways 
regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ. Res.; 97: 
227-35. 
LE CRAS TD, MCMURTRY IF. (2001) Nitric oxide production in the hypoxic lung. Am. 
J. Physiol. Lung Cell. Mol. Physiol.; 280: L575-L582. 
LEACH  RM  AND  TREACHER  DF.  (1995)  Clinical  aspects  of  hypoxic  pulmonary 
vasoconstriction. Exp. Physiol.; 80: 865-875. 
LEDERER DJ, HORN EM, ROSENZWEIG EB, KARMALLY W, JAHNES M, BARST 
RJ,  KAWUT  SM.  (2007)  Plasma  serotonin  levels  are  normal  in  pulmonary  arterial 
hypertension. Pulm. Pharmacol. Ther.; 21: 112-4. 
LEE SD, SHROYER KR, MARKHAM NE, COOL CD, VOELKEL NF, TUDER RM. 
(1998) Monoclonal endothelial cell proliferation is present in primary but not secondary 
pulmonary hypertension. J. Clin. Invest.; 101: 927-934. 
LEE SL, WANG WW, FANBURG BL. (2001) Dexfenfluramine as a mitogen signal via 
the formation of superoxide anion. FASEB J.; 15: 1324-5. 
LEE  SL,  WANG  WW,  FINLAY  GA,  FANBURG  BL.  (1999)  Serotonin  stimulates 
mitogen-activated protein kinase activity through the formation of superoxide anion. Am. J. 
Physiol.; 277: L282-92. 
LEE SL, WANG WW, MOORE BJ, FANBURG BL. (1991) Dual effect of serotonin on 
growth of bovine pulmonary artery smooth muscle cells in culture. Circ. Res.; 68: 1362-8. 
LEVITZKY MG. (2002) Pulmonary Physiology 6
th Edition. McGraw-Hill Medical.  Pages 
89-94. 
LI H, CHEN SJ, CHEN YF, MENG QC, DURAND J, OPARIL S, ELTON TS. (1994) 
Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia.  J. 
Appl. Physiol.; 77: 1451-9. 
LI H, OPARIL S, MENG QC, ELTON TS, CHEN YF. (1995) Selective downregulation of 
ANP-clearance-receptor  gene  expression  in  lung  of  rats  adapted  to  hypoxia.  Am.  J. 
Physiol.; 268: L328-35. 
LINDBERG F AND ANDERSSON KE. (1988) Vasodilator responses to alpha-human-
atrial natriuretic peptide in isolated omental and pulmonary arteries from rabbit and man. 
Acta. Physiol. Scand.; 134: 391-7. 238 
 
LITTLETON-KEARNEY M, HURN PD. (2004) Testosterone as a modulator of vascular 
behavior. Biol. Res. Nurs.; 5: 276-85. 
LIU J, WU S, WEI H, ZHOU K, RUAN Y, LAI W. (2002) Effects of sex hormones and 
their balance on the proliferation of rat vascular endothelial cells. Horm. Res.; 58: 16-20. 
LIU  SF,  CRAWLEY  DE,  EVANS  TW,  BARMES  PJ.  (1991)  Endothelium-dependent 
nonadrenergic,  noncholinergic  neural  relaxation  in  guinea  pig  pulmonary  artery.  J. 
Pharmacol. Exp. Ther.; 260: 541-8. 
LIU  Y,  SUZUKI  YJ,  DAY  RM,  FANBURG  BL.  (2004)  Rho  kinase-induced  nuclear 
translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ. 
Res.; 95: 579-86. 
LOIRAND G, GUERIN P, PACAUD P. (2006) Rho kinases in cardiovascular physiology 
and pathophysiology. Circ. Res.; 98: 322-334. 
LONG  L,  MACLEAN  MR,  JEFFERY  TK,  MORECROFT  I,  YANG  X, 
RUDARAKANCHANA N, SOUTHWOOD M, JAMES V, TREMBATH RC, MORRELL 
NW.  (2006)  Serotonin  increases  susceptibility  to  pulmonary  hypertension  in  BMPR2-
deficient mice. Circ. Res.; 98: 818-27. 
LOPES AAB AND MAEDO NY. (1998) Circulating von willebrand factor antigen as a 
predictor of short-term prognosis in pulmonary hypertension. CHEST; 114: 1276-1282. 
LOYD  JE,  BUTLER  MG,  FOROUD  TM,  CONNEALLY  PM,  PHILLIPS  JA  3RD, 
NEWMAN JH. (1995) Genetic anticipation and abnormal gender ratio at birth in familial 
primary pulmonary hypertension. Am. J. Respir. Crit. Care Med.; 152: 93-7. 
LOYD JE, PRIMM RK, NEWMAN JH. (1984) Familial primary pulmonary hypertension: 
clinical patterns. Am. Rev. Respir. Dis.; 129: 194-7. 
MACHADO RD, ALDRED MA, JAMES V, HARRISON RE, PATEL B, SCHWALBE 
EC,  GRUENIG  E,  JANSSEN  B,  KOEHLER  R,  SEEGER  W,  EICKELBERG  O, 
OLSCHEWSKI  H,  ELLIOTT  CG,  GLISSMEYER  E,  CARLQUIST  J,  KIM  M, 
TORBICKI A,  FIJALKOWSKA A, SZEWCZYK G, PARMA J,  ABRAMOWICZ MJ, 
GALIE N, MORISAKI H, KYOTANI S, NAKANISHI N, MORISAKI T, HUMBERT M, 
SIMONNEAU  G,  SITBON  O,  SOUBRIER  F,  COULET  F,  MORRELL  NW, 
TREMBATH  RC.  (2006)  Mutations  of  the  TGF-beta  type  II  receptor  BMPR2  in 
pulmonary arterial hypertension. Hum. Mutat.; 27: 121-32. 
MACHADO  RD,  PAUCIULO  MW,  THOMSON  JR,  LANE  KB,  MORGAN  NV, 
WHEELER L, PHILLIPS JA 3RD, NEWMAN J, WILLIAMS D, GALIÈ N, MANES A, 
MCNEIL  K,  YACOUB  M,  MIKHAIL  G,  ROGERS  P,  CORRIS  P,  HUMBERT  M, 
DONNAI  D,  MARTENSSON  G,  TRANEBJAERG  L,  LOYD  JE,  TREMBATH  RC, 
NICHOLS WC. (2001) BMPR2 haploinsufficiency as the inherited molecular mechanism 
for primary pulmonary hypertension. Am. J. Hum. Genet.; 68: 92-102. 
MACHADO  RD,  RUDARAKANCHANA  N,  ATKINSON  C,  FLANAGAN  JA, 
HARRISON R, MORRELL NW, TREMBATH RC. (2003) Functional interaction between 
BMPR-II  and  Tctex-1,  a  light  chain  of  Dynein,  is  isoform-specific  and  disrupted  by 
mutations underlying primary pulmonary hypertension. Hum. Mol. Genet.; 12: 3277-86. 239 
 
MACKIE  AR,  BRUEGGEMANN  LI,  HENDERSON  KK,  SHIELS  AJ,  CRIBBS  LL, 
SCROGIN KE, BYRON KL. (2008) Vascular KCNQ potassium channels as novel targets 
for the control of mesenteric artery constriction by vasopressin, based on studies in single 
cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J. 
Pharmacol. Exp. Ther.; 325: 475-83. 
MACLEAN MR, DEUCHAR GA, HICKS MN, MORECROFT I, SHEN S, SHEWARD J, 
COLSTON  J,  LOUGHLIN  L,  NILSEN  M,  DEMPSIE  Y,  HARMAR  A.  (2004) 
Overexpression  of  the  5-hydroxytryptamine  transporter  gene:  effect  on  pulmonary 
hemodynamics and hypoxia-induced pulmonary hypertension. Circulation; 109: 2150-5. 
MACLEAN MR, HERVE P, EDDAHIBI S, ADNOT S. (2000) 5-hydroxytryptamine and 
the  pulmonary  circulation:  receptors,  transporters  and  relevance  to  pulmonary  arterial 
hypertension. Br. J. Pharmacol.; 131: 161-168. 
MACLEAN MR, MCCULLOCH  KM,  BAIRD M. (1994)  Endothelin ETA- and ETB-
receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J. Cardiovasc. 
Pharmacol.; 23: 838-45. 
MACLEAN  MR,  SWEENEY  G,  BAIRD  M,  MCCULLOCH  KM,  HOUSLAY  M, 
MORECROFT  I.  (1996)  5-Hydroxytryptamine  receptors  mediating  vasoconstriction  in 
pulmonary arteries from control and pulmonary hypertensive rats. Br. J. Pharmacol.; 119: 
917-930. 
MADDEN JA, DAWSON CA, HARDER DR. (1985) Hypoxia-induced activation in small 
isolated pulmonary arteries from the cat. J. Appl. Physiol.; 59: 113-188. 
MADDEN  JA,  VADULA  MS,  KURUP,  VP.  (1992)  Effects  of  hypoxia  and  other 
vasoactive agents on pulmonary and cerebral artery smooth muscle cells. Am. J. Physiol.; 
263: L384-93. 
MALEK  AM,  GIBBONS  GH,  DZAU  VJ,  IZUMO  S.  (1993)  Fluid  shear  stress 
differentially modulates expression of genes encoding basic fibroblast growth factor and 
platelet-derived growth factor B chain in vascular endothelium. J. Clin. Invest.; 92: 2013–
2021. 
MANDEGAR M., FUNG YC., HUANG W., REMILLARD CV., RUBIN LJ., YUAN JX. 
(2004) Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the 
development of pulmonary hypertension. Microvasc Res.; 68: 75-103. 
MANIVET  P,  MOUILLET-RICHARD  S,  CALLEBERT  J,  NEBIGIL  CG, 
MAROTEAUX  L,  HOSODA  S,  KELLERMANN  O,  LAUNAY  JM.  (2000)  PDZ-
dependent activation of nitric-oxide synthases by the serotonin 2B receptor. J. Biol. Chem.; 
275: 9324-31. 
MARASINI B, COSSUTTA R, SELMI C, POZZI MR, GARDINALI M, MASSAROTTI 
M, ERARIO M, BATTAGLIOLI L, BIONDI ML. (2005) Polymorphism of the fractalkine 
receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension. Clin. 
Dev. Immunol.; 12: 275-9. 240 
 
MARCOS  E,  ADNOT  S,  PHAM  MH,  NOSJEAN  A,  RAFFESTIN  B,  HAMON  M, 
EDDAHIBI S. (2003) Serotonin transporter inhibitors protect against hypoxic pulmonary 
hypertension. Am. J. Respir. Crit. Care Med.; 168: 487-93. 
MARCOS E, FADEL E, SANCHEZ O, HUMBERT M, DARTEVELLE P, SIMONNEAU 
G,  HAMON  M,  ADNOT  S,  EDDAHIBI  S.  (2004)  Serotonin-induced  smooth  muscle 
hyperplasia in various forms of human pulmonary hypertension. Circ. Res.; 94: 1263-70. 
MARK  EJ,  PATALAS  ED,  CHANG  HT,  EVANS  RJ,  KESSLER  SC.  (1997)  Fatal 
pulmonary hypertension associated with short-term use of fenfluramine and phentermine. 
N. Engl. J. Med.; 337: 602-6. 
MARUTSUKA  K,  HATAKEYAMA  K, SATO Y, YAMASHITA  A,  SUMIYOSHI  A, 
ASADA  Y.  (2003)  Immunohistological  localization  and  possible  functions  of 
adrenomedullin. Hypertens. Res.; 26: S33-S40. 
MASON NA, SPRINGALL DR, BURKE M, POLLOCK J, MIKHAIL G, YACOUB MH, 
POLAK JM. (1998)  High expression of endothelial nitric oxide synthase in plexiform 
lesions of pulmonary hypertension. J. Pathol.; 185: 313-8. 
MASSAGUÉ J AND CHEN YG. (2000) Controlling TGF-beta signaling. Genes Dev.; 14: 
627-44. 
MASSAGUE J. (2003)  Integration of Smad and MAPK pathways: a link and a linker 
revisited. Genes Dev.; 17: 2993-7. 
MATSUI  H,  SHIMOSAWA  T,  ITAKURA  K,  GUANQUN  X,  ANDO  K,  FUJITA  T. 
(2004)  Adrenomedullin can protect against pulmonary vascular remodeling induced  by 
hypoxia. Circulation; 109: 2246-51. 
MCCULLOCH  KM,  DOCHERTY  CC,  MORECROFT  I,  MACLEAN  MR.  (1996) 
EndothelinB receptor-mediated contraction in human pulmonary resistance arteries. Br. J. 
Pharmacol.; 119:1125-1130. 
MCDERMOTT DH, HALCOX JP, SCHENKE WH, WACLAWIW MA, MERRELL MN, 
EPSTEIN N, QUYYUMI AA, MURPHY PM. (2001) Association between polymorphism 
in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and 
atherosclerosis. Circ. Res.; 89: 401-407. 
MCGOON MD AND VANHOUTTE PM. (1984) Aggregating platelets contract isolated 
canine pulmonary arteries by releasing 5-hydroxytryptamine. J. Clin. Invest.; 74: 828-833. 
MCLAUGHLIN VV, GENTHNER DE, PANELLA MM, RICH S. (1998) Reduction in 
pulmonary  vascular  resistance  with  long-term  epoprostenol  (prostacyclin)  therapy  in 
primary pulmonary hypertension. N. Engl. J. Med.; 338: 273-7. 
MCMURTRY MS, ARCHER SL, ALTIERI DC, BONNET S, HAROMY A, HARRY G, 
BONNET  S,  PUTTAGUNTA  L,  MICHELAKIS  ED.  (2005)  Gene  therapy  targeting 
survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial 
hypertension. J. Clin. Invest.; 115: 1479-91. 241 
 
MCMURTRY MS, MOUDGIL R, HASHIMOTO K, BONNET S, MICHELAKIS ED, 
ARCHER SL. (2007) Overexpression of human bone morphogenetic protein receptor 2 
does not ameliorate monocrotaline pulmonary arterial hypertension. Am. J. Physiol. Lung 
Cell Mol. Physiol.; 292: L872-8. 
MCNEILL  AM,  DUCKLES  SP,  KRAUSE  DN.  (1996)  Relaxant  effects  of  17  beta-
estradiol in the rat tail artery are greater in females than males. Eur. J. Pharmacol.; 308: 
305-9. 
MCQUEEN  JK,  WILSON  H,  FINK  G.  (1997)  Estradiol-17  beta  increases  serotonin 
transporter (SERT) mRNA levels and the density of SERT-binding sites in female rat 
brain. Brain Res. Mol. Brain Res.; 45: 13-23. 
MEHTA S, STEWART DJ, LANGLEBEN D, LEVY RD. (1995) Short-term pulmonary 
vasodilation with L-arginine in pulmonary hypertension. Circulation; 92: 1539-45. 
MITANI  Y,  MARUYAMA  K,  SAKURAI  M.  (1997)  Prolonged  administration  of  L-
arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling 
in rats. Circulation; 96: 689-97. 
MITANI  Y,  MUTLU  A,  RUSSELL  JC,  BRINDLEY  DN,  DEALMEIDA  J, 
RABINOVITCH M. (2002) Dexfenfluramine protects against pulmonary hypertension in 
rats. J. Appl. Physiol.; 93: 1770-8. 
MIYATA M, ITO M, SASAJIMA T, OHIRA H, KASUKAWA R. (2001) Effect of a 
serotonin  receptor  antagonist  on  interleukin-6-induced  pulmonary  hypertension  in  rats. 
Chest; 119: 554-61. 
MIYAZONO K, KUSANAGI K, INOUE H. (2001) Divergence and convergence of TGF-
beta/BMP signaling. J. Cell. Physiol.; 187: 265-76. 
MLINAR  B  AND  CORRADETTI  R.  (2006)  Endogenous  5-HT,  released  by  MDMA 
through  serotonin  transporter-  and  secretory  vesicle-dependent  mechanisms,  reduces 
hippocampal  excitatory  synaptic  transmission  by  preferential  activation  of  5-HT1B 
receptors located on CA1 pyramidal neurons. Eur. J. Neurosci.; 18:1559-71. 
MOATTI D, FAURE S, FUMERON F, AMARA MEW, SEKNADJI P, MCDERMOTT 
DH, DEBRE P, AUMONT MC, MURPHY PM, DEPROST D, COMBADIERE C. (2001) 
Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary 
artery disease. Blood; 97: 1925-1928. 
MOLET  S,  FURUKAWA  K,  MAGHAZECHI  A,  HAMID  Q,  GIAID  A.  (2000) 
Chemokine- and cytokine-induced expression of endothelin 1 and endothelin-converting 
enzyme 1 in endothelial cells. J. Allergy Clin. Immunol.; 105: 333-8. 
MORECROFT I, DEMPSIE Y, BADER M, WALTHER DJ, KOTNIK K, LOUGHLIN L, 
NILSEN M, MACLEAN MR. (2007) Effect of tryptophan hydroxylase 1 deficiency on the 
development of hypoxia-induced pulmonary hypertension. Hypertension; 49: 232-6. 
MORECROFT I, HEELEY RP, PRENTICE HM, KIRK A, MACLEAN MR. (1999) 5-
hydroxytryptamine receptors mediating contraction in human small muscular pulmonary 
arteries: importance of the 5-HT1B receptor. Br. J. Pharmacol.; 128: 730-743. 242 
 
MORECROFT I, MURRAY A,  NILSEN M, GURNEY AM, MACLEAN MR. (2009) 
Treatment  with  the  Kv7  potassium  channel  activator  flupirtine  is  beneficial  in  two 
independent mouse models of pulmonary hypertension. Br. J. Pharmacol.; 157: 1241-9. 
MORISAKI  H,  NAKANISHI  N,  KYOTANI  S,  TAKASHIMA  A,  TOMOIKE  H, 
MORISAKI T. (2004)  BMPR2 mutations found in Japanese patients with familial and 
sporadic primary pulmonary hypertension. Hum. Mutat.; 23: 632. 
MORRELL NW, YANG X, UPTON PD, JOURDAN KB, MORGAN N, SHEARES KK, 
TREMBATH RC. (2001) Altered growth responses of pulmonary artery smooth muscle 
cells from patients with primary pulmonary hypertension to transforming growth factor-
beta(1) and bone morphogenetic proteins. Circulation; 104: 790-5. 
MORRELL  NW.  (2006)  Pulmonary  hypertension  due  to  BMPR2  mutation:  a  new 
paradigm for tissue remodeling? Proc. Am. Thorac. Soc.; 3: 680-6. 
MORSE JH, JONES AC, BARST RJ, HODGE SE, WILHELMSEN KC, NYGAARD TG. 
(1997) Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 
2q31-q32. Circulation; 95: 2603-6. 
MORTY  RE,  NEJMAN  B,  KWAPISZEWSKA  G,  HECKER  M,  ZAKRZEWICZ  A, 
KOURI FM, PETERS DM, DUMITRASCU R, SEEGER W, KNAUS P, SCHERMULY 
RT,  EICKELBERG  O.  (2007)  Dysregulated  bone  morphogenetic  protein  signaling  in 
monocrotaline-induced pulmonary arterial hypertension. Arterioscler. Thromb. Vasc. Biol.; 
27: 1072-8. 
MULVANY MJ AND HALPERN W. (1976) Mechanical properties of vascular smooth 
muscle cells in situ. Nature; 260: 617-9. 
NADERALI  EK,  WALKER  AB,  DOYLE  P,  WILLIAMS  G.  (1999)  Comparable 
vasorelaxant effects of 17alpha- and 17beta-oestradiol on rat mesenteric resistance arteries: 
an action independent of the oestrogen receptor. Clin. Sci. (Lond.); 97: 649-55. 
NAGAOKA T, MURAMATSU M, SATO K, MCMURTRY I, OKA M, FUKUCHI Y. 
(2001) Mild hypoxia causes severe pulmonary hypertension in fawn-hooded but not in 
Tester Moriyama rats. Respir. Physiol.; 127: 53-60. 
NAGAYA N, KYOTANI S, UEMATSU M, UENO K, OYA H, NAKANISHI N, SHIRAI 
M,  MORI  H,  MIYATAKE  K,  KANGAWA  K.  (2004)  Effects  of  adrenomedullin 
inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary 
arterial hypertension. Circulation; 109: 351-6. 
NAGAYA N, OKUMURA H, UEMATSU M, SHIMIZU W, ONO F, SHIRAI M, MORI 
H,  MIYATAKE  K,  KANGAWA  K.  (2003)  Repeated  inhalation  of  adrenomedullin 
ameliorates pulmonary hypertension and survival in monocrotaline rats. Am. J. Physiol. 
Heart Circ. Physiol.; 285: H2125-31. 
NAGAYA  N,  UEMATSU M, OKANO Y, SATOH T,  KYOTANI S,  SAKAMAKI  F, 
NAKANISHI N, MIYATAKE K, KUNIEDA T. (1999) Effect of orally active prostacyclin 
analogue on survival of outpatients with primary pulmonary hypertension. J. Am.  Coll. 
Cardiol.; 34: 1188-92. 243 
 
NAGAYA N, UEMATSU M, OYA H, SATO N, SAKAMAKI F, KYOTANI S, UENO K, 
NAKANISHI N, YAMAGISHI M, MIYATAKE K. (2001) Short-term oral administration 
of L-arginine improves hemodynamics and exercise capacity in patients with precapillary 
pulmonary hypertension. Am. J. Respir. Crit. Care Med.; 163: 887-91. 
NAGAYA  N,  YOKOYAMA  C,  KYOTANI  S,  SHIMONISHI  M,  MORISHITA  R, 
UEMATSU  M,  NISHIKIMI  T,  NAKANISHI  N,  OGIHARA  T,  YAMAGISHI  M, 
MIYATAKE K, KANEDA Y, TANABE T. (2000) Gene transfer of human prostacyclin 
synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation; 
102: 2005-10. 
NANDIWADA  PA,  HYMAN  AL,  KADOWITZ  PJ.  (1983)  Pulmonary  vasodilator 
responses to vagal stimulation and acetylcholine in the cat. Circ Res.; 53: 86-95. 
NEWMAN JH, PHILLIPS JA 3RD, LOYD JE. (2008) Narrative review: the enigma of 
pulmonary arterial hypertension: new insights from genetic  studies.  Ann.  Intern.  Med.; 
148: 278-83. 
NEWMAN JH, WHEELER L, LANE KB, LOYD E, GADDIPATI R, PHILLIPS JA 3RD, 
LOYD JE. (2001) Mutation in the gene for bone morphogenetic protein receptor II as a 
cause of primary pulmonary hypertension in a large kindred. N. Engl. J. Med.; 345: 319-
24. 
NI W AND WATTS SW. (2006) 5-hydroxytryptamine in the cardiovascular system: focus 
on the serotonin transporter (SERT). Clin. Exp. Pharmacol. Physiol.; 33: 575-83. 
NI W, WILHELM CS, BADER M, MURPHY DL, LOOKINGLAND K, WATTS SW. 
(2005) (+)-Norfenfluramine-induced arterial contraction is not dependent on endogenous 
5-hydroxytryptamine or 5-hydroxytryptamine transporter.  J. Pharmacol. Exp. Ther.; 314: 
953-60. 
NICHOLS WC, KOLLER DL, SLOVIS B, FOROUD T, TERRY VH, ARNOLD ND, 
SIEMIENIAK DR, WHEELER L, PHILLIPS JA 3RD, NEWMAN JH, CONNEALLY 
PM,  GINSBURG  D,  LOYD  JE.  (1997)  Localization  of  the  gene  for  familial  primary 
pulmonary hypertension to chromosome 2q31-32. Nat. Genet.; 15: 277-80. 
NICOLLS  MR  AND  VOELKEL  NF.  (2007)  Hypoxia  and  the  lung:  beyond  hypoxic 
vasoconstriction. Antioxid. Redox. Signal; 9: 741-3. 
NISHIHARA  A,  WATABE  T,  IMAMURA  T,  MIYAZONO  K.  (2002)  Functional 
heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with 
primary pulmonary hypertension. Mol. Biol. Cell.; 13: 3055-63. 
NISHITOH  H,  ICHIJO  H,  KIMURA  M,  MATSUMOTO  T,  MAKISHIMA  F, 
YAMAGUCHI A, YAMASHITA H, ENOMOTO S, MIYAZONO K. (1996) Identifcation 
of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J. 
Biol. Chem.; 271: 21345-21353. 
NOHE A, HASSEL S, EHRLICH M, NEUBAUER F, SEBALD W, HENIS YI, KNAUS 
P.  (2002)  The  mode  of  bone  morphogenetic  protein  (BMP)  receptor  oligomerization 
determines different BMP-2 signaling pathways. J. Biol. Chem.; 277: 5330-8. 244 
 
NOHE A, KEATING E, KNAUS P, PETERSEN NO. (2004) Signal transduction of bone 
morphogenetic protein receptors. Cell Signal.; 16: 291-9. 
NOREL  X,  WALCH  L,  COSTANTINO  M,  LABAT  C,  GORENNE  I,  DULMET  E, 
ROSSI F, BRINK C. (1996) M1 and M3 muscarinic receptors in human pulmonary arteries. 
Br. J. Pharmacol.; 119: 149-57. 
OLSCHEWSKI H, GHOFRANI HA, SCHMEHL T, WINKLER J, WILKENS H, HÖPER 
MM,  BEHR  J,  KLEBER  FX,  SEEGER  W.  (2000)  Inhaled  iloprost  to  treat  severe 
pulmonary hypertension. An uncontrolled trial. German PPH Study Group.  Ann. Intern. 
Med.; 132: 434-43. 
OLSON TP, SNYDER EM, FRANTZ RP, TURNER ST, JOHNSON BD. (2007) Repeat 
length  polymorphism  of  the  serotonin  transporter  gene  influences  pulmonary  artery 
pressure in heart failure. Am. Heart J.; 153: 426-32. 
OPGAARD OS, DUCKLES SP, KRAUSE DN. (2002) Regional differences in the effect 
of oestrogen on vascular tone in isolated rabbit arteries. Pharmacol. Toxicol.; 91: 77-82. 
OWJI AA, SMITH DM, COPPOCK HA, MORGAN DG, BHOGAL R, GHATEI MA, 
BLOOM  SR.  (1995)  An  abundant  and  specific  binding  site  for  the  novel  vasodilator 
adrenomedullin in the rat. Endocrinology; 136: 2127-34. 
OZAKI M, KAWASHIMA S, YAMASHITA T, OHASHI Y, RIKITAKE Y, INOUE N, 
HIRATA  KI,  HAYASHI  Y,  ITOH  H,  YOKOYAMA  M.  (2001)  Reduced  hypoxic 
pulmonary vascular remodeling by nitric oxide from the endothelium.  Hypertension; 37: 
322-7. 
PAN J, COPLAND I, POST M, YEGER H, CUTZ E. (2006) Mechanical stretch-induced 
serotonin  release  from  pulmonary  neuroendocrine  cells:  implications  for  lung 
development. Am. J. Physiol. Lung Cell Mol. Physiol.; 290: L185-93. 
PARKER  TA,  IVY  DD,  GALAN  HL,  GROVER  TR,  KINSELLA  JP,  ABMAN  SH. 
(2000) Estradiol improves pulmonary hemodynamics and vascular remodeling in perinatal 
pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol.; 278: L374-81. 
PARTANEN M, LAITINEN A, HERVONEN A, TOIVANEN M, LAITINEN LA. (1982) 
Catecholamine-  and  acetylcholinesterase-containing  nerves  in  human  lower  respiratory 
tract. Histochemistry; 76: 175-88. 
PARTILLA  JS,  DEMPSEY  AG,  NAGPAL  AS,  BLOUGH  BE,  BAUMANN  MH, 
ROTHMAN  RB.  (2006)  Interaction  of  amphetamines  and  related  compounds  at  the 
vesicular monoamine transporter. J. Pharmacol. Exp. Ther.; 319: 237-46. 
PARTOVIAN C,  ADNOT S,  EDDAHIBI S, TEIGER E,  LEVAME M, DREYFUS P, 
RAFFESTIN B, FRELIN C. (1998) Heart and lung VEGF mRNA expression in rats with 
monocrotaline- or hypoxia-induced pulmonary hypertension. Am. J. Physiol.; 275: H1948-
56. 
PARTOVIAN C, ADNOT S, RAFFESTIN B, LOUZIER V, LEVAME M, MAVIER IM, 
LEMARCHAND P, EDDAHIBI S. (2000) Adenovirus-mediated lung vascular endothelial 245 
 
growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am. 
J. Respir. Cell Mol. Biol.; 23: 762-71. 
PEPKE-ZABA J, HIGENBOTTAM TW, DINH-XUAN AT, STONE D, WALLWORK J. 
(1991) Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary 
hypertension. Lancet; 338: 1173-4. 
PERCHENET  L,  HILFIGER  L,  MIZRAHI  J,  CLÉMENT-CHOMIENNE  O.  (2001) 
Effects  of  anorexinogen  agents  on  cloned  voltage-gated  K(+)  channel  hKv1.5.  J. 
Pharmacol. Exp. Ther.; 298: 1108-19.  
PERROS F, DORFMÜLLER P, SOUZA R, DURAND-GASSELIN I, GODOT V, CAPEL 
F, ADNOT S, EDDAHIBI S, MAZMANIAN M, FADEL E, HERVÉ P, SIMONNEAU G, 
EMILIE D, HUMBERT M. (2007) Fractalkine-induced smooth muscle cell proliferation in 
pulmonary hypertension. Eur. Respir. J.; 29: 937-43. 
PERROS F, MONTANI D, DORFMÜLLER P, DURAND-GASSELIN I, TCHERAKIAN 
C, LE PAVEC J, MAZMANIAN M, FADEL E, MUSSOT S, MERCIER O, HERVÉ P, 
EMILIE D, EDDAHIBI S, SIMONNEAU G, SOUZA R, HUMBERT M. (2008) Platelet-
derived  growth  factor  expression  and  function  in  idiopathic  pulmonary  arterial 
hypertension. Am. J. Respir. Crit. Care Med.; 178: 81-8. 
PETKOV  V,  MOSGOELLER  W,  ZIESCHE  R,  RADERER  M,  STIEBELLEHNER  L, 
VONBANK K, FUNK GC, HAMILTON G, NOVOTNY C, BURIAN B, BLOCK LH. 
(2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary 
hypertension. J. Clin. Invest.; 111: 1339-46. 
PFEIFER M, BLUMBERG FC, WOLF K, SANDNER P, ELSNER D, RIEGGER GA, 
KURTZ A. (1998) Vascular remodeling and growth factor gene expression in the rat lung 
during hypoxia. Respir. Physiol.; 111: 201-12. 
PLATOSHYN O, YU Y, GOLOVINA VA, MCDANIEL SS, KRICK S, LI L, WANG JY, 
RUBIN LJ, YUAN JX. (2001) Chronic hypoxia decreases K(V) channel expression and 
function in pulmonary artery myocytes.  Am. J.  Physiol.  Lung  Cell  Mol.  Physiol.;  280: 
L801-12. 
PLATOSHYN O, ZHANG S, MCDANIEL SS, YUAN JX. (2002) Cytochrome c activates 
K+ channels before inducing apoptosis. Am. J. Physiol. Cell Physiol.; 283: C1298:-305. 
PORCELLI  RJ.  AND  BERGOFSKY  EH.  (1973)  Adrenergic  receptors  in  pulmonary 
vasoconstrictor responses to gaseous and humoral agents. J. Appl. Physiol.; 34:438-88. 
PORCELLI RJ., VIAU A., DEMENY NE., NAFTCHI NE., BERGOFSKY EH. (1977) 
Relation between hypoxic pulmonary vasoconstriction, its humoral mediators and alpha-
beta adrenergic receptors. Chest; 71:249-251.  
POZEG ZI, MICHELAKIS ED, MCMURTRY MS, THÉBAUD B, WU XC, DYCK JR, 
HASHIMOTO K, WANG S, MOUDGIL R, HARRY G, SULTANIAN R, KOSHAL A, 
ARCHER SL. (2003) In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 
reduces  pulmonary  hypertension  and  restores  hypoxic  pulmonary  vasoconstriction  in 
chronically hypoxic rats. Circulation; 107: 2037-44. 246 
 
QI JG, DING YG, TANG CS, DU JB. (2006) Effect of adrenomedullin1-50 on chronic 
hypoxic pulmonary hypertension in rats. Beijing Da Xue Xue Bao.; 38: 151-4. 
QUAN  A, TEOH  H,  MAN RY.  (1999)  Acute exposure to a low level of testosterone 
impairs relaxation in porcine coronary arteries. Clin. Exp. Pharmacol. Physiol.; 26: 830-2. 
RABINOVITCH  M,  GAMBLE  WJ,  MIETTINEN  OS,  REID  L.  (1981)  Age  and  sex 
influence on pulmonary hypertension of chronic hypoxia and on recovery. Am. J. Physiol.; 
240: H62-72. 
REMILLARD  CV  AND  YUAN  JX.  (2004)  Activation  of  K+  channels:  an  essential 
pathway in programmed cell death. Am. J. Physiol. Lung Cell Mol. Physiol.; 286: L49-67. 
RESTA  TC,  KANAGY  NL,  WALKER  BR.  (2001)  Estradiol-induced  attenuation  of 
pulmonary hypertension is not associated with altered eNOS expression. Am. J. Physiol. 
Lung Cell Mol. Physiol.; 280:  L88-97. 
REYNOLDS  AM,  XIA  W,  HOLMES  MD,  HODGE  SJ,  DANILOV  S,  CURIEL  DT, 
MORRELL NW, REYNOLDS PN. (2007) Bone morphogenetic protein type 2 receptor 
gene  therapy  attenuates  hypoxic  pulmonary  hypertension.  J.  Physiol.  Lung  Cell  Mol. 
Physiol.; 292: L1182-92. 
RICH S, DANTZKER DR, AYRES SM, BERGOFSKY EH, BRUNDAGE BH, DETRE 
KM, FISHMAN AP, GOLDRING RM, GROVES BM, KOERNER SK. (1987) Primary 
pulmonary hypertension. A national prospective study. Ann. Intern. Med.; 107: 216-23. 
RICH  S,  RUBIN  L,  WALKER  AM,  SCHNEEWEISS  S,  ABENHAIM  L.  (2000) 
Anorexigens  and  pulmonary  hypertension  in  the  United  States:  results  from  the 
surveillance of North American pulmonary hypertension. Chest; 117: 870-4. 
 
RICHARDSON  DR,  RANDALL  KR,  SPECK  DF.  (1998)  Cardiopulmonary  System 
Illustrated Edition. Fence Creek Publishing. Pages 252-253. 
RICHTER  A,  YEAGER  ME,  ZAIMAN A, COOL CD, VOELKEL  NF, TUDER RM. 
(2004) Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial 
hypertension. Am. J. Respir. Crit. Care Med.; 170: 1340-8. 
RIVERA HM, OBERBECK DR, KWON B, HOUPT TA, ECKEL LA. (2009) Estradiol 
increases  Pet-1  and  serotonin  transporter  mRNA  in  the  midbrain  raphe  nuclei  of 
ovariectomized rats. Brain Res.; 1259: 51-8. 
ROBBINS  IM,  GAINE SP, SCHILZ R, TAPSON VF, RUBIN  LJ,  LOYD JE.  (2000) 
Epoprostenol  for  treatment  of  pulmonary  hypertension  in  patients  with  systemic  lupus 
erythematosus. Chest; 117: 14-8. 
ROBERTSON  TP,  AARONSON  PI,  JPT  WARD.  (2003)  Ca
2+  sensitization  during 
sustained hypoxic pulmonary vasoconstriction is endothelium dependent. Am. J. Physiol. 
Lung Cell. Mol. Physiol.; 284: L1121-6. 
ROBERTSON TP, DIPP M, WARD JPT, AARONSON PI, EVAN AM. (2000) Inhibition 
of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and 
perfused lung of the rat. Br. J. Pharmacol.; 131: 5-9. 247 
 
ROBERTSON TP, WARD JPT, AARONSON PI. (2001) Hypoxia induces the release of a 
pulmonary-selective,  Ca  -sensitising,  vasoconstrictor  from  the  perfused  rat  lung. 
Cardiovasc. Res.; 50: 145-50. 
ROCHEFORT GY, LEMAIRE MC, EDER V, HANTON G, HYVELIN JM, BONNET P, 
ANTIER  D.  (2006)  Dexfenfluramine  does  not  worsen  but  moderates  progression  of 
chronic hypoxia-induced pulmonary hypertension. Eur. J. Pharmacol.; 550: 149-54. 
RODAT-DESPOIX L, CREVEL H, MARTHAN R, SAVINEAU JP, GUIBERT C. (2008) 
Heterogeneity in 5-HT-induced contractile and proliferative responses in rat pulmonary 
arterial bed. J. Vasc. Res.; 45: 181-92. 
ROSE F, GRIMMINGER F, APPEL J, HELLER M, PIES V, WEISSMANN N, FINK L, 
SCHMIDT S, KRICK S, CAMENISCH G, GASSMANN M, SEEGER W, HANZE J. 
(2002)  Hypoxic  pulmonary  artery  fibroblasts  trigger  proliferation  of  vascular  smooth 
muscle cells.role of hypoxia-inducible transcription factors. FASEB J.; 16: 1660-1. 
ROSENZWEIG  EB,  KERSTEIN  D,  BARST  RJ.  (1999)  Long-term  prostacyclin  for 
pulmonary hypertension with associated congenital heart defects. Circulation; 99: 1858-
65. 
ROTHMAN  RB  AND  BAUMANN  MH.  (2002)  Serotonin  releasing  agents. 
Neurochemical, therapeutic and adverse effects. Pharmacol. Biochem. Behav.; 71: 825-36. 
ROTHMAN RB,  AYESTAS MA, DERSCH CM, BAUMANN MH. (1999)  Aminorex, 
fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for 
primary pulmonary hypertension. Circulation; 100: 869-75. 
ROTHMAN  RB,  BAUMANN  MH,  SAVAGE  JE,  RAUSER  L,  MCBRIDE  A, 
HUFEISEN  SJ,  ROTH  BL.  (2000)  Evidence  for  possible  involvement  of  5-HT(2B) 
receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic 
medications. Circulation; 102: 2836-41. 
RUBIN LJ, BADESCH DB, BARST RJ, GALIE N, BLACK CM, KEOGH A, PULIDO 
T,  FROST  A,  ROUX  S,  LECONTE  I,  LANDZBERG  M,  SIMONNEAU  G.  (2002) 
Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med.; 346: 896-903. 
RUDARAKANCHANA  N,  FLANAGAN  JA,  CHEN  H,  UPTON  PD,  MACHADO  R, 
PATEL  D,  TREMBATH  RC,  MORRELL  NW.  (2002)  Functional  analysis  of  bone 
morphogenetic  protein  type  II  receptor  mutations  underlying  primary  pulmonary 
hypertension. Hum. Mol. Genet.; 11: 1517-25. 
SAGA T AND SAID SI. (1984) Vasoactive intestinal peptide relaxes isolated strips of 
human bronchus, pulmonary artery, and lung parenchyma. Trans. Assoc. Am. Physicians; 
97: 304-10. 
SAID SI, HAMIDI SA, DICKMAN KG, SZEMA AM, LYUBSKY S, LIN RZ, JIANG 
YP,  CHEN  JJ,  WASCHEK  JA,  KORT  S.  (2007)  Moderate  pulmonary  arterial 
hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation; 115: 
1260-8. 248 
 
SAID SI. (2006) Mediators and modulators of pulmonary arterial hypertension.  Am. J. 
Physiol. Lung. Cell. Mol. Physiol.; 291: L547–L558. 
SAJI  T,  OZAWA  Y,  ISHIKITA  T,  MATSUURA  H,  MATSUO  N.  (1995)  Short-term 
hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary 
pulmonary hypertension. Am. J. Cardiol.; 78: 244-7. 
SAKAO S, TARASEVICIENE-STEWART L, COOL CD, TADA Y, KASAHARA Y, 
KUROSU K, TANABE N, TAKIGUCHI Y, TATSUMI K, KURIYAMA T, VOELKEL 
NF. (2007) VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving 
CD34+ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like 
cells. FASEB J.; 21: 3640-52. 
SAKATA J, SHIMOKUBO T, KITAMURA K, NISHIZONO M, IEHIKI Y, KANGAWA 
K, MATSUO H, ETO T. (1994) Distribution and characterization of immunoreactive rat 
adrenomedullin in tissue and plasma. FEBS Lett.; 352: 105-8. 
SARTORE  S,  CHIAVEGATO  A,  FAGGIN  E,  FRANCH  R,  PUATO  M,  AUSONI  S,  
PAULETTO P. (2001) Contribution of adventitial fibroblasts to neointima formation and 
vascular remodeling. Circ. Res.; 89: 1111–1121. 
SCHERMULY RT, DONY E, GHOFRANI HA, PULLAMSETTI S, SAVAI R, ROTH M, 
SYDYKOV  A,  LAI  YJ,  WEISSMANN  N,  SEEGER  W,  GRIMMINGER  F.  (2005) 
Reversal of experimental pulmonary hypertension by PDGF inhibition.  J.  Clin. Invest.; 
115: 2811-21. 
SCOTT PA, TREMBLAY A, BROCHU M, ST-LOUIS J. (2007) Vasorelaxant action of 
17 -estradiol in rat uterine arteries: role of nitric oxide synthases and estrogen receptors. 
Am. J. Physiol. Heart Circ. Physiol.; 293: H3713-9. 
SEEGER  H,  MUECK  AO,  LIPPERT  TH.  (1999)  Effect  of  estradiol  metabolites  on 
prostacyclin synthesis in human endothelial cell cultures. Life Sci.; 65: PL167-70. 
SHAHBAZIAN  A,  PETKOV  V,  BAYKUSCHEVA-GENTSCHEVA  T,  HOEGER  H, 
PAINSIPP E, HOLZER P, MOSGOELLER W. (2007) Involvement of endothelial NO in 
the dilator effect of VIP on rat isolated pulmonary artery. Requl. Pept.; 139: 102-8. 
SHAW L, TAGGART MJ, AUSTIN C. (2000) Mechanisms of 17 beta-oestradiol induced 
vasodilatation in isolated pressurized rat small arteries. Br. J. Pharmacol.; 129: 555-65. 
SHEN  S,  BATTERSBY  S,  WEAVER  M,  CLARK  E,  STEPHENS  K,  HARMAR  AJ. 
(2000a) Refined mapping of the human serotonin transporter (SLC6A4) gene within 17q11 
adjacent to the CPD and NF1 genes. Eur. J. Hum. Genet.; 8: 75-8. 
SHEN S, SPRATT C, SHEWARD WJ, KALLO I, WEST K, MORRISON CF, COEN 
CW,  MARSTON  HM,  HARMAR  AJ.  (2000b)  Overexpression  of  the  human  VPAC2 
receptor in the suprachiasmatic nucleus alters the circadian phenotype of mice. Proc. Natl. 
Acad. Sci. USA; 97: 11575-80. 
SIMONNEAU G, BARST RJ, GALIE N, NAEIJE R, RICH S, BOURGE RC, KEOGH A, 
OUDIZ  R,  FROST  A,  BLACKBURN  SD,  CROW  JW,  RUBIN  LJ;  TREPROSTINIL 
STUDY GROUP. (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin 249 
 
analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, 
placebo-controlled trial. Am. J. Respir. Crit. Care Med.; 165: 800-4. 
SMITH P, HEATH D, YACOUB M, MADDEN B, CASLIN A, GOSNEY J. (1990) The 
ultrastructure of plexogenic pulmonary arteriopathy. J. Pathol.; 160: 111-21. 
SNETKOV VA, KNOCK GA, BAXTER L, THOMAS GD, WARD JPT, AARONSON 
PI.  (2006)  Mechanisms  of  the  prostaglandin  F2α-induced  rise  in  [Ca2+]i  in  rat 
intrapulmonary arteries. J. Physiol.; 571: 147-63. 
SOBIN SS, TREMER HM, HARDY JD, CHIODI HP. (1983) Changes in arteriole in acute 
and chronic hypoxic pulmonary hypertension and recovery in rat. J. Appl. Physiol.; 55: 
1445-55.  
SONG  WC.  (2001)  Biochemistry  and  reproductive  endocrinology  of  estrogen 
sulfotransferase. Ann. N.Y Acad. Sci.; 948: 43-50. 
SONG Y, JONES JE, BEPPU H, KEANEY JF JR, LOSCALZO J, ZHANG YY. (2005) 
Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. 
Circulation; 112: 553-62. 
STEFANO GB, PREVOT V, BEAUVILLAIN JC, CADET P, FIMIANI C, WELTERS I, 
FRICCHIONE GL, BRETON C, LASSALLE P, SALZET M, BILFINGER TV. (2000) 
Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human 
endothelia. Circulation; 101: 1594-7. 
STENMARK KR, FAGAN KA, FRID MG. (2006) Hypoxia-induced pulmonary vascular 
remodeling: cellular and molecular mechanisms. Circ. Res.; 99: 675-91. 
STEUDEL W, ICHINOSE F, HUANG PL, HURFORD WE, JONES RC, BEVAN JA, 
FISHMAN MC,  ZAPOL WM.  (1997)  Pulmonary  vasoconstriction and hypertension in 
mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ. 
Res.; 81: 34-41. 
STRANGE JW, WHARTON J, PHILLIPS PG, WILKINS MR. (2002) Recent insights 
into the pathogenesis and therapeutics of pulmonary hypertension. Clinical Science; 102: 
253-268. 
STUDDY PR, LAPWORTH R, BIRD R. (1983) Angiotensin-converting enzyme and its 
clinical significance- a review. J. Clin. Pathol.; 36: 938-947. 
STUPFEL M, PESCE VH, GOURLET V, BOULEY G, ELABED A, LEMERCERRE C. 
(1984) Sex-related factors in acute hypoxia survival in one strain of mice.  Aviat. Space 
Environ. Med.; 55: 136-40. 
SUDHIR  K, CHOU  TM, MULLEN  WL,  HAUSMANN  D,  COLLINS  P, YOCK  PG, 
CHATTERJEE K. (1995) Mechanisms of estrogen-induced vasodilation: in vivo studies in 
canine coronary conductance and resistance arteries. J. Am. Coll. Cardiol.; 26: 807-14. 
SUGO S, MINAMINO N, SHOJI H, KANGAWA K, KITAMURA K, ETO T, MATSUO 
H. (1994) Production and secretion of adrenomedullin from vascular smooth muscle cells: 250 
 
augmented production by tumour necrosis factor-α. Biochem. Biophys. Res. Comm.; 203: 
719-26. 
SULLIVAN  CC,  DU  L,  CHU  D,  CHO  AJ,  KIDO  M,  WOLF  PL,  JAMIESON  SW, 
THISTLETHWAITE PA. (2003) Induction of pulmonary hypertension by an angiopoietin 
1/TIE2/serotonin pathway. Proc. Natl. Acad. Sci. USA; 100: 12331-6. 
SUZUKI  YJ,  DAY  RM,  TAN  CC,  SANDVEN  TH,  LIANG  Q,  MOLKENTIN  JD, 
FANBURG BL. (2003) Activation of GATA-4 by serotonin in pulmonary artery smooth 
muscle cells. J. Biol. Chem.; 278: 17525-31. 
SYLVESTER JT, GORDON JB, MALAMET RL, WETZEL RC. (1985) Prostaglandins 
and estradiol-induced attenuation of hypoxic pulmonary vasoconstriction. Chest; 88: 252S-
254S. 
TADA  Y,  MAJKA S,  CARR M,  HARRAL J,  CRONA D,  KURIYAMA T, WEST J. 
(2007) Molecular effects of loss of BMPR2 signaling in smooth muscle in a transgenic 
mouse model of PAH. Am. J. Physiol. Lung Cell Mol. Physiol.; 292: L1556-63.  
TAKAHASHI  H,  GOTO  N,  KOJIMA  Y,  TSUDA  Y,  MORIO  Y,  MURAMATSU  M, 
FUKUCHI Y. (2006) Downregulation of type II bone morphogenetic protein receptor in 
hypoxic pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol.; 290: L450-8. 
TAKAHASHI K, KOGAKI S, MATSUSHITA T, NASUNO S, KUROTOBI S, OZONO 
K. (2007) Hypoxia induces alteration of bone morphogenetic protein receptor signaling in 
pulmonary artery endothelial cell. Pediatri. Res.; 61: 392-7. 
TAKEDA M, OTSUKA F, NAKAMURA K, INAGAKI K, SUZUKI J, MIURA D, FUJIO 
H, MATSUBARA H, DATE H, OHE T, MAKINO H. (2004) Characterization of the bone 
morphogenetic protein (BMP) system in human pulmonary arterial smooth muscle cells 
isolated from a sporadic case of primary pulmonary hypertension: roles of BMP type IB 
receptor (activin receptor-like kinase-6) in the mitotic action. Endocrinology; 145: 4344-
54. 
TARASEVICIENE-STEWART L, KASAHARA Y, ALGER L, HIRTH P, MC MAHON 
G, WALTENBERGER J, VOELKEL NF, TUDER RM. (2001) Inhibition of the VEGF 
receptor  2  combined  with  chronic  hypoxia  causes  cell  death-dependent  pulmonary 
endothelial cell proliferation and severe pulmonary hypertension. FASEB J.; 15: 427-38. 
TEICHERT-KULISZEWSKA  K,  KUTRYK  MJ,  KULISZEWSKI  MA,  KAROUBI  G, 
COURTMAN  DW,  ZUCCO  L,  GRANTON  J,  STEWART  DJ.  (2006)  Bone 
morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell 
survival:  implications  for  loss-of-function  mutations  in  the  pathogenesis  of  pulmonary 
hypertension. Circ. Res.; 98: 172-5. 
TEOH  H,  QUAN  A,  LEUNG  SW,  MAN  RY.  (2000a)  Differential  effects  of  17beta-
estradiol and testosterone on the contractile responses of porcine coronary arteries. Br. J. 
Pharmacol.; 129: 1301-8. 
TEOH H, QUAN A, MAN RY. (2000b) Acute impairment of relaxation by low levels of 
testosterone in porcine coronary arteries. Cardiovasc. Res.; 45: 1010-8. 251 
 
THOMSON J, MACHADO R, PAUCIULO M, MORGAN N, YACOUB M, CORRIS P, 
MCNEIL  K,  LOYD  J,  NICHOLS  W,  TREMBATH  R.  (2001)  Familial  and  sporadic 
primary  pulmonary  hypertension  is  caused  by  BMPR2  gene  mutations  resulting  in 
haploinsufficiency of the bone morphogenetic protein tùype II receptor.  J.  Heart  Lung 
Transplant; 20: 149.  
TOFOVIC  SP,  SALAH  EM,  MADY  HH,  JACKSON  EK,  MELHEM  MF.  (2005) 
Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats. J. 
Cardiovasc. Pharmacol.; 46: 430-7. 
TOFOVIC SP, ZHANG X,  JACKSON  EK, DACIC  S,  PETRUSEVSKA  G. (2006) 2-
Methoxyestradiol  mediates  the  protective  effects  of  estradiol  in  monocrotaline-induced 
pulmonary hypertension. Vascul. Pharmacol.; 45: 358-67. 
TSUKAMOTO  A, KANEKO Y, YOSHIDA T,  HAN  K, ICHINOSE M, KIMURA S. 
(1998) 2-Methoxyestradiol, an endogenous metabolite of estrogen, enhances apoptosis and 
beta-galactosidase  expression  in  vascular  endothelial  cells.  Biochem.  Biophys.  Res. 
Commun.; 248: 9-12. 
TUCKER  A,  WEIR  EK,  REEVES  JT,  GROVER  RF.  (1975)  Histamine  H1-  and  H2-
receptors in pulmonary and systemic vasculature of the dog. Am. J. Physiol.; 229: 1008-
1013. 
TUDER  RM,  CHACON  M,  ALGER  L,  WANG  J,  TARASEVICIENE-STEWART  L, 
KASAHARA Y, COOL CD, BISHOP AE, GERACI M, SEMENZA GL, YACOUB M, 
POLAK  JM,  VOELKEL  NF.  (2001)  Expression  of  angiogenesis-related  molecules  in 
plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered 
angiogenesis. J. Pathol.; 195: 367-74. 
TUDER  RM,  COOL  CD,  GERACI  MW,  WANG  J,  ABMAN  SH,  WRIGHT  L, 
BADESCH D, VOELKEL NF. (1999) Prostacyclin synthase expression is decreased in 
lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med.; 
159: 1925-32. 
TUDER RM, GROVES B, BADESCH DB, VOELKEL NF. (1994) Exuberant endothelial 
cell growth and elements of inflammation are present in plexiform lesions of pulmonary 
hypertension. Am. J. Pathol.; 144: 275-285. 
TUDER RM, YUN JH, BHUNIA A, FIJALKOWSKA I. (2007) Hypoxia and chronic lung 
disease. J. Mol. Med.; 85: 1317-1324. 
VALDIMARSDOTTIR G, GOUMANS MJ, ROSENDAHL A, BRUGMAN M, ITOH S, 
LEBRIN F, SIDERAS P, TEN DIJKE P. (2002) Stimulation of Id1 expression by bone 
morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced 
activation of endothelial cells. Circulation; 106: 2263-70. 
VANE JR AND BOTTING RM. (1995) Pharmacodynamic profile of prostacyclin. Am. J. 
Cardiol.; 75: 3A-10A. 
VARGAS R,  DELANEY M,  FARHAT MY,  WOLFE R, REGO  A, RAMWELL  PW. 
(1995)  Effect  of  estradiol  17  beta  on  pressor  responses  of  rat  mesenteric  bed  to 
norepinephrine, K+, and U-46619. J. Cardiovasc. Pharmacol.; 25: 200-6. 252 
 
VARGHESE A, HONG Z, WEIR EK. (2006) Serotonin-induced inhibition of KV current: 
a supporting role in pulmonary vasoconstriction? Circ. Res.; 98: 860-2. 
VICKERS SP, CLIFTON PG, DOURISH CT, TECOTT LH. (1999) Reduced satiating 
effect  of  d-fenfluramine  in  serotonin  5-HT(2C)  receptor  mutant  mice. 
Psychopharmacology (Berl); 143: 309-14. 
VOELKEL  NF,  TUDER  RM,  WADE  K,  HÖPER  M,  LEPLEY  RA,  GOULET  JL, 
KOLLER BH, FITZPATRICK F. (1996) Inhibition of 5-lipoxygenase-activating protein 
(FLAP) reduces pulmonary  vascular reactivity and pulmonary hypertension in hypoxic 
rats. J. Clin. Invest.; 97: 2491-8. 
WAGENVOORT  CA  AND  MULDER  PG.  (1993)  Thrombotic  Lesions  in  Primary 
Plexogenic Arteriopathy. CHEST; 103: 844-49. 
WALTHER  DJ  AND  BADER  M.  (2003)  A  unique  central  tryptophan  hydroxylase 
isoform. Biochem. Pharmacol.; 66: 1673-80. 
WALTHER DJ, PETER JU, BASHAMMAKH S, HÖRTNAGL H, VOITS M, FINK H, 
BADER M. (2003) Synthesis of serotonin by a second tryptophan hydroxylase isoform. 
Science; 299: 76. 
WANG GS, QIAN GS, MAO BL, CAI WQ, CHEN WZ, CHEN Y. (2003) Changes of 
interleukin-6 and Janus kinases in rats with hypoxic pulmonary hypertension. Zhonghua 
Jie He He Hu Xi Za Zhi.; 26: 664-7. 
WAYPA  GB  AND  SCHUMACKER  PT.  (2005)  Hypoxic  pulmonary  vasoconstriction: 
redox events in oxygen sensing. J. Appl. Physiol.; 98: 404-414. 
WEIGAND L, FOXSON J, WANG J, SHIMODA LA, SYLVESTER JT. (2005) Inhibition 
of  hypoxic  pulmonary  vasoconstriction  by  antagonists  of  store-operated  Ca
2+  and 
nonselective cation channels. Am. J. Physiol. Lung. Cell. Mol. Physiol.; 289: L5-L13. 
WEIR  EK,  HONG  Z,  VARGHESE  A.  (2004)  The  serotonin  transporter:  a  vehicle  to 
elucidate pulmonary hypertension? Circ. Res.; 94: 1152-4. 
WEIR  EK,  REEVE  HL,  HUANG  JM,  MICHELAKIS  E,  NELSON  DP,  HAMPL  V, 
ARCHER  SL.  (1996)  Anorexic  agents  aminorex,  fenfluramine,  and  dexfenfluramine 
inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary 
vasoconstriction. Circulation; 94: 2216-20. 
WELSH  CH,  HASSELL  KL,  BADESCH  DB,  KRESSIN  DC,  MARLAR  RA.  (1996) 
Coagulation  and  fibrinolytic  profiles  in  patients  with  severe  pulmonary  hypertension. 
Chest; 110: 710-7. 
WELSH  DJ,  HARNETT  M,  MACLEAN  M,  PEACOCK  AJ.  (2004)  Proliferation  and 
signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter. Am. J. 
Respir. Crit. Care Med.; 170: 252-9. 
WELSH DJ, PEACOCK AJ, MACLEAN MR, HARNETT M. (2001) Chronic hypoxia 
induces  constitutive  p38  mitogen-activated  protein  kinase  activity  that  correlates  with 253 
 
enhanced cellular proliferation in fibroblasts from rat pulmonary but not systemic arteries. 
Am. J. Respir. Crit. Care. Med.; 164: 282-289. 
WEST J, COGAN J, GERACI M, ROBINSON L, NEWMAN J, PHILLIPS JA, LANE K, 
MEYRICK B, LOYD J. (2008b) Gene expression in BMPR2 mutation carriers with and 
without evidence of pulmonary arterial hypertension suggests pathways relevant to disease 
penetrance. BMC Med. Genomics; 1: 45. 
WEST J, FAGAN K, STEUDEL W, FOUTY B, LANE K, HARRAL J, HOEDT-MILLER 
M, TADA Y, OZIMEK J, TUDER R, RODMAN DM. (2004) Pulmonary hypertension in 
transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle.  Circ. 
Res.; 94: 1109-14. 
WEST J, HARRAL J, LANE K, DENG Y, ICKES B, CRONA D, ALBU S, STEWART 
D,  FAGAN  K.  (2008a)  Mice  expressing  BMPR2R899X  transgene  in  smooth  muscle 
develop pulmonary vascular lesions. Am. J. Physiol. Lung Cell Mol. Physiol.; 295: L744-
55. 
WILLERS ED, NEWMAN JH, LOYD JE, ROBBINS IM, WHEELER LA, PRINCE MA, 
STANTON KC, COGAN JA, RUNO JR, BYRNE D, HUMBERT M, SIMONNEAU G, 
SZTRYMF B, MORSE JA, KNOWLES JA, ROBERTS KE, MCELROY JJ, BARST RJ, 
PHILLIPS JA 3RD. (2006) Serotonin transporter polymorphisms in familial and idiopathic 
pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.; 173: 798-802. 
WILSON SM, MASON HS, NG LC, MONTAGUE S, JOHNSTON L, NICHOLSON N, 
MANSFIELD S, HUME JR. (2005) Role of basal extracellular Ca2+ entry during 5-HT-
induced vasoconstriction of canine pulmonary arteries. Br. J. Pharmacol.; 144: 252-64. 
WOJTAROWICZ  A,  PODLASZ  P,  CZAJA  K.  (2003)  Adrenergic  and  cholinergic 
innervation of pulmonary tissue in the pig. Folia Morphol.; 62: 215-218. 
WONG WK, KNOWLES JA, MORSE JH. (2005) Bone morphogenetic protein receptor 
type  II  C-terminus  interacts  with  c-Src:  implication  for  a  role  in  pulmonary  arterial 
hypertension. Am. J. Respir. Cell Mol. Biol.; 33: 438-46. 
WOODS  M,  MITCHELL  JA,  WOOD  EG,  BARKER  S,  WALCOT  NR,  REES  GM, 
WERNER TD. (1999) Endothelin-1 is induced by cytokines in human vascular smooth 
muscle cells: evidence for intracellular endothelin-converting enzyme. Mol. Pharmacol.; 
64: 923-31. 
YAMAMOTO  T,  SAATCIOGLU  F,  MATSUDA  T.  (2002)  Cross-talk  between  bone 
morphogenic proteins and estrogen receptor signaling. Endocrinology; 143: 2635-42. 
YANAGISAWA  M,  KURIHARA  H,  KIMURA  S,  TOMOBE  Y,  KOBAYASHI  M, 
MITSUI Y, YAZAKI Y, GOTO K, MASAKI T. (1988) A novel potent vasoconstrictor 
peptide produced by vascular endothelial cells. Nature; 332: 411-415. 
YANG X, CASTILLA LH, XU X, LI C, GOTAY J, WEINSTEIN M, LIU PP, DENG CX. 
(1999)  Angiogenesis  defects  and  mesenchymal  apoptosis  in  mice  lacking  SMAD5. 
Development; 126: 1571-80. 254 
 
YANG  X,  LONG  L,  SOUTHWOOD  M,  RUDARAKANCHANA  N,  UPTON  PD, 
JEFFERY  TK,  ATKINSON  C,  CHEN  H, TREMBATH  RC, MORRELL  NW.  (2005) 
Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in 
familial pulmonary arterial hypertension. Circ. Res.; 96: 1053-63. 
YEAGER  ME,  HALLEY  GR,  GOLPON  HA,  VOELKEL  NF,  TUDER  RM.  (2001) 
Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform 
lesions in primary pulmonary hypertension. Circ. Res.; 88: e2-e11. 
YEUNG SY, PUCOVSKÝ V, MOFFATT JD, SALDANHA L, SCHWAKE M, OHYA S, 
GREENWOOD IA. (2007) Molecular expression and pharmacological identification of a 
role for K(v)7 channels in murine vascular reactivity. Br. J. Pharmacol.; 151: 758-70. 
YI ES, KIM H, AHN H, STROTHER J, MORRIS T, MASLIAH E, HANSEN LA, PARK 
K, FRIEDMAN PJ. (2000) Distribution of obstructive intimal lesions and their cellular 
phenotypes in chronic pulmonary hypertension: a morphometric and immunohistochemical 
study. Am. J. Respir. Crit. Care Med.; 162: 1577-1586. 
YOSHIHARA F, NISHIKIMI T, HORIO T, YUTANI C, TAKISHITA S, MATSUO H, 
OHE T, KANGAWA K. (1998) Chronic infusion of adrenomedullin reduces pulmonary 
hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline. 
Eur. J. Pharmacol.; 355: 33-9. 
YOUNG KA, IVESTER C, WEST J, CARR M, RODMAN DM. (2006) BMP signaling 
controls PASMC KV channel expression in vitro and in vivo. Am. J. Physiol. Lung Cell 
Mol. Physiol.; 290: L841-8. 
YU AY, SHIMODA LA, IYER NV, HUSO DL, SUN X, MCWILLIAMS R, BEATY T, 
SHAM  JS,  WIENER  CM,  SYLVESTER  JT,  SEMENZA  GL.  (1999)  Impaired 
physiological  responses  to  chronic  hypoxia  in  mice  partially  deficient  for  hypoxia-
inducible factor 1α. J. Clin. Invest.; 103: 691-6. 
YU PB, BEPPU H, KAWAI N, LI E, BLOCH KD. (2005) Bone morphogenetic protein 
(BMP)  type  II  receptor  deletion  reveals  BMP  ligand-specific  gain  of  signaling  in 
pulmonary artery smooth muscle cells. J. Biol. Chem.; 280: 24443-50. 
YU Y, SWEENEY M, ZHANG S, PLATOSHYN O, LANDSBERG J, ROTHMAN A, 
YUAN JX. (2002) PDGF stimulates pulmonary vascular smooth muscle cell proliferation 
by upregulating TRPC6 expression. Am. J. Physiol. Cell Physiol.; 284: C316-30. 
YUAN JX, ALDINGER AM, JUHASZOVA M, WANG J, CONTE JV JR, GAINE SP, 
ORENS JB, RUBIN LJ. (1998) Dysfunctional voltage-gated K+ channels in pulmonary 
artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation; 
98: 1400-6. 
YUAN  JX.  (2004)  Hypoxic  Pulmonary  Vasoconstriction:  Cellular  and  Molecular 
Mechanisms. Springer. Page 4 
YUE TL, WANG X, LOUDEN CS, GUPTA S, PILLARISETTI K, GU JL, HART TK, 
LYSKO  PG,  FEUERSTEIN  GZ.  (1997)  2-Methoxyestradiol,  an  endogenous  estrogen 
metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role 255 
 
for stress-activated protein kinase signaling pathway and Fas expression. Mol. Pharmacol.; 
51: 951-62. 
ZHANG S, FANTOZZI I, TIGNO DD, YI ES, PLATOSHYN O, THISTLEWAITE PA, 
KRIETT JM, YUNG G, RUBIN LJ, YUAN JXJ. (2003) Bone morphogenetic proteins 
induce apoptosis in human pulmonary vascular smooth muscle cells. Am. J. Physiol. Lung 
Cell. Mol. Physiol.; 285: L740-L754. 
ZHAO L, LONG L, MORRELL NW, WILKINS MR. (1999) NPR-A-deficient mice show 
increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation; 99: 605-
7. 
ZHAO  L,  MASON  NA,  MORRELL  NW,  KOJONAZAROV  B,  SADYKOV  A, 
MARIPOV A, MIRRAKHIMOV MM, ALDASHEV A, WILKINS MR. (2001) Sildenafil 
inhibits hypoxia-induced pulmonary hypertension. Circulation; 104: 424-8. 
ZHAO YD, CAMPBELL AI, ROBB M, NG D, STEWART DJ. (2003) Protective role of 
angiopoietin-1 in experimental pulmonary hypertension. Circ. Res.; 92: 984-91. 
ZHU  P,  HUANG  L,  GE  X,  YAN  F,  WU  R,  AO  Q.  (2006)  Transdifferentiation  of 
pulmonary  arteriolar  endothelial  cells  into  smooth  muscle-like  cells  regulated  by 
myocardin  involved  in  hypoxia-induced  pulmonary  vascular  remodelling.  Int.  J.  Exp. 
Path.; 87: 463-474. 
ZOLKOWSKA  D,  ROTHMAN  RB,  BAUMANN  MH.  (2006)  Amphetamine  analogs 
increase plasma serotonin: implications for cardiac and pulmonary disease. J. Pharmacol. 
Exp. Ther.; 318: 604-10. 
 
 
 
 
 
 
 
 
 